

Scientific Programme by Day

Friday, October 7, 2022

Scientific Programme by Day Saturday, October 8, 2022

PGT: Plenary Session

09:00 – 10:30 D3
Epidemic of pancreatic cysts: What all GI doctors need to know!
 Chairs: Gabriele Capurso, IT
 Albrecht Neesse, DE



09:00 – 09:07 IP1
Words of welcome Postgraduate Teaching 2022
 Julia Mayerle, DE

09:07 – 09:35 IP2
Pancreatic cysts: Differential diagnosis and the natural history
 Djuna L. Cahen, NL

09:35 – 09:49 IP3
Case presentation: A lonely cyst ^{CASE}
 Serena Stigliano, IT

09:49 – 09:59 IP4
The right balance between surveillance and surgery - Surveillance: Who, how, how long? ^{CASE}
 Kasper A. Overbeek, NL

09:59 – 10:09 IP5
The right balance to avoid under and overt treatment - Surgery: Who and when? ^{CASE}
 Ihsan Ekin Demir, DE

10:09 – 10:24
Panel Discussion: Epidemic of pancreatic cysts - What all GI doctors need to know!

10:24 – 10:29
Conclusion: Epidemic of pancreatic cysts - What all GI doctors need to know!
 Gabriele Capurso, IT

Nurse Programme

09:00 – 10:30 Lehar 2
ESGENA Opening Session: Shaping our future
 Chairs: Marjon De Pater-Godhelp, NL
 Martina Fellinghauer, AT



09:00 – 09:10 IP6
Welcome
 Marjon De Pater-Godhelp, NL

09:10 – 09:35 IP7
Future of endoscopy: New developments, KI and robotics
 Alexander Meining, DE

09:35 – 10:00 IP8
Specialists and generalists in GI endoscopy nursing: How to implement it in daily routine?

Marjon De Pater-Godhelp, NL

10:00 – 10:30 IP9

Health illiteracy and compliance: What does it mean for endoscopy? An interview

Gerlinde Weilguny-Schöfl, AT

Denise Schäfer, AT

Live Demo

09:00 – 17:30 Stolz 1-2, Foyer
Endoscopy Learning Area & Ultrasound Learning Area

PGT: Video Case Session

11:00 – 12:30 D3
Emergency endoscopy: How red can it get?
 Chairs: Alexander Meining, DE
 Jeanin E. van Hooft, NL



11:00 – 11:30 IP10
Endoscopic management of patients with variceal bleeding
 Sandra Nagl, DE

11:30 – 12:00 IP11
Endoscopic management of patients with non-variceal bleeding
 Ian Mark Gralnek, IL

12:00 – 12:30 IP12
Endoscopic management of perforations
 Oliver Pech, DE

PGT: Session

11:00 – 12:30 A3
30 Years of UEG - Focus on Chronic Diarrhoea: Has our approach to diagnosis and management changed with "globalisation"?
 Chairs: Rachel Gingold-Belfer, IL
 Harry Sokol, FR



11:00 – 11:25 IP13
Current diagnosis strategy of chronic diarrhea
 Vincenzo Stanghellini, IT

11:25 – 11:55 IP14
Clinical case 30 Years of UEG - Focus on Chronic Diarrhoea: Has our approach to diagnosis and management changed with "globalisation"? ^{CASE}
 Lucas Wauters, BE

11:55 – 12:05 IP15
Chronic diarrhea in coeliac disease and microscopic colitis ^{CASE}
 Chris J.J. Mulder, NL

12:05 - 12:15 IP16
Chronic diarrhea in bile acid malabsorption and SIBO
 Jan Tack, BE
 12:15 - 12:30
Q&A

PGT: Session

11:00 - 12:30 C1
ERCP vs EUS: The Fight Club
 Chairs: Paolo Giorgio Arcidiacono, IT
 Marianna Arvanitakis, BE

Q+A LIVE

11:00 - 11:30 IP17
EUS-guided interventions in clinical practice: Just for HPB Centers or for anybody?
 Schalk van der Merwe, BE

11:30 - 11:40 IP18
Difficult papilla or altered anatomy: ERCP first choice
 István Hritz, HU

11:40 - 11:50 IP19
Difficult papilla or altered anatomy: EUS guided way
 Giuseppe Vanella, IT

11:50 - 12:00
Q&A

12:00 - 12:10 IP20
The difficult stone management: Follow the standard way
 Paraskevas Gkolfakis, BE

12:10 - 12:20 IP21
The difficult stone management: Seeing is believing
 George Webster, GB

12:20 - 12:30
Q&A

PGT: Session

11:00 - 12:30 D4
Challenges and controversies in the management in cholangiocarcinoma (CCA)
 Chairs: Michael Trauner, AT
 Verena Keitel-Anselmino, DE

Q+A LIVE

11:00 - 11:10 IP22
Mass forming CCA: Still a challenging diagnosis?
 Verena Keitel-Anselmino, DE

11:10 - 11:20 IP23
Periductal and intraductal CCA: Still a challenging diagnosis?
 Lars Aabakken, NO

11:20 - 11:30
Q&A

11:30 - 12:00 IP24
Management of cholangiocarcinoma: Role of surgery and endoscopy
 Cyriel Y. Ponsioen, NL
 12:00 - 12:30 IP26
Current and emerging medical treatments for advanced biliary tract cancers
 Lorenza Rimassa, IT

PGT: Session

11:00 - 12:30 Strauss 3
Let's talk about Barrett's: Aetiology, diagnosis and management
 Chairs: Raf Bisschops, BE
 Helmut Messmann, DE

Q+A LIVE

11:00 - 11:30 IP27
Epidemiology, aetiology and cancer risk
 Roos E. Pouw, NL

11:30 - 11:45 IP28
Endoscopic diagnosis: Old tricks and new devices ^{CASE}
 Alanna Ebigbo, DE

11:45 - 12:00 IP29
Endoscopic management: What, when and how? ^{CASE}
 Raf Bisschops, BE

12:00 - 12:15 IP30
Surveillance: One size fits all?
 Rehan Jamil Haidry, GB

12:15 - 12:30 IP31
PPI, Aspirin and co: What is the evidence?
 Manon C.W. Spaander, NL

Nurse Programme

11:00 - 12:30 Lehar 2
Health and safety in endoscopy
 Chairs: Elena Daniela Burtea, RO
 Katarina Karlovic, HR

Q+A LIVE

11:00 - 11:18 IP32
Preventing surface alterations in endoscope reprocessing
 Guido Merk, DE

11:18 - 11:36 IP33
Is sustainability realisable in endoscopy?
 Daniela Schröder, DE

11:36 - 11:54 IP34
"Brushing up" on the manual clean
 Liz Connelly, IE

11:54 - 12:12 IP35
PlasmaTYPHOON+

12:12 - 12:30 IP36
The trend towards single-use components
 Sanja Hruškar, HR

Nurse Programme

11:00 - 12:30 Lehar 3
Management of complications
 Chairs: Krisztina Tari, HU
 Eric Pflimlin, CH

Q+A

11:00 - 11:30 IP37
EMR and ESD: Important tools to prevent and treat complications
 Jürgen Hochberger, DE

11:30 - 11:50 IP38
Endoscopic management of bile duct stones
 Andrew Orrock, GB

11:50 - 12:10 IP39
VacStent GI: Complication management of oesophageal leaks
 Thao Ha, DE

12:10 - 12:30 IP40
Simplifying your daily routine: Benefits of single-use endoscopes
 Rasmus Kümmel Holtze, DK

PGT: Video Case Session

13:30 - 15:00 D3
Advanced luminal and hepatobiliary endoscopy
 Chairs: Aryn Haji, GB
 Roberta Maselli, IT

Q+A

13:30 - 14:00 IP41
Diagnosis and characterisation of colorectal lesions
 Shraddha Gulati, GB

14:00 - 14:10 IP42
Colorectal lesions: With cold snare and EMR you can kill all
 Oliver Pech, DE

14:10 - 14:20 IP43
Colorectal lesions: Only ESD leads the way
 Helmut Neumann, DE

14:20 - 14:30
Q&A

14:30 - 15:00 IP44
Diagnosis and management of pancreatic collections
 Geoffroy Vanbiervliet, FR

PGT: Session

13:30 - 15:00 A3
Don't miss the polyp and don't leave it behind!
 Chairs: Michal Filip Kaminski, PL
 Maria Pellisé Urquiza, ES

Q+A

13:30 - 14:00 IP45
All you need to do is maximising your adenoma detection rate
 Silvia Paggi, IT

14:00 - 14:10 IP46
Medium size non pedunculated polyps: En-bloc resection the golden goal
 Sandra Nagl, DE

14:10 - 14:20 IP47
Medium size non pedunculated polyps: Safety first
 David James Tate, BE

14:20 - 14:30
Q&A

14:30 - 14:40 IP48
Surveillance in patients with attenuated polyposis: Is genetic counselling really useful? Pro
 Andrew Latchford, GB

14:40 - 14:50 IP49
Surveillance in patients with attenuated polyposis: Is genetic counselling really useful? Con
 Sabela Carballal, ES

14:50 - 15:00
Q&A

PGT: Session

13:30 - 15:00 C1
Prevention and treatment of intestinal dysplasia in IBD: Are we doing better?
 Chairs: Marietta Iacucci, GB
 Tine Jess, DK

Q+A

13:30 - 14:00 IP50
From chronic inflammation to neoplasia in IBD
 Ann Driessen, BE

14:00 - 14:30 IP51
When and how do we do surveillance colonoscopy?
 James Edward East, GB

14:30 - 14:40 IP52
How to manage dysplasia: Snare, knife or surgery? The endoscopic view
 Raf Bisschops, BE

14:40 - 14:50 IP53
How to manage dysplasia: Snare, knife or surgery? The surgical view
 André D'Hoore, BE

14:50 - 15:00
Q&A

PGT: Session

13:30 - 15:00 D4
30 Years of UEG - Focus on Malabsorption: What has changed in the diagnosis and management?
 Chairs: Carolina Ciacci, IT
 Antonio Di Sabatino, IT

Q+A

13:30 - 13:47 IP54
Malabsorption syndrome: Definition and clinical overview
 Antonio Di Sabatino, IT

13:47 - 14:05 IP55
Testing for malabsorption
 Heinz Florian Hammer, AT

14:05 - 14:15 IP56
Specific situations: Single-nutrient malabsorption
 Jutta Keller, DE

14:15 - 14:25 IP57
Specific situations: Starch malabsorption
 Bodil Ohlsson, SE

14:25 - 14:35 IP58
Specific situations: Surgery-induced malabsorption
 Francisca Joly, FR

14:35 - 15:00
Q&A

PGT: Session

13:30 - 15:00 Strauss 3
Help for HELLP and other pregnancy associated liver disorders
 Chairs: Patrizia Burra, IT
 Verena Keitel-Anselmino, DE

Q+A

13:30 - 14:00 IP59
Evidence-based management of HELLP syndrome
 Melanie Nana, GB

14:00 - 14:30 IP60
Acute and chronic liver disease during pregnancy
 Jennifer Flemming, CA

14:30 - 15:00 IP61
Pregnancy in liver transplant recipient
 Michael Heneghan, GB

Nurse Programme

13:30 - 15:00 Lehar 2
Improving hygiene in endoscopy
 Chairs: Björn Fehrke, CH
 Ulrike Beilenhoff, DE

Q+A

13:30 - 14:00 IP62
Microbiological surveillance: Are we comparing apples and oranges?
 Lionel Pineau, FR

14:00 - 14:30 IP63
Visual inspection of endoscope channels after reprocessing with different process chemicals
 Holger Biering, DE

14:30 - 15:00 IP64
A Debate: Where should endoscopes be reprocessed? In endoscopy or in CSSD department? Who is competent to do reprocessing?
 Ulrike Beilenhoff, DE
 Harry Oussoren, NL

Nurse Programme

13:30 - 15:00 Lehar 3
Effect of COVID-19
 Chairs: Deepa Jegadish Gandhi, IE
 Lindsey Kelsall, GB

Q+A

13:30 - 13:55 IP65
COVID-19: What does it do to staff and patients?
 Georg Brownstone, AT

13:55 - 14:20 IP66
Stress management in endoscopy: Resources and helpful tools
 Georg Brownstone, AT

14:20 - 14:40 IP67
Free Paper: Communication challenges in preparing patients for endoscopic examinations during the Covid-19 pandemic
 Mario Gazic, HR

14:40 - 15:00 IP68
Free Paper: IBD nurse role in Covid vaccination of patients on biological therapy
 Nensi Lusičić, HR

Common Interest Group

15:00 - 17:00 Schubert
Microbiome in pathogenesis of decompensated cirrhosis and as a therapeutic target

PGT: Clinical Case-based Session

15:30 - 17:00 D3
SOS, Budd-Chiari and ITBL: What should be known
 Chairs: Frederick Klauschen, DE
 Jonel Trebicka, DE

Q+A

15:30 - 15:45 IP69
Clinical presentation in a case with vascular liver disease CASE
 Michael Praktiknjo, DE

15:45 - 16:00 IP70
Pathologist view: Diagnostic workup and importance of pathology

Frederick Klauschen, DE

16:00 - 16:15

Q&A

16:15 - 16:45 IP71
Hepatologist view: Clinical presentation and therapy of vascular liver diseases

Jonel Trebicka, DE

16:45 - 17:00 IP72

Therapy and outcome from the presented case ^{CASE}

Michael Praktijnjo, DE

PGT: Clinical Case-based Session

15:30 - 17:00 A3

Dos and don'ts in resectable colorectal cancer

Chairs: Jaroslaw Regula, PL
 Leon M.G. Moons, NL

Q+A LIVE

15:30 - 16:00 IP74
Colon cancer with synchronous not (yet) resectable liver metastases: A real life MDT session ^{CASE}

Thomas Seufferlein, DE

16:00 - 16:15

Q&A

16:15 - 16:30 IP75
The case of rectal cancer diagnosed during screening ^{CASE}

Piotr Wysocki, PL

16:30 - 16:45 IP76
Neoadjuvant and adjuvant therapies for resectable rectal cancer

Jaroslaw Regula, PL

16:45 - 17:00

Q&A

PGT: Clinical Case-based Session

15:30 - 17:00 C1

30 Years of UEG - Focus on Non-cardiac Chest Pain (NCCP): What has changed in the diagnosis and management?

Chairs: Laurie Keefer, US
 Daniel Sifrim, GB
 Jan Tack, BE

Q+A LIVE

15:30 - 15:45 IP77
Did we learn to differentiate between angina like chest pain and severe heartburn? ^{CASE}

Mónica Velosa, GB

15:45 - 16:00 IP78
Diagnosis and medical/endoscopic treatment of Non-cardiac Chest Pain: An update

Daniel Sifrim, GB

16:00 - 16:15

Q&A

16:15 - 16:30 IP79
Non-cardiac Chest Pain due to hypersensitivity / hypervigilance ^{CASE}

Livia Guadagnoli, BE

16:30 - 16:45 IP80

Lifestyle and behavioral approaches to management of NCCP

Laurie Keefer, US

16:45 - 17:00

Q&A

PGT: Clinical Case-based Session

15:30 - 17:00 D4

Nutrition in GI disorders: Center stage or supporting act?

Chairs: Caroline Tuck, AU
 Tim Vanuytsel, BE
 Francisca Joly, FR

Q+A LIVE

15:30 - 15:45 IP81

IBD case ^{CASE}

Lauren Manning, AU

15:45 - 16:00 IP82

Management of active IBD and functional symptoms: Time for diet to take centre stage?

Alicia Sandall, GB

16:00 - 16:15

Q&A

16:15 - 16:30 IP83

GI cancer case ^{CASE}

Filip Van Herpe, BE

16:30 - 16:45 IP84

Nutrition in advanced gastrointestinal cancer

Stephan Bischoff, DE

16:45 - 17:00

Q&A

PGT: Clinical Case-based Session

15:30 - 17:00 Strauss 3

Checkpoint inhibitors in GI-cancer: To ride the double headed dragon

Chairs: Enrico De Toni, DE
 Yinghong Wang, US

Q+A LIVE

15:30 - 15:45 IP85

Sequential treatment of CPI ^{CASE}

Najib Ben Khaled, DE

15:45 - 16:00 IP86

CPI in GI-cancer treatment: Firing up the immune system

Enrico De Toni, DE

16:00 - 16:15

Q&A

16:15 - 16:30

IP87

Adverse autoimmune reaction: And extinguishing the blaze

Malek Shatila, US

16:30 - 16:45

IP88

Adverse autoimmune reaction

Yinghong Wang, US

16:45 - 17:00

Q&A

Nurse Programme

15:30 - 17:00

Lehar 2

Education: New approaches for improving nursing skills

Chairs: Siiri Maasen, EE

Tatjana Gjergek, SI

Q+A LIVE

15:30 - 15:50

IP89

Experience with virtual reality in training: An interview with the developers

Monika Engelke, DE

Alexander Hann, DE

15:50 - 16:10

IP90

Quality of life in Barrett patients: What nurses need to know?

Mirjam van der Ende, NL

16:10 - 16:30

IP91

Recruitment and retention of staff

Fanny Durand, FR

16:30 - 17:00

IP92

The effect of a structured training programme: Hybrid PEG by nurses increase patient safety

Jorgert Kishta, DE

Nurse Programme

15:30 - 17:00

Lehar 3

Advanced roles: Nurses' missions in endoscopy

Chairs: Mario Gazic, HR

Denise Schäfer, AT

Q+A LIVE

15:30 - 15:50

IP93

Nurse led Capsule endoscopy service

Deepa Jegadish Gandhi, IE

15:50 - 16:10

IP94

Nurse endoscopist bowel cancer screening: A possible future pilot in Italy

Tommaso Tassinari, GB

16:10 - 16:30

IP95

The PEG Team: A new advance role for nursing in endoscopy

Chiara Marinello, DE

16:30 - 17:00

IP96

The role of the nurse in the care of dysphagia patients

Lien Timmermans, BE

Industry Symposia

17:30 - 18:30

C1

Most Patients with Ulcerative Colitis 'Can't Wait': The Impact and Clinical Assessment of Bowel Urgency

Q+A LIVE

Scientific Programme by Day Sunday, October 9, 2022

PGT: Session

08:00 – 09:30 D3
Acute severe ulcerative colitis (ASUC): Can we do better?
 Chairs: Pascal Juillerat, CH
 Henit Yanai, IL

Q+A LIVE

08:00 - 08:30 IP97
Epidemiology, differential diagnosis and medical management of ASUC
 Christian Selinger, GB

08:30 - 09:00 IP98
Rescue treatments and JAK-inhibitors: A new hope ?
 Alessandro Armuzzi, IT

09:00 - 09:10 IP99
Optimising colectomy outcome: Gastroenterological view
 Carmen Stefanescu, FR

09:10 - 09:20 IP100
Optimising colectomy outcome: Surgical view
 Yves Panis, FR

09:20 - 09:30
Q&A

PGT: Session

08:00 – 09:30 A3
Acute lower GI bleeding management
 Chairs: Ian Mark Gralnek, IL
 Cesare Hassan, IT

Q+A LIVE

08:00 - 08:25 IP101
Acute Severe Hematochezia: Initial evaluation and management
 Ian Mark Gralnek, IL

08:25 - 08:40 IP102
Endoscopic therapies: What's in your toolbox?
 Marine Camus, FR

08:40 - 08:55 IP103
The role of the interventional radiologist
 Max Seidensticker, DE

08:55 - 09:10
Q&A

09:10 - 09:30 IP104
Is there any role for surgery?
 Mahdi Al-Taher, NL

PGT: Session

08:00 – 09:30 C1
On our way to healing HCC
 Chairs: Bertram Bengsch, DE
 Jordi Bruix, ES

Q+A LIVE

08:00 - 08:20 IP105
HCC: From current clinical standard to central open questions
 Jordi Bruix, ES

08:20 - 08:35 IP106
Clinical implications of molecular profiles of HCC
 Valerie Paradis, FR

08:35 - 08:50 IP107
Clinical implications of immunological profiles of HCC
 Bertram Bengsch, DE

08:50 - 09:00
Q&A

09:00 - 09:30 IP108
Immunotherapy of HCC 2022: Benefits and limitations
 Maria Reig, ES

PGT: Session

08:00 – 09:30 D4
Don't be stuck in the small bowel: Stage, scope and treat!
 Chairs: Cristiano Spada, IT
 Stuart Taylor, GB

Q+A LIVE

08:00 - 08:10 IP109
Finding small bowel Crohn's disease: Scope or scan? Radiology techniques
 Isabelle de Kock, BE

08:10 - 08:20 IP110
Finding small bowel Crohn's disease: Scope or scan? Endoscopy techniques
 Uri Kopylov, IL

08:20 - 08:30
Q&A

08:30 - 08:40 IP111
How to find and stop the bleeding? Radiological diagnosis and treatment
 Florian Wolf, AT

08:40 - 08:50 IP112
How to find and stop the bleeding? Endoscopic diagnosis and treatment
 Xavier Dray, FR

08:50 - 09:00
Q&A

09:00 - 09:30 IP113
How do we remove things that should not be there?
 Edward J Despott, GB

PGT: Session

08:00 – 09:30 Strauss 3
Like rolling stones: Standards and perspectives for biliary stone management
 Chairs: Livia Archibugi, IT
 Alexander Arlt, DE

Q+A LIVE

08:00 - 08:30 IP114
Diagnosis and therapy of biliary stones: When and how?
 Marianna Signoretti, IT

08:30 - 09:00 IP115
ERCP stone removal: Standard and beyond
 Henrike Lenzen, DE

09:00 - 09:10 IP117
Gallbladder stones and cholecystitis: Surgery
 Dejan Radenkovic, RS

09:10 - 09:20 IP116
Gallbladder stones and cholecystitis: Advanced endoscopic options
 Andrea Anderloni, IT

09:20 - 09:30
Q&A

Nurse Programme

08:00 – 09:30 Lehar 2
Management of endoscopy units: Focus on health and safety
 Chairs: Marjon De Pater-Godhelp, NL
 Rafael Santos Oliveira, PT

Q+A LIVE

08:00 - 08:25 IP118
Experiences of sexual harassment in the workplace
 Leigh Donnelly, GB

08:25 - 08:50 IP119
Endoscopy nurse led triage of referrals and waiting list management
 Lindsey Kelsall, GB

08:50 - 09:10 IP120
Free paper: Multidisciplinary approach for functional complaints after oesophageal and gastric cancer surgery
 Chantal t´Hoen, NL

09:10 - 09:30 IP121
Free paper: CHKS accreditation and ISO 9001 certification of an endoscopy unit
 Filomena Laurinda Barbosa Da Silva Maia, PT

Nurse Programme

08:00 – 09:30 Lehar 3
Staff and patient safety
 Chairs: Yuri Guriel, IL
 Hilde Willekens, BE

Q+A LIVE

08:00 - 08:25 IP122
Sedation in GI endoscopy 2022: Similarities and differences in Europe
 Andrea Riphaus, DE

08:25 - 08:45 IP123
Take a break: How to implement sign-in, team time-out and sign-out in daily routine
 Ulrike Beilenhoff, DE

08:45 - 09:10 IP124
Patient safety in endoscopy: What distinguishes professional care
 Michlin Alexander, IL

09:10 - 09:30 IP125
My back, my shoulder, my fingers: Health problems in endoscopy and how to manage it
 Gerlinde Weilguny-Schöfl, AT

Common Interest Group

08:00 – 11:00 Lehar 4
Optimizing Stool banking and Microbiota Therapy

Live Demo

08:00 – 17:30 Stolz 1-2, Foyer
Endoscopy Learning Area & Ultrasound Learning Area

Common Interest Group

08:00 – 10:00 Schubert
European Interdisciplinary Guideline on the Diagnosis and Therapy of Pancreatic Exocrine Insufficiency

TV Studio Session

09:00 – 09:30 TV Studio
Good Morning UEG Week
 Chairs: Axel Dignass, DE
 Matthias Löhr, SE
 Dina Tiniakos, GB

Q+A LIVE

Poster Exhibition

09:00 – 17:30 Science Lounge
Small intestinal

09:00 - 09:00	P0151	09:00 - 09:00	P0161
APRAGLUTIDE DOES NOT IMPACT ANTI-TUMOR AND IMMUNOSUPPRESSIVE EFFICACY OF CONDITIONING CHEMOTHERAPY IN MICE		SMALL INTESTINAL BACTERIAL OVERGROWTH (SIBO) IS ASSOCIATED WITH LIVER FIBROSIS AND INFLAMMATION	
Barbara Biemans, CH		Jutta Keller, DE	
09:00 - 09:00	P0152	09:00 - 09:00	P0162
QUANTITATIVE MAGNETIC RESONANCE ENTEROGRAPHY SHOWS EVIDENCE OF TREATMENT RESPONSE IN PEDIATRIC SMALL BOWEL CROHN'S DISEASE: A PROSPECTIVE STUDY		CLINICAL CHARACTERISTICS OF PATIENTS REFERRED FOR SUSPECTED SMALL INTESTINE BACTERIAL OVERGROWTH EVALUATED WITH BREATH TEST	
Alex Menys, GB		Ernesto Lastiri, ES	
09:00 - 09:00	P0153	09:00 - 09:00	P0163
ANALYSIS OF BLOOD AND FECAL INTESTINAL MICROBIOTA FOCUSING ON ENDOTOXIN IN PATIENTS WITH CHRONIC IDIOPATHIC INTESTINAL-PSEUDO OBSTRUCTION		CLINICAL EFFECTIVENESS OF GLUTEN IMMUNOGENIC PEPTIDES DURING FOLLOW-UP OF CELIAC DISEASE	
Tomoki Ogata, JP		Irene Latras Cortés, ES	
09:00 - 09:00	P0154	09:00 - 09:00	P0164
THE DIAGNOSTIC CAPABILITIES OF NON-INVASIVE FECAL BIOMARKERS OF NSAID-INDUCED INTESTINAL LESIONS IN PATIENTS WITH OSTEOARTHRITIS		IMPACT OF EPITHELIAL LYMPHOGRAM BY FLOW CYTOMETRY IN THE MANAGEMENT OF PREVIOUS INCONCLUSIVE DIAGNOSES OF CELIAC DISEASE	
Andrii Kuzminets, UA		M Pilar Navarro Sánchez, ES	
09:00 - 09:00	P0155	09:00 - 09:00	P0165
A PHASE 1, OPEN-LABEL EVALUATION OF THE PHARMACOKINETICS AND SAFETY OF A SINGLE DOSE OF APRAGLUTIDE IN SUBJECTS WITH NORMAL AND IMPAIRED RENAL FUNCTION		COMPARISON OF OUTCOMES BETWEEN DIRECT OR STRUCTURED PEDIATRIC-TO-ADULT HEALTHCARE TRANSITION IN COELIAC DISEASE	
Nader N. Youssef, CH		Fabiana Zingone, IT	
09:00 - 09:00	P0156	09:00 - 09:00	P0166
NATURAL HISTORY OF CHRONIC INTESTINAL PSEUDO-OBSTRUCTION AND NEED FOR PALLIATIVE CARE		VACCINATION STATUS AND ATTITUDES TOWARDS VACCINES AMONG PATIENTS WITH COELIAC DISEASE	
Kosuke Tanaka, JP		Andrea Costantino, IT	
09:00 - 09:00	P0157	09:00 - 09:00	P0167
EFFICACY AND SAFETY OF RIFAXIMIN FOR PATIENTS WITH CHRONIC INTESTINAL PSEUDO-OBSTRUCTION: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2A TRIAL		LIVER ABNORMALITIES IN CELIAC DISEASE AND RESPONSE TO GLUTEN FREE DIET: A SYSTEMATIC REVIEW AND META-ANALYSIS	
Takaomi Kessoku, JP		Rihab Limam, TN	
09:00 - 09:00	P0158	09:00 - 09:00	P0168
EVALUATION OF INTESTINAL PERMEABILITY TESTING AS BIOMARKER FOR ADAPTIVE RESPONSE IN SHORT BOWEL SYNDROME		THE HEPATOBILIARY DISORDERS IN COELIAC DISEASE	
Janine Büttner, DE		Rihab Limam, TN	
09:00 - 09:00	P0159	09:00 - 09:00	P0169
IMPACT OF FOOD INTAKE ON THE EFFICACY OF TEDUGLUTIDE TREATMENT IN ADULT PATIENTS WITH SHORT BOWEL SYNDROME		NUTRITIONAL STATUS, NUTRIENTS IMBALANCES, FOOD-RELATED BEHAVIORS AND DIETARY SUPPLEMENTS USE AMONG PATIENTS WITH CELIAC DISEASES IN LEBANON: A NATIONAL CROSS-SECTIONAL STUDY	
Brune de Dreuille, FR		Malek-Michael Bouhairie, LB	
09:00 - 09:00	P0160	09:00 - 09:00	P0170
HOW LONG-TERM PROTON PUMP INHIBITOR THERAPY AFFECTS THE GUT MICROBIOTA - A SINGLE-CENTER EXPERIENCE		QUALITY OF LIFE IN TEENAGERS AND ADULTS WITH COELIAC DISEASE: FROM NEWLY SPANISH COELIAC DISEASE QUESTIONNAIRE VALIDATION TO ASSESSMENT IN A POPULATION-BASED STUDY	
Daniele Salvi, IT		Diego Sanchez Munoz, ES	
		09:00 - 09:00	P0171
		CLINICAL PRESENTATION AND PROGNOSIS OF SMALL BOWEL ADENOCARCINOMA IN CELIAC DISEASE PATIENTS	
		Olivier Chatelanat, FR	
		09:00 - 09:00	P0172
		DIAGNOSTIC YIELD OF CAPSULE ENDOSCOPY AND ENTEROSCOPY IN THE DIAGNOSIS OF INTESTINAL LYMPHOMA IN REFRACTORY CELIAC DISEASE TYPE 2 PATIENTS	
		Olivier Chatelanat, FR	

09:00 - 09:00 P0173
DUAL X-RAY ABSORPTIOMETRY-DERIVED BONE QUALITY INDEXES IN CELIAC DISEASE
 Nicoletta Nandi, IT

09:00 - 09:00 P0174
COELIAC DIAGNOSIS IN OLDER ADULTS: DOES AGE REALLY MATTER?
 Olga Fagan, IE

09:00 - 09:00 P0175
COELIAC DISEASE (CD) AND CHRONIC INFLAMMATORY BOWEL DISEASE (IBD) ASSOCIATION
 Driss Azzouzi, MA

09:00 - 09:00 P0176
CELIAK DISEASE: AN UNUSUAL CAUSE OF PORTAL HYPERTENSION
 Ibtissam Khalif, MA

09:00 - 09:00 P0177
THE USE OF NO-BIOPSY APPROACH FOR DIAGNOSING CHILDREN WITH COELIAC DISEASE IS INCREASING
 Tomaz Krencnik, SI

09:00 - 09:00 P0178
NUTRITIONAL STATUS ASSESSMENT IN COELIAC DISEASE
 Daria Maniero, IT

09:00 - 09:00 P0179
GENES AND GENOTYPES IN CELIAC DISEASE
 Roxana Nemteanu, RO

09:00 - 09:00 P0180
USEFULNESS OF INTESTINAL ANTI-ENDOMYSIUM ANTIBODIES IN THE DIAGNOSIS OF CELIAC DISEASE IN ADULTHOOD
 Fabio Monica, IT

09:00 - 09:00 P0181
THE KNOWLEDGE ABOUT COELIAC DISEASE AMONG HEALTHCARE PROFESSIONALS IS NOT SATISFACTORY IN THE DANUBE REGION
 Tomaz Krencnik, SI

09:00 - 09:00 P0182
IMMUNE RESPONSES TO COVID-19 VACCINES IN CELIAC DISEASE
 Jostein Holen Ibsen, NO

09:00 - 09:00 P0183
IS THE GLUTEN-FREE DIET A RISK FACTOR FOR FATTY LIVER DISEASE IN CELIAC DISEASE?
 Asma Ben Mohamed, TN

09:00 - 09:00 P0184
PREVALENCE AND CHARACTERISTICS OF PEOPLE AVOIDING GLUTEN WITHOUT CELIAC DISEASE: A LONG-TERM POPULATION-BASED FOLLOW-UP STUDY
 Juha Taavela, FI

09:00 - 09:00 P0185
SMALL INTESTINAL NEUROENDOCRINE NEOPLASMS WITH PANCREATIC METASTASES
 Anna Caterina Milanetto, IT

09:00 - 09:00 P1026
DISTINCTIVE ENDOSCOPIC FINDINGS PREDICT THE PROGRESSION OF PRIMARY SMALL-BOWEL FOLLICULAR LYMPHOMA
 Akihiko Sumioka, JP

09:00 - 09:00 P0186
HEMORRHAGE POTENTIAL OF SMALL BOWEL ANGIOECTASIAS: CORRELATION WITH HAEMOGLOBIN VALUES
 Tiago Lima Capela, PT

09:00 - 09:00 P0187
CRYPTOGENIC MULTIFOCAL ULCERO-STENOSING SMALL BOWEL ENTEROPATHY (CMUSE): DOES IT EXIST IN CHILDREN?
 Arghya Samanta, IN

09:00 - 09:00 P1033
ASSOCIATION BETWEEN EUPATILIN AND THE REDUCTION OF SMALL BOWEL BLEEDING IN ASPIRIN USERS: A POPULATION-BASED COHORT STUDY USING NATIONWIDE DATABASE OF NATIONAL CLAIM DATA IN KOREA

Poster Exhibition

09:00 - 17:30 Science Lounge
 Clinical cases

09:00 - 09:00 CC001
EOSINOPHILIC GASTRITIS IN A ULCERATIVE COLITIS PATIENT TREATED WITH ADALIMUMAB
 Julia López Cardona, ES

09:00 - 09:00 CC002
OCCULT GASTROINTESTINAL BLEEDING AS A MANIFESTATION OF CYTOMEGALOVIRUS GASTRITIS IN AN IMMUNOCOMPETENT HOST

09:00 - 09:00 CC003
UNUSUAL DIAGNOSIS IN A PATIENT WITH DYSPEPSIA
 Isabel Garrido Garrido, PT

09:00 - 09:00 CC004
ACQUIRED TRACHEOESOPHAGEAL FISTULA-CASE REPORT
 Violeta Hristova Janik, MK

09:00 - 09:00 CC005
DUODENAL OBSTRUCTION DUE TO STRONGYLOIDES STERCORALIS INFECTION
 Ana Rita Franco, PT

09:00 - 09:00 CC006
A RARE PATHOGEN IN THE STOMACH BLAMED FOR DELAYED GASTRIC EMPTYING
 Isabel Garrido Garrido, PT

09:00 - 09:00 CC007
HEMOSUCCUS PANCREATICUS AS A RARE CAUSE OF RECURRENT PANCREATITIS
 Ignacio Blanco Nodal, ES

09:00 - 09:00	CC008	09:00 - 09:00	CC021
A FATAL CASE REPORT OF ACUTE ESOPHAGEAL NECROSIS SECONDARY TO PERFORATED DUODENAL TUMOR		PSEUDOACHALASIA – MEETING AN OLD FRIEND	
Kaouthar Rais, MA		Sofia Bragança, PT	
09:00 - 09:00	CC009	09:00 - 09:00	CC022
A CHILD WITH MASSIVE UPPER GI BLEED: EXPECT THE UNEXPECTED		SEVERE ESOPHAGEAL DYSMOTILITY IN A PATIENT WITH LONG COVID-19. A UNIQUE CASE REPORT	
Deepak Johnson, IN		Ali Al-Adhami, GB	
09:00 - 09:00	CC010	09:00 - 09:00	CC023
A CASE OF LIFE THREATENING ACUTE UPPER GASTROINTESTINAL BLEEDING WITH AN ANOMALOUS BLOOD SUPPLY: THE DANGERS OF A CONGENITALLY ABSENT SPLENIC ARTERY		ESOPHAGEAL MALT LYMPHOMA, AN UNKNOWN ENEMY DUE TO ITS RARITY	
Sabir Hossain, GB		María del Mar Díaz Alcázar, ES	
09:00 - 09:00	CC011	09:00 - 09:00	CC024
HEMOSTATIC SPRAY AS THERAPY OF PANCREATIC STUMP BLEEDING AFTER CEPHALIC DUODENOPANCREATECTOMY		TRACHEOESOPHAGEAL FISTULA AS A RARE COMPLICATION AFTER SELF-EXPANDABLE METAL STENT INSERTION FOR TREATMENT OF MALIGNANT ESOPHAGEAL CARCINOMA	
Daniela Falcão, PT		Santa Ivanova, LV	
09:00 - 09:00	CC012	09:00 - 09:00	CC025
BLACK ESOPHAGUS: A CASE OF ACUTE ESOPHAGEAL NECROSIS IN A PATIENT POST-CORONARY ARTERY BYPASS		SPONTANEOUS RESOLUTION OF CHOLECYSTODUODENAL FISTULA SECONDARY TO DUODENAL ULCER	
Nikko Theodore Raymundo, PH		Emanuel Dias, PT	
09:00 - 09:00	CC014	09:00 - 09:00	CC026
RECURRENT UPPER GI BLEEDING IN A CASE OF HAEMOBILIA DUE TO ARTERIO-BILIARY FISTULA		GASTRIC ULCER WITH LIVER PENETRATION	
Ahmed Alzamzamy, EG		Emanuel Dias, PT	
09:00 - 09:00	CC015	09:00 - 09:00	CC027
AN UNEXPECTED ENDOSCOPIC FINDING OF UPPER GASTROINTESTINAL BLEEDING		A CASE OF SYNCHRONOUS MULTIPLE ADVANCED GASTRIC CARCINOMA WITH HER2-POSITIVE AND NEGATIVE	
Anastasios Koutsoumourakis, GR		Tomohiro Kurokawa, JP	
09:00 - 09:00	CC016	09:00 - 09:00	CC028
A CASE OF DUODENAL DIVERTICULAR PERFORATION TREATED CONSERVATIVELY: JUDGING THE INDICATIONS FOR SURGICAL TREATMENT		A CHALLENGING ALPHA-FETOPROTEIN AFTER LIVER TRANSPLANTATION	
Yuri Sasaki, JP		Emanuel Dias, PT	
09:00 - 09:00	CC017	09:00 - 09:00	CC029
BLACK ESOPHAGUS IN A PATIENT WITH SCHIZOPHRENIA		DIAGNOSTIC VALUE OF ENDOSCOPIC ULTRASOUND (EUS) GUIDED FINE NEEDLE BIOPSY (FNB) FOR DIFFUSE GASTRIC CARCINOMA	
Irgen Tafaj, AL		Ruxandra Georgeta Mare, RO	
09:00 - 09:00	CC018	09:00 - 09:00	CC030
ESOPHAGEAL VARICEAL BLEEDING IN A 10-YEARS-OLD GIRL AS A COMPLICATION OF NEONATAL UMBILICAL CATHETERIZATION – A CASE REPORT IN COVID-19 PANDEMIC		PRIMARY GASTRIC CHORIOCARCINOMA COEXISTING WITH GASTRIC ADENOCARCINOMA WITH ENTEROBLASTIC DIFFERENTIATION	
Alessandro Cantone, IT		Emanuel Dias, PT	
09:00 - 09:00	CC019	09:00 - 09:00	CC031
DYSPEPSIA AS PRESENTATION OF AN INCIDENTAL CASE OF EXTRAPULMONARY TUBERCULOSIS		A RARE CASE OF EXTENSIVE FUNDIC GLAND POLYPOSIS ASSOCIATED WITH PROTON PUMP INHIBITOR THERAPY	
Abdul Gany Mussagi, MZ		Francis Teh, SG	
09:00 - 09:00	CC020	09:00 - 09:00	CC032
IMMUNE CHECKPOINT INHIBITOR INDUCED GASTROPARESIS		AN UNUSUAL TUMOR AND ITS PRESENTATION IN A YOUNG ADULT	
Maryam Alahmad, AE		Tania Carvalho, PT	
		09:00 - 09:00	CC033
		A RARE CASE PRESENTATION: PREGNANCY AND GASTRIC CARCINOMA	
		Luís Relvas, PT	

09:00 - 09:00 CC034
SUCCESSFUL PRIMARY CLOSURE AFTER ENDOSCOPIC RESECTION OF DUODENAL SUBEPITHELIAL LESION HISTOLOGICALLY PROVEN TO NEUROENDOCRINE TUMOR USING THE PURSE-STRING TECHNIQUE

Ga Ram You, KR

09:00 - 09:00 CC035
WIDESPREAD PRIMARY GASTROINTESTINAL KAPOSÍ'S SARCOMA

Tiago Ribeiro, PT

09:00 - 09:00 CC036
PRIMARY ADENOCARCINOMA OF THE FOURTH PORTION OF DUODENUM. A CASE REPORT

Stela Taci, AL

09:00 - 09:00 CC037
A CASE OF ISOLATED MICROGASTRIA IN A 22 MONTHS CHILD TREATED WITH REPEATED SESSIONS OF ENDOSCOPIC BALLOON DILATION

Mohamed Sarhan, EG

09:00 - 09:00 CC038
RECURRENT ABDOMINAL PAIN AS AN ISOLATED MANIFESTATION OF ACQUIRED ANGIOEDEMA – A RARE CLINICAL PRESENTATION

Deema ALSoub, QA

09:00 - 09:00 CC039
A RARE CAUSE OF ABDOMINAL PAIN: A SCARCE DISEASE IN A "NEW" ORGAN, TO BE CONSIDERED

Sara Archer, PT

09:00 - 09:00 CC041
SCHISTOSOMIASIS -A RARE CAUSE OF ISOLATED TERMINAL ILEAL STRICTURE

Kamran Mushtaq, QA

09:00 - 09:00 CC042
TREATMENT OF REFRACTORY CELIAC DISEASE TYPE 1 WITH VEDOLIZUMAB - PRESENTATION OF TWO CASES

Knut E.A. Lundin, NO

09:00 - 09:00 CC043
LYMPHOCYTIC GASTRITIS: CELIAC INVOLVEMENT BEYOND THE SMALL BOWEL

María del Mar Díaz Alcázar, ES

09:00 - 09:00 CC044
ULCERATIVE JEJUNITIS - 2 OVERLAPPING ENTITIES

Fátima Nélia Abreu, PT

09:00 - 09:00 CC045
ACUTE INTESTINAL INVAGINATION REVEALING COELIAC DISEASE

Yasmine Fetati, TN

09:00 - 09:00 CC046
SMALL-BOWEL VILLOUS ATROPHY IN A YOUNG AFGHAN PATIENT – A CHALLENGING DIAGNOSIS

Joao Paulo Laranjeira Correia, PT

09:00 - 09:00 CC047
ANAL HIGHWAY TO THE MOUTH : GASTROJEJUNOCOLIC FISTULA AFTER BILLROTH II

Jennifer Aoun, BE

09:00 - 09:00 CC048
IRON DEFICIENCY ANEMIA: WHEN TO REPEAT ENDOSCOPIC STUDIES?

Raquel R. Mendes, PT

09:00 - 09:00 CC049
SYNCHRONOUS SMALL BOWEL ADENOCARCINOMAS IN A PATIENT WITH LYNCH SYNDROME PRESENTING WITH IRON DEFICIENCY ANEMIA

Ana Rita Franco, PT

09:00 - 09:00 CC050
A RARE DUODENAL POLYP: FOVEOLAR ADENOMA

Margarida Rajão Saraiva, PT

09:00 - 09:00 CC051
MILD GASTROINTESTINAL BLEEDING: ATYPICAL ETIOLOGY AND APPROACH

Sónia Barros, PT

09:00 - 09:00 CC052
UNEXPECTED UPPER GASTROINTESTINAL BLEEDING AFTER DUODENOPANCREATECTOMY

María del Mar Díaz Alcázar, ES

09:00 - 09:00 CC053
A RARE CAUSE OF ACUTE MESENTERIC THROMBOSIS - A CLINICAL CASE

Juliana Serrazina, PT

09:00 - 09:00 CC054
BEVACIZUMAB IN OSLER WEBER RENDU SYNDROME - A LIFE'S CHANGING THERAPEUTIC

Luís Correia Gomes, PT

09:00 - 09:00 CC055
COEXISTING EVANS' SYNDROME AND CROHN'S DISEASE

Bea Regine Panganiban, PH

09:00 - 09:00 CC056
A RARE CASE OF SECUKINUMAB-ASSOCIATED ULCERATIVE COLITIS IN A PATIENT WITH SARCOIDOSIS

Isabel Garrido Garrido, PT

09:00 - 09:00 CC057
A CHALLENGING DIAGNOSIS OF CROHN'S DISEASE

Sofia Ventura, PT

09:00 - 09:00 CC058
MID-GASTROINTESTINAL BLEEDING DUE TO ARTERIOVENOUS MALFORMATION OF THE JEJUNUM

Fernando Berdugo-Hurtado, ES

09:00 - 09:00 CC059
TERMINAL ILEUM MALT LYMPHOMA IN A PATIENT WITH CROHN'S DISEASE - A TROUBLESOME SITUATION

Joao Paulo Laranjeira Correia, PT

09:00 - 09:00 CC060
NEW ONSET OF IBD IN A PATIENT AFFECTED BY SEVERE PSORIASIS: A CASE OF SECONDARY FAILURE TO USTEKINUMAB SUCCESSFULLY TREATED WITH RISANKIZUMAB

Davide Giuseppe Ribaldone, IT

09:00 - 09:00 CC061
CASE REPORT: SIMULTANEOUS INTESTINAL HISTOPLASMOSIS AND PERITONEAL TUBERCULOSIS IN A PATIENT RECEIVING INFlixIMAB

Aitana Aurelie Valencia, MX

09:00 - 09:00 CC062
HYPERBARIC OXYGEN THERAPY IN COMBINATION WITH USTEKINUMAB ACHIEVED FISTULA HEALING IN A YOUNG PATIENT WITH SEVERE REFRACTORY PERIANAL CROHN'S DISEASE

Wen Hao Justin Leong, SG

09:00 - 09:00 CC063
PRIMARYTESTICULAR DIFFUSE LARGE B-CELL LYMPHOMA FOLLOWING VEDOLIZUMAB INDUCTION THERAPY FOR ULCERATIVE COLITIS

Ana Catarina Carvalho, PT

09:00 - 09:00 CC064
SCREENING FOR LATENT TUBERCULOSIS IN INFLAMMATORY BOWEL DISEASE – WILL IT BE ENOUGH?

Margarida Gomes Gonçalves, PT

09:00 - 09:00 CC065
SUCCESS OF DUAL BIOLOGICAL THERAPY IN REFRACTORY POST-SURGICAL PENETRATING CROHN'S DISEASE

Cristina manzotti, IT

09:00 - 09:00 CC066
SECUKINUMAB INDUCED ULCERATIVE COLITIS IN A PATIENT WITH PSORIASIS AND SUBSEQUENT MANAGEMENT

Muhammad Taha Khan, GB

09:00 - 09:00 CC067
VARICELLA ZOSTER VIRUS ENCEPHALITIS: A POTENTIALLY SERIOUS COMPLICATION DURING TREATMENT WITH VEDOLIZUMAB

Marta Garcia-Calonge, ES

09:00 - 09:00 CC068
MICHELASSI STRICTUREPLASTY - RESULTS ON AN EFFECTIVE BOWEL-SPARING TECHNIQUE IN CROHN'S DISEASE

João A. Cunha Neves, PT

09:00 - 09:00 CC069
TOFACITINIB AS A TREATMENT FOR REFRACTORY IMMUNE CHECKPOINT INHIBITOR-INDUCED ENTEROCOLITIS

José Requena de Torre, ES

09:00 - 09:00 CC070
INMUNE-MEDIATED COLITIS IN A PACIENT WITH ULCERATIVE COLITIS IN THE CONTEXT OF STAGE IV PULMONARY NEOPLASM TREATED WITH PEMBROLIZUMAB

Ariadna Altadill, ES

09:00 - 09:00 CC071
A CASE OF PAN-COLONIC INFLAMMATION CAUSED BY THE INTENTIONAL RECTAL ADMINISTRATION OF AN METHAMPHETAMINE ENEMA

Lushen Pillay, GB

09:00 - 09:00 CC072
MIGRATORY INTESTINAL STENOSIS BY PRIMARY INTESTINAL AMYLOIDOSIS. A CASE REPORT

Belen Garcia Sague, ES

09:00 - 09:00 CC073
SEQUELAE AFTER AN UNNOTICED ACUTE GASTROENTERITIS: GASTROPARESIS AND SUBOCCLUSIVE SYNDROME DUE TO POSTVIRAL DYSAUTONOMIA

María del Mar Díaz Alcázar, ES

09:00 - 09:00 CC074
RARE CASE OF ISOLATED PERITONEAL CYSTIC ECHINOCOCCOSIS IN A 33-YEAR-OLD MALE PATIENT

Caroline Schwarz, AT

09:00 - 09:00 CC075
WHEN A PHOTO WORTHS MORE THAN A PARASITOLOGICAL CULTURE

Luís Correia Gomes, PT

09:00 - 09:00 CC076
COLITIS AS THE MAIN PRESENTATION OF COVID-19: A CASE REPORT

Vlasta Orsic Fric, HR

09:00 - 09:00 CC077
PARADOXICAL DETERIORATION IN INTESTINAL TUBERCULOSIS; A RARE COMPLICATION OF AN INCREASING PATHOLOGY

Isabel Cacho Soblechero, ES

09:00 - 09:00 CC079
A RARE CAUSE OF LOWER DIGESTIVE BLEEDING

Diana Ramos Silva, PT

09:00 - 09:00 CC080
ULCERATED POLYPOIDAL LESION IN RECTUM: NOT ALWAYS A MALIGNANCY

Arghya Samanta, IN

09:00 - 09:00 CC081
A RARE CAUSE OF HEMATOCHYZIA: LARGE SUBMUCOSAL METASTATIC MELANOMA TO THE RECTUM

Afroditi Orfanidou, GR

09:00 - 09:00 CC082
RECTAL MASS SECONDARY TO RECTAL ISCHEMIA – CASE REPORT

Montri Gururatsakul, TH

09:00 - 09:00 CC083
RARE TUMOUR OF THE RECTUM: HOW TO APPROACH IT?

Margarida Rajão Saraiva, PT

09:00 - 09:00 CC084
A CASE OF DISSEMINATED CARCINOMATOSIS OF BONE MARROW AS THE FIRST PRESENTATION OF RELAPSE CURATIVELY RESECTED RECTAL CANCER– IMMUNOHISTOCHEMICAL ANALYSIS OF THE DISTRIBUTION OF RANKL

Yoshitaka Shimada, JP

09:00 - 09:00 CC085
PERIANAL PAGET'S DISEASE - A RARE DIAGNOSIS

Sofia Ventura, PT

09:00 - 09:00 CC086
SIGNET RING CELL CARCINOMA OF THE COLON: A RARE CAUSE OF IRON DEFICIENCY ANEMIA AT YOUNG AGE
 Asmaa Gameel, EG

09:00 - 09:00 CC087
CHRONIC LIMPLOCITIC LEUKEMIA INFILTRATION IN COLONIC ADENOMA: A CASE REPORT
 Annalisa de Leone, IT

09:00 - 09:00 CC088
A CHALLENGING CASE OF LYNCH SYNDROME AND THE FEASIBILITY OF ENDOSCOPIC SUBMUCOSAL DISSECTION IN LESIONS INVOLVING SURGICAL ANASTOMOSIS
 Raquel R. Mendes, PT

09:00 - 09:00 CC089
SACRAL OSTEOMYELITIS FOLLOWING ANASTOMOTIC LEAK IN A PATIENT TREATED FOR RECTAL CANCER
 Darren Fernandes, GB

09:00 - 09:00 CC090
UNDERWATER ENDOSCOPIC MUCOSAL RESECTION OF A REMNANT COLONIC NEOPLASM ATTACHED TO ENDOSCOPIC SUBMUCOSAL DISSECTION SCAR: A CASE REPORT
 Hyunsoo Kim, KR

09:00 - 09:00 CC091
A CHALLENGING CASE OF DILATION-ASSISTED FULL THICKNESS RESECTION THROUGH A STOMIA OF A COLONIC RESIDUAL POST-MUCOSECTOMY SCAR
 Alberto Barchi, IT

09:00 - 09:00 CC092
BEVACIZUMAB IN HEREDITARY HEMORRHAGIC TELANGIECTASIA. WHEN ALL THE TREATMENTS FAIL
 Sandra Diez Ruiz, ES

09:00 - 09:00 CC093
NUTCRACKER SYNDROME: UN USUAL CAUSE OF ABDOMINAL PAIN
 Sakina El Mamouni, MA

09:00 - 09:00 CC094
LEAD POISONING- AN ALLOCATED BULLET WITH LONG TERM CONSEQUENCES
 Jéssica Chaves, PT

09:00 - 09:00 CC095
WILSON DISEASE, WHEN THE GENETICS DOES NOT SUPPORT THE DIAGNOSIS

09:00 - 09:00 CC096
A RARE CASE OF GRANULOMATOUS HEPATITIS FOLLOWING INTRAVESICAL INSTILLATION OF BACILLUS CALMETTE-GUÉRIN
 Isabel Garrido Garrido, PT

09:00 - 09:00 CC097
CYP2D6 POLYMORPHISM MAY CONTRIBUTE TO TRAZODONE-INDUCED HEPATOTOXICITY: A RARE CASE OF IDIOSYNCRATIC DRUG-DRUG-GENE INDUCED LIVER INJURY
 Kymentie Ferdinande, BE

09:00 - 09:00 CC098
NEGATIVE WOUND VACUUM THERAPY IN FLOOD SYNDROME AS BRIDGE TO LIVER TRANSPLANT
 Renato Medas, PT

09:00 - 09:00 CC099
DEVELOPMENT OF CEREBRAL EDEMA WITH CONSEQUENT SEIZURES: RARE BUT IMPORTANT COMPLICATION OF TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) IN CIRRHOSIS
 Maryam Alahmad, AE

09:00 - 09:00 CC100
PEMBROLIZUMAB-INDUCED EXACERBATION OF HEPATITIS D
 Anna Fichtl, DE

09:00 - 09:00 CC101
GUILLAIN-BARRE SYNDROME FOLLOWING ACUTE VIRAL HEPATITIS A: A VERY UNCOMMON COMPLICATION
 María Lorena Cadena Herrera, ES

09:00 - 09:00 CC102
HEPATOBIILIARY DISORDERS IN INFLAMMATORY BOWEL DISEASE: WHAT COULD BE THE OPTIMAL MANAGEMENT WHEN PRIMARY BILIARY CHOLANGITIS PRECEDES THE ONSET OF CROHN ILEITIS? A SIXTY-SIX YEARS OLD FEMALE PATIENT CASE REPORT
 Marina Cipullo, IT

09:00 - 09:00 CC104
SYPHILITIC HEPATITIS IN A PATIENT WITH LATE LATENT SYPHILIS: A CASE REPORT
 Roxana Nemteanu, RO

09:00 - 09:00 CC105
AUTOIMMUNE HEPATITIS AFTER SARS COV-2 VACCINATION: REVIEW OF THREE CASES
 Sandra Diez Ruiz, ES

09:00 - 09:00 CC106
AUTOIMMUNE HEPATITIS FOLLOWING COVID-19 VACCINATION. A THREE-CASE REPORT
 Alessandro Caroli, IT

09:00 - 09:00 CC107
HIGH-RISK HEPATITIS: AN UNEXPECTED TURNOUT
 Margarida Rajão Saraiva, PT

09:00 - 09:00 CC108
LIVER TRANSPLANTATION DUE TO HEREDITARY TRANSTHYRETIN AMYLOIDOSIS: STILL THE BEST THERAPEUTIC OPTION EVEN WITH NORMAL LIVER?
 María del Mar Díaz Alcázar, ES

09:00 - 09:00 CC109
ENDOSONOGRAPHY GUIDED LIVER ABSCESS DRAINAGE, CASE AND NEED FOR CONSENSUS
 Shankar Zanwar, IN

09:00 - 09:00 CC110
A SUCCESSFUL INTERDISCIPLINARY MANAGEMENT OF A FULMINANT VACCINE (CHADOX1 NCOV-19) INDUCED PORTAL VEIN THROMBOSIS WITH A LONG-SEGMENT INFARCTION OF SMALL INTESTINE
 Eugen Zizer, DE

09:00 - 09:00 CC111
17Q12 MICRODELETION: A RARE ETIOLOGY OF INTRAHEPATIC CHOLESTASIS
 Tania Carvalho, PT

09:00 - 09:00 CC112
LAMBERT EATON MYASTHENIC SYNDROME AS A FIRST MANIFESTATION OF GALLBLADDER ADENOCARCINOMA – CASE REPORT
 Matus Scur, SK

09:00 - 09:00 CC113
CASE REPORT: INFLUENZA A (H1N1) PRESENTING AS SEVERE ACUTE PANCREATITIS
 Laura E Moreno Luna, MX

09:00 - 09:00 CC114
A CASE OF A COMBINED MUTATION OF R122H ON THE PRSS1 GENE AND A A1S1K MUTATION ON THE CFTR GENE HEREDITARY PANCREATITIS TREATED WITH TOTAL PANCREATECTOMY
 Navkiran Randhawa, US

09:00 - 09:00 CC115
A CASE OF PANCREATIC CARCINOMA AFTER AUTOIMMUNE PANCREATITIS TREATMENT
 Ayu Tachibana, JP

09:00 - 09:00 CC116
INDUCTION AND MAINTAINANCE OF STEROID-FREE REMISSION OVER 52 WEEKS WITH VEDOLIZUMAB IN A CASE WITH STEROID-REFRACTORY TYPE 2 AUTOIMMUNE PANCREATITIS
 Florian Tran, DE

09:00 - 09:00 CC117
INTRA ABDOMINAL PSEUDO - INFLAMMATORY TUMOR MIMICKING A PANCREATIC CYSTIC LESION
 Meryem Nasiri, MA

09:00 - 09:00 CC118
UNDIFFERENTIATED PANCREATIC CARCINOMA WITH OSTEOCLAST-LIKE CELLS – A RARE AND CHALLENGING TUMOR
 Alexandra Vilaia, RO

09:00 - 09:00 CC119
PANCREATIC ACINAR CELL CARCINOMA: A STUDY OF 4 CASES

09:00 - 09:00 CC120
OBSTRUCTIVE JAUNDICE SECONDARY TO CHILDHOOD BURKITT'S LYMPHOMA, MIMICKING PANCREATIC ADENOCARCINOMA WITH BILIARY OBSTRUCTION AND PERITONEAL CARCINOMATOSIS: A RARE CASE REPORT
 Wafaa Khannoussi, MA

09:00 - 09:00 CC121
ATYPICAL INITIAL PRESENTATION OF CROHN'S DISEASE: INFLAMMATORY AMPULLARY PSEUDOTUMOR CAUSING OBSTRUCTION OF THE COMMON BILE DUCT – A CASE REPORT AND REVIEW OF THE LITERATURE OF PSEUDOTUMORS LINKED TO CROHN'S DISEASE
 Malek-Michael Bouhairie, LB

09:00 - 09:00 CC122
A CASE OF UNRESECTABLE LOCALLY ADVANCED PANCREATIC CANCER SUCCESSFULLY RESECTED BY COMBINING CHEMOTHERAPY AND HIFU THERAPY
 Atsushi Sofuni, JP

09:00 - 09:00 CC123
CENTRAL PANCREATECTOMY IN SURGICAL TREATMENT OF PANCREATIC INSULINOMA - A CASE REPORT
 Uros Milosevic, RS

09:00 - 09:00 CC124
ENDOSCOPIC CLOSURE OF A PERSISTENT GASTROGASTRIC FISTULA FOLLOWING GASTROSTOMY TUBE REMOVAL USING COMBINATION THERAPY WITH AN *OVER-THE-SCOPE* DEVICE AND *THROUGH THE SCOPE (TTS)* CLIPS: A CASE REPORT
 Daniel Zúñiga, CR

09:00 - 09:00 CC125
A CASE OF POST-GASTRECTOMY ANASTOMOTIC LEAKAGE REFRACTORY TO ENDOSCOPIC VACUUM THERAPY, SAVED BY COVERED ESOPHAGEAL STENTING
 Alberto Barchi, IT

09:00 - 09:00 CC126
CURATIVE ENDOSCOPIC SUBMUCOSAL DISECTION NON-DIFFERENTIATED GASTRIC CANCER USING POCKET CREATION METHOD AT THE PATIENT WITH A PRIMERY BILIARY LIVER CIRRHOSIS
 Kiosov Oleksandr, UA

09:00 - 09:00 CC127
A CHALLENGING CASE OF ENDOSCOPIC CLOSURE OF PERSISTENT GASTROGASTRIC FISTULAE
 Isabel Garrido Garrido, PT

09:00 - 09:00 CC128
A STONE IN THE ROAD
 Inês Rodrigues, PT

09:00 - 09:00 CC129
TWO-STAGED APPROACH FOR MANAGEMENT OF A COMPLEX INTRA-THORACIC ESOPHAGOGASTRIC ANASTOMOTIC DEHISCENCE
 Juliana Serrazina, PT

09:00 - 09:00 CC130
ECTOPIC SEBACEOUS GLANDS OF ESOPHAGUS - A POSSIBLE LINK WITH REFLUX ESOPHAGITIS?

09:00 - 09:00 CC131
A RARE CASE OF LYMPHOCYTIC ESOPHAGITIS IN A WOMAN WITH SJÖGREN'S SYNDROME
 Vibor Šeša, HR

09:00 - 09:00 CC132
GASTRIC CROHN'S: A RARE CAUSE OF INTERMITTENT ABDOMINAL PAIN
 Ahmed Altonbary, EG

09:00 - 09:00 CC133
ESOPHAGEAL PERFORATION BY A FOREIGN BODY – TECHNICAL CHALLENGE AND ENDOSCOPIC SUCCESS
 Ricardo Rios Crespo, PT

09:00 - 09:00 CC134
AN INFREQUENT CASE OF HIGH-GRADE CAUSTIC ESOPHAGITIS AND ITS COMPLICATIONS
 Isabel Carvalho, PT

09:00 - 09:00 CC135
GASTRIC BAROTRAUMA INDUCED BY SELICK-MANEUVER PERFORMED TO ENABLE ENDOSCOPIC SUBMUCOSAL DISSECTION
 Daniela Falcão, PT

09:00 - 09:00 CC136
SOLITARY PEUTZ-JEGHER POLYP IN THE JEJUNUM TREATED WITH ENDOLOOP-ASSISTED POLYPECTOMY – A CASE REPORT
 Nikko Theodore Raymundo, PH

09:00 - 09:00 CC137
PNEUMOPERICARDIUM SECONDARY A GASTROPERICARDIAL FISTULA: AN UNUSUAL COMPLICATION OF GASTRIC DIVERTICULUM
 Ana López Mourelle, ES

09:00 - 09:00 CC138
A LATE HEMATOMA AFTER ENDOSCOPIC FULL-THICKNESS RESECTION OF THE APPENDICEAL ORIFICE: WHAT WE SHOULD LEARN FROM PREOPERATIVE ANATOMICAL ASSESSMENT. A CASE REPORT
 Giulia Gibiino, IT

09:00 - 09:00 CC139
ENDOSCOPIC MANAGEMENT OF A LARGE PROLAPSING PEDUNCULATED LIPOSARCOMA OF THE RECTUM CAUSING RECURRENT HEMATOCHEZIA
 Juliana Serrazina, PT

09:00 - 09:00 CC140
AN UNCONVENTIONAL ENDOSCOPIC RESOLUTION OF A RARE CHOLELITHIASIS COMPLICATION
 João Pedro Pereira, PT

09:00 - 09:00 CC141
AORTIC GRAFT CAECAL MALPOSITION: A RARE BUT TREATABLE COMPLICATION IN CASES OF HIGH CLINICAL SUSPICION
 Asimena Mpampali, GR

09:00 - 09:00 CC142
FROM BREAST TO THE ALIMENTARY CANAL, A DIAGNOSTIC CONUNDRUM
 Adeel Rahat, PK

09:00 - 09:00 CC143
THE IMPORTANCE OF ENDOSCOPY IN DIAGNOSIS OF ACUTE APPENDICITIS- A CASE REPORT
 Patricia Mester, DE

09:00 - 09:00 CC144
LOOP-AND-LEAVE AS AN EFFECTIVE STRATEGY FOR MANAGEMENT OF LARGE COLONIC LIPOMA: A CASE REPORT
 Juliana Serrazina, PT

09:00 - 09:00 CC145
ENDOSCOPIC REMOVAL OF RECTAL FOREIGN BODY USING OBSTETRIC VACUUM EXTRACTOR
 Muhammad Aasim Khan, PK

09:00 - 09:00 CC146
SPONTANEOUS COLIC PERFORATION - A DIAGNOSTIC AND ETIOLOGICAL CHALLENGE
 Margarida Gomes Gonçalves, PT

09:00 - 09:00 CC147
A RARE COMPLICATION POST-POLYPECTOMY: PARALYTIC ILEUS
 Pilar Navajas Hernández, ES

09:00 - 09:00 CC148
EOSINOPHILIC CHOLANGITIS PRESENTING AS BILIARY STRICTURE - BENIGN DISEASE MIMICKING SINISTER DIAGNOSIS
 Muhammad Khan, QA

09:00 - 09:00 CC149
HEMATOMA POST-ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY. AN ANALYSIS OF THREE CASES
 Sandra Diez Ruiz, ES

09:00 - 09:00 CC150
MAIN BILE DUCT STENOSIS AND RECURRENT PANCREATITIS AFTER AMPULLECTOMY: AN UNEXPECTED ETIOLOGY
 Ricardo Rios Crespo, PT

09:00 - 09:00 CC151
POSSIBILITIES OF VIDEO-CHOLANGIOSCOPY IN DONOR CHOLEDOCHAL DETACHMENT OF A PATIENT AFTER ORTHOTOPIC LIVER TRANSPLANTATION
 Lomali Generdukaev, RU

09:00 - 09:00 CC152
ENDOSCOPIC NASOPANCREATIC DRAINAGE(ENPD) CONTRIBUTING TO HEALING OF ANASTOMOTIC ULCER AND PANCREATIC DUCT FISTULA AFTER GASTRIC CANCER SURGERY: A CASE REPORT
 Ryogo Minami, JP

09:00 - 09:00 CC153
BILIARY TUBERCULOSIS OBSTRUCTION: A DIAGNOSTIC DILEMMA
 Fatima-Zahra Chabib, MA

09:00 - 09:00 CC154
TRANS PAPILLARY GALL BLADDER DRAINAGE (ERCP APPROACH) – FOR A HIGH-RISK SURGICAL CANDIDATE, CASE REPORT
 Montri Gururatsakul, TH

09:00 - 09:00 CC155
ENDOSCOPIC MANAGEMENT OF GASTROJEJUNOCOLIC FISTULA AS AN UNUSUAL COMPLICATION OF ENDOSCOPIC ULTRASOUND-GUIDED GASTROENTEROSTOMY
 Alzbeta Hujova, CZ

09:00 - 09:00 CC156
AN UNEXPECTED COMPLICATION OF ENDOSCOPIC ULTRASOUND-GUIDED LIVER BIOPSY
 Isabel Garrido Garrido, PT

09:00 - 09:00	CC157	09:00 - 09:00	CC170
LAMS IN CROHN'S DISEASE WITH INTRA ABDOMINAL ABSCESS A CASE REPORT		MECKEL 'S DIVERTICULUM OF DISTAL ILEUM - HOW TO DIAGNOSE AND HOW TO TREAT IT	
Abdulaziz Al Nuaimi, AE		Natalija Ljubivic Skoric, HR	
09:00 - 09:00	CC158	09:00 - 09:00	CC171
THE KEY ROLE OF THE ENDOSCOPY ULTRASOUND IN THE DIAGNOSIS AND TREATMENT OF A RARE CASE OF INTESTINAL SUBOCCLUSION IN A YOUNG BOY		ACQUIRED JEJUNAL DIVERTICULAR AN UNCOMMON ENTITY FOR BLEEDING. VIDEO CAPSULE ENDOSCOPY AND DEEP ENTEROSCOPY AS DIAGNOSTIC AND THERAPEUTIC APPROACH	
Angelo Brunori, IT		Xochiquetzal Sanchez-Chavez, MX	
09:00 - 09:00	CC159	09:00 - 09:00	CC172
SPLenic INJURY FOLLOWING ENDOSCOPIC ULTRASOUND AND FINE NEEDLE BIOPSY - A RARE COMPLICATION		SMALL BOWEL TUMOR - DIAGNOSTIC CHALLENGE	
Montri Gururatsakul, TH		Natalija Ljubivic Skoric, HR	
09:00 - 09:00	CC160	09:00 - 09:00	CC173
PANCREATIC TUBERCULOSIS DIAGNOSED VIA ENDOSCOPIC ULTRASOUND-GUIDED FINE NEEDLE ASPIRATION AND POLYMERASE CHAIN REACTION		CAVERNOUS HEMANGIOMA OF THE SMALL BOWEL AS AN INFREQUENT CAUSE OF OCCULT GASTROINTESTINAL BLEEDING	
Kaoutar Chahi, MA		Lorena Carballo-Folgozo, ES	
09:00 - 09:00	CC161	09:00 - 09:00	CC174
EUS-GUIDED GASTRO-JEJUNOSTOMY TO TREAT A CASE OF BENIGN GASTRIC OUTLET OBSTRUCTION		VASCULAR ANOMALIES OF THE GASTROINTESTINAL TRACT	
Flavio Metelli, IT		Irene Latras Cortés, ES	
09:00 - 09:00	CC162	09:00 - 09:00	CC175
PRIMARY ATYPICAL CARCINOID TUMOR OF THE MEDIASTINUM: A VERY RARE FINDING DETECTED BY ENDOSCOPIC ULTRASOUND		DESPITE ADVANCES IN ENTEROSCOPY, PATIENTS WITH PEUTZ JEGHERS SYNDROME STILL NEED PROPER FOLLOW UP WITH SMALL BOWEL CAPSULE ENDOSCOPY TO AVOID SURGICAL RESECTION	
Asmaa Gameel, EG		Cristina Carretero, ES	
09:00 - 09:00	CC163	09:00 - 09:00	CC176
MEDIASTINAL FIBROSARCOMA: UNUSUAL PRESENTATION OF A RARE TUMOR		A RARE CAUSE OF HYPERAMILASEMIA	
Ahmed Altonbary, EG		Irene Latras Cortés, ES	
09:00 - 09:00	CC164	09:00 - 09:00	CC177
PANCREATIC TUBERCULOSIS MIMICKING PANCREATIC CANCER: A RARE CLINICAL ENTITY		PANCREAS IN THE HERNIAL SAC, A RARE FINDING IN HIATAL HERNIA	
Ahmed Altonbary, EG		María del Mar Díaz Alcázar, ES	
09:00 - 09:00	CC165	09:00 - 09:00	CC178
A PANCREATIC MASS IN A PATIENT WITH PREVIOUS HEMATOLOGICAL MALIGNANCY - AN UNUSUAL DIAGNOSIS		PREOPERATIVE DIAGNOSIS OF SYMPTOMATIC INCOMPLETE ANNULAR PÂNCREAS IN A YOUNG ADULT	
Luís Correia Gomes, PT		Rita Matos Prata, PT	
09:00 - 09:00	CC166	09:00 - 09:00	CC179
A RARE CAUSE OF GASTRIC COMPRESSION		SINGLE-SESSION DUODENAL STENTING AND EUS-GUIDED GASTRO-CHOLECYSTOSTOMY WITH A LUMINAL-APPOSING STENT IN A PATIENT WITH MALIGNANT GASTRIC OUTLET AND BILIARY OBSTRUCTION	
Marco Pereira, PT		Filipa Bordalo Ferreira, PT	
09:00 - 09:00	CC167	09:00 - 09:00	CC180
SINGLE BALLOON ENTEROSCOPY USING GEL IMMERSION METHOD IN EXAMINATION OF UPPER SMALL BOWEL OBSTRUCTION		TRANSGASTRIC NEGATIVE-PRESSURE (E-VAC) THERAPY FOR PANCREATOCUTANEOUS FISTULA FOLLOWING ENDOSCOPIC NECROSECTOMY	
09:00 - 09:00	CC168	09:00 - 09:00	CC181
JEJUNAL VENOUS MALFORMATION IN COWDEN SYNDROME: A CASE REPORT		PLASTIC BILIARY STENT ANCHORED IN EXTERNAL BILIARY DRAINAGE: A RARE ADVERSE EVENT - THE RESOLUTION POSSIBLE	
Mariapaola Piazzolla, IT		Daniel Conceição, PT	
09:00 - 09:00	CC169		
MESENTERIC TUMOR MASQUERADING AS TREITZ ANGLE INTUSSUSCEPTION: A TWIST TO REMEMBER...			
Sofia Bragança, PT			

09:00 - 09:00 CC182
EUS GUIDED THERAPY OF AN ACUTE POST-TRAUMATIC PANCREATIC FLUID COLLECTION IN A PEDIATRIC PATIENT USING LUMEN APPOSING METAL STENT
 Jochen Weigt, DE

09:00 - 09:00 CC183
A DIFFICULT RETRIEVAL OF A PROXIMALLY MIGRATED PANCREATIC STENT
 Sinan Sadalla, IT

09:00 - 09:00 CC185
COMBINED ENDOSCOPIC THERAPY OF POSTOPERATIVE ANASTOMOTIC LEAK - DRAIN FIRST, STENT LATER
 Filipa Bordalo Ferreira, PT

09:00 - 09:00 CC187
MULTIMODALENDOSCOPIC APPROACH TO MANAGEMENT OF RECURRENT SLEEVE GASTRECTOMY FISTULA

09:00 - 09:00 CC188
CELIAC DISEASE AND PERITONEAL TUBERCULOSIS: INCIDENTAL OR DOCUMENTED ASSOCIATION?
 Cyrine Ben mehrez, TN

09:00 - 09:00 CC189
NEW ONSET ULCERATIVE COLITIS FOLLOWING MRNA COVID-19 VACCINATION: A CASE SERIES
 Sophie Hoile, AU

09:00 - 09:00 CC190
LIVER TRANSPLANTATION IN THE ERA OF SARS-COV-2: TO TRANSPLANT OR NOT TO TRANSPLANT?
 Maja Sremac, HR

Poster Exhibition
 09:00 - 17:30 Science Lounge
Endoscopy and imaging

09:00 - 09:00 P0875
NURSE DELIVERED ELECTIVETHERAPEUTIC AND EMERGENCY UPPER GI ENDOSCOPY
 Charles Clisby, GB

09:00 - 09:00 P0876
THE AID OF ARTIFICIAL INTELLIGENCE (AI) IN OESOPHAGOGASTRODUODENOSCOPY (OGD) TO IMPROVE QUALITY OF THE UPPER GASTROINTESTINAL STUDY - A DESCRIPTIVE REPORT
 Gabriel Ying Chai Sit, HK

09:00 - 09:00 P0877
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, CONTROLLED TRIAL OF EFFECTS OF USING INTRAVENOUS METOCLOPRAMIDE TO INCREASE MUCOSAL VISUALIZATION DURING ENDOSCOPY IN PATIENTS WITH ACUTE UPPER GASTROINTESTINAL BLEEDING
 Paveeyada Manupeeraphant, TH

09:00 - 09:00 P0878
SINGLE CENTRE EXPERIENCE OF MANAGING BURIED PEG BUMPER USING FLAMINGO DEVICE
 Jennifer Fisher, GB

09:00 - 09:00 P0879
ALGORITHM FOR ENDOSCOPIC DIAGNOSIS OF SUPERFICIAL NON-AMPULLARY DUODENAL EPITHELIAL TUMORS USING COMPUTER ANALYSIS
 Marina Kubo, JP

09:00 - 09:00 P0880
PREDICTORS OF SPONTANEOUS PASSAGE OF INGESTED FOREIGN BODIES IN ADULTS: A SINGLE-CENTER 13-YEAR EXPERIENCE
 Tawfik Khoury, IL

09:00 - 09:00 P0881
STRATEGY OF ENDOSCOPIC TREATMENT FOR NON-AMPULLARY DUODENAL TUMORS IN OUR INSTITUTION
 Masayoshi Ono, JP

09:00 - 09:00 P0882
ENDOSCOPIC TRANS-ORAL OUTLET REDUCTION IS EFFECTIVE FOR BILIARY REFLUX AFTER LAPAROSCOPIC ONE ANASTOMOSIS GASTRIC BYPASS
 Relly Reicher, IL

09:00 - 09:00 P0883
IN-VIVO DETECTION AND DIAGNOSIS OF GASTRIC PRENEOPLASTIC LESIONS BY FOURTH-GENERATION ENDOCYTOSCOPY: A PILOT STUDY
 Riccardo Vasapolli, DE

09:00 - 09:00 P0884
THE ASSOCIATION BETWEEN LOW BODY-MASS INDEX AND SERIOUS POST-ENDOSCOPIC ADVERSE EVENTS
 Haggai Bar-Yoseph, CA

09:00 - 09:00 P0885
PRACTICE OF ENDOSCOPY BY SURGEONS – A WEO GLOBAL SURVEY
 Philip Wai Yan Chiu, HK

09:00 - 09:00 P0886
DECISION-TO-SCOPE (DTS) SCORE: A NOVEL TOOL WITH EXCELLENT ACCURACY IN PREDICTING FOREIGN BODIES IN THE UPPER GASTROINTESTINAL TRACT
 Tiago Lima Capela, PT

09:00 - 09:00 P0887
EFFECTS OF TRANEXAMIC ACID AND ADRENALINE INJECTATES ON HISTOPATHOLOGICAL HEALING AFTER GASTRIC AND COLONIC ENDOSCOPIC SUBMUCOSAL DISSECTION IN AN IN VIVO PORCINE MODEL
 Anton Bermont, IL

09:00 - 09:00 P0888
DUODENAL NEUROENDOCRINE TUMORS: SHORT AND LONG-TERM OUTCOMES OF ENDOSCOPIC SUBMUCOSAL DISSECTION PERFORMED IN THE WESTERN SETTING
 Sunil Gupta, AU

09:00 - 09:00 P0889
ARTIFICIAL INTELLIGENCE ASSISTED PATTERN RECOGNITION DURING THIRD-SPACE ENDOSCOPY
 Markus Wolfgang Scheppach, DE

09:00 - 09:00 P0890
PHYSICIAN-GUIDED PERIPROCEDURAL MANAGEMENT OF EDOXABAN THERAPY AND CLINICAL OUTCOMES IN PATIENTS UNDERGOING ENDOSCOPIC PROCEDURES: A SUB-ANALYSIS OF THE GLOBAL EMIT-AF/VTE PROGRAM
 Thomas Vanassche, BE

09:00 - 09:00 P0891
BURIED BUMPER SYNDROME: AN INCIDENCE STUDY AND CLINICAL CHARACTERIZATION OF A RARE COMPLICATION OF PERCUTANEOUS ENDOSCOPIC GASTROSTOMY
 Emanuel Dias, PT

09:00 - 09:00 P0892
CAP ASSISTED ENDOSCOPY AS A TOOL FOR VATER PAPANILLA AND DUODENAL SURVEILLANCE IN PATIENTS WITH COLONIC POLYPOSIS
 Cláudia Pinto, PT

09:00 - 09:00 P0893
SUBJECTIVE ASSESSMENT OF THE PYLORIC SPHINCTER DURING ENDOSCOPY AND ITS CORRELATION IN FLIP PANOMETRY
 Ian Levenfus, CH

09:00 - 09:00 P0894
IMMEDIATE DISCHARGE AFTER PERCUTANEOUS ENDOSCOPIC GASTROSTOMY TUBE REMOVAL IN HEAD AND NECK CANCER PATIENTS IN ONCOLOGICAL REMISSION: A FEASIBILITY AND SAFETY STUDY
 Fátima Francisco, PT

09:00 - 09:00 P0895
EVALUATION OF STANDARD BOWEL PREPARATION REGIMES VERSUS PLENUV (NOVEL LOW VOLUME REGIME): CLEANSE STUDY
 Ahmir Ahmad, GB

09:00 - 09:00 P0896
AUTOMATED MEASUREMENT OF COLONOSCOPY WITHDRAWAL TIME USING CONVOLUTIONAL NEURAL NETWORKS
 Rawen Kader, GB

09:00 - 09:00 P0897
EFFECTIVENESS AND SAFETY OF 1L PEG-ASC VERSUS STANDARD BOWEL PREPARATIONS FOR COLONOSCOPY: A SYSTEMATIC REVIEW AND META-ANALYSIS
 Marcello Fabio Maida, IT

09:00 - 09:00 P0898
COMAPRISONS UNDERWATER ENDOSCOPIC SUBMUCOSAL DISSECTION AND CONVENTIONAL ENDOSCOPIC SUBMUCOSAL DISSECTION FOR SUPERFICIAL COLORECTAL NEOPLASIAS
 Chang Kyo Oh, KR

09:00 - 09:00 P0899
THE SNARE DEVICE WITH THINNER LOOP WIRE COULD PROVIDE HIGHER PERFORMANCE FOR COLD SNARE POLYPECTOMY IN AN EXPERIMENTAL MODEL
 Kyouhei Maejima, JP

09:00 - 09:00 P0900
FACTORS AFFECTING POLYP DETECTION ON SCREENING COLONOSCOPY: A PROSPECTIVE OBSERVATIONAL STUDY

Georgios Sachtouris, GR

09:00 - 09:00 P0901
QUALITY OF COLONOSCOPY IN A LARGE ENDOSCOPY CENTER IN ESTONIA
 Thomas Zimmerer, EE

09:00 - 09:00 P0902
CLINICAL OUTCOMES AND RISK FACTORS RELATED WITH POOR PROGNOSIS AFTER ENDOSCOPIC RESECTION IN ≥10 MM SIZED RECTAL NEUROENDOCRINE TUMOR: A MULTICENTER, RETROSPECTIVE STUDY
 Hyung Wook Kim, KR

09:00 - 09:00 P0903
AUTOMATED DETECTION OF ANATOMICAL LANDMARKS DURING COLONOSCOPY USING A DEEP LEARNING MODEL
 Mahsa Taghiakbari, CA

09:00 - 09:00 P0904
MEASURING THE OBSERVER (HAWTHORNE) EFFECT ON ADENOMA DETECTION RATES
 Mahsa Taghiakbari, CA

09:00 - 09:00 P0905
DEEP LEARNING FOR INSTRUMENT RECOGNITION FOR POLYPECTOMIES IN COLONOSCOPY
 Joel Troya, DE

09:00 - 09:00 P0907
PLENUV (1L PEG PLUS ASCORBATE) VERSUS MOVIPREP (2L PEG PLUS ASCORBATE) IN A COLORECTAL CANCER SCREENING SETTING, A RANDOMIZED CONTROLLED TRIAL (PLEMO)
 Soeren Roepstorff, DK

09:00 - 09:00 P0908
DEVELOPMENT AND VALIDATION OF THE GLOBAL POLYPECTOMY ASSESSMENT TOOL (GPAT) - A NOVEL ONLINE ASSESSMENT TOOL FOR ANY COLORECTAL POLYPECTOMY
 David James Tate, BE

09:00 - 09:00 P0909
WATER EXCHANGE TECHNIQUE IMPROVES COLONOSCOPY IN PATIENTS WITH SPINAL CORD INJURY - RESULTS OF A MATCHED RETROSPECTIVE COHORT STUDY
 Thorsten Brechmann, DE

09:00 - 09:00 P0910
ARE DIMINUTIVE AND SMALL POLYPS DANGEROUS?
 Asma Ben Mohamed, TN

09:00 - 09:00 P0911
CHARACTERISTICS AND RENTABILITY OF URGENT COLONOSCOPY IN LOWER GASTROINTESTINAL BLEEDING. EXPERIENCE IN A THIRD LEVEL CENTER
 Mónica Ayude Galego, ES

09:00 - 09:00 P0912
INTEREST OF ENDOSCOPIC TREATMENT OF SIGMOID VOLVULUS

Rachid Laroussi, MA

09:00 - 09:00 P0913
COMPARISON OF SYNERGISTIC SEDATION WITH MIDAZOLAM AND PROPOFOL VERSUS MIDAZOLAM AND PETHIDINE IN COLONOSCOPIES: A PROSPECTIVE, RANDOMIZED STUDY

Yongwook Jung, KR

09:00 - 09:00 P0914
SHORT AND LONG-TERM OUTCOMES OF ENDOSCOPIC REMOVAL OF LARGE (>20 MM) COLORECTAL POLYPS

Anna Rawa-Golebiewska, PL

09:00 - 09:00 P0915
PRE-COLONOSCOPY PREPARATION GUIDED BY A PERSONALIZED DIGITAL PLATFORM IS ASSOCIATED WITH LOWER RATES OF INADEQUATE PREPARATION COMPARED TO DIGITAL WRITTEN INSTRUCTIONS

Liat Deutsch (Mlynarsky), IL

09:00 - 09:00 P0916
ACUITY OF ARTIFICIAL INTELLIGENCE ASSISTED COLONOSCOPY IN LYNCH SYNDROME PATIENTS

Cláudia Pinto, PT

09:00 - 09:00 P0917
IMPACT OF REINFORCED EDUCATION BY TELEPHONE AND SHORT MESSAGE SERVICE ON THE QUALITY OF BOWEL PREPARATION: A RANDOMIZED CONTROLLED STUDY

Imane Haraki, MA

09:00 - 09:00 P0918
SEDATION FOR COLONOSCOPY IN PATIENTS WITH SPINAL CORD INJURY DEPENDS ON THE INJURY'S CHARACTERISTICS, BUT IS FEASIBLY AND SAFELY ADMINISTERED AS NURSE ASSISTED SEDATION

Thorsten Brechmann, DE

09:00 - 09:00 P0919
CLINICAL OUTCOMES: A PILOT FIT PROGRAM TO TRIAGE NON-URGENT COLONOSCOPY REFERRALS

Lakshman Kumar, IE

09:00 - 09:00 P0920
REAL-TIME COMPUTER-AIDED POLYP/ADENOMA DETECTION DURING SCREENING COLONOSCOPY: A SINGLE-CENTER DIAGNOSTIC TRIAL

Jorge Baquerizo-Burgos, EC

09:00 - 09:00 P0921
CHOLANGIOSCOPY-GUIDED BIOPSY IN THE DIAGNOSIS OF INDETERMINATE BILIARY STRICTURES- DISAPPOINTING RESULTS AFTER 6 YEARS HARD WORK

Petko Karagyozov, BG

09:00 - 09:00 P0922
RISK FACTORS FOR POST-ENDOSCOPIC RETROGRADE CHOLANGIO-PANCREATOGRAPHY PANCREATITIS (PEP) IN CHILDREN WITH CHRONIC PANCREATITIS AND ITS PREDICTION USING 4-HOUR POST-PROCEDURE SERUM AMYLASE AND LIPASE LEVELS

Arghya Samanta, IN

09:00 - 09:00 P0923
REAL LIFE PATENCY OF PLASTIC BILIARY STENTS IN THE PANDEMIC ERA - IS STENT REMOVAL AFTER 6 MONTHS SAFE?

Marta Freitas, PT

09:00 - 09:00 P0925
RADIATION DOSE OPTIMIZATION IN ERCP: PROSPECTIVE INTERVENTIONAL STUDY

Catarina Frias Gomes, PT

09:00 - 09:00 P0926
WIRE-GUIDED CYSTOTOME DILATATION OF DIFFICULT BENIGN BILIO-PANCREATIC STRICTURES: SINGLE CENTER EXPERIENCE

Omar Ksissa, IT

09:00 - 09:00 P0927
CLINICAL OUTCOMES OF ENDOSCOPIC PAPILLECTOMY; A LARGE MULTICENTER RETROSPECTIVE STUDY

Eisuke Iwasaki, JP

09:00 - 09:00 P0928
ERCP IN PATIENTS WITH ROUX-EN-Y RECONSTRUCTION AFTER GASTRECTOMY: A SINGLE-CENTER OBSERVATIONAL STUDY

Andrea Palermo, IT

09:00 - 09:00 P0929
ENDOSCOPIC TREATMENT OF COMPLICATIONS OF HYDATID CYSTS OF LIVER RUPTURED IN THE BILE DUCTS

Tarik Addajou, MA

09:00 - 09:00 P0930
SECONDARY SCLEROSING CHOLANGITIS IN PATIENTS WITH COVID-19 ARDS - A CLINICAL-ENDOSCOPIC ANALYSIS

Vlad Pavel, DE

09:00 - 09:00 P0931
OUTCOMES OF ENDOSCOPIC DRAINAGE IN CHILDREN WITH PANCREATIC FLUID COLLECTIONS: A SYSTEMATIC REVIEW AND META-ANALYSIS

Zaheer Nabi, IN

09:00 - 09:00 P0932
TRANSESOPHAGEAL EUS IN THE DIAGNOSIS OF THE LUNG MASSES: A MULTICENTER EXPERIENCE WITH FINE-NEEDLE ASPIRATION (FNA) AND FINE-NEEDLE BIOPSY (FNB) NEEDLES

Danilo Paduano, IT

09:00 - 09:00 P0933
ENDOSCOPIC ULTRASOUND-GUIDED FINE NEEDLE BIOPSY- PROMISING RESULTS WITH NEWLY DESIGNED NEEDLE WITH MULTI-BLADE THREE-PRONG TIP

Petko Karagyozov, BG

09:00 - 09:00 P0934
ENDOSCOPIC ULTRASONOGRAPHIC FINDINGS OF SUBEPITHELIAL LESION IN THE UPPER GASTROINTESTINAL TRACT WITH AN INCREASE IN SIZE

Seo Yeon Cho, KR

09:00 - 09:00 P0935
SAFETY AND EFFICACY OF ENDOSCOPIC CONVENTIONAL CYANOACRYLATE GLUE VS EUS-GUIDED COIL PLUS CYANOACRYLATE TECHNIQUE IN THE TREATMENT OF GASTRIC VARICES:A RANDOMIZED CONTROLLED TRIAL (NCT05038319)

Tummalapalli S A Satya Maharshi, IN

09:00 - 09:00 P0936
ENDOSCOPIC ULTRASOUND-GUIDED ELASTOGRAPHY FOR DETERMING MALIGNANCY OF SOLID PANCREATIC LESIONS. PROSPECTIVE REGISTRY FROM A REFERRAL CENTER

Daniel De la Iglesia-García, ES

09:00 - 09:00 P0937
ACCURACY OF EUS-GUIDED TISSUE SAMPLING FOR THE PATHOLOGICAL DIAGNOSIS OF SOLID LIVER LESIONS

Daniel De la Iglesia-García, ES

09:00 - 09:00 P0938
USEFULNESS OF CONTRAST-ENHANCED ENDOSCOPIC ULTRASOUND (CH-EUS) TO GUIDE THE TREATMENT CHOICE IN SUPERFICIAL RECTAL LESIONS: A CASE SERIES

Giulia Gibiino, IT

09:00 - 09:00 P0939
SELECTIVE TISSUE SEPARATION IMPROVES DIAGNOSTIC YIELD OF EUS GUIDED TISSUE ACQUISITION

Shreeram Akerkar, NO

09:00 - 09:00 P0940
COMPARISON OF DIAGNOSTIC ACCURACY OF EUS GUIDED FINE-NEEDLE BIOPSY AND CYTOLOGY WITH ROSE IN PANCREATIC SOLID LESIONS (PSLS) USING NEWER GENERATION BIOPSY NEEDLES

Sridhar Sundaram, IN

09:00 - 09:00 P0941
THE USE OF ANTITHROMBOTIC AND ANTICOAGULANT AGENTS DID NOT INCREASE THE BLEEDING RISK AFTER ENDOSONOGRAPHY (EUS)-GUIDED PUNCTURE

Simona Bota, AT

09:00 - 09:00 P0942
ENDOSCOPIC ULTRASOUND (EUS) STILL RELEVANT IN DIFFICULT PSEUDOACHALASIA WORKUP

Chris Chia, SG

09:00 - 09:00 P0943
ENDOSCOPIC ULTRASOUND GUIDED CYSTOGASTROSTOMY IS TECHNICALLY FEASIBLE, SAFE AND EFFECTIVE IN TODDLERS AND SMALL CHILDREN

Sridhar Sundaram, IN

09:00 - 09:00 P0944
THE RISK OF MALIGNANCY OF DIAGNOSTIC CATEGORIES DEFINED BY PAPANICOLAOU SOCIETY OF CYTOPATHOLOGY SYSTEM IN EUS-FNA SAMPLING OF SOLID PANCREATIC LESIONS

Béla Vasas, HU

09:00 - 09:00 P0945
ROLE OF NOVEL MOTORIZED SPIRAL ENTEROSCOPY IN THE EVALUATION OF SMALL BOWEL DISEASES: A SYSTEMATIC REVIEW AND META-ANALYSIS

Zaheer Nabi, IN

09:00 - 09:00 P0946
EFFICACY AND SAFETY OF CONTINUOUS INTRAVENOUS MIDAZOLAM INFUSION AND PETHIDINE HYDROCHLORIDE IN DOUBLE-BALLOON SMALL INTESTINE ENDOSCOPY: A MULTICENTER RANDOMIZED CONTROLLED TRIAL

Takuro Hamada, JP

09:00 - 09:00 P0947
HIGHER LEVELS OF OPIOID ANALGESIA AND SEDATION ARE REQUIRED TO MAINTAIN ADEQUATE PATIENT COMFORT AND IMPROVE PROCEDURE SUCCESS IN DEVICE ASSISTED ENTEROSCOPY. IS CONSCIOUS SEDATION ENOUGH?

Caroline Walker, IE

09:00 - 09:00 P0948
TWO DECADES OF CAPSULE ENDOSCOPY: INDICATIONS, DETECTION, COMPLETION AND RETENTION RATES

Anastasios Koulaouzidis, DK

09:00 - 09:00 P0949
SMARTPILL™ WIRELESS MOTILITY CAPSULE ASSESSMENT OF INTRA- AND INTER-INDIVIDUAL VARIABILITY OF SPECIFIC GASTRIC PH RANGES FOLLOWING A LOW-FAT, LOW-CALORIE MEAL: IMPLICATIONS FOR DRUG DELIVERY

Per Martin Hellström, SE

09:00 - 09:00 P0950
DIAGNOSTIC ACCURACY OF CAPSULE ENDOSCOPY READING ASSISTED BY ARTIFICIAL INTELLIGENCE FOR EXPERT READERS: INTERIM ANALYSIS OF A SINGLE CENTER EXPERIENCE

Stefania Piccirelli, IT

09:00 - 09:00 P0951
ROLE OF ARTIFICIAL INTELLIGENCE IN SMALL BOWEL CAPSULE ENDOSCOPY TRAINING

Stefania Piccirelli, IT

09:00 - 09:00 P0952
EFFICIENCY OF THE CAPSULE ENDOSCOPY, ARE THE QUALITY CRITERIA OF THE ESGE MET? EXPERIENCE IN A CENTER

María del Mar Díaz Alcázar, ES

09:00 - 09:00 P0953
REANALYSIS OF NEGATIVE SMALL BOWEL CAPSULE ENDOSCOPY BY DEEP CONVOLUTIONAL NEURAL NETWORK MODEL IMPROVED DIAGNOSTIC YIELD AND COULD CHANGE THE OUTCOME

Kyungseok Choi, KR

09:00 - 09:00 P0954
IS VIDEO CAPSULE ENDOSCOPY SUPERIOR TO CT-ENTEROGRAPHY IN ASSESSING SMALL INTESTINAL PATHOLOGY IN OCCULT GASTROINTESTINAL BLEEDING FOLLOWING NEGATIVE UPPER ENDOSCOPY AND COLONOSCOPY? A DIAGNOSTIC TEST ACCURACY META-ANALYSIS

Mohammad Yaghoobi, CA

09:00 - 09:00 P0955
NON-INVASIVE PAN-ENTERIC EVALUATION IN CROHN'S DISEASE – USEFULNESS OF CAPSULE ENDOSCOPY IN UPSTAGING AND CHANGING DISEASE MANAGEMENT

Joao Paulo Laranjeira Correia, PT

09:00 - 09:00 P0956
COLON CAPSULE ENDOSCOPY: PREDICTORS OF INADEQUATE BOWEL PREPARATION

Tiago Lima Capela, PT

09:00 - 09:00 P0957
CAPSULE ENDOSCOPY WITH ARTIFICIAL INTELLIGENCE ASSISTED TECHNOLOGY: AI IN CLINICAL PRACTICE

Fintan O'Hara, IE

09:00 - 09:00 P0958
CAPSULE ENDOSCOPY: AUTOMATIC IDENTIFICATION AND DIFFERENTIATION OF SMALL BOWEL LESIONS WITH DISTINCT HEMORRHAGIC POTENTIAL USING A CONVOLUTIONAL NEURAL NETWORK

Tiago Ribeiro, PT

09:00 - 09:00 P0959
VIDEO CAPSULE ENDOSCOPY IN PATIENTS WITH SURGICALLY ALTERED PROXIMAL SMALL BOWEL IS ASSOCIATED WITH LONGER TRANSIT TIMES, INADEQUATE PREPARATION AND REDUCED DIAGNOSTIC YIELD

Tamar Thurm, IL

09:00 - 09:00 P0960
VIDEO CAPSULE ENDOSCOPY STUDIES IN PATIENTS WITH DIABETES MELLITUS ARE CHARACTERIZED BY INADEQUATE PREPARATION AND LONGER TRANSIT TIMES

Liat Deutsch (Mlynarsky), IL

09:00 - 09:00 P0961
AUTOMATED PROMPTS RESULT IN HIGH PROKINETIC USE WITHOUT IMPROVING COLON CAPSULE PERFORMANCE

Conor Costigan, IE

09:00 - 09:00 P0962
EVALUATION OF SPLEEN STIFFNESS IN HEALTHY POPULATION: A VIBRATION-CONTROLLED TRANSIENT ELASTOGRAPHY STUDY

Haluk Tarik Kani, TR

09:00 - 09:00 P0963
EUS-GUIDED HEPATICOGASTROSTOMY; CLINICAL OUTCOMES AND COMPLICATIONS. EXPERIENCE OF A MAIN FRENCH REGIONAL HOSPITAL

Houda EL Moufid, FR

09:00 - 09:00 P0964
SELF-EXPANDABLE METALLIC STENTS FOR PALLIATION OF MALIGNANT DYSPHAGIA - EFFICACY AND SAFETY

Filipa Bordalo Ferreira, PT

09:00 - 09:00 P0965
RISK FACTORS FOR REFRACTORY BENIGN ESOPHAGEAL STRICTURES

Asmae Sair, MA

09:00 - 09:00 P0966
ENDOSCOPIC STRICTUROTOMY VERSUS ENDOSCOPIC BALLOON DILATION FOR THE TREATMENT OF INTESTINAL STRICTURES IN CROHN'S DISEASE

Gherzon Casanova, ES

09:00 - 09:00 P0967
A NATIONWIDE, MULTICENTER, PROSPECTIVE COHORT OF ENDOSCOPIC ULTRASOUND-GUIDED GASTROENTEROSTOMY IN PATIENTS WITH MALIGNANT GASTRIC OUTLET OBSTRUCTION

Yu-Ting Kuo, TW

09:00 - 09:00 P0968
PERCUTANEOUS CHOLECYSTOSTOMY FOR ACUTE CALCULOUS CHOLECYSTITIS AN OBSERVATIONAL STUDY FROM A SINGLE INSTITUTE

09:00 - 09:00 P1036
DEVELOPMENT AND VALIDATION OF A FEATURE EXTRACTION-BASED LOGICAL

ANTHROPOMORPHIC DIAGNOSTIC SYSTEM FOR EARLY GASTRIC CANCER UNDER THE MAGNIFYING IMAGE ENHANCED ENDOSCOPY INCORPORATED WITH PRIOR KNOWLEDGE

Jia Li, CN

09:00 - 09:00 P1037
DETECTION OF GASTRIC NEOPLASMS WITH A NEW HEATMAP-BASED ARTIFICIAL INTELLIGENCE SYSTEM

Hae Yeon Kang, KR

09:00 - 09:00 P1038
LOCAL RECURRENCE AFTER ENDOSCOPIC RESECTION OF SESSILE SERRATED LESIONS: A MULTICENTER PROSPECTIVE STUDY BY THE OSAKA GUT FORUM

Satoki Shichijo, JP

09:00 - 09:00 P1039
A PROSPECTIVE STUDY OF DEVELOPING AND VALIDATING THE EFFECT OF AN ARTIFICIAL INTELLIGENCE SOPHOGA STRODUODENOSCOPY REPORTING SYSTEM

Lihui Zhang, CN

09:00 - 09:00 P1040
ARTIFICIAL INTELLIGENCE ASSISTANCE IMPROVES AS ENDOSCOPIST FATIGUE INCREASES: SECONDARY ANALYSIS OF TWO RANDOMIZED TRIALS

Zihua Lu, CN

09:00 - 09:00 P1041
LONG-TERM EFFECTIVENESS OF ARTIFICIAL INTELLIGENCE SYSTEM IN IMPROVING ADENOMA DETECTION RATE: A MULTICENTER SELF-CONTROLLED STUDY

Zihua Lu, CN

09:00 - 09:00 P1042
THE ARTIFICIAL INTELLIGENCE-ASSISTED SMALL BOWEL CAPSULE ENDOSCOPY (TANTALUS), MULTICENTRE STUDY – AI IN CAPSULE ENDOSCOPY WELL WITHIN OUR REACH!
 Anastasios Koulaouzidis, DK

09:00 - 09:00 P1044
EFFECT OF AN AUTOMATED FLEXIBLE ENDOSCOPE CHANNELS BRUSHING SYSTEM ON IMPROVING THE REPROCESSING QUALITY: A PROSPECTIVE, RANDOMIZED CONTROLLED STUDY
 Renduo Shang, CN

Poster Exhibition

09:00 – 17:30 Science Lounge
Surgery

09:00 - 09:00 P0969
FIRST EXPERIENCE OF ENDOSCOPIC STENTING OF THE MAIN PANCREATIC DUCT IN PATIENTS WITH PANCREATIC FLUID COLLECTIONS AFTER PANCREAS TRANSPLANTATION
 Shabnam Suleymanova, RU

09:00 - 09:00 P0970
RISK FACTORS AND TREATMENT STRATEGIES OF DELAYED GASTRIC EMPTYING AFTER LAPAROSCOPIC PANCREATODUODENECTOMY
 Yong Liu, CN

09:00 - 09:00 P0971
ENDOSCOPIC OVERSTITCH SUTURE OF PARIETAL LEAKS AFTER GASTROINTESTINAL COMPLEX RESECTIONS IS FEASIBLE, SAFE AND REDUCE THE NEED FOR HOSPITALIZATION
 Giuseppe Grande, IT

09:00 - 09:00 P0972
COMPARISON BETWEEN LAPAROSCOPIC AND OPEN APPROACHES FOR SECOND COLORECTAL RESECTION AFTER COLECTOMY OR PROCTECTOMY
 Hiroaki Nozawa, JP

09:00 - 09:00 P0973
A FRENCH MULTICENTRIC PROSPECTIVE STUDY OF SURGICAL TREATMENT OF HEMORRHOIDAL DISEASE WITH RADIO FREQUENCY
 Jean-Michel Rouillon, FR

09:00 - 09:00 P0974
MANAGEMENT OF SUPERFICIAL GASTROINTESTINAL NEOPLASTIC LESIONS ASSOCIATED WITH SEVERE SUBMUCOSAL FIBROSIS - ENDOSCOPIC SUBMUCOSAL DISSECTION TO THE RESCUE!
 Rui Mendo, PT

09:00 - 09:00 P0975
DEVELOPMENT OF A NEW 3D PRINTED ENDOSCOPIC GRASPING INSTRUMENT
 Boban Sudarevic, DE

Poster Exhibition

09:00 – 17:30 Science Lounge
Nutrition

09:00 - 09:00 P0188
THE EVIDENCE REGARDING BODY COMPOSITION PARAMETERS IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE: A SYSTEMATIC REVIEW OF LONGITUDINAL STUDIES AND META-ANALYSIS
 Dóra Mátis, HU

09:00 - 09:00 P0189
MODIFIED HIDA TEST FOR THE DIAGNOSIS OF BILE REFLUX IN PATIENTS WHO UNDERWENT MINI-GASTRIC BYPASS BARIATRIC SURGERY
 Tawfik Khoury, IL

09:00 - 09:00 P0190
EVALUATION OF THE EFFICACY AND SAFETY OF ENDOSCOPIC SLEEVE GASTROPLASTY (ESG) IN THE MANAGEMENT OF PATIENTS WITH OBESITY IN A FOLLOW-UP FROM 12 TO 48 MONTHS
 Bruno Queiroz Sander, BR

09:00 - 09:00 P0191
EFFICACY AND SAFETY OF ENDOSCOPICALLY IMPLANTED DUODENAL-JEJUNAL BYPASS LINERS VS. INTRAGASTRIC BALLOONS IN A REAL-WORLD POPULATION – A PROPENSITY SCORE MATCHING ANALYSIS
 Jürgen Stein, DE

09:00 - 09:00 P0192
COMPARATIVE EFFICACY AND SAFETY OF DIFFERENT INTRAGASTRIC BALLOONS IN A REAL-WORLD POPULATION – A PROPENSITY SCORE MATCHING ANALYSIS
 Nathalena Hein, DE

09:00 - 09:00 P0193
THE IMPACT OF THE DUODENOJEJUNAL BYPASS LINER ON IRON HOMEOSTASIS
 Oliver Schröder, DE

09:00 - 09:00 P0194
GHEE BUTTER FROM BOVINE COLOSTRUM ALLEVIATES INTESTINAL INFLAMMATION IN DEXTRAN SULFATE SODIUM-INDUCED COLITIS IN MICE
 Aleksandra Tarasiuk, PL

09:00 - 09:00 P0195
SIGNIFICANT IMPROVEMENTS IN STRESS AND COGNITIVE OUTCOMES WITH *BIFIDOBACTERIUM LONGUM* 1714 SUPPLEMENTATION – A REAL-WORLD EXPERIENCE PROGRAMME IN ATHLETES
 Katy Sorensen, IE

09:00 - 09:00 P0196
PATIENTS' EXPERIENCES OF DIETARY CHANGES DURING A STRUCTURED DIETARY INTERVENTION FOR IRRITABLE BOWEL SYNDROME
 Cecilia Weznaver, SE

09:00 - 09:00 P0197
ABSORPTION AND METABOLIZATION OF THE NATURALLY OCCURRING SWEETENERS ERYTHRITOL AND XYLITOL IN HUMANS: A DOSE-RANGING STUDY

Valentine Bordier, CH

09:00 - 09:00 P0198
COOKING METHODS ONLY NEGLIGIBLY AFFECT DIETARY FIBER CONTENT AND COMPOSITION

João Sabino, BE

09:00 - 09:00 P0199
THE BURDEN OF DISORDERS OF GUT-BRAIN INTERACTION IN OBESITY AND THE EFFECT OF DIFFERENT TREATMENTS ON QUALITY OF LIFE

Esther Colomier, BE

09:00 - 09:00 P0200
COMPREHENSIVE ANALYSIS OF NUTRITIONAL PARAMETERS IN PATIENTS WITH IDIOPATHIC ACHALASIA: A PROSPECTIVE STUDY

Maragoni Rajesh Goud, IN

09:00 - 09:00 P0201
ORTHOREXIA NERVOSA IS MORE PREVALENT IN PATIENTS WITH IRRITABLE BOWEL SYNDROME COMPARED TO HEALTHY CONTROLS

Caroline Tuck, AU

09:00 - 09:00 P0202
THE EFFECT OF RIBOFLAVIN SUPPLEMENTATION ON THE SYSTEMIC REDOX STATUS IN HEALTHY VOLUNTEERS: A POST-HOC ANALYSIS OF THE RIBOGUT TRIAL

Antonius Timotheus Otten, NL

09:00 - 09:00 P0203
GUT MICROBIOTA AND ITS ASSOCIATION WITH SMALL INTESTINAL BACTERIAL OVERGROWTH IN PATIENTS WITH HYPERLIPIDEMIA

Khrystyna Kvit, UA

09:00 - 09:00 P0204
IDENTIFYING ARFIDS IN SEVERE DGBIS WHO PRESENT TO TERTIARY CARE GI PSYCHOLOGY AND DIETETICS

Lee D Martin, GB

09:00 - 09:00 P0205
RISK STRATIFICATION, PREVENTION AND OCCURRENCE OF REFEEDING SYNDROME IN ADULTS USING A COMPUTER-BASED TOOL: A PROSPECTIVE COHORT STUDY

Alia Hadeji, BE

09:00 - 09:00 P0206
COMPLICATIONS OF PERCUTANEOUS ENDOSCOPIC GASTROSTOMY (PEG) TUBE PLACEMENT BY PROVIDER TRAINING: A RETROSPECTIVE ANALYSIS

Patricia Ziegler, US

09:00 - 09:00 P0207
MALNUTRITION WITH LOW MUSCLE MASS IS COMMON AFTER WEANING OFF HOME-PARENTERAL NUTRITION FOR CHRONIC INTESTINAL FAILURE

Lucas Wauters, BE

09:00 - 09:00 P0208
DOES A NURSE-LED PERCUTANEOUS ENDOSCOPIC GASTROSTOMY OUTPATIENT CLINIC HAS IMPACT IN PATIENT 'S OUTCOME?

Helder Vilar, PT

Poster Exhibition

09:00 - 17:30 Science Lounge
 Health economics / Digitalisation in GI / Education In GI / Gender and diversity

09:00 - 09:00 P0976
GUT MICROBIOME TO REDUCE CARBON EMISSION

Hüseyin Sancar Bozkurt, TR

09:00 - 09:00 P0977
ADALIMUMAB IN CROHN'S DISEASE AND ULCERATIVE COLITIS IN SPAIN

Joan Antoni Schoenenberger-Arnaiz, ES

09:00 - 09:00 P0978
UNMET MEDICAL NEEDS IN SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE IDENTIFIED FROM A QUALITATIVE SURVEY OF PATIENTS AND HEALTHCARE PROVIDERS

Nader N. Youssef, CH

09:00 - 09:00 P0979
USEFULNESS OF ENZYMATIC CLEANING IN A THERMOSTATIC CHAMBER FOR ENDOSCOPE CLEANING: A MULTICENTER PROSPECTIVE STUDY

Akira Nakanishi, JP

09:00 - 09:00 P0980
FATIGUE IMPROVEMENT CORRELATES WITH REDUCTIONS IN WORK PRODUCTIVITY IMPAIRMENT AND RELATED INDIRECT COST IN PATIENTS WITH CROHN'S DISEASE: POST HOC ANALYSIS OF PHASE 3 RISANKIZUMAB INDUCTION TRIALS

Subrata Ghosh, IE

09:00 - 09:00 P0981
A RETROSPECTIVE STUDY COMPARING THE USE OF THE AGE, BLOOD TESTS AND COMORBIDITIES (ABC) SCORE TO PREDICT 30-DAY MORTALITY IN ACUTE UPPER AND LOWER GI BLEEDING WITH CURRENT SCORES USED AT MATER DEI HOSPITAL

Glenn Costa, MT

09:00 - 09:00 P0982
INFORMED CONSENT FOR GASTROINTESTINAL ENDOSCOPY: RESULTS OF A SURVEY ON CURRENT PRACTICES IN MEMBER SOCIETIES OF THE EUROPEAN SOCIETY OF GASTROINTESTINAL ENDOSCOPY

Georgios Tziatzios, GR

09:00 - 09:00 P0983
REASONS FOR CHOICE OF ADVANCED THERAPIES (BIOLOGICS AND JAKIS) FOR THE TREATMENT OF ULCERATIVE COLITIS IN EUROPE

Grace O'Neill, GB

- 09:00 - 09:00 P0984
CLINICAL AND HEALTH OUTCOMES ASSOCIATED WITH TREATMENT SEQUENCES FOR MODERATE-TO-SEVERE ULCERATIVE COLITIS
 Marla C. Dubinsky, US
- 09:00 - 09:00 P0985
IMPACT OF TREATMENT SWITCH ON CLINICAL OUTCOMES IN CROHN'S DISEASE PATIENTS IN THE UNITED STATES AND 5 EUROPEAN COUNTRIES (FRANCE, GERMANY, ITALY, SPAIN, UK)
 Jim Kershaw, GB
- 09:00 - 09:00 P0986
IMPACT OF SUBOPTIMAL RESPONSE ON CLINICAL AND HUMANISTIC BURDEN IN CROHN'S DISEASE
 Jim Kershaw, GB
- 09:00 - 09:00 P0987
IMPACT OF DISEASE FLARES ON RESOURCE USE, HEALTH-RELATED QUALITY OF LIFE AND PRODUCTIVITY IN PATIENTS WITH ULCERATIVE COLITIS IN EUROPE: AN ANALYSIS OF NATIONAL HEALTH AND WELLNESS SURVEY DATA
 Myrlene Sanon, US
- 09:00 - 09:00 P0988
IMPACT OF DISEASE FLARES ON RESOURCE USE, HEALTH-RELATED QUALITY OF LIFE AND PRODUCTIVITY IN PATIENTS WITH CROHN'S DISEASE IN EUROPE: AN ANALYSIS OF NATIONAL HEALTH AND WELLNESS SURVEY DATA
 Myrlene Sanon, US
- 09:00 - 09:00 P0989
PRE-ENDOSCOPY ANESTHESIOLOGY CLINIC EVALUATION DOES NOT REDUCE COMPLICATION RATES IN HIGH-RISK PATIENTS FOR SEDATION
 Niv Zmora, IL
- 09:00 - 09:00 P0990
ESTIMATING THE ENVIRONMENTAL IMPACT OF ENDOSCOPIC ACTIVITY AT A TERTIARY CENTER: A PILOT STUDY
 Tiago Ribeiro, PT
- 09:00 - 09:00 P0991
ASSESSMENT OF RESOURCE USE IN PATIENTS WITH HYPERMOBILE EHLERS DANLOS SYNDROME AND THEIR DIFFERENT FUNCTIONAL GI DISORDERS
 Shraya Pandya, GB
- 09:00 - 09:00 P0992
APPLICATION OF MACHINE LEARNING ALGORITHM BASED ON MULTI-FEATURE FITTING IN THE DIAGNOSIS OF WHITISH NEOPLASTIC GASTRIC LESIONS UNDER WHITE LIGHT GASTROSCOPY
 Xiaoquan Zeng, CN
- 09:00 - 09:00 P0993
DIAGNOSTIC ACCURACY OF 3D-BASED AI TECHNOLOGY TO IDENTIFY THE STATUS OF THE PREDICTED RESECTION IN MARGINS IN PATIENTS WITH LOCALLY ADVANCED AND RECURRENT RECTAL CANCER
 Gianluca Pellino, IT
- 09:00 - 09:00 P0994
IT TAKES A VILLAGE: ENGINEERING AND BEHAVIORAL RESEARCH TOWARD THE DEVELOPMENT OF A DIGITAL OUTCOME MEASURE FOR CONSTIPATION MANAGEMENT THAT PATIENTS AND DOCTORS WANT TO USE
 V Vien Lee, SG
- 09:00 - 09:00 P0995
CLINICAL VALIDATION OF DEEP LEARNING-BASED BOWEL PREPARATION ASSESSMENT SYSTEM: A SINGLE CENTER, PROSPECTIVE, TANDEM STUDY
- 09:00 - 09:00 P0996
PSYCHOLOGICAL INTERVENTIONS IMPROVE QUALITY OF LIFE IN PATIENTS WITH CANCER – A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS
 Anna Sára Bognár, HU
- 09:00 - 09:00 P0997
THE STATUS OF CLINICAL NUTRITION EDUCATION IN IRELAND: INTEGRATING CLINICAL NUTRITION EDUCATION INTO UNDERGRADUATE TRAINING. AN INITIATIVE OF THE IRISH SOCIETY OF CLINICAL NUTRITION AND METABOLISM
 Neasa McGettigan, IE
- 09:00 - 09:00 P0998
COMPARATIVE ANALYSIS OF NUTRITIONAL BEHAVIOUR OF THE UKRAINIAN AND FOREIGN STUDENTS OF DANYLO HALYTSKY LVIV NATIONAL MEDICAL UNIVERSITY
 Christina Nasadyuk, UA
- 09:00 - 09:00 P1000
THE RELATIONSHIP BETWEEN DIET, THE GUT MICROBIOME AND HEALTH OUTCOMES: PERCEPTIONS OF CONSUMERS AND NUTRITION PROFESSIONALS
 Georgina Williams, AU
- 09:00 - 09:00 P1001
PHENOMENON OF AN INCREASE OF THE BLOOD-BRAIN BARRIER PERMEABILITY IN RATS WITH STRESS-INDUCED METASTATIC COLON ADENOCARCINOMA
 Ilana Agranovich, RU
- 09:00 - 09:00 P1002
COMPREHENSIVE LIFESTYLE-MODIFICATION IN PATIENTS WITH CROHN'S DISEASE - A RANDOMIZED CONTROLLED TRIAL
 Jost Langhorst, DE
- 09:00 - 09:00 P1003
BRADYENTERIA SYNDROME AND COMORBIDITY
 Konstantine S. Shemerovskii, RU
- 09:00 - 09:00 P1004
EXPERIENCE IN ORGANIZING URGENT TRAINING FOR GI PROFESSIONALS ON EMERGENCY CARE FOR ABDOMINAL INJURIES DURING THE WAR IN UKRAINE
 Oksana Popova, UA
- 09:00 - 09:00 P1005
USE OF VIDEO GAMES AND ACQUISITION OF ENDOSCOPIC SKILLS. A STUDY FROM TERTIARY CARE HOSPITAL, PAKISTAN 🇵🇰
 Farhana Kayani, PK

- 09:00 - 09:00 P1006
TOWARDS A GREENER ENDOSCOPY ROOM: RECYCLING PLASTIC WASTE
 Djuna de Jong, NL
- 09:00 - 09:00 P1007
VIGATU - FIRST EXPERIENCES WITH THE VIRTUAL REALITY-BASED PERSONAL ENDOSCOPY TRAINER
 Alexander Hann, DE
- 09:00 - 09:00 P1008
GOOD FOR THE ENVIRONMENT AND THE POCKET – AN AUDIT OF WASTE GENERATION AND RECYCLING PRACTICES WITHIN AN IRISH ENDOSCOPY UNIT
 Neil O'Morain, IE
- 09:00 - 09:00 P1009
EFFECT OF TRADITIONAL CHINESE MEDICINE HOT IRONING THERAPY ON RECOVERY OF GASTROINTESTINAL FUNCTION IN PATIENTS AFTER GASTROINTESTINAL ANASTOMOSIS
 Tingting Zhang, CN
- 09:00 - 09:00 P1010
TRANSCRIPTIONALLY INACTIVE NRF2 INFLUENCE COLON MORPHOLOGY AND FUNCTION IN FEMALE MICE VIA MODULATION OF ESTROGEN LEVEL AND ESTROGEN RECEPTORS EXPRESSION
 Aleksandra Piechota-Polanczyk, PL
- 09:00 - 09:00 P1011
HIGH PREVALENCE OF SIGNIFICANT GASTROINTESTINAL PATHOLOGIES AMONG PATIENTS REFERRED FROM PRISON TO GASTROENTEROLOGY
 Mohamed G. Shiha, GB
- 09:00 - 09:00 P1012
ESTROGEN REGULATES DUODENAL GLUCOSE ABSORPTION THROUGH THE EFFECT OF ESTROGEN RECEPTOR-A ON GLUCOSE TRANSPORTERS

Poster Exhibition

09:00 – 17:30 Science Lounge
Other lower GI disorders

- 09:00 - 09:00 P0533
THE ORAL TISSUE TRANSGLUTAMINASE INHIBITOR ZED1227 PREVENTS GLUTEN-INDUCED ENTEROPATHY IN A HUMANIZED MOUSE MODEL OF CELIAC DISEASE
 Hicham El Mard, DE
- 09:00 - 09:00 P0534
MULTIDISCIPLINARY BELGIAN POSITION STATEMENT ON THE MANAGEMENT OF IMMUNE CHECKPOINT INHIBITOR ASSOCIATED COLITIS
 Aranzazu Jauregui Amezaga, BE
- 09:00 - 09:00 P0535
GENETIC FEATURES OF GLUTEN-RELATED DISORDERS IN UKRAINIAN PATIENTS
 Olena Gubska, UA

- 09:00 - 09:00 P0536
ISOLATED TERMINAL ILEITIS: THE NATURAL COURSE OF DISEASE
 Jayne Doherty, IE
- 09:00 - 09:00 P0537
ALTERATIONS OF GUT MICROBIOTA IN FUNCTIONAL DIARRHEA - A RETROSPECTIVE SINGLE-CENTER STUDY
 Cecilia Lina Pugliano, IT
- 09:00 - 09:00 P0538
A PROBIOTIC FORMULA FOR MODULATION OF COLORECTAL CANCER RISK VIA REDUCING CRC-ASSOCIATED BACTERIA
 Jessie Qiaoyi Liang, HK
- 09:00 - 09:00 P0539
INTRODUCTION OF THE PROBIOTIC STRAIN, E COLI NISSLE 1917, REDUCES MICROBIAL DIVERSITY, PARTIALLY MEDIATED BY HOST-ACTIVATED TYPE VI SECRETION SYSTEM
 Haggai Bar-Yoseph, CA
- 09:00 - 09:00 P0540
DIET-MICROBIOME INTERACTIONS AND THEIR POTENTIAL IMPACT ON THE HUMAN HEALTH
 Dilyara Safina, RU
- 09:00 - 09:00 P0541
BAY3295079 BENEFICIALLY MODULATES HUMAN MICROBIAL COMPOSITION AND ACTIVITY *IN VITRO*
 Ramy Ammar, DE
- 09:00 - 09:00 P0542
ROLE OF GUT MICROBIOME AND SHORT CHAIN FATTY ACIDS IN MEDIATING STW 5-II EFFECT ON GUT EPITHELIAL AND IMMUNE REGULATION: AN *IN VITRO* STUDY
 Ramy Ammar, DE
- 09:00 - 09:00 P0543
CHANGES IN THE GUT MICROBIOME ASSOCIATED WITH MURINE MC38 COLON TUMORS BY ANTI-PD-L1 ANTIBODY AND 17B-ESTRADIOL TREATMENT
 Chin-Hee Song, KR
- 09:00 - 09:00 P0544
ALTERATION OF GUT MICROBIOTA BY ENDOGENOUS AND EXOGENOUS ANDROGENS IN AZOXYMETHANE/DEXTRAN SULFATE SODIUM-INDUCED COLON CANCER MOUSE MODEL
 Nayoung Kim, KR
- 09:00 - 09:00 P0545
INHIBITION OF *IN VITRO* CLOSTRIDIODES DIFFICILE BIOFILM FORMATION BY THE PROBIOTIC YEAST SACCHAROMYCES BOULARDII CNCM I-745 THROUGH MODIFICATION OF THE EXTRACELLULAR MATRIX COMPOSITION
 Sylvie Bouttier, FR
- 09:00 - 09:00 P0546
INTESTINAL MICROBIOTA TRANSPLANT FOR RECURRENT CLOSTRIDIODES DIFFICILE INFECTION RESTORES MICROBIAL ARYLSULFATASES AND SULFATIDE DEGRADATION: A NOVEL MECHANISM OF EFFICACY?
 Benjamin Mullish, GB

09:00 - 09:00 P0547
THE PECULIARITIES OF INTESTINAL MICROBIOME IN PATIENTS WITH OSTEOARTHRITIS
 Andrii Kuzminets, UA

09:00 - 09:00 P0548
S. BOULARDII CNCM I-745 STIMULATES IMMUNITY BY INCREASING INTRACELLULAR BACTERICIDAL ACTIVITY AGAINST SALMONELLA TYPHIMURIUM IN MACROPHAGES
 Dorota Czerucka, MC

09:00 - 09:00 P0549
ECONOMIC AND CHRONOLOGIC OPTIMIZATION OF FECAL DONOR RECRUITMENT IN THE BACTERIOTHERAPY CLINIC. ANALYSIS OF 5 YEARS OF ACTIVITY
 Lael Werner, IL

09:00 - 09:00 P0550
DOT-BLOT HYBRIDIZATION FOR THE RAPID AND SIMULTANEOUS DETECTION OF CAMPYLOBACTER JEJUNI AND CAMPYLOBACTER COLI

09:00 - 09:00 P0551
CLINICAL CHARACTERISTICS AND OUTCOMES OF CLOSTRIDIODES DIFFICILE INFECTION IN THE INTENSIVE CARE UNIT
 Ji Eun Baik, KR

09:00 - 09:00 P0552
PERFORMANCE OF COMBINED STOOL AND SERUM CYTOMEGALOVIRUS REAL-TIME POLYMERASE CHAIN REACTION IN DIAGNOSING CMV COLITIS
 Onuma Sattayalertyanyong, TH

09:00 - 09:00 P0553
CHARACTERISATION OF THE MUCOSAL IMMUNE RESPONSE IN COLONIC SPIROCHAETOSIS
 Kening Fan, AU

09:00 - 09:00 P0554
CHANGES OF CLOSTRIDIODES DIFFICILE INFECTION RATE DURING FIRST STAGES OF COVID-19 PANDEMIC ERA -A RETROSPECTIVE STUDY FROM A ROMANIAN TERTIARY CENTER
 Mirela Chirvase, RO

09:00 - 09:00 P0555
RISK FACTORS FOR TREATMENT FAILURE AFTER FECAL MICROBIOTA TRANSPLANTATION IN CLOSTRIDIODES DIFFICILE INFECTION
 Jung-Hwan Lee, KR

09:00 - 09:00 P0556
EVALUATION OF THE RECURRENCE RATE OF CLOSTRIDIODES DIFFICILE INFECTION AFTER ADMINISTRATION OF BEZLOTOXUMAB IN A SINGLE CENTER
 Francisco Lopez Romero-Salazar, ES

09:00 - 09:00 P0557
THE EFFICACY AND SAFETY OF HEMOSTATIC POWDER UI-EWD IN PATIENTS WITH LOWER GASTROINTESTINAL BLEEDING
 Jongbeom Shin, KR

09:00 - 09:00 P0558
CAN HOSPITAL ADMISSIONS FOR LOWER GASTROINTESTINAL BLEEDING BE REDUCED? IMPLEMENTATION OF TWO SCALES FOR THE PREDICTION OF SAFETY DISCHARGE IN A RETROSPECTIVE COHORT
 Laura Gonzalez Gonzalez, ES

09:00 - 09:00 P0559
MANAGEMENT AND OUTCOMES OF LOWER GASTROINTESTINAL BLEEDING IN PATIENTS ON ANTICOAGULATION
 Laura Gonzalez Gonzalez, ES

09:00 - 09:00 P0560
SAFETY OF PERFORMING LEFT SIDE COLONOSCOPY VERSUS TOTAL COLONOSCOPY IN PATIENTS LESS THAN 45 YEARS OLD AGE PRESENTED WITH FEATURES SUGGESTIVE OF PERIANAL DISEASE
 Mohamed Al-Shekhani, IQ

09:00 - 09:00 P0561
EFFECT OF LONG-TERM TREATMENT WITH SOMATOSTATIN ANALOGUES IN PATIENTS WITH GASTROINTESTINAL ANGIODYSPLASIA: A SINGLE-CENTER EXPERIENCE
 Alba Jiménez-Masip, ES

09:00 - 09:00 P0562
CHARACTERISTIC OF THE PATIENTS AND LESIONS WITH DELAYED BLEEDING AFTER COLORECTAL ESD THAT DO NOT REQUIRE HEMOSTASIS
 Satsuki Takahashi, JP

09:00 - 09:00 P0563
THE FACTOR ANALYSIS INFLUENCING THE DIAGNOSTIC YIELDS OF CAPSULE ENDOSCOPY IN PATIENTS WITH OBSCURE GI BLEEDING
 Keehyung Hong, KR

09:00 - 09:00 P0564
OUTCOMES OF TRANSCATHETER AORTIC VALVE IMPLANTATION IN GASTROINTESTINAL BLEEDING
 Irene Latras Cortés, ES

09:00 - 09:00 P0565
INTRARECTAL FORMALIN TREATMENT FOR HAEMORRHAGIC RADIATION INDUCED PROCTOPATHY: EFFICACY AND SAFETY
 Darina Kohoutova, GB

09:00 - 09:00 P0566
INTERNATIONAL ON-LINE QUESTIONNAIRE ABOUT SEVERE LOWER GASTROINTESTINAL BLEEDING MANAGEMENT. DO WE HAVE IT CLEAR?
 Mónica Ayude Galego, ES

09:00 - 09:00 P0567
HYDRAULIC LOCAL INFUSION OF EPINEPHRINE-CONTAINING SALINE IS EFFECTIVE IN PREVENTING POSTOPERATIVE BLEEDING IN COLD SNARE POLYPECTOMY UNDER ANTICOAGULATION THERAPY
 Mitsunori Yasuda, JP

09:00 - 09:00	P0568	09:00 - 09:00	P0579
BARRIERS AND WILLINGNESS FOR COLORECTAL CANCER SCREENING IN A MUSLIM POPULATION OF SOUTH ASIAN COUNTRY: NATIONWIDE SURVEY (INTERIM ANALYSIS)		DETECTING COLORECTAL ADENOMAS AND CANCER VIA VOLATILE ORGANIC COMPOUNDS IN EXHALED BREATH, A PROOF OF PRINCIPLE STUDY TO IMPROVE SCREENING	
Tauqeer Shaikh, PK		Hao Ran Cheng, NL	
09:00 - 09:00	P0569	09:00 - 09:00	P0580
SOCIOECONOMIC AND ETHNIC DISPARITIES IN COLORECTAL SCREENING BEFORE AND DURING THE COVID-19 PANDEMIC: A POPULATION-BASED STUDY IN ISRAEL		LOWER HEALTHCARE COSTS ASSOCIATED WITH COLORECTAL CANCER TREATMENT FOLLOWING SCREEN DETECTION	
Zohar Levi, IL		Jannie Dressler, DK	
09:00 - 09:00	P0570	09:00 - 09:00	P0581
IMPACT OF THE COVID-19 PANDEMIC ON THE COLORECTAL CANCER SCREENING PROCEDURES IN THE CZECH REPUBLIC		QUALITY OF ENDOSCOPIC SCREENING FOR COLORECTAL CANCER IN ITALY: A NATIONAL SURVEY	
Stepan Suchanek, CZ		Marcello Fabio Maida, IT	
09:00 - 09:00	P0571	09:00 - 09:00	P0582
SERINE, AN AMINO-ACID INVOLVED IN PRO-CARCINOGENIC EFFECTS OF COLIBACTIN-PRODUCING <i>ESCHERICHIA COLI</i> IN THE COLON		CHANGE IN COLONOSCOPY RECEIVING RATE FOR POSITIVE FECAL IMMUNOCHEMICAL TEST AND A DELAY OF COLORECTAL CANCER DETECTION UNDER THE COVID-19 PANDEMIC	
Amandine Devaux, FR		Fumiaki Ishibashi, JP	
09:00 - 09:00	P0572	09:00 - 09:00	P0583
SLC26A9 PROMOTES COLORECTAL TUMORIGENESIS VIA WNT/β-CATENIN SIGNALING		ROUTINE IMMUNOHISTOCHEMICAL ANALYSIS OF MISMATCH REPAIR PROTEINS IN COLORECTAL CANCER - A PROSPECTIVE ANALYSIS	
Zhiyuan Ma, CN		Joana Lemos Garcia, PT	
09:00 - 09:00	P0573	09:00 - 09:00	P0584
TRIGLYCERIDE GLUCOSE INDEX (TYG INDEX) AND RISK OF COLORECTAL ADENOMATOUS POLYPS		FIRST CLINICAL EXPERIENCES OF THE NON-COMMERCIAL, PUBLICLY AVAILABLE POLYP DETECTION SYSTEM ENDOMIND	
Dae Sung Kim, KR		Alexander Hann, DE	
09:00 - 09:00	P0574	09:00 - 09:00	P0585
COLORECTAL CANCER IN PATIENTS WITH SERRATED POLYPOSIS SYNDROME: THE CONTRIBUTION OF THE ADENOMA CARCINOMA PATHWAY		DIFFERENCES IN ERYTHROCYTE AND SERUM MEMBRANE FATTY ACID LEVELS IN PATIENTS WITH COLORECTAL CANCER OF DIFFERENT LOCATIONS, WITH A FOCUS ON EARLY CANCER	
Joep IJspeert, NL		Margarita Vitalievna Kruchinina, RU	
09:00 - 09:00	P0575	09:00 - 09:00	P0586
CANCER-ASSOCIATED FIBROBLASTS ARE KEY DETERMINANTS OF TUMOUR PROGRESSION IN THE EARLIEST STAGE OF COLORECTAL CANCER		A PROSPECTIVE STUDY OF REAL-TIME USE OF COMPUTER-AIDED CHARACTERIZATION FOR COLORECTAL LESIONS	
Hao Dang, NL		Masashi Misawa, JP	
09:00 - 09:00	P0576	09:00 - 09:00	P0587
ESTABLISHMENT OF CRISPR-CAS9 RIBONUCLEOPROTEINS AS A GENOME EDITING TOOL FOR ARRAYED PHENOTYPIC SCREENING IN COLORECTAL CANCER		APPLICATION OF MODULAR MULTI-SENSOR VOC ANALYSER FOR NON-INVASIVE DETECTION OF COLORECTAL CANCER 	
		Linda Anarkulova, LV	
09:00 - 09:00	P0577	09:00 - 09:00	P0588
INCREMENTAL YIELD OF ARTIFICIAL INTELLIGENCE IN A FECAL OCCULT BLOOD TEST BASED ORGANIZED SCREENING POPULATION PROGRAM		BOWEL LAVAGE FLUID: CHARACTERIZATION AND MRNA ARRAY OF EXTRACELLULAR VESICLES IN COLORECTAL CANCER PATIENTS	
Eugenia Vittoria Pesatori, IT		Marina Alorda-Clara, ES	
09:00 - 09:00	P0578	09:00 - 09:00	P0589
PREDICTION OF LYMPH NODE METASTASIS IN T1 COLORECTAL CANCER BY ARTIFICIAL INTELLIGENCE USING HISTOLOGIC WHOLE-SLIDE IMAGES		CLINICOPATHOLOGICAL FEATURE OF DEPRESSED-TYPE COLORECTAL NEOPLASM	
		Shinei Kudo, JP	

09:00 - 09:00 P0590
WHICH IS THE BETTER PREDICTOR OF LYMPH NODE METASTASIS IN T1 COLORECTAL CANCER, LEAST OR PREDOMINANT DIFFERENTIATION? -A SINGLE-CENTER STUDY OF 853 LESIONS-

Osamu Shiina, JP

09:00 - 09:00 P0591
IS A NEGATIVE FIT FALSELY REASSURING?: A RETROSPECTIVE EVALUATION

Sarah Manning, GB

09:00 - 09:00 P0592
COLONIC POLYPS: SMALL IN SIZE, BIG IN IMPACT?

Sasha Thrumurthy, SG

09:00 - 09:00 P0593
IMMUNOREACT 0: BIOPSY-BASED IMMUNE BIOMARKER AS PREDICTORS OF RESPONSE TO NEOADJUVANT THERAPY FOR RECTAL CANCER: A SYSTEMATIC REVIEW AND META-ANALYSIS

Astghik Stepanyan, IT

09:00 - 09:00 P0594
A SIMPLE SCORING MODEL BASED ON ENDOSCOPIC FEATURES FOR SELECTION OF COLORECTAL CANCER AMENABLE TO ENDOSCOPIC RESECTION

09:00 - 09:00 P0595
RISK OF ADVANCED LESIONS AT SURVEILLANCE COLONOSCOPY COMPARING PATIENTS WITH SERRATED LESIONS AND HIGH-GRADE DYSPLASTIC ADENOMAS

Edgard Medawar, CA

09:00 - 09:00 P0596
THE EFFECT OF EDIBLE SEAWEED CONSUMPTION ON RISK OF COLORECTAL CANCER: A SYSTEMATIC REVIEW

Muhammad Luthfi Adnan, ID

09:00 - 09:00 P0597
MODIFIED UNDERWATER ENDOSCOPIC MUCOSAL RESECTION FOR INTERMEDIATE-SIZE SESSILE COLORECTAL POLYPS

Dong Hyun Kim, KR

09:00 - 09:00 P0598
COMPOUND SCREENING IN A 3D SPHEROID MODEL IDENTIFIES CURCUMIN ANALOG AS A COLORECTAL CANCER STEM CELL INHIBITOR

Marta Bento Afonso, PT

09:00 - 09:00 P0599
RATES OF SYNCHRONOUS ADVANCED NEOPLASIA AND COLORECTAL CANCER IN PATIENTS WITH COLONIC SERRATED LESIONS

Roupen Djinbachian, CA

09:00 - 09:00 P0600
MANAGEMENT OF COLORECTAL HIGH-GRADE DYSPLASIA OR CANCER RESECTED BY COLD SNARE POLYPECTOMY: A MULTICENTRE EXPLORATORY STUDY

Izumi Hisada, JP

09:00 - 09:00 P0601
A PILOT CONSEQUENCES OF COLORECTAL CANCER VIRTUAL CLINIC IN LINCOLNSHIRE DURING THE COVID-19 PANDEMIC

Darren Fernandes, GB

09:00 - 09:00 P0603
EVALUATION OF SHORT-TERM OUTCOMES FOR UNDERWATER ENDOSCOPIC MUCOSAL RESECTION AND ENDOSCOPIC SUBMUCOSAL DISSECTION FOR COLORECTAL POLYP 21-30 MM: A PROSPECTIVERANDOMIZED CONTROLLED PHASE 2 TRIAL

Kenichiro Okimoto, JP

09:00 - 09:00 P0604
IMPACT OF FECAL IMMUNOCHEMICAL TEST SCREENING ON COLORECTAL CANCER INCIDENCE AND MORTALITY

Pieter Henk Abraham Wisse, NL

09:00 - 09:00 P0605
ENDOSCOPIC SUBMUCOSAL DISSECTION OR PIECEMEAL ENDOSCOPIC MUCOSAL RESECTION FOR LARGE SUPERFICIAL COLORECTAL LESIONS: COST-EFFECTIVENESS IN THE ERA OF SYSTEMATIC COUNTERTRACTION

Timothee Wallenhorst, FR

09:00 - 09:00 P0607
3D COMPUTED TOMOGRAPHY IN PREOPERATIVE ANALYSIS OF VASCULAR ANATOMY OF PATIENTS WITH RIGHT SIDED COLON CANCER

Stepan Grytsenko, UA

09:00 - 09:00 P0608
COMPARISON OF TREATMENT OUTCOMES BETWEEN HOT SNARE POLYPECTOMY AND ENDOSCOPIC MUCOSAL RESECTION WITH BIPOLAR SNARE FOR 10-15 MM COLORECTAL LESIONS

Nobuhisa Minakata, JP

09:00 - 09:00 P0609
DISCOVERY OF NOVEL COLON CANCER STEM CELL INHIBITORS BY INDUCING MULTIPLE REGULATED CELL DEATH PATHWAYS

Marta Bento Afonso, PT

09:00 - 09:00 P0610
SHORT-TERM OUTCOMES OF STAGE II/III NON-RIGHT-SIDED OBSTRUCTIVE COLON CANCER WITH SELF-EXPANDING METALLIC STENT OR TRANS-ANAL COLORECTAL TUBE PLACEMENT

Konomu Uno, JP

09:00 - 09:00 P0611
MALIGNANT COLORECTAL POLYPS - ARE WE GETTING SUFFICIENT INFORMATION TO GUIDE MANAGEMENT?

Cláudio Rodrigues, PT

09:00 - 09:00 P0612
QUALITY OF LIFE AND FUNCTIONAL OUTCOMES AFTER ILEORECTAL OR ILEOSIGMOIDAL ANASTOMOSIS VERSUS ILEAL POUCH-ANAL ANASTOMOSIS IN PATIENTS WITH FAMILIAL ADENOMATOUS POLYPOSIS

Arthur S. Aelvoet, NL

09:00 - 09:00 P0613
THE NECESSARY PROPRIETY OF ADDITIONAL SURGERY FOR ELDERLY PATIENTS WITH T1 COLORECTAL CANCERS TREATED BY ENDOSCOPIC RESECTION

Hideyuki Miyachi, JP

09:00 - 09:00 P0614
IMPACT OF PRE-TREATMENT SARCOPENIA IN PATIENTS WITH COLORECTAL CANCER
 Myriam Ayari, TN

09:00 - 09:00 P0615
ENDOSCOPIC SUBMUCOSAL DISSECTION IS SAFE AND EFFECTIVE FOR LESIONS LOCATED AT THE ANO-RECTAL JUNCTION: ANALYSIS FROM TWO REFERRAL EUROPEAN CENTRES

Mariana Figueiredo Ferreira, BE

09:00 - 09:00 P0616
CLINICAL AUDIT OF ENBLOC RESECTION FOR LARGE COLORECTAL MUCOSAL LESIONS USING ENDOSCOPIC SUBMUCOSAL DISSECTION (ESD) FROM A SINGLE CENTER FROM A REGION NON ENDEMIC FOR COLORECTAL CANCER – ASSESSING THE PREDICTIVE FACTORS FOR DIFFICULT ESD AND LEARNING CURVE FOR ESD

Jaseem Ansari, IN

09:00 - 09:00 P0617
CLINICAL OUTCOMES OF ENDOSCOPIC STENT INSERTION OR BYPASS OPERATION FOR MALIGNANT COLONIC OBSTRUCTION DUE TO PANCREATOBILIARY CANCER

Chan Su Park, KR

09:00 - 09:00 P0618
THE ENGLISH BOWEL CANCER SCREENING PROGRAMME; DESIGNED FOR AN ASYMPTOMATIC POPULATION, BUT IS THIS THE CASE?

Ajay M Verma, GB

09:00 - 09:00 P0619
ACTION OF 4-THIAZOLIDINONE DERIVATIVES ON FREE RADICAL OXIDATION IN RAT`S COLON MUCOSA UNDER THE CONDITIONS OF COLORECTAL CANCER

Nataliya Denysenko, UA

09:00 - 09:00 P0620
A DUAL STRAIN *BIFIDOBACTERIUM LONGUM* PROBIOTIC IS ASSOCIATED WITH SIGNIFICANT IMPROVEMENTS IN GASTROINTESTINAL AND PSYCHOSOCIAL SYMPTOMS IN PEOPLE WITH IRRITABLE BOWEL SYNDROME – A REAL-WORLD EXPERIENCE PROGRAMME

Fiona Kinnear, IE

09:00 - 09:00 P0621
DO IRRITABLE BOWEL SYNDROME PATIENTS WITH AND WITHOUT HYPERMOBILITY SPECTRUM DISORDERS DIFFER IN GASTROINTESTINAL SYMPTOMS, PSYCHOLOGICAL COMORBIDITIES, AND QUALITY OF LIFE?

Lisa Vork, NL

09:00 - 09:00 P0622
NETWORK MODELLING IN CHRONIC CONSTIPATION: DELINEATING DISEASE PHENOTYPES

Rebekah Rajiah, GB

09:00 - 09:00 P0623
FECAL CALPROTECTIN IS CORRELATED WITH SERUM CYTOKINES IN DIARRHEA SUBTYPE IRRITABLE BOWEL SYNDROME

Juan Ignacio Olmos, AR

09:00 - 09:00 P0624
BENIGN JOINT HYPERMOBILITY SYNDROME IN IRRITABLE BOWEL SYNDROME
 Irina Midenfjord, SE

09:00 - 09:00 P0625
PREVALENCE OF ANTIGLIADIN IGG ANTIBODIES (AGA IGG) AND THE ASSOCIATION WITH SYMPTOMS IN IRRITABLE BOWEL SYNDROME

Joost Algera, SE

09:00 - 09:00 P0626
INTESTINAL PERMEABILITY, ABDOMINAL SYMPTOMS AND PSYCHOLOGICAL COMORBIDITIES IN IBS-D PATIENTS

Giovanni Marasco, IT

09:00 - 09:00 P0627
GASTROINTESTINAL SYMPTOMS AND AUTONOMIC DYSFUNCTION IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS: EARLY DETECTION AND MONITORING THROUGH THE COMPASS 31 SCORE

Daniele Brinch, IT

09:00 - 09:00 P0628
STW 5-II COUNTERACTED STRESS-INDUCED INFLAMMATION AND TIGHT JUNCTION DISRUPTION IN IBS-LIKE MODEL USING INTESTINAL ORGANOID

Mohamed Elbadawi, DE

09:00 - 09:00 P0629
IMPORTANCE OF BOWEL HABITS AS A RISK FACTOR OF INADEQUATE BOWEL PREPARATION IN COLONOSCOPY: A PROSPECTIVE QUESTIONNAIRE-BASED OBSERVATIONAL STUDY

Natsumi Maeda, JP

09:00 - 09:00 P0630
STUDY OF THE DIAGNOSTIC ABILITY OF ULTRASONOGRAPHY COMPARED TO CT FOR FECES IN THE RECTUM

Noboru Misawa, JP

09:00 - 09:00 P0632
PREVALENCE AND PATHOPHYSIOLOGY OF FECAL CONSISTENCY DISORDERS AND THEIR IMPACT ON CLINICAL SEVERITY AND QUALITY OF LIFE IN PATIENTS WITH FECAL INCONTINENCE

Alba Raventós, ES

09:00 - 09:00 P0633
EFFECTIVE DIAGNOSIS OF DYSSYNERGIC DEFECTION IN REFRACTORY CONSTIPATION BY MINIMALLY INVASIVE PROTOCOL

Christian Lambiase, IT

09:00 - 09:00 P0634
CHARACTERIZATION OF DEFECTION DISORDERS FROM A STRUCTURAL AND A FUNCTIONAL PERSPECTIVE IN A COHORT OF 588 PATIENTS

Lluís Mundet, ES

09:00 - 09:00 P0635
IMPACT ON QUALITY OF LIFE BEFORE AND AFTER TREATMENT INTERVENTION FOR CHRONIC INTESTINAL PSEUDO-OBSTRUCTION

Kota Takahashi, JP

09:00 - 09:00 P0636
CHARACTERISTIC PATTERNS IN HIGH RESOLUTION ANORECTAL MANOMETRY IN PATIENTS WITH FECAL INCONTINENCE AFTER LOW ANTERIOR RESECTION SURGERY

Ignacio Blanco Nodal, ES

09:00 - 09:00 P0637
PROSPECTIVE ASSESSMENT OF ANAL DISTENSIBILITY USING ENDOFLIP IN HEALTHY VOLUNTEERS

Annika Rasijeff, GB

09:00 - 09:00 P0638
EFFECT OF *BIFIDOBACTERIUM BIFIDUM G9-1* ON FECAL SHORT-CHAIN FATTY ACIDS IN PATIENTS WITH CHRONIC CONSTIPATION: A MULTICENTER, OBSERVATIONAL STUDY

Tomoki Ogata, JP

09:00 - 09:00 P0639
VALIDATION OF THE RAPID BAROSTAT BAG (RBB) PUMP AND COMPARISON WITH CONVENTIONAL ELECTROMECHANICAL BAROSTAT

Annika Rasijeff, GB

09:00 - 09:00 P0640
TSH RECEPTOR ANTIBODIES (TRAB) – A POTENTIAL NEW BIOMARKER TO DIFFER BETWEEN IRRITABLE BOWEL SYNDROME AND ENDOMETRIOSIS

Bodil Ohlsson, SE

09:00 - 09:00 P0641
SYMPTOM CLUSTERS OUTSIDE THE ROME IV CONSENSUS CAN BE IDENTIFIED IN BOTH EASTERN AND WESTERN PATIENTS WITH A DISORDER OF GUT-BRAIN INTERACTION: PRELIMINARY RESULTS OF AN ONGOING INTERNATIONAL MULTICENTER STUDY

Esther Colomier, BE

09:00 - 09:00 P0642
COMPARISON OF THE HABITUAL DIETARY INTAKE AND DIET QUALITY IN PATIENTS WITH IRRITABLE BOWEL SYNDROME AND THE GENERAL POPULATION

Esther Colomier, BE

09:00 - 09:00 P0643
IDENTIFYING DIFFERENT IRRITABLE BOWEL SYNDROME SUBGROUPS BASED ON BOWEL HABITS AND PSYCHOLOGICAL COMORBIDITY: A REPLICATION STUDY USING MIXTURE MODELLING

Inês A. Trindade, SE

09:00 - 09:00 P0644
KOMBUCHA-BASED SPECIALIZED FOOD PRODUCT FOR TREATMENT OF CONSTIPATION

Vladimir Pilipenko, RU

09:00 - 09:00 P0645
NON-COELIAC GLUTEN SENSITIVITY APPEARS TO BE THE MAJOR PRESENTING AETIOLOGY BEHIND IBS

Taliah Su'a, NZ

09:00 - 09:00 P0646
ROLE OF DIETARY HABITS ON SYMPTOM CONTROL AND GUT MICROBIOTA COMPOSITION IN PATIENTS WITH IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C)

Salvatore Crucillà, IT

09:00 - 09:00 P0647
GENERAL LIFE SATISFACTION IN IBS PATIENTS IS ASSOCIATED WITH PSYCHOLOGICAL SYMPTOM BURDEN AND QUALITY OF LIFE, RATHER THAN GASTROINTESTINAL SYMPTOM SEVERITY

Johanna Theodora Wilhelmina Snijkers, NL

09:00 - 09:00 P0648
IRRITABLE BOWEL SYNDROME SYMPTOM SEVERITY AND ASSOCIATION WITH SHORT-CHAIN FERMENTABLE CARBOHYDRATES CONSUMPTION AFTER BARIATRIC SURGERY: AN OBSERVATIONAL PROSPECTIVE STUDY

Pauline Van Ouytsel, BE

09:00 - 09:00 P0649
EFFECT OF IBEROGAST (STW5) ON TOLERANCE TO COLONIC GAS IN PATIENTS WITH IRRITABLE BOWEL SYNDROME

Ariadna Aguilar, ES

09:00 - 09:00 P0650
INTESTINAL METHANOGEN OVERGROWTH IN AN IRISH COHORT - A CHALLENGING PROBLEM

Aislinn Mary Keane McCarthy, IE

09:00 - 09:00 P0651
IMPACT OF INTEGRATED MULTIDISCIPLINARY MANAGEMENT ON SUBSEQUENT HEALTH CARE UTILISATION BY COMPLEX PATIENTS WITH DISORDERS OF BRAIN-GUT INTERACTION: A PROSPECTIVE 12-MONTH CONTROL COHORT STUDY

Benjamin McKillen, AU

09:00 - 09:00 P0652
13C-BUTYRATE AND 13C-GLUCOSE BREATH TESTING TO DETECT MESENTERIC ISCHEMIA, A PROOF OF PRINCIPAL STUDY IN HEALTHY VOLUNTEERS

Duygu Harmankaya, NL

09:00 - 09:00 P0653
AGE-ADJUSTED CHARLSON COMORBIDITY INDEX PREDICTS COLONIC DIVERTICULAR REBLEEDING

Hyesu You, KR

09:00 - 09:00 P0654
CURRENT TREATMENT AND MANAGEMENT OF DIVERTICULAR DISEASE IN GERMANY: CHALLENGING DIAGNOSIS AND SUCCESSFUL PROBIOTIC THERAPY


Manfred Gross, DE

09:00 - 09:00 P0655
PRIOR ABDOMINAL SURGERY: A POTENTIAL RISK FACTOR FOR COLONIC DIVERTICULOSIS OR DIVERTICULITIS

Haim Shirin, IL

- 09:00 - 09:00 P0656
DIVERTICULOSIS IS ASSOCIATED WITH FUTURE EXTRA-GI HEALTH CARE UTILISATION BUT NOT GI HEALTH CARE UTILISATION
 Michael P. Jones, AU
- 09:00 - 09:00 P0657
ETIOLOGIC AND PHYSIOLOGIC CHARACTERISTICS OF FECAL INCONTINENCE IN MEN
 Dan Carter, IL
- 09:00 - 09:00 P0658
SCLEROTHERAPY WITH POLIDOCANOL FOAM VERSUS HEMORRHOIDAL ARTERY LIGATION WITH RECTO ANAL REPAIR IN THE TREATMENT OF SECOND AND THIRD-GRADE HEMORRHOIDAL DISEASE: A RANDOMIZED, PILOT STUDY
 Daniela Falcão, PT
- 09:00 - 09:00 P0659
CELL SHAPE CHARACTERISTICS OF HUMAN SKELETAL MUSCLE CELLS AS A PREDICTOR OF MYOGENIC COMPETENCY: A NEW PARADIGM TOWARDS PRECISION CELL THERAPY FOR INCONTINENCE
 Charlotte Desprez, FR
- 09:00 - 09:00 P0660
A SYSTEMATIC REVIEW OF OUTCOMES ASSOCIATED WITH SETON PLACEMENT AND OTHER NON-INVASIVE TECHNIQUES FOR COMPLEX CRYPTOGLANDULAR FISTULA
 Dimitri Bennett, US
- 09:00 - 09:00 P0661
RELATIONSHIP BETWEEN ANAL FUNCTIONAL LUMEN IMAGING PROBE (ENDOFLIP®) RESULTS AND THE CLINICAL PRESENTATION OF FAECAL INCONTINENCE
 Charlotte Desprez, FR
- 09:00 - 09:00 P0666
THE EFFECTIVENESS OF PERSONALIZED COLORECTAL CANCER SCREENING BASED ON PRIOR FECAL HEMOGLOBIN CONCENTRATION: PERFECT-FIT STUDY PROTOCOL
 Esther Toes-Zoutendijk, NL
- 09:00 - 09:00 P0667
DIAGNOSTIC VALUE OF BIOPSY FOR LESIONS FOUND IN THE TERMINAL ILEUM DURING COLONOSCOPY
 Dae Sung Kim, KR
- 09:00 - 09:00 P0668
EVALUATION OF 2 DIFFERENT REGIMENS OF COLON PREPARATION FOR AN ADVANCED CLEENING USING A 2LT PEG-CS WITH SIMETHICONE: A RANDOMIZED, CONTROLLED STUDY - THE ERACLES STUDY
 Giuseppe Grande, IT
- 09:00 - 09:00 P1034
THE LOW FODMAP DIET IS EFFECTIVE IN IBS-C TERTIARY CARE NORMAL CLINICAL PRACTICE AND DOES NOT INCREASE CONSTIPATION
 Lee D Martin, GB

Poster Exhibition

- 09:00 - 17:30 Science Lounge
Pancreas
- 09:00 - 09:00 P0795
SILENCING OF *AHR* AND *DELA* GENES INFLUENCES POST-TRANSCRIPTIONAL EXPRESSION OF EACH OTHER AND CHEMORESISTANCE OF PANCREATIC CANCER CELLS, IN VITRO
 Zilvinas Dambrauskas, LT
- 09:00 - 09:00 P0796
WHAT IS THE SIGNIFICANCE OF A FAECAL ELASTASE-1 LEVEL BETWEEN 200 - 500MG/G?
 Darren Fernandes, GB
- 09:00 - 09:00 P0797
NOVEL PANCREAS PERFUSION CIRCUIT WITH PRE-DETERMINED PHYSIOLOGICAL PARAMETERS; A PILOT STUDY
 Zainab L. Rai, GB
- 09:00 - 09:00 P0798
OPTIMIZATION OF DOSE LEVELS OF ORALLY ADMINISTERED PANCREATIC ENZYME SUPPLEMENTS IN THE TINY-TIMSG DYNAMIC IN-VITRO GASTROINTESTINAL MODEL
 María-Luisa Orera-Peña, ES
- 09:00 - 09:00 P0799
LOSS OF *ONECUT1* ALTERS PANCREATIC EXOCRINE DEVELOPMENT
 Jana Krüger, DE
- 09:00 - 09:00 P0800
MODELLING PANCREATIC FACETS OF JOHANSON-BLIZZARD SYNDROME IN A DISH
 Markus Breunig, DE
- 09:00 - 09:00 P0801
PROINFLAMMATORY CYTOQUINES MAY HELP TO IDENTIFY EXOCRINE PANCREATIC INSUFFICIENCY PATIENTS IN A DIARRHEA-PREDOMINANT IBS- POPULATION 
 Juan Ignacio Olmos, AR
- 09:00 - 09:00 P0802
PPDPF IMPACTS PANCREATIC DIFFERENTIATION OF HUMAN PLURIPOTENT STEM CELL DERIVED PANCREATIC PROGENITORS
 Markus Breunig, DE
- 09:00 - 09:00 P0803
THE EFFECT AND MECHANISM OF LPS AND ASCITIC FLUID OF SEVERE ACUTE PANCREATITIS ON INTESTINAL BARRIER FUNCTION IN VITRO
 Yanping Song, CN
- 09:00 - 09:06 P0804
***TBX3* SHOWS SWITCHING EXPRESSION PATTERNS IN THE EMBRYONIC PANCREAS AND FINE-TUNES REGENERATION FROM ACUTE PANCREATITIS**
 Markus Breunig, DE

09:06 - 09:06 P0805
PREDICTIVE MODEL OF PERSISTENT CHOLEDOCOLITIASIS IN PATIENTS WITH ACUTE BILIARY PANCREATITIS

Alejandro Mínguez Sabater, ES

09:06 - 09:06 P0806
LOW BODY MASS INDEX INCREASES THE RISK OF ACUTE PANCREATITIS IN TYPE 2 DIABETES: A NATIONWIDE COHORT STUDY

Young Hoon Choi, KR

09:06 - 09:06 P0807
ACUTE PANCREATITIS INCREASES THE RISK OF GASTROINTESTINAL CANCER IN TYPE 2 DIABETIC PATIENTS: A KOREAN NATIONWIDE COHORT STUDY

Jin Ho Choi, KR

09:06 - 09:06 P0808
RECANALIZATION IN SPLANCHNIC VEIN THROMBOSIS ASSOCIATED TO ACUTE PANCREATITIS

Clara Ramos Belinchón, ES

09:06 - 09:06 P0811
ENDOSCOPIC PANCREATIC SPHINCTEROTOMY IN PATIENTS WITH IPMN-RELATED RECURRENT PANCREATITIS: A SINGLE CENTER EXPERIENCE

Tommaso Schepis, IT

09:06 - 09:06 P0812
ACUTE PANCREATITIS IN PATIENTS AFTER LIVER TRANSPLANTATION

Alzbeta Hujova, CZ

09:06 - 09:06 P0813
ENDOSCOPIC MINOR PAPANILLA SPHINCTEROTOMY IN PATIENTS WITH PANCREAS DIVISUM AND ACUTE RECURRENT PANCREATITIS: A METANALYSIS

Tommaso Schepis, IT

09:06 - 09:06 P0814
EXPLORING THE OPTIMAL TIMING OF PERFORMING ENDOSCOPIC ULTRASOUND AFTER AN EPISODE OF ACUTE IDIOPATHIC PANCREATITIS

Tawfik Khoury, IL

09:06 - 09:12 P0816
STUDY OF BILIARY MICROLITHIASIS IN THE CAUSATION OF ACUTE AND RECURRENT PANCREATITIS IN CHILDREN

09:12 - 09:12 P0818
ACUTE PANCREATITIS FOLLOWING PANCREATODUODENECTOMY: A PROSPECTIVE STUDY OF DIFFUSION-WEIGHTED MAGNETIC RESONANCE IMAGING, SERUM BIOMARKERS, AND CLINICAL FEATURES

09:12 - 09:12 P0819
ASGE SOP 2019 CHOLEDOCHOLITHIASIS CRITERIA ARE NOT RELIABLE IN PATIENTS WITH ACUTE BILIARY PANCREATITIS: A SINGLE CENTER EXPERIENCE

David Drobne, SI

09:12 - 09:18 P0820
ARTERIAL BLEEDING COMPLICATING ACUTE NECROTIZING PANCREATITIS: RISK FACTORS AND PREDICTIVE FEATURES

Diane Lorenzo, FR

09:18 - 09:18 P0821
THE ROLE OF TOTAL BILIRUBIN IN PREDICTING SEVERE ACUTE PANCREATITIS

Francisco Valverde-López, ES

09:18 - 09:24 P0822
THE EFFECT OF IMMUNE ENHANCEMENT WITH TA1 ON THE INCIDENCE OF INFECTED PANCREATIC NECROSIS IN ACUTE NECROTIZING PANCREATITIS PATIENTS MAY BE DEPENDENT ON LYMPHOCYTE COUNT: A POSTHOC ANALYSIS OF A MULTICENTER RANDOMIZED TRIAL

Wenjia Mao, CN

09:24 - 09:24 P0823
COMPARATIVE EFFECTS OF INTRAVENOUS DICLOFENAC AND BUPRENORPHINE FOR PAIN RELIEF IN PATIENTS WITH ACUTE PANCREATITIS: A RANDOMIZED CONTROLLED STUDY

Mayank Saini, IN

09:24 - 09:24 P0824
THE EFFECT OF FATTY PANCREAS ON ACUTE PANCREATITIS SEVERITY

Tawfik Khoury, IL

09:24 - 09:30 P0825
THE INCIDENCE OF RECURRENT ACUTE PANCREATITIS AND CHRONIC PANCREATITIS AFTER ACUTE PANCREATITIS. A SYSTEMATIC REVIEW AND META-ANALYSIS

Endre-Botond Gagy, HU

09:30 - 09:30 P0826
THE DEGREE OF OBESITY HAS A SERIOUS DETRIMENTAL EFFECT ON THE COURSE OF ACUTE PANCREATITIS AND THE DEVELOPMENT OF COMORBIDITIES: ANALYSIS OF AN INTERNATIONAL PROSPECTIVE COHORT OF 2244 CASES

Andrea Szentesi, HU

09:30 - 09:30 P0827
EFFECT OF CHOLECYSTECTOMY ON PREVENTING RECURRENCE OF ACUTE PANCREATITIS

Gulseren Seven, TR

09:30 - 09:36 P0828
A 2-YEAR FOLLOW-UP OF ACUTE PANCREATITIS: PRELIMINARY RESULTS OF THE GOULASH-PLUS STUDY OF ENDOCRINE AND EXOCRINE INSUFFICIENCY

Alexandra Mikó, HU

09:36 - 09:42 P0829
COMPLIANCE WITH EVIDENCE-BASED CLINICAL GUIDELINES IN THE MANAGEMENT OF ACUTE BILIARY PANCREATITIS: THE MANCTRA-1 INTERNATIONAL COHORT STUDY

Gianluca Pellino, IT

09:42 - 09:42 P0830
ON ADMISSION RISK FACTORS AND PREDICTORS OF NON-MILD DISEASE COURSE OF PAEDIATRIC ACUTE PANCREATITIS: A SYSTEMATIC REVIEW AND META-ANALYSIS

Márk Félix Juhász, HU

09:42 - 09:42 P0831
SEVERITY OF ACUTE PANCREATITIS IS GREATLY ASSOCIATED WITH THE RISK OF DEVELOPING NEW-ONSET DIABETES OR DYSGLYCAEMIA AFTER INFLAMMATION -AMETA-ANALYSIS OF 72,813 PATIENTS
 Olga Julia Zahariev, HU

09:42 - 09:42 P0832
GUT MICROBIOTA COMPOSITION IS SIGNIFICANTLY ALTERED IN PATIENTS WITH CHRONIC PANCREATITIS
 Peter Macinga, CZ

09:42 - 09:42 P0833
MITOFUSIN 2 REGULATES THE NICOTINE INDUCED ACTIVATION OF PANCREATIC STELLATE CELL VIA PI3K/AKT/MTOR SIGNALING PATHWAY
 Ran Xue, CN

09:42 - 09:42 P0834
INHIBITION OF ORAI1 PROTECTS THE PANCREATIC TISSUE AND REDUCES THE PROGRESSION OF FIBROSIS IN CHRONIC PANCREATITIS
 Viktória Szabó, HU

09:42 - 09:42 P0835
EXOCRINE PANCREATIC FUNCTION IN PATIENTS AFTER MILD OR MODERATE COVID-19 DISEASE
 Iryna Biriuchenko, UA

09:42 - 09:42 P0836
BACTERIAL METABOLISM AND EXTERNAL SECRETORY INSUFFICIENCY PANCREAS

09:42 - 09:42 P0837
SHEAR-WAVE VERSUS STRAIN ELASTOGRAPHY IN ENDOSCOPIC ULTRASOUND FOR THE DIAGNOSIS OF CHRONIC PANCREATITIS
 Yasunobu Yamashita, JP

09:42 - 09:42 P0838
EUS-GUIDED DRAINAGE OF PANCREATIC WALLED-OFF NECROSIS WITH LUMEN-APPOSING METAL STENT AND DOUBLE-PIGTAIL PLASTIC STENTS: COMPARISON OF EFFICACY AND SAFETY
 Yang Jianfeng, CN

09:42 - 09:42 P0839
SOFT SELF-EXPANDING METAL STENT TO TREAT PAINFUL PANCREATIC DUCT STRICTURES IN PATIENTS WITH CHRONIC PANCREATITIS:A MULTICENTER TRIAL
 Jacques Deviere, BE

09:42 - 09:42 P0840
GENETIC AND IDIOPATHIC CHRONIC PANCREATITIS DISPLAY DISTINCT CLINICAL FEATURES AT DIAGNOSIS
 Giuseppe Dell'Anna, IT

09:42 - 09:42 P0841
ASSESSMENT OF PAIN AND QUALITY OF LIFE IN A SPANISH CHRONIC PANCREATITIS COHORT
 Daniel Oyón, ES

09:42 - 09:42 P0842
EVOLUTION OF INDETERMINATE FOR CHRONIC PANCREATITIS AS DIAGNOSED ON EUS [ACCORDING TO ROSEMONT CRITERIA] IN PATIENTS OF RECURRENT ACUTE PANCREATITIS WITH 1 YEAR FOLLOW UP
 Arun Vaidya, IN

09:42 - 09:42 P0843
DEVELOPMENT OF A NEW LATERAL FLOW ASSAY FOR THE QUANTIFICATION OF FAECAL PANCREATIC ELASTASE AT POINT OF CARE
 Joana Afonso, CH

09:42 - 09:42 P0844
CHRONIC PANCREATITIS ASSOCIATED WITH HETEROZYGOUS CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR COMPARED WITH AN ALCOHOL-RELATED CHRONIC PANCREATITIS-19 YEARS COHORT STUDY
 Abubaker Y.M Ahmed, GB

09:42 - 09:42 P0845
PANCREATIC DUCT WALL THICKENING ON ENDOSCOPIC ULTRASOUND: A NEW IMAGING FINDING IN AUTOIMMUNE PANCREATITIS
 Takeshi Hisa, JP

09:42 - 09:42 P0846
EFFICACY AND SAFETY OF LUMEN-APPOSING METAL STENTS IN ENDOSCOPIC ULTRASOUND-GUIDED DRAINAGE OF ABDOMINAL FLUID COLLECTIONS AND THE INFLUENCE OF INSERTING A COAXIAL DOUBLE PIGTAIL PLASTIC STENT
 Celia Perez Estrada, ES

09:42 - 09:42 P0847
HIGHER VOLUME GROWTH RATE IS ASSOCIATED WITH DEVELOPMENT OF WORRISOME FEATURES IN PATIENTS WITH BRANCH DUCT-INTRADUCTAL PAPILLARY MUCINOUS NEOPLASMS
 Tommaso Innocenti, IT

09:42 - 09:42 P0848
DIABETES MELLITUS AND THE RISK OF PROGRESSION OR MALIGNANCY OF PANCREATIC CYSTIC NEOPLASMS IN PATIENTS UNDERGOING SURVEILLANCE: A SYSTEMATIC REVIEW AND META-ANALYSIS
 Aijaz Sofi, US

09:42 - 09:42 P0849
ADDED VALUE OF SECRETIN DURING MAGNETIC RESONANCE IMAGING TO IDENTIFY DUCTAL COMMUNICATION IN PANCREATIC CYSTIC NEOPLASMS (IMAGE-S): PROSPECTIVE STUDY
 Myrte Gorris, NL

09:42 - 09:42 P0850
CONTINUOUS SMOKING MAY PLAY A ROLE IN THE PROGRESSION FROM "TRIVIAL" (THE GOOD) BD-IPMNS TO IPMNS WITH AN INDICATION FOR SURGERY ("THE BAD") AND PANCREATIC CANCER (THE "UGLY")
 Gaetano Lauri, IT

09:42 - 09:42 P0851
ARTIFICIAL INTELLIGENCE FOR AUTOMATIC DIAGNOSIS OF MUCINOUS PANCREATIC CYSTIC LESIONS IN ENDOSCOPIC ULTRASOUND: A PILOT STUDY

Tiago Ribeiro, PT

09:42 - 09:42 P0852
PANCREATIC RESECTIONS FOR CYSTIC NEOPLASMS: FROM SURGEON'S PRESUMPTION TO PATHOLOGIST'S REALITY

Anna Burelli, IT

09:42 - 09:42 P0853
PANCREATIC CYST FLUID INTERLEUKIN-1 BETA (IL-1B) LEVEL IN PREDICTING THE RISK OF MALIGNANCY IN PANCREATIC CYSTS

Mariam Zaghloul, EG

09:42 - 09:42 P0854
GASTROINTESTINAL FINDINGS IN VON HIPPEL LINDAU DISEASE: CHARACTERISTIC OF PANCREATIC CYSTS

Ali Emre Bardak, TR

09:42 - 09:42 P0855
EVALUATING THE USE OF IRREVERSIBLE ELECTROPORATION FOR PANCREATIC CANCER TREATMENT: PILOT IN VITRO STUDIES

Ibrahim A Khawaja, GB

09:42 - 09:42 P0856
COMPARISON OF PBMC FUNCTIONS AND AHR, ELAVL-1 EXPRESSION IN PANCREATIC CANCER VS HEALTHY PATIENTS

Antanas Gulbinas, LT

09:42 - 09:42 P0857
CHEMICAL ENHANCEMENT OF IRREVERSIBLE ELECTROPORATION IN PANCREATIC CANCER CELL LINES WITH CALCIUM: A PILOT STUDY

Zainab L. Rai, GB

09:42 - 09:42 P0858
ROLE OF ENDOSCOPIC ULTRASOUND COMBINED WITH A NEWLY MODIFIED SCORING SYSTEM TO DETECT PANCREATIC HIGH-GRADE PRECANCEROUS LESIONS

Ryota Sagami, JP

09:42 - 09:42 P0859
COMBINED EUS AND ERCP REDUCES TIME TO ONSET OF TREATMENT IN PANCREATICOBILIARY MALIGNANCY

James Gauci, GB

09:42 - 09:42 P0860
EPIDEMIOLOGY, CLINICAL CHARACTERISTICS, PROGNOSIS, AND NOMOGRAM FOR PRIMARY PANCREATIC LYMPHOMA PATIENTS: A SEER POPULATION-BASED STUDY

09:42 - 09:42 P0861
FOCAL PANCREATIC PARENCHYMA ATROPHY IS COMMON AND MAY HELP DETECT THE INTRADUCTAL SPREADING SUBTYPE OF PANCREATIC CARCINOMA

Jun Nakahodo, JP

09:42 - 09:42 P0862
EFFECT INVESTIGATION OF LAG TIME BETWEEN THE START OF DIAGNOSTIC PROCEDURE AND TREATMENT OF PANCREATIC CANCER PATIENTS: A SYSTEMATIC REVIEW AND META-ANALYSIS

Anna Noemi Nemeth, HU

09:42 - 09:42 P0863
THE DIAGNOSTIC AND PROGNOSTIC VALUE OF APELIN (APLN) AND SERUM AMYLOID A3 (SAA3) ADIPOCYTOKINE MEASUREMENT IN PATIENTS WITH PANCREATIC DUCTAL ADENOCARCINOMA (PDAC) COMPARED TO CHRONIC PANCREATITIS (CP) AND HEALTHY SUBJECTS

Michal Stasiak, PL

09:42 - 09:42 P0864
THE ASSOCIATION BETWEEN PROTON PUMP INHIBITORS AND PANCREATIC CANCER

Tawfik Khoury, IL

09:42 - 09:42 P0865
A NOVEL, MULTIPRONGED, SINGLE-PASS EUS NEEDLE FOR IMPROVED TISSUE DIAGNOSIS OF SOLID PANCREATIC LESIONS

Jesse Lachter, IL

09:42 - 09:42 P0866
THE IMPACT OF A MULTIDISCIPLINARY TEAM APPROACH ON THE MANAGEMENT OF FOCAL PANCREATIC LESIONS: A TERTIARY SINGLE-CENTER EXPERIENCE

Paraskevas Gkolfakis, BE

09:42 - 09:42 P0867
OUTCOME OF METAL VERSUS PLASTIC STENTS FOR BILIARY OBSTRUCTION IN PATIENTS WITH PANCREATIC CARCINOMA UNDERGOING NEOADJUVANT CHEMORADIOTHERAPY: META-ANALYSIS

Jimil Shah, IN

09:42 - 09:42 P0868
DIAGNOSTIC ADEQUACY OF NEEDLES USED IN EUS-GUIDED TISSUE ACQUISITION OF SOLID PANCREATIC MASSES – A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS

Marie Anne Engh, HU

09:42 - 09:42 P0869
CURRENT SMOKING IS ASSOCIATED WITH SHORTER PROGRESSION-FREE SURVIVAL IN PANCREATIC CANCER PATIENTS TREATED WITH FIRST-LINE FOLFIRINOX, BUT NOT WITH OTHER INTENSIFIED REGIMENS

Pilar Lazzano, IT

09:42 - 09:42 P0870
SHEAR-WAVE ELASTOGRAPHY VERSUS STRAIN ELASTOGRAPHY WITH HISTOGRAM ANALYSIS IN SOLID PANCREATIC LESIONS: A PILOT STUDY

09:42 - 09:42 P0871
IMMUNOHISTOCHEMICAL EVALUATION OF THE EXPRESSION OF SPECIFIC MEMBRANE ANTIGENS IN PATIENTS WITH PANCREATIC DUCTAL ADENOCARCINOMA UNDERGOING SURGERY

Alberto Nicoletti, IT

- 09:42 - 09:42 P0872
A NOVEL TECHNOLOGY FOR MOLECULAR PROFILING OF KRAS GENE IN TUMOR SAMPLES AND LIQUID BIOPSIES IN PATIENTS WITH PANCREATIC DUCTAL ADENOCARCINOMA
 Bárbara Morão, PT
- 09:42 - 09:42 P0873
SPORADIC AND MEN1-RELATED GASTRINOMA AND ZOLLINGER ELLISON SYNDROME: DIFFERENCES IN CLINICAL MANIFESTATION AND SEVERITY
 Alice Laffusa, IT
- 09:42 - 09:42 P0874
SINGLE CENTER 43 YEARS' EXPERIENCE OF ENUCLEATION OF PANCREATIC INSULINOMAS: EARLY- AND LONG-TERM RESULTS
 Anna Caterina Milanetto, IT

Poster Exhibition

09:00 – 17:30 Science Lounge
 Poster Exhibition

Poster Exhibition

09:00 – 17:30 Science Lounge
 Liver & biliary

- 09:00 - 09:00 P0669
SZN-043 INDUCED QUICK AND ROBUST HEPATOCYTE PROLIFERATION IN A 14-DAY DAILY DOSING EDU-LABELING STUDY IN SCID MICE
 Chenggang Lu, US
- 09:00 - 09:00 P0670
INHIBITION OF BCL-2 AND MCL-1 EFFECTIVELY INDUCES CELL DEATH IN HEPATOCELLULAR CARCINOMA (HCC) CELL LINES
 Franziska Walz, DE
- 09:00 - 09:00 P0671
THE ROLE AND MECHANISM OF IRBITIN HYPOXIA INDUCED ACTIVATION OF HEPATIC STELLATE CELLS
- 09:00 - 09:00 P0672
CASR AS AN IMPORTANT PROTECTIVE FACTOR COMBINED TO THE REGULATION OF HEPATIC STELLATE CELL ACTIVATION
- 09:00 - 09:00 P0673
RELATIONSHIP BETWEEN THE RATIO OF THE MAIN PHYLOTYPES OF THE GUT MICROBIOTA AND BODY COMPOSITION IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE
 Nataliia Cherehliuk, UA
- 09:00 - 09:00 P0674
DOPAMINE REGULATES AUTOPHAGY DURING TGF- β 1-INDUCED ACTIVATION OF HEPATIC STELLATE CELLS
- 09:00 - 09:00 P0675
STERILE FECAL FILTRATE TRANSFER FOR THE TREATMENT OF PATIENTS WITH HEPATIC ENCEPHALOPATHY
 Rolandas Gedgaudas, LT

- 09:00 - 09:00 P0676
POINT SHEARWAVE ELASTOGRAPHY TECHNIQUES FOR THE ASSESSMENT OF LIVER STIFFNESS
 Alina Popescu, RO
- 09:00 - 09:00 P0677
PROGNOSTIC IMPACT OF NEUTROPHIL-TO-LYMPHOCYTE RATIO IN CIRRHOSIS
 Ameny Neji, TN
- 09:00 - 09:00 P0678
THE POSITIVE EFFECTS OF SYMBIOTICS ON LIVER STEATOSIS BY IMPROVING GUT MICROBIOLOGY-RANDOMIZED CONTROLLED TRIAL
 Miloš Mitrović, RS
- 09:00 - 09:00 P0679
METABOLIC-ASSOCIATED FATTY LIVER DISEASE INVOLVES DEVIATIONS IN CYTOKERATINS AND GOLGI PROTEIN 73
 Anna Rycyk-Bojarzynska, PL
- 09:00 - 09:00 P0680
BACTERIOPHAGES TO TREAT LIVER DISEASE ELIMINATING HARMFUL BACTERIA (BATTLE) - STUDY PROTOCOL
 Frederik Cold, DK
- 09:00 - 09:00 P0681
INDICATORS OF THE MAIN PHYLOTYPES OF THE INTESTINAL MICROBIOTA AND VISCERAL OBESITY IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE
 Yana Nikiforova, UA
- 09:00 - 09:00 P0682
GUT MICROBIOTA DYSBIOSIS AND FUNCTIONAL BACTERIA IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE AND CHRONIC KIDNEY DISEASE
 Doina Georgescu, RO
- 09:00 - 09:00 P0683
COMPREHENSIVE MRNA EXPRESSION PROFILE AND IDENTIFICATION OF CRUCIAL GENES IN LIVER REGENERATION
 Yong Liu, CN
- 09:00 - 09:00 P0684
THE DIAGNOSTIC ROLE OF CYTOKERATIN 8/18 IMMUNOHISTOCHEMICAL MARKER FOR LEAN NON-ALCOHOLIC FATTY LIVER DISEASE
 Filiz Akyuz, TR
- 09:00 - 09:00 P0685
THE INFLUENCE OF SUPERIMPOSED SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS-2 (SARS-COV-2) LIFESTYLE CHANGES ON METABOLIC DYSFUNCTION ASSOCIATED FATTY LIVER DISEASE (MAFLD) EVOLUTION: A MATTER OF BODY COMPOSITION
 Mario Romeo, IT
- 09:00 - 09:00 P0686
IMPACT OF RENAMING NAFLD TO MAFLD IN A SINGLE ITALIAN CENTER
 Valentina Cossiga, IT
- 09:00 - 09:00 P0687
WILSON'S DISEASE DIAGNOSIS IN PAEDIATRIC AGE
 Daniela Araújo, PT

09:00 - 09:00 P0688
RESISTANT STARCH SUPPRESSES HIGH-FAT DIET-INDUCED STEATOSIS
 Ryutaro Yoshida, JP

09:00 - 09:00 P0689
FEATURES OF ERYTHROCYTE AND SERUM MEMBRANE FATTY ACID SPECTRA ASSOCIATED WITH ALCOHOLIC AND NON-ALCOHOLIC GENESIS OF FATTY LIVER DISEASE
 Margarita Vitalieвна Kruchinina, RU

09:00 - 09:00 P0690
PREVALENCE AND ASSOCIATED FACTORS OF METABOLIC-ASSOCIATED FATTY LIVER DISEASE IN OVERWEIGHT AND OBESE FINNISH CHILDREN AND ADOLESCENTS
 Hanna Riekkö, FI

09:00 - 09:00 P0692
THE ROLE AND MECHANISM OF S100A6 IN PROMOTING NON-ALCOHOLIC FATTY LIVER DISEASE BY NEGATIVELY REGULATING LIPOPHAGY SIGNALING PATHWAY

09:00 - 09:00 P0693
SHORT-CHAIN FATTY ACIDS AND INSULIN RESISTANCE PROGRESSION IN OBESE CHILDREN WITH NONALCOHOLIC FATTY LIVER DISEASE
 Natalia Zavhorodnia, UA


09:00 - 09:00 P0694
INSULIN RESISTANCE IN THE LIVER FIBROSIS FORMATION IN OBESE CHILDREN WITH NON-ALCOHOLIC FATTY LIVER DISEASE
 Natalia Zavhorodnia, UA

09:00 - 09:00 P0695
HEART RATE VARIABILITY IN CHILDREN WITH NON-ALCOHOLIC FATTY LIVER DISEASE DEPENDING ON INTESTINAL MICROBIOTA COMPOSITION
 Natalia Zavhorodnia, UA

09:00 - 09:00 P0696
PREDICTIVE VALUE OF SERUM ADIPONECTIN AND CHEMERIN LEVELS IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE
 Mohamed Abdel-Samiee, EG

09:00 - 09:00 P0697
VALIDATION OF SEMI-AUTOMATIC SEGMENTATION METHOD TO DETERMINE TOTAL LIVER VOLUME ON CT SCANS IN POLYCYSTIC LIVER DISEASE
 Thijs Barten, NL

09:00 - 09:00 P0698
IMPAIRED QUALITY OF LIFE MAY HINDER THE ACHIEVEMENT OF THERAPY GOALS IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE
 Yulia Golubeva, RU

09:00 - 09:00 P0699
METABOLIC ASSOCIATED FATTY LIVER DISEASE (MAFLD) AND COVID-19: AN INTERPLAY LEADING TO POOR PATIENT OUTCOME? 
 Vladimir Milivojević, RS

09:00 - 09:00 P0700
NOVEL MAFLD CLASSIFICATION: A MORE REALISTIC CONCEPT OF FATTY LIVER DISEASE
 Juliana Serrazina, PT

09:00 - 09:00 P0701
PREDICTIVE SCORES IN PATIENTS WITH TYPE 2 DIABETES
 Ruxandra Georgeta Mare, RO

09:00 - 09:00 P0702
ESTIMATION OF THE PREVALENCE OF NON-ALCOHOLIC FATTY LIVER DISEASE DURING OBSTRUCTIVE SLEEP APNEA SYNDROME
 Asma Ben Mohamed, TN

09:00 - 09:00 P0703
EFFECTIVENESS OF THE FIBROSCAN-ASAT (FAST) SCORE IN IDENTIFYING NON-ALCOHOLIC STEATOHEPATITIS (NASH) PATIENTS WITH SIGNIFICANT ACTIVITY AND FIBROSIS: A PROSPECTIVE STUDY
 Khellaf Amalou, DZ

09:00 - 09:00 P0704
ALCOHOL BIOMARKERS AS PREDICTORS OF READMISSION AND FATAL OUTCOME IN PATIENTS WITH ALCOHOL-RELATED LIVER CIRRHOSIS
 Karolina Ikonnikova, RU

09:00 - 09:00 P0705
SZN-043, AN R-SPONDIN MIMETIC IN DEVELOPMENT FOR THE TREATMENT OF LIVER DISEASE, DEMONSTRATES A STRONG SAFETY PROFILE IN NONCLINICAL TOXICOLOGY STUDIES
 Jay Tibbitts, US

09:00 - 09:00 P0706
INTESTINAL ENDOTOXEMIA IS ONE OF THE FACTORS OF METABOLIC DISORDERS AND PROGRESSION OF NON-ALCOHOLIC FATTY LIVER DISEASE
 Yana Nikiforova, UA

09:00 - 09:00 P0708
LIVER FIBROSIS AND STEATOSIS ASSESSMENT USING ELASTOGRAPHIC TECHNIQUES: A COMPARISON BETWEEN NONALCOHOLIC FATTY LIVER DISEASE AND ALCOHOLIC LIVER DISEASE
 Camelia Gianina Foncea, RO

09:00 - 09:00 P0709
THE FREQUENCY AND IMPACT OF INFECTIONS IN PATIENTS WITH ALCOHOLIC HEPATITIS
 Camelia Gianina Foncea, RO

09:00 - 09:00 P0710
ROLE OF OSTEOPONTIN AS A POTENTIAL SERUM MARKER OF HCV RELATED HEPATOCELLULAR CARCINOMA
 Ehab Ahmed Abdelatti, EG

09:00 - 09:00 P0712
PRELIMINARY RESULTS ON LSECTIN INDUCTION BY ANTI-INFLAMMATORY CYTOKINES IN HEPATIC ANTIGEN PRESENTING CELLS FROM CIRRHOTIC MICE
 Enrique Angel Gomis, ES

09:00 - 09:00 P0713
ELECTRON PARAMAGNETIC RESONANCE ALBUMIN FUNCTION TEST AS A MARKER OF THE SEVERITY OF THE LIVER CIRRHOSIS

Anastasia Turkina, RU

09:00 - 09:00 P0714
CONTRIBUTION OF THE NEW PROGNOSTIC SCORE LIVER-RENAL-RISK (LIRER) IN PREDICTING SURVIVAL IN CIRRHOTIC PATIENTS

Maha Mtir, TN

09:00 - 09:00 P0715
LIVER-RENAL-RISK (LIRER): PERFORMANCE AND RELIABILITY IN PREDICTING THE OCCURRENCE OF HEPATORENAL SYNDROME IN CIRRHOTICS

Maha Mtir, TN

09:00 - 09:00 P0716
PREDICTION MODEL OF 30-DAY INPATIENT MORTALITY FOR ALCOHOLIC HEPATITIS

Hassam Ali, US

09:00 - 09:00 P0718
RELATION OF PROTEIN S AND PORTAL VEIN THROMBOSIS IN EGYPTIAN PATIENTS WITH HCV RELATED LIVER CIRRHOSIS

Ehab Ahmed Abdelatti, EG

09:00 - 09:00 P0719
BAVENO VII CRITERIA AS NON-INVASIVE PREDICTORS OF ESOPHAGEAL VARICES AND RISK OF DECOMPENSATION

Joao Paulo Laranjeira Correia, PT

09:00 - 09:00 P0720
THE IMPACT OF COVID-19 PANDEMIC IN LIVER CIRRHOSIS HOSPITAL ADMISSIONS

Viviana Martins, PT

09:00 - 09:00 P0721
LIVER-SPECIFIC PROGNOSTIC SCORES ABILITY TO PREDICT MORTALITY IN CIRRHOTIC PATIENTS ADMITTED TO THE GASTROENTEROLOGY INTENSIVE CARE UNIT

Khoulood Babbou, TN

09:00 - 09:00 P0722
DEVELOPMENT OF A MODEL TO PREDICT 90-DAY MORTALITY AMONG PATIENTS WITH ACUTE VARICEAL BLEEDING

Isabel Garrido Garrido, PT

09:00 - 09:00 P0723
SPLENIC ARTERY ANEURYSMS AND PORTAL HYPERTENSION: CAUSE OR CONSEQUENCE

Ibtissam Khalif, MA

09:00 - 09:00 P0724
USEFULNESS OF MELD AND MELD-NA FOR PREDICTING MORTALITY IN CIRRHOTIC PATIENTS WITH SPONTANEOUS BACTERIAL PERITONITIS

Ali Al-Adhami, GB

09:00 - 09:00 P0725
TREATMENT AND OUTCOMES OF POST-BANDING ULCER BLEEDING AFTER PROPHYLACTIC ENDOSCOPIC BAND LIGATION

Renato Medas, PT

09:00 - 09:00 P0726
LATE-STAGE PRESENTATION OF CIRRHOSIS WITH DECOMPENSATION IS ALARMINGLY COMMON AND FAVORABLE OUTCOME IS ONLY OBSERVED WITH ETIOLOGIC THERAPY

Michael Schwarz, AT

09:00 - 09:00 P0727
FRAILTY IS INDEPENDENTLY ASSOCIATED WITH DEPRESSION AND MINIMAL HEPATIC ENCEPHALOPATHY IN CIRRHOSIS

Bernard El Khoury, LB

09:00 - 09:00 P0728
LIVER FRAILTY INDEX PREDICTS POOR OUTCOMES IN PATIENTS HOSPITALIZED FOR ACUTE DECOMPENSATION OF CIRRHOSIS

Simone Incicco, IT

09:00 - 09:00 P0729
DISTURBANCES IN SODIUM AND CHLORIDE HOMEOSTASIS PREDICT OUTCOMES IN STABLE AND CRITICALLY ILL PATIENTS WITH CIRRHOSIS – NOT TWO SIDES OF THE SAME COIN

Georg Semmler, AT

09:00 - 09:00 P0730
MCP1, CRP AND PROCALCITONIN AS NOVEL DIAGNOSTIC MARKERS IN CIRRHOTIC PATIENTS WITH SPONTANEOUS BACTERIAL PERITONITIS

Gamal Soliman, EG

09:00 - 09:00 P0731
CLINICAL OUTCOMES OF CRYPTOGENIC COMPARED WITH VIRAL CIRRHOSIS

Zeineb Benzarti, TN

09:00 - 09:00 P0732
MALNUTRITION IN PATIENTS WITH CHRONIC LIVER DISEASE UNDERGOING INPATIENT LIVER TRANSPLANT EVALUATION

Katherine Cooper, US

09:00 - 09:00 P0733
MIRNA 203 AS AN EARLY PREDICTIVE MARKER FOR GENOTYPE 4 HCV INDUCED HCC

Mohamed Elzallat, EG

09:00 - 09:00 P0734
HIGH SERO-PREVALENCE OF HEPATITIS E VIRUS AMONG HEALTHY ASYMPTOMATIC BLOOD DONORS IN PAKISTAN: CAN THE RISK OF TRANSFUSION DEPENDENT TRANSMISSION BE IGNORED?

Adeel Rahat, PK

09:00 - 09:00 P0735
ESOPHAGEAL VARICEAL RECURRENCE 4 YEARS BEYOND ENDOSCOPIC BAND LIGATION IN HEPATITIS C PATIENTS WHO ACHIEVED SUSTAINED VIROLOGICAL RESPONSE WITH ORAL DIRECT ACTING ANTIVIRAL THERAPIES

Abdel Ghani Badran, EG

09:00 - 09:00 P0736
CLINICAL SPECTRUM AND OUTCOMES OF PATIENTS WITH SEVERE SPONTANEOUS HEPATITIS B FLARES AND REACTIVATION

Ankur Jindal, IN

09:00 - 09:00 P0737
CLINICAL COURSE AND PREDICTORS OF OUTCOME OF SEVERE HEPATITIS B REACTIVATION PRESENTING WITH NEW-ONSET ASCITES

Ankur Jindal, IN

09:00 - 09:00 P0738
OCCULT HEPATITIS C AFTER DIRECT ACTING ANTI VIRAL , A STUDY IN A COHORT OF EGYPTIAN PATIENTS

09:00 - 09:00 P0739
ELIMINATE: A PCR RECORD-BASED HCV MACRO-ELIMINATION PROJECT IN AUSTRIA

David Bauer, AT

09:00 - 09:00 P0740
EFFECT OF DIRECT ACTING ANTIVIRAL DRUGS ON THE OCCURRENCE AND RECURRENCE OF INTRA- AND EXTRA-HEPATIC MALIGNANCIES IN PATIENTS WITH CHRONIC HEPATITIS C

Pompilia-Iuliana Radu, CH

09:00 - 09:00 P0741
HEPATITIS B VIRUS SCREENING AND PROPHYLAXIS THERAPY IN PATIENTS WITH SOLID TUMORS TREATED WITH ANTICANCER THERAPIES

Lian Bannon, IL

09:00 - 09:00 P0742
PREVALENCE OF INFECTIVE AND NON-INFECTIVE HEPATITIS AND JAUNDICE IN A TERTIARY FEVER HOSPITAL: ALEXANDRIA GOVERNORATE, EGYPT

Amr Aboelfetouh, EG

09:00 - 09:00 P0743
LIFESTYLE IN PRIMARY BILIARY CHOLANGITIS: LET'S PAY ATTENTION!

Valentina Cossiga, IT

09:00 - 09:00 P0744
COVID-19 ASSOCIATED SECONDARY SCLEROSING CHOLANGITIS - A CASE SERIES OF 4 PATIENTS

Filipa Bordalo Ferreira, PT

09:00 - 09:00 P0745
COLECTOMY IN ULCERATIVE COLITIS DOES NOT PREVENT DEVELOPMENT OF PRIMARY SCLEROSING CHOLANGITIS

Aiva Lundberg Båve, SE

09:00 - 09:00 P0746
PRIMARY SCLEROSING CHOLANGITIS (PSC) AND CHRONIC INFLAMMATORY BOWEL DISEASE (IBD) ASSOCIATION

Driss Azzouzi, MA

09:00 - 09:00 P0747
CROSS-SECTIONAL IMAGING BASED DIAGNOSIS OF SARCOPENIA IS ASSOCIATED WITH IMPAIRED TRANSPLANT-FREE SURVIVAL IN PATIENTS WITH PRIMARY SCLEROSING CHOLANGITIS

Pedram Keshoofi, DE

09:00 - 09:00 P0748
KLF14 ALLEVIATES IMMUNE LIVER INJURY IN MICE VIA NF-B SIGNALING PATHWAY

09:00 - 09:00 P0749
AUTOIMMUNE HEPATITIS FOLLOWING COVID-19 VACCINE

Teresa Arzallus Marco, ES

09:00 - 09:00 P0750
TRAINED IMMUNITY IN LIVER CIRRHOSIS: FROM MOLECULAR MECHANISMS TO PROGNOSIS IMPLICATIONS. A PRELIMINARY OBSERVATION

Marcello Dallio, IT

09:00 - 09:00 P0751
INTERDISCIPLINARY APPROACH IS ESSENTIAL FOR SUFFICIENT DIAGNOSIS AND THERAPY IN IGG4-RELATED DISEASE INVOLVING MULTIPLE ORGANS

Sandra Christoph, DE

09:00 - 09:00 P0752
INCIDENTAL M2-AMA POSITIVITY BY IMMUNOBLOT IS A STRONG INDICATOR OF PRIMARY BILIARY CHOLANGITIS

Ilkay Ergenç, TR

09:00 - 09:00 P0753
ANTI-MITOCHONDRIAL ANTIBODY-NEGATIVE PRIMARY BILIARY CHOLANGITIS: EPIDEMIOLOGICAL, CLINICAL, BIOLOGICAL, HISTOLOGICAL AND EVOLUTIONARY CHARACTERISTICS

Rahma Ayadi, TN

09:00 - 09:00 P0754
THE PREVALENCE OF SEROLOGICAL MARKERS OF HEPATITIS E VIRUS AND ITS IMPACT ON CLINICAL COURSE OF AUTOIMMUNE HEPATITIS

Maciej K. Janik, PL

09:00 - 09:00 P0755
LONG-TERM OUTCOMES IN PEDIATRIC LIVER TRANSPLANTATION: A SINGLE CENTER 20 YEARS EXPERIENCE

Maria Guarino, IT

09:00 - 09:00 P0756
ELASTOGRAPHY BY FIBROSCAN AND POINT SHEAR WAVE FOR ANALYSIS OF LIVER STIFFNESS: A PROSPECTIVE STUDY

Ilaria Ditunno, IT

09:00 - 09:00 P0757
PERFORMANCE OF A 2D-SWE FOR THE DIAGNOSIS OF LIVER FIBROSIS USING TRANSIENT ELASTOGRAPHY AS REFERENCE METHOD

Camelia Gianina Foncea, RO

09:00 - 09:00 P0758
POSSIBLE THERAPEUTIC IMPACT OF LONG NON-CODING LINC01018 ON AN EXPERIMENTALLY INDUCED MODEL OF HEPATOCELLULAR CARCINOMA

Mohamed Elzallat, EG

09:00 - 09:00	P0759	CHARACTERISTICS AND SURVIVAL OF PATIENTS WITH HEPATOCELLULAR CARCINOMA IN NATURAL HISTORY IN A WESTERN COUNTRY Helena González-Sánchez, ES	09:00 - 09:00	P0771	THE ASSOCIATION BETWEEN COFFEE CONSUMPTION AND NON-ALCOHOLIC FATTY LIVER DISEASE: A CASE-CONTROL STUDY Nadi Anass, MA
09:00 - 09:00	P0760	IMPACT OF THE COVID-19 PANDEMIC IN THE DIAGNOSIS AND THERAPY OF SINGLE HEPATOCELLULAR CARCINOMA LESS THAN 3 CM IN A WESTERN COUNTRY Marta Garcia-Calonge, ES	09:00 - 09:00	P0772	ASSESSMENT OF ACCESSIBILITY TO DIAGNOSIS AND TREATMENT OF HEPATITIS C: A LARGE RETROSPECTIVE COHORT FROM A TERTIARY CARE HOSPITAL IN TURKEY Merve Eren Durmuş, TR
09:00 - 09:00	P0761	PREVALENCE AND PATTERN OF ALCOHOL CONSUMPTION IN PATIENTS WITH HEPATOCELLULAR CARCINOMA Daniel Muiño Dominguez, ES	09:00 - 09:00	P0773	INCREASING OF GUT BACTERIAL BILE SALT HYDROLASE ACTIVITY BY PROBIOTIC LACTOBACILLUS PLANTARUM IN PATIENTS WITH DYSLIPIDEMIA: A RANDOMIZED STUDY Artem Neverovskiy, UA
09:00 - 09:00	P0762	WHAT CHANGED IN HEPATOCELLULAR CARCINOMA PRESENTATION IN THE LAST ELEVEN YEARS? COMPARISON OF TWO SEQUENTIAL TIME SERIES FROM A TERTIARY HOSPITAL Daniel Conceição, PT	09:00 - 09:00	P0774	EFFECT OF ANTIBIOTICS AND ERCP STENT PLACEMENT IN THE BILIARY MICROBIOME IN THE CHOLEDOCHOLITHIASIS PATIENTS WITH ACUTE BILIARY INFECTION Yu-Chieh Weng, CN
09:00 - 09:00	P0763	CLINICAL CHARACTERISTICS AND RISK FACTORS OF EXTRAHEPATIC RECURRENCE AFTER HEPATECTOMY OF HEPATOCELLULAR CARCINOMA WITHOUT INTRAHEPATIC HEPATOCELLULAR CARCINOMA: A MULTI-INSTITUTIONAL 15-YEAR OBSERVATIONAL STUDY	09:00 - 09:00	P0775	EFFECTS OF BILE ACIDS ON METABOLIC PROFILE IN OBESE ANIMAL MODEL Chi Hyeok An, KR
09:00 - 09:00	P0764	EARLY EXTRAHEPATIC RECURRENCE AFTER HEPATECTOMY FOR HEPATOCELLULAR CARCINOMA SIGNIFICANTLY REDUCES SURVIVAL: A 15-YEAR OBSERVATIONAL STUDY	09:00 - 09:00	P0776	DELAYED VERSUS EARLY LAPAROSCOPIC CHOLECYSTECTOMY POST PERCUTANEOUS CHOLECYSTOSTOMY. DOES IT MATTER?
09:00 - 09:00	P0765	IDENTIFICATION OF CT VALUES THAT COULD BE PREDICTIVE OF NECROSIS (N-CTAV) IN HEPATOCELLULAR CARCINOMA AFTER LENVATINIB TREATMENT Makoto Chuma, JP	09:00 - 09:00	P0777	RISK FACTORS ASSOCIATED WITH HEMORRHAGIC AND THROMBOEMBOLIC COMPLICATIONS AFTER ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY (ERCP) Javier Castro Rodríguez, ES
09:00 - 09:00	P0766	THE VALUE OF THIOREDOXIN LEVEL AND ITS GENE POLYMORPHISM IN THE DIAGNOSIS OF POST- HCV HEPATOCELLULAR CARCINOMA Mohamed Alborai, EG	09:00 - 09:00	P0778	THE IMPACT OF HOSPITAL LEVEL OF CARE ON THE MANAGEMENT OF ACUTE CHOLECYSTITIS: A POPULATION-BASED STUDY Lars Enochsson, SE
09:00 - 09:00	P0767	PAROXYSMAL NOCTURNAL HEMOGLOBINURIA: A RARE CAUSE OF VASCULAR LIVER DISEASE Ibtissam Khalif, MA	09:00 - 09:00	P0779	EFFECTIVENESS AND FACTORS AFFECTING TECHNICAL SUCCESS OF AN ENDOSCOPIC SPHINCTEROTOMY IN PATIENTS WITH LARGE STONES AND COMMON BILE DUCT EMPYREMENT Benayad Aourarh, MA
09:00 - 09:00	P0768	LIVER VASCULAR DISEASE AND MYELOPROLIFERATIVE SYNDROMES Zineb Amzal, MA	09:00 - 09:00	P0780	LOW-PHOSPHOLIPID-ASSOCIATED CHOLELITHIASIS (LPAC) SYNDROME - CLINICAL, RADIOLOGICAL AND GENETIC ASPECTS OF A CASE SERIES Filipa Bordalo Ferreira, PT
09:00 - 09:00	P0769	VASCULAR LIVER DISEASE AND THROMBOPHILIA Yousra Jebari, MA	09:00 - 09:00	P0781	THE RISK FACTORS OF RECURRENT CHOLEDOCHOLITHIASIS IN PATIENTS AFTER GASTRECTOMY Jun Heo, KR
09:00 - 09:00	P0770	ORAL MUCOSAL HEALTH IN LIVER TRANSPLANT RECIPIENTS Antonella Santonicola, IT			

09:00 - 09:00 P0782
CAN DI-ISOPROPYL IMINODIACETIC ACID (DISIDA) SCAN PREDICT THE RECURRENT BILIARY EVENTS ?
Soon Ju Hwang, KR

09:00 - 09:00 P0783
CHOLECYSTECTOMY REDUCES THE RISK OF MYOCARDIAL INFARCTION AND CEREBRAL INFARCTION IN PATIENTS WITH GALLSTONE-RELATED INFECTION
Chaneun Park, KR

09:00 - 09:00 P0784
THE YIELD OF ENDOSCOPIC ULTRASOUND IN INVESTIGATION OF INCIDENTAL COMMON BILE DUCT DILATATION
Tawfik Khoury, IL

09:00 - 09:00 P0785
ULTRASOUND-BASED ASSESSMENT OF BILIARY MANIFESTATIONS IN ADULT PATIENTS WITH CYSTIC FIBROSIS. PREVALENCE AND RISK FACTORS
Almudena Marinero Martínez-Lázaro, ES

09:00 - 09:00 P0786
RISK FACTORS FOR GALLSTONES IN PATIENTS WITH LIVER CIRRHOSIS
Zeineb Benzarti, TN

09:00 - 09:00 P0787
FLUORESCENCE IN SITU HYBRIDIZATION IN PRIMARY DIAGNOSIS OF BILIARY STRICTURES
Vincent Zoundjiekpon, CZ

09:00 - 09:00 P0788
IMPACT OF METFORMIN ON THE INCIDENCE OF HUMAN CHOLANGIOCARCINOMA IN DIABETIC PATIENTS: A SYSTEMATIC REVIEW AND META-ANALYSIS
Alice Laffusa, IT

09:00 - 09:00 P0789
LONG-TERM EFFICACY OF PLASTIC VERSUS METAL STENTS IN INOPERABLE PERIHILAR CHOLANGIOCARCINOMA; A RETROSPECTIVE COHORT STUDY
Jeska A. Fritzsche, NL

09:00 - 09:00 P0790
ENDOSCOPIC RADIOFREQUENCY ABLATION FOR MALIGNANT BILIARY OBSTRUCTION: RISK FACTORS FOR BILIARY INFECTION
Yang Jianfeng, CN

09:00 - 09:00 P0791
EFFICACY OF ENDOSCOPIC PAPILLECTOMY FOR EARLY AMPULLARY CARCINOMA
Ko Suzuki, JP

09:00 - 09:00 P0792
PROGNOSTIC FACTORS IN PATIENTS RECEIVING PEMBROLIZUMAB WITH ADVANCED BILIARY TRACT CANCER
Chan Su Park, KR

09:00 - 09:00 P0793
IGG4-RELATED SCLEROSING CHOLANGITIS MAY BE A RISK FACTOR FOR BILE DUCT CANCER

09:00 - 09:06 P0794
TIMING OF ERCP AND OUTCOMES IN PATIENTS ADMITTED WITH ACUTE GALLSTONE CHOLANGITIS: A RETROSPECTIVE MULTICENTRE AUDIT
Chris Watters, GB

09:06 - 09:06 P1035
KNOCKDOWN OF HSDL2 PROMOTES CELL PROLIFERATION, MIGRATION AND INVASION BY INHIBITING FERROPTOSIS VIA P53PATHWAY IN CHOLANGIOCARCINOMA
Zheng Lu, CN

Poster Exhibition

09:00 - 17:30 Science Lounge
H. pylori

09:00 - 09:00 P0121
PREVALENCE OF *HELICOBACTER PYLORI* IN OBESE PATIENTS UNDERGOING PREOPERATIVE ENDOSCOPIC EVALUATION FOR BARIATRIC SURGERY: EXPERIENCE FROM A SINGLE CENTER IN NORTHERN ITALY
Nicolò Mezzina, IT

09:00 - 09:00 P0122
REFRACTORY *H. PYLORI* INFECTION AND GASTRIC MICROBIOTA

09:00 - 09:00 P0123
EFFECT OF *HELICOBACTER PYLORI* VIRULENCE FACTORS ON THE MORPHOLOGICAL CHANGES OF GASTRIC MUCOSA IN PATIENTS WITH CHRONIC GASTRITIS AND THEIR ROLE IN CLARITHROMYCIN PRIMARY RESISTANCE
Liliia Nikulina, UA

09:00 - 09:00 P0124
EVALUATION OF IL-17F A7488G POLYMORPHISM IN *HELICOBACTER PYLORI*-INFECTED PATIENTS IN QOM-IRAN

09:00 - 09:00 P0125
PERNICIOUS ANEMIA AND *HELICOBACTER PYLORI* INFECTION : AN INTRICATE ASSOCIATION
Maha Mtir, TN

09:00 - 09:00 P0126
EVALUATION OF THE ACCURACY OF THE "LIAISON[®] MERIDIAN *HELICOBACTER PYLORI* SA" STOOL ANTIGEN TEST FOR THE DIAGNOSIS OF *H. PYLORI* INFECTION: A SPANISH MULTICENTRE STUDY
Olga Perez Nyssen, ES

09:00 - 09:00 P0127
HOW ARE JAPANESE PATIENTS WITH AUTOIMMUNE GASTRITIS AFFECTED BY *H. PYLORI* INFECTION?: AN EVALUATION OF SEROLOGICAL, ENDOSCOPIC, AND HISTOLOGICAL FINDINGS
Naoki Sumi, JP

09:00 - 09:00 P0128
PCR IMPROVES DETECTION OF *HELICOBACTER PYLORI* IN UNSELECTED ADULT PATIENTS UNDERGOING ROUTINE GASTROSCOPY
Thomas Butler, IE

09:00 - 09:00 P0129
ALCOHOL INCREASES TREATMENT FAILURE FOR *HELICOBACTER PYLORI* ERADICATION IN ASIAN POPULATIONS
Xiaoyong Wang, CN

09:00 - 09:00 P0130
THE EFFECT OF LACTOBACILLUS REUTERI-CONTAINING QUADRUPLE THERAPY IN FIRST-LINE ERADICATION THERAPY FOR *HELICOBACTER PYLORI* INFECTION: A SINGLE-CENTER OPEN-LABEL RANDOMIZED CONTROLLED STUDY
Cailing Li, CN

09:00 - 09:00 P0131
EFFECTIVENESS AND SAFETY OF BISMUTH QUADRUPLE REGIMEN CONTAINING AMOXICILLIN AND FURAZOLIDONE FOR *HELICOBACTER PYLORI* INFECTION: A STUDY BASED ON REAL-WORLD DATA

09:00 - 09:00 P0132
EFFECTIVENESS AND SAFETY OF BISMUTH QUADRUPLE REGIMEN CONTAINING FURAZOLIDONE AND TETRACYCLINE FOR *HELICOBACTER PYLORI* INFECTION: A STUDY BASED ON REAL-WORLD DATA

09:00 - 09:00 P0133
OPTIMIZATION OF VONOPRAZAN-AMOXICILLIN DUAL THERAPY FOR ERADICATING *HELICOBACTER PYLORI* INFECTION IN CHINA: A PROSPECTIVE, RANDOMIZED CLINICAL PILOT STUDY
Yi Hu, CN

09:00 - 09:00 P0134
ALTERED GUT MICROBIOTA AND SHORT-CHAIN FATTY ACIDS AFTER VONOPRAZAN-AMOXICILLIN DUAL THERAPY FOR *HELICOBACTER PYLORI* ERADICATION
Yi Hu, CN

09:00 - 09:00 P0135
COMPARISON OF THE EFFECTIVENESS OF *HELICOBACTER PYLORI* ERADICATION REGIMENS BETWEEN THE ELDERLY AND NON-ELDERLY POPULATIONS: DATA FROM THE EUROPEAN REGISTRY ON *H. PYLORI* MANAGEMENT (HP-EUREG)
Paulius Jonaitis, LT

09:00 - 09:00 P0136
A PHASE 1, DOUBLE-BLIND, PARALLEL-GROUP STUDY TO EVALUATE THE PHARMACOKINETICS, SAFETY AND TOLERABILITY OF VONOPRAZAN- OR ESOPEPRAZOLE-BASED BISMUTH-CONTAINING QUADRUPLE THERAPY FOR *HELICOBACTER PYLORI* ERADICATION IN CHINA
Jia Miao, CN

09:00 - 09:00 P0137
REINFORCED MEDICATION ADHERENCE IMPROVES *H. PYLORI* ERADICATION RATE IN DEVELOPING COUNTRIES: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS

09:00 - 09:00 P0138
ROLE OF COMPLIANCE IN *HELICOBACTER PYLORI* TREATMENTS: RESULTS FROM THE EUROPEAN REGISTRY ON *H. PYLORI* MANAGEMENT (HP-EUREG)
Olga Perez Nyssen, ES

09:00 - 09:00 P0139
EMPIRIC "THREE-IN-ONE" BISMUTH QUADRUPLE THERAPY FOR *HELICOBACTER PYLORI* ERADICATION IN THE SECOND LINE: A PROSPECTIVE STUDY IN SOUTHERN ITALY
Giuseppe Losurdo, IT

09:00 - 09:00 P0140
EFFECT OF METRONIDAZOLE RESISTANCE ON *HELICOBACTER PYLORI* ERADICATION REGIMENS
Giuseppe Losurdo, IT

09:00 - 09:00 P0141
ANTIBIOTIC RESISTANCE OF *HELICOBACTER PYLORI* IN PRIMARY CARE: AN OBSERVATIONAL COHORT STUDY
Lieke M. Koggel, NL

09:00 - 09:00 P0142
EFFECTIVENESS AND SAFETY OF HIGH-DOSE DUAL THERAPY: RESULTS OF THE EUROPEAN REGISTRY ON *HELICOBACTER PYLORI* MANAGEMENT (HP-EUREG)
Olga Perez Nyssen, ES

09:00 - 09:00 P0143
DIFFERENCES OF *HELICOBACTER PYLORI* DIAGNOSTICS AND TREATMENTS IN THE ELDERLY AND NON-ELDERLY POPULATIONS: DATA FROM THE EUROPEAN REGISTRY ON *H. PYLORI* MANAGEMENT (HP-EUREG)
Paulius Jonaitis, LT

09:00 - 09:00 P0144
ERRORS IN EMPIRICAL ANTIBIOTIC THERAPIES FOR *HELICOBACTER PYLORI* ERADICATION IN 45,778 PATIENTS: DATA FROM THE EUROPEAN REGISTRY ON *H. PYLORI* MANAGEMENT (HP-EUREG)
Samuel Jesús Martínez-Domínguez, ES

09:00 - 09:00 P0145
PROSPECTIVE RANDOMIZED STUDY: HIGH-DOSE AMOXICILLIN DUAL THERAPY VERSUS BISMUTH QUADRUPLE THERAPY FOR *HELICOBACTER PYLORI* ERADICATION
Tiago Lima Capela, PT

09:00 - 09:00 P0147
ROLE OF THE PROTON PUMP INHIBITORS IN *HELICOBACTER PYLORI* ERADICATION: RESULTS FROM THE EUROPEAN REGISTRY ON *H. PYLORI* MANAGEMENT (HP-EUREG)
Olga Perez Nyssen, ES

09:00 - 09:00 P0149
EFFECTIVENESS AND SAFETY OF NOVEL VONOPRAZAN-BASED REGIMEN FOR *H. PYLORI* ERADICATION: A SINGLE CENTER, PROSPECTIVE, RANDOMIZED TRIAL
Xiaoyong Wang, CN

09:00 - 09:00 P0150
AN EVOLVING RESISTANT PANDEMIC. RISING COMMUNITY *H. PYLORI* TREATMENT FAILURE TO CLARITHROMYCIN-BASED TRIPLE THERAPY; AN OBSERVATIONAL STUDY
Thomas Butler, IE

09:00 - 09:00 P1030
HELICOBACTER PYLORI&NBSP;INFECTION PROMOTES CARCINOGENESIS BY UP-REGULATING ACE2 EXPRESSION

09:00 - 09:00 P1031
HELICOBACTER PYLORI INFECTION MEDIATES P53 REGULATION OF MITF-INDUCED MITOPHAGY

09:00 - 09:00 P1032
HELICOBACTER PYLORI INFECTION INHIBITS P53 REGULATION OF PGK1-MEDIATED GLYCOLYSIS

Poster Exhibition


09:00 – 17:30 Science Lounge
Oesophageal, gastric and duodenal disorders

09:00 - 09:00 P0002
RNA SEQUENCING REVEALS FEW MOLECULAR DIFFERENCES IN OESOPHAGEAL MUCOSA BETWEEN PATIENTS WITH EROSIIVE AND NON-EROSIVE REFLUX DISEASE
 Ahsen Ustaoglu, GB

09:00 - 09:00 P0003
THE ACTIVITY OF THE JAK/ STAT PATHWAY IS DECREASED IN PATIENTS WITH ACHALASIA
 Sezgi Kipcak, TR

09:00 - 09:00 P0004
CALORIC RESTRICTION CONDITIONS AS A MODULATOR SIGNAL FOR SIRTUINS (SIRTS) EXPRESSION - A NOVEL VIEW OF GASTRIC CANCER METASTASIS? (IN VITRO STUDY)
 Agata Poniewierska-Baran, PL

09:00 - 09:00 P0005
HEPATITIS B REPLICATION MARKERS ALONG WITH ENTRY RECEPTOR ON PLACENTA INDICATE: ANOTHER HOME FOR THE VIRUS
 Ashish Kumar Vyas, IN

09:00 - 09:00 P0006
MODERN STUDY ABOUT THE ROLE OF MACROPHAGES AND TRANSFORMING FACTOR B1 IN THE PATHOGENESIS OF PRIMARY SCLEROSING CHOLANGITIS AND ITS ASSOCIATION WITH INFLAMMATORY INTESTINAL DISEASES 
 Gulnoza Goyibova, UZ

09:00 - 09:00 P0007
FERULIC ACID TREATS GASTRIC ULCER VIA SUPPRESSING OXIDATIVE STRESS AND INFLAMMATION
 Aleyna Ermis, TR

09:00 - 09:00 P0008
SEVERE GASTRITIS AND DUODENITIS IN PATIENTS TREATED WITH IMMUNE CHECKPOINT INHIBITORS: A MULTICENTER STUDY
 Clément Bresteau, FR

09:00 - 09:00 P0009
A SINGLE-CELL TRANSCRIPTIONAL LANDSCAPE OF IMMUNE CELLS REVEALS A DISEASE-SPECIFIC COMPOSITION AND TRANSCRIPTIONAL PHENOTYPE IN HUMAN ACHALASIA

Quan-Lin Li, CN
 09:00 - 09:00 P0010
TISSUE ADHESIVE POLYACRYLAMIDE HYDROGEL INCORPORATING TRIAMCINOLONE ACETONIDE IS EFFECTIVE FOR PREVENTION OF FIBROSIS IN RATS' ESOPHAGUS

09:00 - 09:00 P0011
FUNCTIONAL DYSPEPSIA DUODEUM MUCOSAL ASSOCIATED MICROBIOTA: COMPARISON BETWEEN FRESH BIOPSY AND HISTORICAL FORMALIN-FIXED PARAFFIN-EMBEDDED BIOPSIES IS VIABLE
 Emily Hoedt, AU

09:00 - 09:00 P0012
CIRCULATING PLASMA MICROBIOME AND GASTRIC CANCER
 Darja Nikitina, LT

09:00 - 09:00 P0013
THE EFFECTS OF VARIABLE DOSES OF HERBAL FORMULATIONS ON THE DUODENAL MUCOSA-ASSOCIATED MICROBIOTA FROM SUBJECTS WITH AND WITHOUT FUNCTIONAL DYSPEPSIA AND SELECT ISOLATES OF DUODENAL BACTERIA
 Lauren Schooth, AU

09:00 - 09:00 P0014
THE SAFETY AND EFFICACY OF DIRECT ORAL ANTICOAGULANT RESUMPTION FOLLOWING A GASTROINTESTINAL BLEEDING EPISODE: A SYSTEMATIC REVIEW AND META-ANALYSIS
 Daniel Palinkas, HU

09:00 - 09:00 P0015
PREDICTIVE ABILITY OF AVAILABLE SCORES IN MASSIVE UPPER GASTROINTESTINAL BLEEDING
 Rita Jiménez-Rosales, ES

09:00 - 09:00 P0016
USEFULNESS OF THE MODIFIED PRENDOSCOPIC ROCKALL INDEX TO PREDICT OUTCOMES IN UPPER GASTROINTESTINAL BLEEDING DUE TO PEPTIC ULCER
 Laura Patricia Llovet Soto, ES

09:00 - 09:00 P0017
AN AUDIT OF LOCAL MANAGEMENT OF UPPER GASTROINTESTINAL BLEEDS IN A UNITED KINGDOM DISTRICT GENERAL HOSPITAL
 Aamie Patel, GB

09:00 - 09:00 P0018
COMPARISON OF RISK SCORING SYSTEMS FOR PATIENTS PRESENTING WITH ACUTE UPPER GASTRO-INTESTINAL BLEEDING
 Sara Nacer, MA

09:00 - 09:00 P0020
HEDONIC AND SOMATIC RESPONSES TO MEAL INGESTION IN FUNCTIONAL DYSPEPSIA

Dan Meir Livovsky, IL

09:00 - 09:00 P0021
PRECISION MEDICINE IN DYSPEPSIA. DEVELOPMENT AND INTERNAL VALIDATION OF A PREDICTIVE PROGNOSIS MODEL OF RESPONSE TO PROTON-PUMP INHIBITOR IN ADULT PATIENTS WITH FUNCTIONAL DYSPEPSIA

Sebastián Fernando Niño Ramirez, CO

09:00 - 09:00 P0022
PREVALENCE AND IMPACT OF MIGRAINE HEADACHES IN ROME IV-BASED FUNCTIONAL DYSPEPSIA

Fabien Wuestenberghs, FR

09:00 - 09:00 P0023
INTRAVENOUS FERRIC CARBOXYMALTOSE TREATMENT IS SAFE, EFFECTIVE, AND LONG-LASTING IN PATIENTS WITH CORPUS ATROPHIC GASTRITIS

Ludovica Dottori, IT

09:00 - 09:00 P0024
MECHANISMS OF ACTION OF AN HERBAL MULTI-COMPONENT PREPARATION IN FUNCTIONAL DYSPEPSIA: EFFECTS ON GASTRIC MOTILITY

Maria-Riera Piqué-Borràs, CH

09:00 - 09:00 P0025
OVERLAP OF FUNCTIONAL GASTROINTESTINAL DISORDERS REFLECTING BRAIN-GUT INTERACTIONS: A SYSTEMATIC REVIEW AND META-ANALYSIS

Ayesha Shah, AU

09:00 - 09:00 P0026
ENRICHMENT OF PATIENTS WITH EHLERS DANLOS SYNDROME IN IDIOPATHIC GASTROPARESIS – A GENE SET ENRICHMENT ANALYSIS

Sandra Smieszek, US

09:00 - 09:00 P0027
THE EFFECT OF SINGLE AND REPEATED DOSES OF RIVASTIGMINE ON GASTRIC MYOELECTRIC ACTIVITY IN EXPERIMENTAL PIGS

Jan Bures, CZ

09:00 - 09:00 P0028
LONG-TERM OUTCOMES OF PER-ORAL ENDOSCOPIC MYOTOMY IN ESOPHAGEAL MOTILITY DISORDERS: A SYSTEMATIC REVIEW AND META-ANALYSIS

Zaheer Nabi, IN

09:00 - 09:00 P0029
CHICAGO CLASSIFICATION VERSION 3 VERSUS VERSION 4: WHAT ARE THE DIAGNOSTIC IMPLICATIONS?

Marta Freitas, PT

09:00 - 09:00 P0030
AUTONOMIC AUTOANTIBODIES IN ACHALASIA

Dana Ben-Ami Shor, IL

09:00 - 09:00 P0031
PREVALENCE OF DELAYED GASTRIC EMPTYING IN DIABETIC PATIENTS WITH GASTROPARESIS-LIKE SYMPTOMS

I-Hsuan Huang, BE

09:00 - 09:00 P0032
G-POEM FOR REFRACTORY GASTROPARESIS: BASAL SYMPTOM SEVERITY AND INTRAGASTRIC MEAL DISTRIBUTION DURING GASTRIC EMPTYING SCINTIGRAPHY MAY BE PREDICTORS OF 12-MONTH CLINICAL OUTCOME

Alberto Barchi, IT

09:00 - 09:00 P0033
GASTROESOPHAGEAL REFLUX DISEASE AFTER PERORAL ENDOSCOPIC MYOTOMY

Pablo Miranda, ES

09:00 - 09:00 P0035
ASSOCIATION BETWEEN GASTRIC EMPTYING AND SYMPTOMS IN A LARGE COHORT OF PATIENTS WITH DYSPEPSIA

Jutta Keller, DE

09:00 - 09:00 P0036
A RANDOMIZED CONTROLLED TRIAL TO COMPARE TRANSVERSE VERSUS LONGITUDINAL INCISION FOR ENTRY INTO THE SUBMUCOSAL SPACE DURING PER ORAL ENDOSCOPIC MYOTOMY FOR ESOPHAGEAL MOTILITY DISORDERS

Harshal Mandavdhare, IN

09:00 - 09:00 P0037
A BASELINE SEVERITY INFLATION ANALYSIS IN STUDY VP-VLY-686-3301 OF TRADIPITANT IN GASTROPARESIS

Jesse L. Carlin, US

09:00 - 09:00 P0038
QUANTITATIVE ASSESSMENT OF ESOPHAGEAL BOLUS RETENTION WITH HIGH-RESOLUTION IMPEDANCE MANOMETRY

Katsuyuki Oura, JP

09:00 - 09:00 P0039
THE EFFECT OF BODY POSITION ON HIGH RESOLUTION ESOPHAGEAL MANOMETRY METRICS AND DIAGNOSIS IN ASIAN PATIENTS UNDERGOING ESOPHAGEAL MOTILITY TESTING

Jonathan Kuang, SG

09:00 - 09:00 P0040
IMPACT OF REFLUX BURDEN IN PATIENTS WITH INEFFECTIVE ESOPHAGEAL MOTILITY ACCORDING TO THE CRITERIA PROPOSED BY CCV4.0 COMPARED TO CCV3.0

Pierfrancesco Visaggi, IT

09:00 - 09:00 P0041
DOES BODY MASS INDEX INFLUENCE THE PARAMETERS OF HIGH-RESOLUTION ESOPHAGEAL MANOMETRY?

Teodora Surdea-Blaga, RO

09:00 - 09:00 P0042
ANXIETY, DEPRESSION AND QUALITY OF LIFE PATIENTS WITH FUNCTIONAL DYSPEPSIA: A CROSS-SECTIONAL STUDY

Tatyana Kugler, UA

09:00 - 09:00 P0043
DEFINING A THRESHOLD OF SEVERE FUNCTIONAL DYSPEPSIA FOR USE IN A CLINICAL SETTING

Michael P. Jones, AU

09:00 - 09:00 P0044
DUAL ASSESSMENT OF GASTRIC FUNCTION WITH SIMULTANEOUS GASTRIC EMPTYING AND BODY-SURFACE GASTRIC MAPPING IN PATIENTS WITH GASTROPARESIS-LIKE SYMPTOM AND FUNCTIONAL DYSPEPSIA

I-Hsuan Huang, BE

09:00 - 09:00 P0045
CHRONOTYPES CORRELATES WITH PRESENCE AND SEVERITY OF UPPER GASTROINTESTINAL TRACT SYMPTOMS AND AFFECTS PATIENT'S QUALITY OF LIFE

Sara Rurgo, IT

09:00 - 09:00 P0046
ASSESSING PREVALENCE AND CLINICAL FEATURES OF POSITIVE HYDROGEN BREATH TESTS IN PATIENTS REFERRED TO A TERTIARY UNIT, WITH SPECIAL ATTENTION TO FUNCTIONAL GASTROINTESTINAL CONDITIONS AND HEDS

Humayra Dervin, GB

09:00 - 09:00 P0047
QUANTIFYING THE BURDEN OF FOOD RELATED ALLERGIC REACTIONS IN HYPERMOBILE EHLERS DANLOS SYNDROME

Rabia Topan, GB

09:00 - 09:00 P0048
NO GENDER DIFFERENCES IN EOE DISEASE PRESENTATION, TREATMENT, AND COMPLICATIONS IN THE DANISH DANEOE COHORT – A POPULATION-BASED STUDY OF 236 PATIENTS

Line Tegtmeister Frandsen, DK

09:00 - 09:00 P0049
POPULATION-BASED INCIDENCE AND PREVALENCE OF EOSINOPHILIC OESOPHAGITIS IN DENMARK: A NATIONWIDE STUDY 2008 – 2018

Anne Lund Krarup, DK

09:00 - 09:00 P0050
THE DESCRIPTION OF THE EOE COPENHAGEN COHORT OF PATIENTS WITH EOSINOPHILIC OESOPHAGITIS [ALK1]REFERRED TO A TERTIARY FACILITY IN DENMARK COMPARED TO THE POPULATION BASED DANEOE COHORT

Anne Lund Krarup, DK

09:00 - 09:00 P0051
DELAYED DIAGNOSIS OF EOSINOPHILIC OESOPHAGITIS IN THOSE PRESENTING TO THE EMERGENCY DEPARTMENT WITH FOOD BOLUS IMPACTION

Dominic Ayi Gyimah, GB

09:00 - 09:00 P0052
CHROMOENDOSCOPY WITH IODINE-POTASSIUM IODINE SOLUTION IMPROVES THE DETECTION OF EOSINOPHILIC ESOPHAGITIS - A COMPARATIVE STUDY

Sigurd Strumse Lauritzen, NO

09:00 - 09:00 P0053
THE PHENOTYPE OF PATIENTS WITH COMPLICATED EOSINOPHILIC OESOPHAGITIS – A POPULATION BASED STUDY OF THE DANEOE COHORT

Anne Lund Krarup, DK

09:00 - 09:00 P0054
TOLERANCE TO STERILIZED COW'S MILK IN PATIENTS WITH EOSINOPHILIC ESOPHAGITIS TRIGGERED BY MILK

M Pilar Navarro Sánchez, ES

09:00 - 09:00 P0055
SPORADIC VERSUS FAMILIAL PRESENTATION OF EOSINOPHILIC ESOPHAGITIS: A COMPARATIVE ANALYSIS OF THE EOE CONNECT REGISTRY ON DEMOGRAPHIC, CLINICAL CHARACTERISTICS AND EARLY-LIFE EXPOSURES

M Pilar Navarro Sánchez, ES

09:00 - 09:00 P0056
BURP-EXCRETED NITRIC OXIDE (BUENO): SETTING THE STANDARDS

Francesca Racca, IT

09:00 - 09:00 P0057
HOW TO PREDICT PROTON PUMP INHIBITORS RESPONSES IN EOSINOPHILIC ESOPHAGITIS PATIENTS. AN IMPOSSIBLE MISSION?

María Machín Delgado, ES

09:00 - 09:00 P0058
EOSINOPHILIC ESOPHAGITIS: MOST NON-RESPONDERS TO FIRST COURSE OF PPIS ACHIEVE SUSTAINED HISTOLOGICAL REMISSION FOLLOWING SEQUENTIAL TREATMENT WITH TOPICAL STEROIDS AND SECOND COURSE OF PPIS MONOTHERAPY

Pierfrancesco Visaggi, IT

09:00 - 09:00 P0059
CLINICAL HISTORY REPRESENTS A PERFECT SCREENING STRATEGY FOR EOSINOPHILIC ESOPHAGITIS IN PATIENTS REPORTING DYSPHAGIA: A CROSS-SECTIONAL CASE-CONTROL STUDY

Pierfrancesco Visaggi, IT

09:00 - 09:00 P0060
EOSINOPHILIC ESOPHAGITIS, PREVALENCE, INCIDENCE AND PRESENTING FEATURES IN SOUTHWEST SWEDEN: A 20-YEAR POPULATION-BASED STUDY

John Plate, SE

09:00 - 09:00 P0061
HISTOPATHOLOGY BUT NOT MENTAL HEALTH ASSESSMENT DISTINGUISHES INDIVIDUALS WITH AND WITHOUT EROSIIVE REFLUX DISEASE AND CONTROLS WITHOUT REFLUX DISEASE – A CROSS-SECTIONAL POPULATION-BASED STUDY

Nicholas J. Talley, AU

09:00 - 09:00 P0062
OESOPHAGEAL DYSMOTILITY AND GASTROESOPHAGEAL REFUX IN RESPIRATORY DISEASE: AN ONGOING CONUNDRUM OF WHO SHOULD UNDERGO LUNG TRANSPLANTATION

Ali Alghubari, GB

09:00 - 09:00 P0063
EFFECT OF HIATUS HERNIA ON REFLUX PATTERNS AND MUCOSAL INTEGRITY IN PATIENTS WITH NON-EROSIVE REFLUX DISEASE

Akinari Sawada, JP

09:00 - 09:00 P0064
STRAIGHT LEG RAISE TEST: A NOVEL PROVOCATIVE TEST TO ASSESS ESOPHAGEAL CONTRACTION RESERVE
 Pierfrancesco Visaggi, IT

09:00 - 09:00 P0065
POST-REFLUX SWALLOW-INDUCED PERISTALTIC WAVE INDEX CORRELATES WITH BODY MASS INDEX AND IMPROVES WITH BARIATRIC SURGERY-INDUCED WEIGHT LOSS, REGARDLESS OF ESOPHAGEAL ACID EXPOSURE
 Marcella Pesce, IT

09:00 - 09:00 P0066
CENSORING REFLUX EPISODES BY THE WINGATE CONSENSUS REDUCES SUPPORTIVE EVIDENCE FOR GERD PROVIDED BY PH/IMPEDANCE MONITORING
 Sebastien Kindt, BE

09:00 - 09:00 P0067
VALIDATION OF THE LYON CONSENSUS CRITERIA FOR GERD DIAGNOSIS IN A GREEK POPULATION; A RETROSPECTIVE STUDY
 Georgios Karamanolis, GR

09:00 - 09:00 P0068
LCI IMPROVES THE VISIBILITY OF MINIMAL CHANGE ESOPHAGITIS- A LAB COLOR VALUE BASED QUANTITATIVE ANALYSIS
 Li Wang, CN

09:00 - 09:00 P0069
LOW ESOPHAGEAL BASELINE IMPEDANCE AND NUMBER OF CHANNELS INVOLVED ARE ASSOCIATED WITH BARRETT'S ESOPHAGUS SEGMENT LENGTH
 Nir Bar, US

09:00 - 09:00 P0070
BARIUM OESOPHAGRAM DOES NOT RELIABLY DETECT CLINICALLY RELEVANT REFLUX DEFINED BY 24-HOUR MULTICHANNEL INTRALUMINAL IMPEDANCE PH
 Nir Bar, US

09:00 - 09:00 P0071
HEALING WATER LEADS TO REDUCTION OF HEARTBURN: RANDOMISED, PLACEBO-CONTROLLED PHASE-III TRIAL (STOMACH STILL)
 Joachim Labenz, DE

09:00 - 09:00 P0072
VONOPRAZAN OR MORE THAN DOUBLE-DOSE PROTON PUMP INHIBITOR MAINTENANCE THERAPY SHOULD BE PERFORMED IN PATIENTS WITH SYSTEMIC SCLEROSIS WITH ABSENT CONTRACTILITY
 Shiko Kuribayashi, JP

09:00 - 09:00 P0073
EFFICACY AND SAFETY OF HIP1601 (DUAL DELAYED-RELEASE ESOMEPRAZOLE) 40MG IN EROSIIVE ESOPHAGITIS COMPARED TO HGP1705 (DELAYED-RELEASE ESOMEPRAZOLE) 40MG: A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, NON-INFERIORITY STUDY
 Hyun Lim, KR

09:00 - 09:00 P0074
EFFECTS OF TRANSCUTANEOUS ELECTRICAL STIMULATION SYSTEM ON HEARTBURN, REGURGITATION AND ESOPHAGEAL ACID EXPOSURE IN GERD PATIENTS
 Ram Dickman, IL

09:00 - 09:00 P0075
MANAGEMENT OF RECURRENT GASTROESOPHAGEAL REFLUX DISEASE AFTER NISSEN OR TRANSORAL INCISIONLESS FUNDOPLICATION UTILIZING EITHER ANTIREFLUX MUCOSECTOMY OR RESECTION AND PPLICATION: AN UPDATED MULTICENTER STUDY
 Navkiran Randhawa, US

09:00 - 09:00 P0076
MOSAPRIDE CITRATE COMBINED WITH ESOMEPRAZOLE IS EFFECTIVE IN GASTROESOPHAGEAL REFLUX DISEASE BY IMPROVING DELAYED GASTRIC EMPTYING. - PRELIMINARY RESULTS -
 Beom Jin Kim, KR

09:00 - 09:00 P0077
THE EFFECTS OF TEGOPRAZAN VERSUS ESOMEPRAZOLE FOR RELIEF OF NIGHTTIME HEARTBURN AND SLEEP QUALITY IN GERD: A MULTICENTER DOUBLE-BLIND RANDOMIZED CONTROLLED TRIAL
 Sang Kil Lee, KR

09:00 - 09:00 P0078
EFFECT OF A COMBINATION ORAL FORMULATION OF HYALURONIC ACID WITH CHONDROITIN SULPHATE AND WITH MAGNESIUM TRISILICATE IN GASTRO-ESOPHAGEAL REFLUX DISEASE
 Annelies Geeraerts, BE

09:00 - 09:00 P0079
COMPARISON OF MEDICAL THERAPIES FOR NON-EROSIVE REFLUX DISEASE: SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS
 Pierfrancesco Visaggi, IT

09:00 - 09:00 P0080
HIATUS HERNIA: PREVALENCE, PRESENTATION, AND EVALUATION OF ESOPHAGEAL SEQUELA
 Fadi Abu Baker, IL

09:00 - 09:00 P0081
CONTRIBUTION OF ENZYMIC ACTIVITY OF HEME OXYGENASE (HMOX) AND ITS BYPRODUCT, CARBON MONOXIDE (CO) IN BARRETT'S METAPLASIA DEVELOPMENT
 Kinga Krukowska, PL

09:00 - 09:00 P0082
INSULIN-LIKE GROWTH FACTOR-1 (IGF-1) IS ELEVATED IN SERUM OF PATIENTS WITH BARRETT'S ESOPHAGUS: LONGITUDINAL STUDY
 Hugo Uchima, ES

09:00 - 09:00 P0083
THE NATURAL COURSE OF UNTREATED NEOPLASIA IN BARRETT'S ESOPHAGUS - A CASE-SERIES
 Eva Verheij, NL

09:00 - 09:00 P0084
CAN ENDOSCOPIC EVIDENCE OF BILE REFLUX PREDICT THE DEVELOPMENT OF BARRETT'S ESOPHAGUS?
 Yugo Iwaya, JP

09:00 - 09:00 P0085
CIRCUMFERENTIAL ENDOSCOPIC SUBMUCOSAL DISSECTION OF NEOPLASTIC BARRETT'S ESOPHAGUS
 Masami Omae, SE

09:00 - 09:00 P0086
BARRETT'S OESOPHAGUS SURVEILLANCE – CAN WE DO BETTER?
 Mina Soliman, GB

09:00 - 09:00 P0087
OPTICAL FLOW AS A METHOD FOR QUALITY ASSURANCE IN AI-AIDED EXAMINATION OF BARRETT'S ESOPHAGUS AND BARRETT'S ESOPHAGUS RELATED NEOPLASIA
 Michael Meinikheim, DE

09:00 - 09:00 P0088
DOES BARRETT'S ESOPHAGUS START TOO EARLY IN LIFE? ANALYSIS OF ENDOSCOPIC FINDINGS IN A PEDIATRIC COHORT

09:00 - 09:00 P0089
EARLY DETECTION OF BARRETT'S ESOPHAGUS AND ESOPHAGEAL CANCER IN PRIMARY CARE USING TRANSNASAL ENDOSCOPY: A PROSPECTIVE COHORT STUDY
 Lotte J. Huibertse, NL

09:00 - 09:00 P0090
MICROBIAL BIOMARKERS OF ESOPHAGEAL SQUAMOUS CELL CARCINOMA AND PRECANCEROUS LESIONS BY METAGENOMICS

09:00 - 09:00 P0091
CLINICAL OUTCOMES OF ENDOSCOPIC RESECTION FOR THE TREATMENT OF ESOPHAGEAL GASTROINTESTINAL STROMAL TUMORS: A TEN-YEAR EXPERIENCE FROM A LARGE TERTIARY CENTER IN CHINA

09:00 - 09:00 P0092
COMPREHENSIVE GENETIC ANALYSES IN CHRONIC ESOPHAGITIS AND ESOPHAGEAL SQUAMOUS CELL CARCINOMA CLASSIFIED BY THE SEVERITY OF LUGOL-VOIDING LESIONS
 Naoki Akizue, JP

09:00 - 09:00 P0093
LONG-TERM OUTCOMES AND PROGNOSTIC FACTORS OF SUPERFICIAL ESOPHAGEAL CANCER IN PATIENTS AGED ≥65 YEARS
 Da Hyun Jung, KR

09:00 - 09:00 P0094
SCREENING FOR METACHRONOUS ESOPHAGEAL SECOND PRIMARY TUMORS IN PATIENTS WITH HEAD AND NECK CANCER
 Laurelle van Tilburg, NL

09:00 - 09:00 P0095
ESOPHAGEAL STENTING FOR ESOPHAGOGASTRIC CANCER PALLIATION: HOW TO PROSPECTIVELY EVALUATE QUALITY OF LIFE?
 Cláudia Pinto, PT

09:00 - 09:00 P0096
CAN CONCOMITANT USE OF H2RA PLAY AN IMPORTANT ROLE IN PREVENTING THE GASTRIC MUCOSAL INJURIES LIKE P-CAB OR PPI IN PATIENTS TAKING ASPIRIN ?

09:00 - 09:00 P0097
RANDOMIZED CLINICAL TRIAL: EFFICACY AND SAFETY OF FEXUPRAZAN IN PATIENTS WITH ACUTE OR CHRONIC GASTRITIS
 Gwang Ha Kim, KR

09:00 - 09:00 P0098
THE EFFICACY AND SAFETY OF KEVERPRAZAN (H008) IN THE TREATMENT OF DUODENAL ULCER: A MULTICENTERED, RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROL TRIAL IN CHINA
 Niandi Tan, CN

09:00 - 09:00 P0099
DEVELOPMENT AND VALIDATION OF A NOMOGRAM PREDICTING THE OVERALL SURVIVAL FOR PATIENTS WITH PRIMARY GASTRIC MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA: A SEER-BASED STUDY
 Dan Wang, CN

09:00 - 09:00 P0100
LOCAL RECURRENCE AFTER ENDOSCOPIC SUBMUCOSAL DISSECTION OF EARLY GASTRIC CANCER

09:00 - 09:00 P0101
INVESTIGATING IDA: LARGE-SCALE DATA SHOWING PERSISTENT GAPS AT THE FRONT DOOR
 George Howell, GB

09:00 - 09:00 P0102
GASTRIC XANTHOMA: YELLOW TRAFFIC LIGHT ALSO IN THE WESTERN WORLD
 Sara Molina Tejedor, ES

09:00 - 09:00 P0103
GASTRIC CANCER MISSED IN A WELL-DEFINED SPANISH POPULATION
 Rosa Maria Saiz Chumillas, ES

09:00 - 09:00 P0104
MALT LYMPHOMA A LONG-TERM FOLLOW-UP FROM A SINGLE CENTER EXPERIENCE
 Luís Correia Gomes, PT

09:00 - 09:00 P0105
VALIDATION OF A DSC SCORE AS SCREENING TEST FOR GASTRIC PRECANCEROUS LESIONS IN A NON-HIGH-INCIDENCE AREA
 Valli De Re, IT

09:00 - 09:00 P0106
A STUDY ON THE USEFULNESS OF LINKED COLOR IMAGING DEPENDING ON DOCTORS AND LESIONS USING EYE TRACKING
 Masayuki Higashino, JP

09:00 - 09:00 P0107
CONFOCAL LASER ENDOMICROSCOPY (PCLE) DETECTS MUCOSAL NEOPLASTIC VASCULAR PATTERN IN GASTRIC LINITIS PLASTICA
 Paola Spessotto, IT

09:00 - 09:00 P0108
ENDOSCOPIC TREATMENT OUTCOMES FOR DUODENAL NEUROENDOCRINE TUMOR
 Jin Hee Noh, KR

09:00 - 09:00 P0109
GASTRIC NEOPLASTIC LESIONS IN AUTOIMMUNE ATROPHIC GASTRITIS: OCCURRENCE AND PREDICTORS
 Emanuele Dilaghi, IT

09:00 - 09:00 P0110
USEFULNESS OF LINKED COLOR IMAGING FOR DETECTION AND CHARACTERIZATION OF EARLY UNDIFFERENTIATED-TYPE GASTRIC CANCER
 Wansik Lee, KR

09:00 - 09:00 P0111
CLINICOPATHOLOGICAL AND ENDOSCOPIC FEATURES OF GASTRIC ADENOCARCINOMA OF THE FUNDIC GLAND TYPE
 Jia Cao, CN

09:00 - 09:00 P0112
A 10-YEAR EXPERIENCE WITH TYPE I GASTRIC NEUROENDOCRINE TUMOURS
 Raquel Ortigão, PT

09:00 - 09:00 P0113
CLINICAL COMPARISON OF ENDOSCOPIC RESECTION VERSUS SURGICAL TREATMENT AMONG PRIMARY DUODENAL GASTROINTESTINAL STROMAL TUMORS (DIGESTS)
 Quan-Lin Li, CN

09:00 - 09:00 P0114
PREVALENCE AND PREDICTORS OF MALNUTRITION IN PATIENTS WITH GASTRIC CANCER – A SINGLE CENTRE PROSPECTIVE STUDY
 Prachi Patil, IN

09:00 - 09:00 P0115
PIECEMEAL COLD SNARE POLYPECTOMY FOR THE REMOVAL OF LARGE DUODENAL ADENOMAS
 Oliver Cronin, AU

09:00 - 09:00 P0116
HP INFECTION IN GASTRIC DIFFUSE LARGE B CELL LYMPHOMA: FREQUENCY, RESPONSE TO TREATMENT AND IMPACT ON LYMPHOMA PROGRESSION
 Ghada Gharbi, TN

09:00 - 09:00 P0118
USE OF MUCOLYTIC SOLUTION BEFORE GASTROSCOPY – A DOUBLE-BLIND, RANDOMIZED STUDY
 Michal Stepan, CZ

09:00 - 09:00 P0119
ONE TIME SCREENING GASTROSCOPY IN LOW TO MODERATE UPPER GASTROINTESTINAL CANCERS PREVALENCE POPULATION – IS IT WORTH?
 Krzysztof Budzyń, PL

09:00 - 09:00 P0120
CYSTIC FIBROSIS-RELATED GI DISEASE: A GROWING BURDEN FOR BOTH SERVICES
 Ciaran Mc Closkey, IE

09:00 - 09:00 P1027
BLUE LIGHT IMAGING AND LINKED COLOR IMAGING AS A SCREENING MODE FOR ESOPHAGEAL SQUAMOUS CELL CARCINOMA IN HIGH-RISK PATIENTS: A MULTICENTRE RANDOMIZED CONTROLLED TRIAL
 Yohei Ogata, JP

09:00 - 09:06 P1028
THE EFFECT OF DATA DIVERSITY ON THE PERFORMANCE OF DEEP LEARNING MODELS FOR PREDICTING EARLY GASTRIC CANCER UNDER ENDOSCOPY
 Conghui Shi, CN

09:06 - 09:06 P1029
REALTIME ARTIFICIAL INTELLIGENCE ASSISTED DEVICE CAN EFFECTIVELY IMPROVE EARLY GASTRIC CANCER DETECTION: A HISTORICAL MULTICENTER CONTROLLED TRIAL

Poster Exhibition

09:00 – 17:30 Science Lounge
COVID-19

09:00 - 09:06 P1013
THE IMPACT OF THE COVID-19 PANDEMIC ON PATIENTS WITH ULCERATIVE COLITIS: RESULTS FROM A GLOBAL UC PATIENT SURVEY
 Laurent Peyrin-Biroulet, FR

09:06 - 09:06 P1014
ZONULIN CONCENTRATION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES WITH AND WITHOUT COVID-19 INFECTION
 Anna Kagramanova, RU

09:06 - 09:06 P1015
DIFFERENCE BETWEEN COVID-19 ALPHA VARIANT, B.1.1.7, AND THE ORIGINAL VIRUS IN GASTROINTESTINAL SYMPTOMS AND MORTALITY, IS A NEGATIVE CORRELATION EXISTS?
 Yaron Niv, IL

09:06 - 09:06 P1016
FEATURES OF MICROBIOTA DISTURBANCES INTESTINE IN PATIENTS WHO UNDERWENT COVID-19

09:06 - 09:06 P1017
BNT162B2 MRNA COVID-19 VACCINE SAFETY IN INFLAMMATORY BOWEL DISEASE PATIENTS ON BIOLOGIC THERAPY: A MONOCENTRIC REAL-WORLD STUDY
 Raffaele Pellegrino, IT

09:06 - 09:06 P1018
IMMUNOGENICITY AGAINST SARS-COV-2 VARIANTS AFTER THIRD DOSE OF MRNA COVID-19 VACCINE IN PATIENTS WITH IBD FROM PUERTO RICO 🇵🇷
 Paola López-Marte, PR

09:06 - 09:06 P1019
PATIENTS WITH LOW ALT LEVELS ARE AT INCREASED RISK FOR SEVERE COVID-19

Asher Shafrir, IL

09:06 - 09:06 P1020
COMPARING PATIENT PROFILES OF COVID-19 VACCINATED AND UNVACCINATED CROHN'S DISEASE PATIENTS

Elizabeth Baynton, GB

09:06 - 09:06 P1021
THE SAFETY OF ENDOSCOPY UNITS DURING THE COVID-19 PANDEMIC

Margarida Gomes Gonçalves, PT

09:06 - 09:06 P1022
AN ELUSIVE MANIFESTATION OF COVID-19: DYSPHAGIA DUE TO ESOPHAGO-GASTRIC JUNCTION DISORDERS

Anastasios Manolakis, GR

09:06 - 09:06 P1023
INFLAMMATORY BOWEL DISEASES DURING THE SARS-COV2 PANDEMIC ERA: THE EFFECTS OF COVID-19 ON PSYCHOLOGICAL STATUS AND DISEASE ACTIVITY

Maria Giulia Demarzo, IT

09:06 - 09:06 P1024
PARAMETRIC IMAGING WITH CONTRAST-ENHANCED ULTRASOUND (CEUS): A NOVEL APPROACH TO ASSESS SMALL BOWEL MANIFESTATION IN SEVERE COVID-19 DISEASE

Hauke Tews, DE

09:06 - 09:06 P1025
THE IMPACT OF COVID-19 ON GASTROENTEROLOGY DEPARTMENT

Delia Ionela Negru-Vodă, RO

Poster Exhibition

09:00 – 17:30

Science Lounge

IBD

09:00 - 09:00 P0209
PROTEOMIC PROFILE OF SERUM AND URINE IN NEWLY DIAGNOSED PATIENTS WITH INFLAMMATORY BOWEL DISEASE: NEW APPROACH FOR BIOMARKER DISCOVERY

Montse Baldan Martin, ES

09:00 - 09:00 P0210
SURGICAL RESECTIONS FROM IBD PATIENTS EXHIBIT DIFFERENT METABOLITE-SENSING GPCRS EXPRESSION, METABOLIC PROFILES AND MICROBIAL DYSBIOSIS

Cristina Bauset, ES

09:00 - 09:00 P0211
PROPIONATE AMELIORATES DSS-INDUCED COLITIS BY M2A MACROPHAGE POLARIZATION AND SECRETING INTERLEUKIN-10 VIA HISTONE DEACETYLASE

Xiaoli Wang, CN

09:00 - 09:00 P0212
AN INSIDE OUT APPROACH TO IDENTIFY PERIPHERAL PATIENT PATHOTYPE-SPECIFIC BIOMARKERS FROM A HIGH-CONTENT, MULTI-DIMENSIONAL DATASET OF HETEROGENOUS IBD POPULATIONS

Aisling Hall, US

09:00 - 09:00 P0213
EFFECTS OF ANTI-TNFA AND ANTI-A4B7 DRUGS ON CIRCULATING DENDRITIC CELLS MIGRATORY CAPACITY IN INFLAMMATORY BOWEL DISEASE

Irene Soletto, ES

09:00 - 09:00 P0214
THE OVERLAP BETWEEN CANNABINOID AND NOCICEPTIN SIGNALING AND ITS ROLE IN INTESTINAL INFLAMMATION – A PILOT STUDY

Maria Wołyniak, PL

09:00 - 09:00 P0215
IFN γ -TREATED MACROPHAGES INDUCE EMT THROUGH THE WNT PATHWAY: RELEVANCE IN CROHN'S DISEASE

Cristina Bauset, ES

09:00 - 09:00 P0216
DECODING THE TAXONOMIC AND FUNCTIONAL PROFILES OF MICROBIOTA IN INFLAMMATORY BOWEL DISEASES – A MULTI-OMICS APPROACH

Giuseppe Lo Sasso, CH

09:00 - 09:00 P0217
HUMAN INTESTINAL CD103+SIRPA+ CONVENTIONAL DENDRITIC CELLS FROM PATIENTS WITH CROHN'S DISEASE PRIME IL-17+ T-CELLS

David Bernardo, ES

09:00 - 09:00 P0218
EXCLUSIVE ENTERAL NUTRITION DRIVES PROTECTIVE MICROBIOME MODULATION IN PEDIATRIC CROHN'S DISEASE

Deborah Häcker, DE

09:00 - 09:00 P0219
MUCOSAL AND PLASMA METABOLOMES IN NEW-ONSET PAEDIATRIC INFLAMMATORY BOWEL DISEASE: CORRELATIONS WITH DISEASE CHARACTERISTICS AND PLASMA INFLAMMATION PROTEIN MARKERS

Niklas Nyström, SE

09:00 - 09:00 P0220
LOW DRUG LEVELS ARE IMMUNOGENIC: EXCESS INFLIXIMAB COMPETES WITH IFX/TNF COMPLEXES TO DECREASE COMPLEX-INDUCED IMMUNOGENICITY

Sigal Pressman, IL

09:00 - 09:00 P0221
THE SOLUTE CARRIER *SLC22A4*/OCTN1 AS A NOVEL IBD DETERMINANT AT THE MICROBE-HOST INTERFACE

Letizia Masi, IT

09:00 - 09:00 P0222
DISTINCT MUCOSAL HOST-MICROBE INTERACTIONS IN RELATION TO CLINICAL PHENOTYPES IN INFLAMMATORY BOWEL DISEASE

Arno R. Bourgonje, NL

- 09:00 - 09:00 P0223
MUCUS COMPOSITION ALTERATIONS IN INFLAMMATORY BOWEL DISEASES
 Kawsar Kaboub, IL
- 09:00 - 09:00 P0224
CHARACTERIZATION OF THE CYTOKINE EXPRESSION IN HUMAN COLON ORGANOID FROM INFLAMMATORY BOWEL DISEASE PATIENTS
 Tünde Molnár, HU
- 09:00 - 09:00 P0225
ELEVATED ADAPTIVE IMMUNE RESPONSES TO MULTIPLE *LACHNOSPIRACEAE* BACTERIAL FLAGELLINS IN THERAPY-NAIVE PEDIATRIC CD PATIENTS ARE ASSOCIATED WITH DISTINCT IMMUNE PATHOLOGY
 Daniëlle M. H. Barendregt, NL
- 09:00 - 09:00 P0226
DIFFERENTIAL EXPRESSION OF MIR-424-5P AND MIR-378C IN STENOTIC AND PENETRATING LESIONS OF CROHN'S DISEASE ASSOCIATES WITH ALTERED TRANSCRIPTION OF GENES INVOLVED IN VASCULAR REGULATION
 Sandra Coll, ES
- 09:00 - 09:00 P0227
ACCUMULATION OF PRO-INFLAMMATORY CD4⁺ T CELLS AND ACTIVATED TCR V β 1⁺ T CELLS IN INFLAMED GUT TISSUE OF CROHN'S DISEASE PATIENTS
 Jan Devan, CH
- 09:00 - 09:00 P0228
THE HEALTH DATA RESEARCH HUB FOR INFLAMMATORY BOWEL DISEASE - GUT REACTION- 3 YEARS ON
 Laetitia Pele, GB
- 09:00 - 09:00 P0229
IMMUNE AND NON IMMUNE CHANGES FOLLOWING FMT IN EXPERIMENTAL COLITIS: EMERGING PATHWAYS OF FMT-DERIVED MUCOSAL HEALING
 Letizia Masi, IT
- 09:00 - 09:00 P0230
THE IMPACT OF VITAMIN D DEFICIENCY ON COVID-19 INFECTION AND RESPONSE TO VACCINATION
 Jayne Doherty, IE
- 09:00 - 09:00 P0231
TRANSCRIPTOME CHANGES IN A COMMENSAL *ESCHERICHIA COLI* STRAIN FROM HEALTHY DONOR AFTER INCUBATION WITH IGA IN VITRO
 Mariia Siniagina, RU
- 09:00 - 09:00 P0232
INTERACTION BETWEEN CHITINASE 3-LIKE 1 (CHI3L1) AND BACTERIAL PROTEIN CHIA: A DECISIVE STEP FOR CROHN'S DISEASE-ASSOCIATED ADHERENT AND INVASIVE *E. COLI* TO ENTER WITHIN HUMAN MACROPHAGES
 Margot Fargeas, FR
- 09:00 - 09:00 P0233
DEEP LEARNING-BASED IMAGE ANALYSIS REVEALS SIGNIFICANT DIFFERENCES IN NUMBER AND DISTRIBUTION OF CD3 AND $\gamma\delta$ T CELLS BETWEEN CROHN'S COLITIS AND ULCERATIVE COLITIS
 Elin Synnøve Røyset, NO
- 09:00 - 09:00 P0234
CLAUDIN-2 OVEREXPRESSION IN STEM CELL ZONE CORRELATES WITH INCREASED INTESTINAL PERMEABILITY AND EPITHELIAL CELL PROLIFERATION DURING SHORT RECOVERY PERIOD IN ACUTE MURINE DSS MODEL OF INFLAMMATORY BOWEL DISEASE
 Snježana Čužić, HR
- 09:00 - 09:00 P0235
IDENTIFICATION OF A DISTINCT MICROBIOTA SIGNATURE IN CROHN'S DISEASE-ASSOCIATED AND CRYPTOGLANDULAR PERIANAL FISTULAS
 Marieke Barnhoorn, NL
- 09:00 - 09:00 P0236
SERUM PROTEOME PROFILES IN CROHN'S DISEASE PATIENTS WITH DIFFERENT PHENOTYPES TOWARDS BIOMARKER IDENTIFICATION
 Laura Alexandra Lucaciu, RO
- 09:00 - 09:00 P0237
SALIVARY EXOSOMES AGGRAVATE COLITIS BY REGULATING THE GUT IMMUNITY
 Congyi Yang, CN
- 09:00 - 09:00 P0238
THE INTERACTION BETWEEN SEROTONIN REUPTAKE TRANSPORTER AND BRAIN-DERIVED NEUROTROPHIC FACTOR IN INFLAMMATORY BOWEL DISEASE PATIENTS
 Marta Ditmer, PL
- 09:00 - 09:00 P0239
INTESTINAL CD8⁺ T CELL EXHAUSTION IS LINKED TO DISEASE ACTIVITY IN ULCERATIVE COLITIS
 Maximilian Grigorian, DE
- 09:00 - 09:00 P0240
FOOD ADDITIVE NANOPARTICLES IS ASSOCIATED WITH SPECIFIC PRO-INFLAMMATORY BACTERIAL CHANGES IN CROHN'S DISEASE. THE ENIGMA STUDY
 Jingwan Zhang, HK
- 09:00 - 09:00 P0241
EMERGING ROLE OF IL-33/ST2 AND GUT MICROBIOTA AXIS IN THE INFLAMMATORY PROCESS OF ULCERATIVE COLITIS PATIENTS WITH ILEAL POUCH-ANAL ANASTOMOSIS
 Loris Riccardo Lopetuso, IT
- 09:00 - 09:00 P0242
GENOMIC DIVERSITY OF *FAECALIBACTERIUM PRAUSNITZII* STRAINS FROM MICROBIOTA OF PATIENTS WITH INFLAMMATORY BOWEL DISEASES AND HEALTHY VOLUNTEERS
 Mariia Markelova, RU

09:00 - 09:00 P0243
A PROSPECTIVE INTERVENTIONAL STUDY TO EVALUATE THE EFFECT OF HYPOXIA ON HEALTHY VOLUNTEERS AND PATIENTS WITH INFLAMMATORY BOWEL DISEASE: THE ALTITUDE IBD STUDY

Thomas Greuter, CH

09:00 - 09:00 P0244
PARTICULATE MATTER FROM NATURAL PRECURSOR INCREASES SUSCEPTIBILITY TO INFLAMMATORY BOWEL DISEASE

Mariia Korbush, UA

09:00 - 09:00 P0245
MYCOBACTERIUM AVIUM PARATUBERCULOSIS INCIDENCE IN PATIENTS WITH CROHN'S DISEASE AND CONTROLS: A SINGLE CENTRE STUDY

Tim Nugent, IE

09:00 - 09:00 P0246
PREVALENCE AND RISK FACTOR OF PERIODONTITIS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A CASE-CONTROL, PROSPECTIVE STUDY

Davide Giuseppe Ribaldone, IT

09:00 - 09:00 P0247
RISK FACTORS AND LONG-TERM OUTCOMES ASSOCIATED WITH IMMUNOSUPPRESSION IN PATIENTS WITH ULCERATIVE PROCTITIS: RESULTS FROM THE ENEIDA REGISTRY

Manuel Barreiro de Acosta, ES

09:00 - 09:00 P0248
ECONOMIC IMPACT OF INFLAMMATORY BOWEL DISEASE IN CATALONIA. A POPULATION-BASED ANALYSIS

Eduard Brunet, ES

09:00 - 09:00 P0249
SEROLOGIC RESPONSE WITH ANTIMICROBIAL ANTIBODIES DURING THE PRECLINICAL PHASE OF INFLAMMATORY BOWEL DISEASE

Iago Rodríguez-Lago, ES

09:00 - 09:00 P0250
THE BI-DIRECTIONAL RISK OF INFLAMMATORY BOWEL DISEASE AND ANXIETY OR DEPRESSION: A SYSTEMATIC REVIEW AND META-ANALYSIS

Tania Bisgaard, DK

09:00 - 09:00 P0251
RISK OF POLYPS AND COLORECTAL CANCER IN PATIENTS WITH MICROSCOPIC COLITIS: CASE-CONTROL STUDY WITH LONG-TERM FOLLOW-UP

Ingrid Fajardo, ES

09:00 - 09:00 P0252
EVOLUTION OF DISEASE PHENOTYPE, TIME TO BIOLOGICAL THERAPY AND MEDIUM-, LONG-TERM SURGERY RATES IN CROHN'S DISEASE PATIENTS IN WESTERN HUNGARY – A POPULATION-BASED STUDY BETWEEN 2007–2018, DATA FROM THE VESZPREM COUNTY COHORT

Lorant Gonczi, HU

09:00 - 09:00 P0253
INCIDENCE, PREVALENCE, DISEASE PHENOTYPE AND MAXIMAL THERAPEUTIC STEP IN ULCERATIVE COLITIS PATIENTS IN WESTERN HUNGARY – A POPULATION-BASED STUDY BETWEEN 2007–2018, DATA FROM THE VESZPREM COUNTY COHORT

Lorant Gonczi, HU

09:00 - 09:00 P0254
EVOLUTION OF DISEASE PHENOTYPE, TIME TO BIOLOGICAL THERAPY AND MEDIUM-, LONG-TERM COLECTOMY RATES IN ULCERATIVE COLITIS PATIENTS IN WESTERN HUNGARY – A POPULATION-BASED STUDY BETWEEN 2007–2018, DATA FROM THE VESZPREM COUNTY COHORT

Lorant Gonczi, HU

09:00 - 09:00 P0255
RISK OF AND RISK FACTORS FOR COLORECTAL CANCER IN ULCERATIVE COLITIS – A POPULATION-BASED STUDY FROM WESTERN HUNGARY BETWEEN 1977–2018, DATA FROM THE VESZPREM COUNTY COHORT

Petra Anna Golovics, HU

09:00 - 09:00 P0256
EVOLUTION OF DISEASE PHENOTYPE, TIME TO BIOLOGICAL THERAPY AND MEDIUM-, LONG-TERM SURGERY RATES IN IBD-U PATIENTS IN WESTERN HUNGARY – A POPULATION-BASED STUDY BETWEEN 1977–2018, DATA FROM THE VESZPREM COUNTY COHORT

Lorant Gonczi, HU

09:00 - 09:00 P0257
SUBCLINICAL INFLAMMATORY BOWEL DISEASE PRECEDES THE DIAGNOSIS AND LEADS TO AN INCREASE IN HEALTHCARE RESOURCES UTILIZATION: MULTICENTER CASE-CONTROL STUDY

Iago Rodríguez-Lago, ES

09:00 - 09:00 P0258
PHENOTYPIC DIFFERENCES IN INFLAMMATORY BOWEL DISEASE BETWEEN WOMEN AND MEN: SEXEII STUDY OF ENEIDA

Carla Jerusalem Gargallo Puyuelo, ES

09:00 - 09:00 P0260
DE NOVO INFLAMMATORY BOWEL DISEASE PICKED UP VIA NATIONAL BOWEL CANCER SCREENING PROGRAMME: 10 YEAR EXPERIENCE AT A LARGE ENGLISH SCREENING CENTRE

Kirakoula Georgas, GB

09:00 - 09:00 P0261
DISEASE ACTIVITY PATTERNS OF INFLAMMATORY BOWEL DISEASE - A DANISH NATIONWIDE COHORT STUDY 1995-2018

Mads Damsgaard Wewer, DK

09:00 - 09:00 P0262
THE BURDEN OF URINARY SYMPTOMS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES: A CROSS-SECTIONAL OBSERVATIONAL STUDY

Raffaele Pellegrino, IT

09:00 - 09:00 P0263
HIDRADENITIS SUPPURATIVA AND INFLAMMATORY BOWEL DISEASE IN A CASE-CONTROL STUDY
 Benedetto Neri, IT

09:00 - 09:00 P0264
A SYSTEMATIC REVIEW AND META-ANALYSIS OF SLEEP QUALITY IN INACTIVE INFLAMMATORY BOWEL DISEASE
 Shauna Madigan, AU

09:00 - 09:00 P0265
RISK OF CERVICAL CANCER IN INCIDENT ULCERATIVE COLITIS: A NATIONWIDE POPULATION-BASED STUDY SPANNING 10 YEARS
 Hyun-Soo Kim, KR

09:00 - 09:00 P0266
A SYSTEMATIC REVIEW ON CLINICAL OUTCOMES IN PAEDIATRIC INFLAMMATORY BOWEL DISEASE PATIENTS
 Jonathan Van Hecke, BE

09:00 - 09:00 P0267
PREVALENCE OF IRON DEFICIENCY AND ANAEMIA IN THE OUTPATIENT INFLAMMATORY BOWEL DISEASE POPULATION: A DUTCH NATIONAL CROSS-SECTIONAL STUDY
 Roberta Loveikyte, NL

09:00 - 09:00 P0268
THE IMPACT OF SMOKING ON ULCERATIVE COLITIS AND INTERACTION WITH FAMILY HISTORY: A KOREAN POPULATION-BASED COHORT STUDY

09:00 - 09:00 P0269
THE EFFECTS OF INFLAMMATORY BOWEL DISEASE ON CAREGIVERS: ABSENTEEISM AND JOB PRESENTEEISM. A SEGHPN MULTICENTER STUDY (SPANISH SOCIETY OF PEDIATRIC GASTROENTEROLOGY, HEPATOLOGY AND NUTRITION)
 Marta Velasco Rodríguez-Belvis, ES

09:00 - 09:00 P0270
EXPOSURE TO SYSTEMIC ANTIBIOTICS INCREASES THE RISK OF INFLAMMATORY BOWEL DISEASE IN A DOSE-DEPENDENT MANNER: A POPULATION-BASED CASE-CONTROL STUDY IN KOREA
 Shin Ju Oh, KR

09:00 - 09:00 P0271
MORTALITY IN ELDERLY-ONSET INFLAMMATORY BOWEL DISEASES – A POPULATION-BASED STUDY FROM THE EPIDEMIOLOGICAL DATABASE OF THE ISRAELI IBD RESEARCH NUCLEUS (EPI-IIRN)
 Dana Ben Hur, IL

09:00 - 09:00 P0272
FACTORS ASSOCIATED WITH TREATMENT PERSISTENCE OF ANTI-TNF AGENTS AS FIRST LINE BIOLOGIC TREATMENT IN GREEK PATIENTS WITH INFLAMMATORY BOWEL DISEASES
 Eleni Orfanoudaki, GR

09:00 - 09:00 P0273
EPIDEMIOLOGY AND CHANGES IN PHARMACOLOGIC TREATMENT OF PEDIATRIC INFLAMMATORY BOWEL DISEASE OVER 10 YEARS IN CATALONIA
 Ines Loverdos, ES

09:00 - 09:00 P0274
POOR SLEEP IN IBD IS ASSOCIATED WITH ACTIVE DISEASE, ANXIETY AND DEPRESSION, AND OUTCOMES SUCH AS INCREASED FATIGUE, INCREASED DISABILITY, AND POOR QUALITY OF LIFE
 Shauna Madigan, AU

09:00 - 09:00 P0275
NEW-ONSET INFLAMMATORY BOWEL DISEASE DURING TREATMENT WITH THE ANTI-INTERLEUKIN-17A MONOCLONAL ANTIBODY SECUKINUMAB. A CASE SERIES PRESENTATION
 Gerasimos Gerasimatos, GR

09:00 - 09:00 P0276
IMPACT OF INFLAMMATORY BOWEL DISEASE ON THE QUALITY OF LIFE OF PATIENT'S HOUSEHOLD MEMBERS
 Manuel López-Vico, ES

09:00 - 09:00 P0277
EFFECTIVENESS OF SARS-COV2 BOOSTER VACCINATION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE (IBD): PRELIMINARY REPORT FROM A SINGLE REFERRAL CENTER IN SOUTHERN ITALY
 Daniele Brinch, IT

09:00 - 09:00 P0278
NAFLD AND LIVER FIBROSIS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A CASE-CONTROL STUDY
 Samuel Jesús Martínez-Domínguez, ES

09:00 - 09:00 P0279
EFFECTIVENESS OF SMOKING CESSATION INTERVENTIONS IN PATIENTS WITH CROHN'S DISEASE: A SYSTEMATIC REVIEW
 Sahar Nasr, TN

09:00 - 09:00 P0280
EVALUATION OF STRESS, ANXIETY, DEPRESSION LEVELS AND INTESTINAL GENE EXPRESSION IN NEWLY DIAGNOSED IBD PATIENTS
 Sanja Dragasevic, RS

09:00 - 09:00 P0281
THE UK INFLAMMATORY BOWEL DISEASE BIORESOURCE: PROGRESSING FROM GENETICS TO FUNCTION AND CLINICAL TRANSLATION IN CROHN'S DISEASE & ULCERATIVE COLITIS IN ADULTS, YOUNG PEOPLE AND CHILDREN
 Laetitia Pele, GB

09:00 - 09:00 P0282
INVESTIGATION OF SOMATIC MUTATIONS IN BIOPSIES FROM PATIENTS WITH INFLAMMATORY BOWEL DISEASE
 Iwan Jonathan Hidding, NL


09:00 - 09:00 P0283
TOWARDS A PERSONALIZED APPROACH IN ULCERATIVE COLITIS: ROLE OF OCTN1 IN PREDICTING DISEASE SEVERITY AND INDIVIDUAL RESPONSE TO THERAPY
 Pierluigi Puca, IT

09:00 - 09:00 P0284
ELEVATED ARTIFICIAL SWEETENER BODY LEVELS ARE ASSOCIATED WITH CROHN'S DISEASE.THE ENIGMA STUDY
 Jielun Hu, CN

09:00 - 09:00 P0285
MORE SEVERE CROHN'S DISEASE CLINICAL PRESENTATION IN AN INFLAMMATORY BOWEL DISEASE (IBD) CENTER OF EMERGENCY DEPARTMENT DURING COVID-19 PANDEMIC
 Antonio Cuomo, IT

09:00 - 09:00 P0286
COVID19 VACCINATION COVERAGE IN FLEMISH PATIENTS WITH IMMUNE-MEDIATED INFLAMMATORY DISEASES
 Liselotte Fierens, BE

09:00 - 09:00 P0287
INFLAMMATORY BOWEL DISEASE AND SOLID ORGAN TRANSPLANTATION: A SINGLE CENTRE EXPERIENCE
 Sara Archer, PT


09:00 - 09:00 P0288
THE DISEASE SEVERITY INDEX FOR INFLAMMATORY BOWEL DISEASE IS ASSOCIATED WITH PSYCHOLOGICAL SYMPTOMS, QUALITY OF LIFE, AND PREDICTS A MORE COMPLICATED DISEASE COURSE 
 Akhilesh Swaminathan, NZ

09:00 - 09:00 P0289
CYTOMEGALOVIRUS IN INFLAMMATORY BOWEL DISEASE: USEFULNESS OF A POSITIVE RESULT WITH DIFFERENT DIAGNOSTIC TECHNIQUES IN TREATMENT CHOICE
 Irene González Díaz, ES

09:00 - 09:00 P0290
NEUTROPHIL-LYMPHOCYTE RATIO ROLE TO PREDICT DISEASE ACTIVITY AND SEVERITY IN ULCERATIVE COLITIS
 Sanaa Berrag, MA

09:00 - 09:00 P0291
EFFECT OF TRANSITION CARE ON CLINICAL OUTCOMES AND TREATMENT ADHERENCE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: AN OBSERVATIONAL PROSPECTIVE STUDY
 Olga Maria Nardone, IT

09:00 - 09:00 P0292
RADIOLOGIC EVALUATION OF FILGOTINIB TREATMENT IN PERIANAL FISTULIZING CROHN'S DISEASE USING A NOVEL SCORING SYSTEM
 Jordi Rimola, ES

09:00 - 09:00 P0293
PREVALENCE AND CLINICAL FACTORS ASSOCIATED WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE (IBD) 
 Marina Lopes, BR

09:00 - 09:00 P0294
E- CONSULTS IN INFLAMMATORY BOWEL DISEASE (TELEIBD): FACILITATING COMMUNICATION BETWEEN SPECIALIZED AND PRIMARY CARE
 Marta Ramos Alonso, ES

09:00 - 09:00 P0295
BOWEL URGENCY COMMUNICATION GAP BETWEEN HEALTH CARE PROFESSIONALS AND PATIENTS WITH ULCERATIVE COLITIS IN THE US AND EUROPE: COMMUNICATING NEEDS AND FEATURES OF IBD EXPERIENCES (CONFIDE) SURVEY
 Simon Travis, GB

09:00 - 09:00 P0296
THE IMPACT OF BOWEL URGENCY ON THE LIVES OF PATIENTS WITH ULCERATIVE COLITIS IN THE US AND EUROPE: COMMUNICATING NEEDS AND FEATURES OF IBD EXPERIENCES (CONFIDE) SURVEY
 Stefan Schreiber, DE

09:00 - 09:00 P0297
QUALITY CRITERIA IN SCREENING COLONOSCOPY FOR COLORECTAL CANCER IN INFLAMMATORY BOWEL DISEASE
 Joao Paulo Laranjeira Correia, PT

09:00 - 09:00 P0298
SARCOPENIA AS A PREDICTIVE MARKER IN INFLAMMATORY BOWEL DISEASE
 Joao Paulo Laranjeira Correia, PT

09:00 - 09:00 P0299
INDICATIONS, OUTCOMES AND OTHER ASPECTS RELATED TO THE USE OF THE ENDOSCOPIC CAPSULE IN THE PEDIATRIC AGE
 Laura María Palomino Pérez, ES

09:00 - 09:00 P0300
POSSIBILITIES FOR DIFFERENTIAL DIAGNOSIS OF NOSOLOGICAL FORMS OF INFLAMMATORY BOWEL DISEASE USING ERYTHROCYTE AND BLOOD SERUM MEMBRANE FATTY ACIDS
 Margarita Vitalievna Kruchinina, RU

09:00 - 09:00 P0301
DELAYED IBD DIAGNOSIS LEADS TO WORSE OUTCOMES OVER YEARS, WITH MULTIPLE IMPLICATIONS ON SERVICE DELIVERY
 Abhishek Rao, GB

09:00 - 09:00 P0302
SYSTEMATIC REVIEW AND META-ANALYSIS: MICROSCOPIC COLITIS IS A RISK FACTOR FOR LOW BONE DENSITY
 Anett Rancz, HU

09:00 - 09:00 P0303
NON-INVASIVE ASSESSMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES
 Sanja Dragasevic, RS

09:00 - 09:00 P0304
TRYPTOPHAN DEGRADATION PRODUCTS AS UNIFYING BIOMARKERS OF SEVERITY AND LONG-TERM DISEASE CONTROL IN CHRONIC INFLAMMATORY DISEASES

Danielle Harris, DE

09:00 - 09:00 P0305
ENDOSCOPIC SCORES AS PREDICTORS OF TREATMENT FAILURE IN ULCERATIVE COLITIS

Tiago Lima Capela, PT

09:00 - 09:00 P0306
METAGENOMIC ANALYSIS OF A SIGNATURE GUT MICROBIOME BIOMARKER IN CROHN'S DISEASE ACROSS FIVE POPULATIONS

Jingwan Zhang, HK

09:00 - 09:00 P0307
ENDOSCOPIC FEATURES OF NON-IBD COLITIS

Giuseppe Grande, IT

09:00 - 09:00 P0308
RELATIONSHIP BETWEEN INTESTINAL ULTRASOUND, FECAL CALPROTECTIN AND HARVEY BRADSHAW INDEX IN THE ASSESSMENT OF INFLAMMATORY ACTIVITY IN CROHN'S DISEASE

Manuel Barreiro de Acosta, ES

09:00 - 09:00 P0309
SMOKING AND COLITIS-ASSOCIATED COLORECTAL NEOPLASIA: EXPLORING THE RELATIONSHIP

Anouk Wijnands, NL

09:00 - 09:00 P0310
SARCOPENIA IS A POOR PROGNOSTIC FACTOR FOR ENDOSCOPIC REMISSION IN PATIENTS WITH CROHN'S DISEASE

Mauro Grova, IT

09:00 - 09:00 P0311
ENDOSCOPIC AND HISTOLOGICAL PREDICTORS OF COMPLETE REMISSION AFTER THREE MONTHS OF CONVENTIONAL TREATMENT IN ULCERATIVE COLITIS BASED ON MAYO ENDOSCOPIC SCORE AND NANCY HISTOLOGICAL INDEX

Øyvind Steinsbø, NO

09:00 - 09:00 P0312
VISCERAL OBESITY, DEFINED ACCORDING TO THE ANTHROPOMETRIC CRITERIA, IS NOT ASSOCIATED WITH A WORSE INFLAMMATORY BOWEL DISEASE COURSE AND DOES NOT LEAD TO AN ADDITIONAL INCREASE IN PROINFLAMMATORY RESPONSE

Alina Niezgodka-Kłósak, PL

09:00 - 09:00 P0313
METABOLIC ASSOCIATED LIVER DISEASE AND SEX AS KEY FACTORS OF CARDIOVASCULAR RISK IN INFLAMMATORY BOWEL DISEASE

Sandra García Mateo, ES

09:00 - 09:00 P0314
EVALUATION OF ACUTE INFLAMMATORY AND STRUCTURAL CHANGES OF SACROILIITIS ON MR ENTEROGRAPHY: A DIRECT COMPARISON WITH SACROILIAC JOINT MRI

Ilkay Ergenç, TR

09:00 - 09:00 P0315
NATURAL HISTORY AND IMPACT OF IBS-TYPE SYMPTOMS IN INFLAMMATORY BOWEL DISEASE DURING 6 YEARS OF LONGITUDINAL FOLLOW-UP

Keeley Maria Fairbrass, GB

09:00 - 09:00 P0316
CHARACTERISTICS AND IMPACT OF ANXIETY AND DEPRESSION TRAJECTORIES IN INFLAMMATORY BOWEL DISEASE

Keeley Maria Fairbrass, GB

09:00 - 09:00 P0317
AN OPTIMIZATION OF INFLAMMATORY BOWEL DISEASES DIAGNOSIS USING AN ARTIFICIAL INTELLIGENCE

Irina Rasmagina, RU

09:00 - 09:00 P0318
USTEKINUMAB DRUG EXPOSURE IS NOT LINKED TO CHANGES IN BOWEL WALL THICKNESS, BUT DOES ASSOCIATE WITH TRANSMURAL REMISSION IN CROHN'S DISEASE

Bram Verstockt, BE

09:00 - 09:00 P0319
PROGNOSTIC MODEL FOR THE OCCURRENCE OF A COMPOSITE OUTCOME IN CROHN'S DISEASE PATIENTS UNDER INFLIXIMAB MAINTENANCE THERAPY

Fernando Magro, PT

09:00 - 09:00 P0320
CONTRAST-ENHANCED INTESTINAL ULTRASOUND: TIME TO REFRESH THE NON-INVASIVE MONITORING IN CROHN'S DISEASE

Tiago Lima Capela, PT

09:00 - 09:00 P0321
INFLUENCE OF CELIAC DISEASE ON THE COURSE OF INFLAMMATORY BOWEL DISEASE

Gulustan Babayeva, AZ

09:00 - 09:00 P0322
PLASMA FATTY ACID BINDING PROTEIN 2, INTERLEUKIN-10 AND LIPOPOLYSACCHARIDES AS BIOMARKERS FOR MICROSCOPIC COLITIS

Vytautas Kiudelis, LT

09:00 - 09:00 P0323
THE EFFECT OF INDUCTION THERAPY WITH INFLIXIMAB OR VEDOLIZUMAB ON HEPCIDIN AND IRON STATUS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE

Roberta Loveikyte, NL

09:00 - 09:00 P0324
C-REACTIVE PROTEIN/ALBUMIN RATIO (CAR) AS A MARKER FOR DETECTING ACUTE SEVERE ULCERATIVE COLITIS IN EGYPTIAN PATIENTS

Ahmed El Lakany, EG

09:00 - 09:00 P0325
RISK FACTORS OF CYTOMEGALOVIRUS COLITIS IN INFLAMMATORY BOWEL DISEASE
 Sara Nacer, MA

09:00 - 09:00 P0326
THE EFFECT OF RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM BLOCKING AGENTS ON THE 5- AND 10-YEAR DISEASE COURSE OF CROHN'S DISEASE PATIENTS WITH HYPERTENSION
 Christian Karime, US

09:00 - 09:00 P0327
A MARKER OF PROTEOLYTIC DEGRADATION OF CROSS-LINKED TYPE V COLLAGEN IS UPREGULATED IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
 Martin Pehrsson, DK

09:00 - 09:00 P0328
HISTOLOGIC DISEASE ACTIVITY CORRELATES WITH ENDOSCOPIC SEVERITY IN PATIENTS WITH MODERATE TO SEVERE CROHN'S DISEASE
 Walter Reinisch, AT

09:00 - 09:00 P0329
THERAPEUTIC DRUG MONITORING OF VEDOLIZUMAB IN INFLAMMATORY BOWEL DISEASE PATIENTS - TUMMY TRIAL
 Merve Sivridas, NL

09:00 - 09:00 P0330
DIETARY BEHAVIOR AND RISK OF ORTHOREXIA IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
 Martina Cappelletti, IT

09:00 - 09:00 P0331
RESPONSIVENESS OF FECAL CALPROTECTIN AND QUALITY OF LIFE QUESTIONNAIRES TO CHANGE IN POUCH DISEASE ACTIVITY. RESULTS FROM A PROSPECTIVE TRIAL
 Jacob Ollech, IL

09:00 - 09:00 P0332
PREVALENCE OF DISEASE RELATED MALNUTRITION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A MULTICENTRIC CROSS-SECTIONAL STUDY
 Chiara Vigano', IT

09:00 - 09:00 P0333
LATENT TUBERCULOSIS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE CANDIDATES TO BIOLOGICS: PREVALENCE AND EFFECTIVENESS OF CHEMOPROPHYLAXIS
 Daniele Brinch, IT

09:00 - 09:00 P0334
TELEMONITORING IBD WITH THE APP CARE4TODAY IBD: A REAL-LIFE CASE-CONTROL STUDY
 Andrea Costantino, IT

09:00 - 09:00 P0335
MUCIN MRNA ISOFORM SIGNATURES AS POTENTIAL NOVEL BIOMARKERS TO EVALUATE DISEASE STATUS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES
 Wout Arras, BE

09:00 - 09:00 P0336
BIOMARKERS OF EXTRACELLULAR MATRIX TURNOVER AND NEUTROPHIL ACTIVITY PREDICT LONG-TERM RESPONSE TO VEDOLIZUMAB IN PATIENTS WITH CROHN'S DISEASE
 Marta Sorokina Alexdóttir, DK

09:00 - 09:00 P0337
HEPATIC STEATOSIS BUT NOT FIBROSIS IS INDEPENDENTLY ASSOCIATED WITH A POOR OUTCOME IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES
 Hye Kyung Hyun, KR

09:00 - 09:00 P0338
USE OF PLATELET-LYMPHOCYTE RATIO AND NEUTROPHIL-LYMPHOCYTE RATIO AS A POTENTIAL PROGNOSTIC MARKER IN IBD
 Olga Fagan, IE

09:00 - 09:00 P0339
DETECTION OF IRON RESTRICTED ERYTHROPOIESIS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: OVERCOMING THE INFLAMMATION TANGLER
 Aysegül Aksan, DE

09:00 - 09:00 P0340
RENAL INVOLVEMENT IN A COHORT OF PAEDIATRIC PATIENTS WITH INFLAMMATORY BOWEL DISEASE
 Smaragdi Fessatou, GR

09:00 - 09:00 P0341
A PHARMACIST-LED POST INDUCTION REVIEW CLINIC IMPROVES COMPLIANCE WITH KEY PERFORMANCE INDICATORS FOR PATIENTS NEWLY STARTED ON BIOLOGIC THERAPIES IN INFLAMMATORY BOWEL DISEASE
 Dania Al-Zarrad, GB

09:00 - 09:00 P0342
PREDICTIVE MODEL FOR OUTCOMES IN INFLAMMATORY BOWEL DISEASE PATIENTS ON MAINTENANCE INFlixIMAB THERAPY
 Rochelle Wong, US

09:00 - 09:00 P0343
TOXIN GENE POLYMERASE CHAIN REACTION ASSAY FOR *CLOSTRIDIoidES DIFFICILE* CAN BE AN INDICATOR SUGGESTING THE NEED FOR RAPID ESCALATION OF TREATMENT IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
 Seulji Kim, KR

09:00 - 09:00 P0344
HIGHER ADALIMUMAB TROUGH LEVELS ARE ASSOCIATED WITH HISTOLOGIC REMISSION AND MUCOSAL HEALING
 Rochelle Wong, US

09:00 - 09:00 P0345
TYPE I COLLAGEN DEGRADATION FRAGMENTS (C1M) AND HUMAN NEUTROPHIL ELASTASE-DERIVED FRAGMENTS OF CALPROTECTIN (CPA9-HNE) REFLECT BIOCHEMICAL AND ENDOSCOPIC DISEASE ACTIVITY IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES
 Arno R. Bourgonje, NL

- 09:00 - 09:00 P0346
THE ROLE OF TIM-4 IN THE PATHOGENESIS OF ULCERATIVE COLITIS IN MICE
 09:00 - 09:00 P0347
PROTEOMIC ANALYSES DO NOT REVEAL SUBCLINICAL INFLAMMATION IN FATIGUED PATIENTS WITH QUIESCENT INFLAMMATORY BOWEL DISEASE
 Arno R. Bourgonje, NL
- 09:00 - 09:00 P0348
ASSOCIATION OF SERUM VITAMIN D LEVELS WITH DRUG TROUGH CONCENTRATIONS AND ANTI-DRUG ANTIBODY LEVELS DURING INFLIXIMAB THERAPY IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
 Aysegül Aksan, DE
- 09:00 - 09:00 P0349
POTENTIAL BIOMARKER PAI-1 PROMOTES THE DISEASE ACTIVITY AND THERAPEUTIC RESPONSE IN BIOLOGICAL SAMPLES OF INFLAMMATORY BOWEL DISEASES
 Boldizsár Jójárt, HU
- 09:00 - 09:00 P0350
USE OF HAEMATOLOGICAL IRON PARAMETERS ALONE OR IN COMBINATION TO DETECT IRON DEFICIENCY IN INFLAMMATORY BOWEL DISEASE
 Aysegül Aksan, DE
- 09:00 - 09:00 P0351
LATENT CROHN'S DISEASE SUBGROUPS ARE IDENTIFIED BY FAECAL CALPROTECTIN PROFILES: A RETROSPECTIVE ANALYSIS OF THE LOTHIAN CROHN'S DISEASE INCEPTION COHORT
 Nathan Constantine-Cooke, GB
- 09:00 - 09:00 P0352
COMPARISON OF CLINICAL IMPROVEMENT AS MEASURED BY TWO QUALITY-OF-LIFE INDEXES: A POOLED ANALYSIS OF VEDOLIZUMAB RANDOMIZED CLINICAL TRIALS IN INFLAMMATORY BOWEL DISEASE
 Christian Agboton, CH
- 09:00 - 09:00 P0353
USE OF FAECAL CALPROTECTIN AS A PROGNOSTIC MARKER OF RESPONSE TO TREATMENT WITH FILGOTINIB: *POST HOC* ANALYSIS FROM THE SELECTION STUDY
 Alessandra Oortwijn, NL
- 09:00 - 09:00 P0354
MEASURING ADALIMUMAB AND INFLIXIMAB TROUGH LEVELS FROM FINGER PRICK BLOOD WITH A RAPID POINT-OF-CARE ASSAY
 Joana Afonso, CH
- 09:00 - 09:00 P0355
REAL-TIME CLASSIFICATION OF CROHN'S DISEASE CLINICAL REMISSION BY HEALTH-RELATED QUALITY OF LIFE (HRQOL) QUESTIONNAIRES IN COMBINATION WITH BIOMARKERS: DATA FROM A REAL-WORLD PROSPECTIVE INCEPTION COHORT
 Henit Yanai, IL
- 09:00 - 09:00 P0356
CRP TO ALBUMIN RATIO AND NEUTROPHIL TO LYMPHOCYTIC RATIO AS A PREDICTOR OF MUCOSAL HEALING IN EGYPTIAN PATIENTS WITH ULCERATIVE COLITIS TREATED WITH BIOLOGICAL THERAPY
 Mohamed Eltabbakh, EG
- 09:00 - 09:00 P0357
ARTIFICIAL INTELLIGENCE IN HISTOPATHOLOGICAL DIAGNOSIS OF IBD – A PILOT STUDY
 Petra Čačić, HR
- 09:00 - 09:00 P0358
THERAPEUTIC DRUG MONITORING: STANDARDIZATION OF PROMONITOR QUICK IFX AND PROMONITOR QUICK ADL POINT OF CARE TESTS WITH WHO INTERNATIONAL STANDARDS FOR THE QUANTIFICATION OF INFLIXIMAB AND ADALIMUMAB IN WHOLE BLOOD AND SERUM
 Amagoia Ametzazurra, ES
- 09:00 - 09:00 P0359
CORRELATION OF THE PROMONITOR QUICK ADL LATERAL FLOW-BASED POINT OF CARE TEST TO QUANTIFY ADALIMUMAB IN A FINGER PRICK OR SERUM SAMPLES WITH THE REFERENCE ELISA TECHNIQUE
 Amagoia Ametzazurra, ES
- 09:00 - 09:00 P0360
THE IMPACT OF DRUG LEVELS TO ANTI-TNF AND ANTI-INTEGRIN AGENTS ON COVID-19 VACCINE RESPONSE IN PATIENTS WITH IBD
 Jayne Doherty, IE
- 09:00 - 09:00 P0361
ANORECTAL DISORDERS AMONG IBD PATIENTS IN REMISSION, WITH FECAL INCONTINENCE AND TREATED WITH BIOLOGICS – PILOT STUDY FROM A TERTIARY REFERRAL CENTER
 Mislav Jelakovic, HR
- 09:00 - 09:00 P0362
DECREASED MUSCLE MASS AND STRENGTH IN INFLAMMATORY BOWEL DISEASE PATIENTS
 Ilkay Ergenç, TR
- 09:00 - 09:00 P0363
COMPARATIVE FREQUENCY OF STRUCTURAL CHANGES IN THE PANCREAS IN CHRONIC PANCREATITIS AND INFLAMMATORY BOWEL DISEASES BY ENDOSONOGRAPHY
 Ekaterina Lomakina, RU
- 09:00 - 09:00 P0364
ADAPTATION OF QUESTIONNAIRES USED IN THE TRANS-IBD RANDOMISED CLINICAL TRIAL
 Patrícia Sarlós, HU
- 09:00 - 09:00 P0365
INFLAMMATORY BOWEL DISEASE WITH CONCOMITANT ENDOMETRIOSIS: FREQUENCY AND CHARACTERIZATION IN A CASE-CONTROL PROSPECTIVE STUDY
 Benedetto Neri, IT

09:00 - 09:00 P0366
PREDICTIVE FACTORS OF MALNUTRITION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES
 Oumaima Chatti, TN

09:00 - 09:00 P0367
PARAMETERS AFFECTING FISTULA TREATMENT RESPONSE IN PERIANAL FISTULIZING CROHN'S DISEASE UNDER BIOLOGICAL THERAPY: A MACHINE LEARNING MODEL STUDY
 Hazal Salva, TR

09:00 - 09:00 P0368
SARS-COV-2 INFECTION DOES NOT WORSEN THE CLINICAL COURSE OF INFLAMMATORY BOWEL DISEASE: A 1-YEAR PROSPECTIVE CASE-CONTROL STUDY
 Benedetto Neri, IT

09:00 - 09:00 P0369
SCREENING FOR SARCOPENIA IN CROHN'S DISEASE, SHOULD IT BE A MUST ?
 Maha Mtir, TN

09:00 - 09:00 P0370
SUPERB MICRO-VASCULAR IMAGING FOR PREDICTING THE ACTIVITY OF TERMINAL ILEUM LESIONS IN PATIENTS WITH CROHN'S DISEASE
 Hiroshi Shimazaki, JP

09:00 - 09:00 P0371
RADIOMICS COULD PREDICT SURGERY AT 10 YEARS IN CROHN'S DISEASE
 Lucrezia Laterza, IT

09:00 - 09:00 P0372
MAGNETIC RESONANCE TEXTURE ANALYSIS IS SUPERIOR TO MAGNETIZATION TRANSFER IMAGING FOR LONGITUDINAL ASSESSMENT OF FIBROSIS IN EXPERIMENTAL COLITIS
 Simon Bos, BE

09:00 - 09:00 P0373
USEFULNESS AND LIMITATIONS OF COMPUTER-AIDED DETECTION (CADE) SYSTEM IN SURVEILLANCE COLONOSCOPY IN PATIENTS WITH ULCERATIVE COLITIS
 Yasuharu Maeda, JP

09:00 - 09:00 P0374
FACTORS ASSOCIATED WITH CUMULATIVE BOWEL DAMAGE USING LEMANN INDEX IN CROHN'S DISEASE – A TERTIARY CENTER EXPERIENCE
 Viktor Domislovic, HR

09:00 - 09:00 P0375
MAGNIFI-CD INDEX IS A STRONG PROGNOSTIC FACTOR IN PATIENTS WITH PERIANAL FISTULIZING CROHN'S DISEASE
 Nicolas Richard, FR

09:00 - 09:00 P0376
RELATIONSHIP BETWEEN DISEASE ACTIVITY AS ASSESSED BY THE MAYO SCORE AND WORK PRODUCTIVITY IN PATIENTS WITH ULCERATIVE COLITIS IN THE TOFACITINIB OCTAVE PHASE 3 INDUCTION AND MAINTENANCE STUDIES
 Julian Panés, ES

09:00 - 09:00 P0377
RELATIONSHIP BETWEEN HEALTH-RELATED QUALITY OF LIFE AND WORK PRODUCTIVITY IN PATIENTS WITH ULCERATIVE COLITIS IN THE TOFACITINIB OCTAVE PHASE 3 INDUCTION AND MAINTENANCE STUDIES
 Julian Panés, ES

09:00 - 09:00 P0378
PRESENCE OF RISK FACTORS ASSOCIATED WITH COLECTOMY AMONG PATIENTS WITH COLECTOMY IN THE TOFACITINIB OCTAVE ULCERATIVE COLITIS CLINICAL PROGRAMME
 Joana Torres, PT

09:00 - 09:00 P0379
A MULTI-CENTRE STUDY OF BEHAVIOURS, ATTITUDES AND BARRIERS TO EXERCISE IN INFLAMMATORY BOWEL DISEASE, A SURVEY FROM THE PATIENT'S PERSPECTIVE
 Neasa McGettigan, IE

09:00 - 09:00 P0380
PREDICTOR OF THROMBOEMBOLIC COMPLICATIONS IN PATIENTS WITH SEVERE ULCERATIVE COLITIS AND MEASURES FOR THEIR PREVENTION
 Albina Lishchinskaya, RU

09:00 - 09:00 P0381
VENLAFAXINE AS AN ADJUVANT THERAPY FOR INFLAMMATORY BOWEL DISEASE PATIENTS WITH ANXIOUS AND DEPRESSIVE SYMPTOMS: A RANDOMIZED CONTROLLED TRIAL

09:00 - 09:00 P0382
REDUCED HUMORAL RESPONSE TO TWO DOSES OF COVID-19 VACCINE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: DATA FROM ESCAPE-IBD, AN IG-IBD STUDY
 Fabio Salvatore Macaluso, IT

09:00 - 09:00 P0383
EFFICACY, PERSISTENCE AND OPTIMIZATION OF USTEKINUMAB IN ULCERATIVE COLITIS: CLINICAL DATA
 Irene Latras Cortés, ES

09:00 - 09:00 P0384
THE RISK OF SERIOUS INFECTIONS BEFORE AND AFTER ANTI-TNF THERAPY IN INFLAMMATORY BOWEL DISEASE – A RETROSPECTIVE COHORT STUDY
 Johanna Holmgren, SE

09:00 - 09:00 P0385
ASSOCIATION OF ANTIBIOTIC USE WITH DURABILITY OF BIOLOGIC AGENTS IN INFLAMMATORY BOWEL DISEASE: A REPORT FROM THE EPI-IIRN
 Yuri Gorelik, IL

09:00 - 09:00 P0386
EFFICACY AND SAFETY OF MIRIKIZUMAB AS INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 LUCENT-1 STUDY
 Geert D'Haens, NL

09:00 - 09:00 P0387
USTEKINUMAB THERAPY AFTER BIOLOGIC FAILURE IN PATIENTS WITH CROHN'S DISEASE –A REAL-WORLD SINGLE CENTRE EXPERIENCE

Uday Nagesh Shivaji, GB

09:00 - 09:00 P0388
SWITCHING INTRAVENOUS TO SUBCUTANEOUS INFLIXIMAB WAS SAFE AND SUCCESSFUL SHORT TERM IN ULCERATIVE COLITIS AND CROHN PATIENTS – A BELGIAN SINGLE CENTER EXPERIENCE

Leander Cornelis, BE

09:00 - 09:00 P0389
PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF ETRASIMOD: RESULTS FROM A PHASE 1 DRUG-DRUG INTERACTION STUDY IN HEALTHY VOLUNTEERS

Caroline A. Lee, US

09:00 - 09:00 P0390
A PHASE 1 DRUG INTERACTION STUDY EVALUATING THE EFFECTS OF ITRACONAZOLE ON THE PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF ETRASIMOD IN HEALTHY VOLUNTEERS

Caroline A. Lee, US

09:00 - 09:00 P0391
MODEL-PREDICTED LYMPHOCYTE RESPONSE AND RECOVERY PROFILES FOR THE SPHINGOSINE 1-PHOSPHATE RECEPTOR MODULATORS OZANIMOD AND ETRASIMOD

Caroline A. Lee, US

09:00 - 09:00 P0392
HEALTHCARE UTILISATION WITH USTEKINUMAB TREATMENT IN A REAL-WORLD COHORT IN NORTH WEST LONDON: AN ANALYSIS BY AGE AND LINE OF THERAPY

Nikolaos Kamperidis, GB

09:00 - 09:00 P0393
IMPACT OF THE HLA-DQA1*05 ALLELE ON LOSS OF RESPONSE AND PRESENCE OF ANTI-DRUG ANTIBODIES TO USTEKINUMAB IN CROHN'S DISEASE AND ULCERATIVE COLITIS PATIENTS

Tariq Ahmad, GB

09:00 - 09:00 P0394
REAL-WORLD EVIDENCE OF THE EFFECTIVENESS AND SAFETY OF USTEKINUMAB FOR THE TREATMENT OF CROHN'S DISEASE: SYSTEMATIC REVIEW AND META-ANALYSIS OF OBSERVATIONAL STUDIES

Cristina Rubín de Céliz, ES

09:00 - 09:00 P0395
CORTICOSTEROID-SPARING EFFECTS OF USTEKINUMAB THERAPY FOR ULCERATIVE COLITIS THROUGH 4 YEARS: UNIFI LONG-TERM EXTENSION

Ramesh Arasaradnam, GB

09:00 - 09:00 P0396
EFFICACY AND SAFETY OF USTEKINUMAB FOR ULCERATIVE COLITIS THROUGH 4 YEARS: FINAL RESULTS FROM THE UNIFI LONG-TERM EXTENSION

Waqas Afif, CA

09:00 - 09:00 P0397
VIRTUAL BIOLOGICS CLINIC: A STREAMLINED MULTI-DISCIPLINARY TEAM (MDT) APPROACH TO IMPROVE INFLAMMATORY BOWEL DISEASE (IBD) CARE

Su Maung, GB

09:00 - 09:00 P0398
IMPACT OF BIOLOGIC THERAPIES AND SMALL MOLECULES ON THE RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ULCERATIVE COLITIS: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS

Mohammad Shehab, KW

09:00 - 09:00 P0399
EARLY INTERVENTION WITH BIOLOGICS IN CROHN'S DISEASE - HOW EARLY IS EARLY?

Joana Revés, PT

09:00 - 09:00 P0400
NON-MEDICAL, MANDATORY SWITCH AMONG ADALIMUMAB BIOSIMILARS AND FROM THE ORIGINATOR ADALIMUMAB TO BIOSIMILARS IN INFLAMMATORY BOWEL DISEASE PATIENTS – A PROSPECTIVE, MULTICENTRE STUDY ON EFFICACY, DRUG SUSTAINABILITY AND SAFETY

Lorant Gonczi, HU

09:00 - 09:00 P0401
HEALTH-RELATED QUALITY OF LIFE WITH GUSELKUMAB INDUCTION AND MAINTENANCE THERAPY AS MEASURED BY PROMIS-29: RESULTS THROUGH WEEK 48 OF PHASE 2 GALAXI 1 STUDY

Geert D'Haens, NL

09:00 - 09:00 P0402
OZANIMOD EFFICACY BY BASELINE ENDOSCOPIC DISEASE DISTRIBUTION IN PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS: A POST HOC ANALYSIS FROM TRUE NORTH

Axel Dignass, DE

09:00 - 09:00 P0403
EVALUATION OF OZANIMOD EFFICACY AND SAFETY IN OLDER PATIENTS WITH ULCERATIVE COLITIS: POST HOC ANALYSIS FROM THE PHASE 3 TRUE NORTH STUDY

Peter Irving, GB

09:00 - 09:00 P0404
ASSOCIATION BETWEEN ABSOLUTE LYMPHOCYTE COUNT AND OZANIMOD EFFICACY AND SAFETY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 TRUE NORTH STUDY

Sarah Harris, US

09:00 - 09:00 P0405
IMPACT OF OZANIMOD ON FECAL CALPROTECTIN LEVELS AND THE ASSOCIATION WITH OZANIMOD EFFICACY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 TRUE NORTH STUDY

Sarah Harris, US

09:00 - 09:00 P0406
COMBINATION THERAPY IS NOT ASSOCIATED WITH IMPROVED RATES OF CLINICAL OR ENDOSCOPIC REMISSION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE TREATED WITH USTEKINUMAB OR VEDOLIZUMAB

Angus W Jeffrey, AU

09:00 - 09:00 P0407
HIGH C-REACTIVE PROTEIN LEVEL OF ACUTE SEVERE ULCERATIVE COLITIS IS ASSOCIATED WITH RE-ADMISSION DUE TO AGGRAVATION OF ULCERATIVE COLITIS: A KASID MULTICENTER STUDY

Hyesu You, KR

09:00 - 09:00 P0408
TOFACITINIB FOR THE TREATMENT OF MODERATE - SEVERE ULCERATIVE COLITIS. THE GREEK EXPERIENCE

Gerassimos J. Mantzaris, GR

09:00 - 09:00 P0409
EFFECTIVENESS AND SAFETY OF VEDOLIZUMAB AND USTEKINUMAB THERAPY FOR COMPLEX PERIANAL FISTULA IN CROHN'S DISEASE: THE HEAL STUDY

María José Casanova, ES

09:00 - 09:00 P0410
EFFECT OF A GLUTEN-FREE DIET ON THE DISEASES SEVERITY, QUALITY OF LIFE, AND INFLAMMATORY MARKERS AMONG PATIENTS WITH MILD TO MODERATE ULCERATIVE COLITIS: A TRIPLE-BLIND RANDOMIZED PLACEBO-CONTROLLED TRIAL

Forough Alborziavanaki, IR

09:00 - 09:00 P0412
ONE YEAR OF USTEKINUMAB THERAPY IMPROVES NUTRITIONAL STATUS IN PATIENTS WITH CROHN'S DISEASE

Lorenzo Bertani, IT

09:00 - 09:00 P0413
EFFECTIVENESS AND SAFETY OF RISANKIZUMAB INDUCTION THERAPY IN PATIENTS WITH CROHN'S DISEASE: A GETAID COHORT STUDY

Mathurin Fumery, FR

09:00 - 09:00 P0414
BIOLOGICALS AND SMALL MOLECULE COMBOTHERAPIES: PROMISING EXPERIENCE IN REFRACTORY IBD PATIENTS

Pascal Juillerat, CH

09:00 - 09:00 P0415
DELAYED IBD DIAGNOSIS INCREASES RISK OF REQUIRING BIOLOGICS IN FIRST 4-YEARS - AN INCEPTION COHORT STUDY

Abhishek Rao, GB

09:00 - 09:00 P0416
6-THIOGUANINE NUCLEOTIDE LEVELS AND ANTI-TUMOUR NECROSIS FACTOR ALPHA TROUGH LEVELS IN INFLAMMATORY BOWEL DISEASE PATIENTS ON COMBINATION THERAPY: A RETROSPECTIVE MULTICENTRE STUDY

Natalie Yu, AU

09:00 - 09:00 P0417
INCREASE IN CIRCULATING T AND B LYMPHOCYTE SUBSETS AFTER TREATMENT WITH THE POTENT, SELECTIVE, ORAL, SMALL MOLECULE $\alpha_4\beta_7$ INHIBITOR MORF-057 IN HEALTHY SUBJECTS

Ali Hussain, US

09:00 - 09:00 P0418
EXPLORATORY ANALYSIS OF FILGOTINIB SAFETY DATA IN A SELECTED POPULATION OF PATIENTS WITH RHEUMATOID ARTHRITIS: DATA FROM FINCH 1-4 AND DARWIN 1-3 STUDIES IN PERSPECTIVE TO INTEGRATED ULCERATIVE COLITIS SAFETY DATA

Alessandra Oortwijn, NL

09:00 - 09:00 P0419
EFFECTIVENESS AND SAFETY OF SWITCHING FROM ADALIMUMAB REFERENCE TO BIOSIMILAR IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: THE ADA-SWITCH STUDY

María José Casanova, ES

09:00 - 09:00 P0420
ANTI-INFLAMMATORY AND BARRIER STABILIZING EFFECTS OF A HERBAL COMBINATION MEDICINE OF MYRRH, COFFEE CHARCOAL AND CHAMOMILE FLOWER EXTRACT IN A MULTI-COMPONENT CELL MODEL OF THE INFLAMED INTESTINAL MUCOSA

Cica Vissiennon, DE

09:00 - 09:00 P0421
USTEKINUMAB IMPROVES HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH MODERATE-TO-SEVERE CROHN'S DISEASE: RESULTS UP TO WEEK 104 OF THE STARDUST TRIAL

Laurent Peyrin-Biroulet, FR

09:00 - 09:00 P0422
SAFETY OF COVID-19 VACCINE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: DATA OF A NATIONAL STUDY (ESCAPE-IBD)

Alessia Todeschini, IT

09:00 - 09:00 P0423
THE PERSISTENCE OF ANTI-SPIKE ANTIBODIES FOLLOWING TWO SARS-COV-2 VACCINES IN PATIENTS WITH INFLAMMATORY BOWEL- AND JOINT DISEASES ON IMMUNOSUPPRESSIVE THERAPY COMPARED TO HEALTHY CONTROLS - A PROSPECTIVE COHORT STUDY

Kristin Kaasen Jørgensen, NO

09:00 - 09:00 P0424
HOW IS THE CLINICAL COURSE AND DRUG TOXICITY IN LATE-ONSET IBD PATIENTS?

Filiz Akyuz, TR

09:00 - 09:00 P0425
HEAD-TO-HEAD PHARMACOKINETIC ANALYSIS OF INFLIXIMAB MONO- VS COMBINATION THERAPY IN PAEDIATRIC CROHN'S DISEASE

Ruben J. Colman, NL

09:00 - 09:00 P0426
PREDICTORS OF NON-RESPONSE TO STEROIDS IN SEVERE ACUTE ULCERATIVE COLITIS: A SINGLE-CENTRE RETROSPECTIVE STUDY

Vita Karpavičiūtė, LT

09:00 - 09:00 P0427
EFFECTIVENESS, SAFETY, AND DRUG SUSTAINABILITY OF BIOLOGICS IN ELDERLY PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A SINGLE CENTER RETROSPECTIVE STUDY

Petra Anna Golovics, HU

09:00 - 09:00 P0428
IMPACT OF CONCOMITANT THIOPURINE ON THE EFFICACY AND SAFETY OF FILGOTINIB TREATMENT IN PATIENTS WITH ULCERATIVE COLITIS: *POST HOC* ANALYSIS OF THE PHASE 2B/3 SELECTION STUDY

Kenji Watanabe, JP

09:00 - 09:00 P0429
HISTOLOGICAL FEATURES OF JOINT INFLAMMATION IN INFLAMMATORY BOWEL DISEASE PATIENTS WITH PERIPHERAL ARTHRITIS

Laura Parisio, IT

09:00 - 09:00 P0430
THE IMPACT OF SARS-COV-2 PANDEMIC IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A SYSTEMATIC REVIEW OF CLINICAL DATA

Mohamed Mohamed, GB

09:00 - 09:00 P0431
A PILOT FEASIBILITY STUDY OF A NOVEL WHOLE-FOOD, SULPHIDE-REDUCING (5-SURE) DIET STRATEGY FOR THE TREATMENT OF SYMPTOMS IN PATIENTS WITH AN ULCERATIVE-COLITIS POUCH

Chu K (CK) Yao, AU

09:00 - 09:00 P0432
FROM INTRAVENOUS TO SUBCUTANEOUS INFLIXIMAB – A TRANSITION LEADING TO CHANGES?

María José Temido, PT

09:00 - 09:00 P0433
PSYCHOLOGICAL INTERVENTIONS IMPROVE OUTCOMES IN INFLAMMATORY DIGESTIVE SYSTEM DISEASES. A META-ANALYSIS

Beatrix Fogarasi, HU

09:00 - 09:00 P0434
LINKING LOCATION SPECIFIC GENE EXPRESSION PATTERNS TO POTENTIAL VEDOLIZUMAB OUTCOMES IN CROHN'S DISEASE PATIENTS

Bernat Regí, ES

09:00 - 09:00 P0435
CROHN'S DISEASE (CD): THE PREDICTIVE VALUE OF MONTREAL CLINICAL PATTERNS, AND BIOLOGICAL TREATMENT IN A LATIN AMERICAN IBD REFERENCE CENTER

Alicia Maria Sambuelli, AR

09:00 - 09:00 P0436
STEROID USE IN A HIGH PROPORTION OF IBD PATIENTS – FIRST RESULTS FROM THE GERMAN COHORT OF THE IBD-DICE STUDY

Irina Blumenstein, DE

09:00 - 09:00 P0437
INDUCTION AND MAINTENANCE TREATMENT WITH RISANKIZUMAB LEADS TO SYMPTOMATIC RELIEF IN PATIENTS WITH MODERATE TO SEVERE CROHN'S DISEASE

Joana Torres, PT

09:00 - 09:00 P0438
COMPARATIVE ANALYSIS OF ORIGINATOR VERSUS BIOSIMILAR COUNTERPARTS WHEN TREATING ULCERATIVE COLITIS

Elizabeth Baynton, GB

09:00 - 09:00 P0439
USTEKINUMAB PERSISTENCE IN THE TREATMENT OF CROHN'S DISEASE, FISTULIZING CROHN'S DISEASE AND ULCERATIVE COLITIS

John K. Marshall, CA

09:00 - 09:00 P0440
EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS RECEIVING 16 WEEKS' EXTENDED INDUCTION TREATMENT FOLLOWED BY 52 WEEKS' MAINTENANCE TREATMENT IN THE U-ACHIEVE/U-ACCOMPLISH TRIALS

Remo Panaccione, CA

09:00 - 09:00 P0441
AN ANALYSIS OF HIGHER SECONDARY EFFICACY FAILURE RATES AMONG ULCERATIVE COLITIS PATIENTS WHEN COMPARING THE EU TO THE US

Paul Zimmerman, US

09:00 - 09:00 P0442
LONG-TERM TREATMENT PERSISTENCE WITH INFLIXIMAB IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A REAL-WORLD STUDY

Margarida Gomes Gonçalves, PT

09:00 - 09:00 P0443
QINGDAI (QD) FOR PATIENTS WITH ACTIVE ULCERATIVE COLITIS: A RETROSPECTIVE ISRAELI NATIONAL EXPERIENCE

Nir Salomon, IL

09:00 - 09:00 P0444
SWITCH FROM INTRAVENOUS TO SUB-CUTANEOUS INFLIXIMAB IN INFLAMMATORY BOWEL DISEASE: WHICH CONSEQUENCES FROM A PHARMACOKINETIC PERSPECTIVE?


Guillaume Bouguen, FR

09:00 - 09:00 P0445
SAFETY OF TOFACITINIB IN THE TREATMENT OF ULCERATIVE COLITIS:

Irene Rodríguez Mendiluze, ES

09:00 - 09:00 P0446
EFFICACY AND SAFETY OF USTEKINUMAB IN ASIAN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: A SUBPOPULATION ANALYSIS OF UNIFI LONG-TERM EXTENSION THROUGH 3 YEARS
 Yasuo Suzuki, JP

09:00 - 09:00 P0447
LIVE VACCINES IN CHILDREN EXPOSED TO BIOLOGICAL AGENTS FOR IBD IN UTERO AND/OR DURING BREASTFEEDING: ARE THEY SAFE? RESULTS FROM THE DUMBO REGISTRY OF GETECCU
 Maria Chaparro Sanchez, ES

09:00 - 09:00 P0448
THE CONTRIBUTION OF THE POLYMORPHISM OF THE ABCB1 GENE IN RESPONSE TO TREATMENT IN TUNISIAN INFLAMMATORY BOWEL DISEASE PATIENTS 
 Fatma Zine El Abidine, TN

09:00 - 09:00 P0449
SAFETY AND EFFICACY OF AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR REFRACTORY CROHN'S DISEASE AFTER CYCLOPHOSPHAMIDE-FREE MOBILIZATION: PRELIMINARY RESULTS
 Antonio Giordano, ES

09:00 - 09:00 P0450
SWITCHING FROM AN INTENSIFIED REGIMEN OF INFlixIMAB TO A SUBCUTANEOUS STANDARD DOSE IN ADULTS WITH INFLAMMATORY BOWEL DISEASE: OUR EXPERIENCE IN A TERTIARY HOSPITAL
 Beatriz Sicilia Aladrén, ES

09:00 - 09:00 P0451
EFFICACY AND SAFETY OF USTEKINUMAB IN ASIAN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE: A SUBPOPULATION ANALYSIS OF UNIFI/IM-UNIFI LONG-TERM EXTENSION THROUGH 5 YEARS
 Toshifumi Hibi, JP

09:00 - 09:00 P0452
OPTIMIZING DUAL-TARGETED THERAPIES IN INFLAMMATORY BOWEL DISEASE VIA MULTIPLE MECHANISMS OF ACTION
 Zelin Feng, CN

09:00 - 09:00 P0453
BURDEN OF BOWEL URGENCY ACROSS SPECIFIC TREATMENT GROUPS AMONG CROHN'S DISEASE PATIENTS – REAL WORLD GLOBAL STUDY ANALYSES
 Raja Atreya, DE

09:00 - 09:00 P0454
CHANGES IN QUALITY OF LIFE IN IBD PATIENTS DURING VEDOLIZUMAB THERAPY- RESULTS FROM THE PATIENT SUPPORT PROGRAM IN THREE REFERRAL CENTERS IN SERBIA
 Aleksandra Sokic Milutinovic, RS

09:00 - 09:00 P0455
OUTCOMES OF ANTI-TNF TREATMENT IN CROHN'S DISEASE: A REAL LIFE, TERTIARY CENTER EXPERIENCE
 Ilkay Ergenç, TR

09:00 - 09:00 P0456
CYTOMEGALOVIRUS INFECTION IN PATIENTS WITH ACTIVE ULCERATIVE COLITIS - A PROSPECTIVE OBSERVATIONAL STUDY

Jakub Szlak, PL

09:00 - 09:00 P0457
LOW CONCENTRATION OF CITRATE IN AN ADALIMUMAB FORMULATION DOES NOT IMPACT THE INTENSITY OF INJECTION SITE PAIN: EVALUATION FOLLOWING A SINGLE DOSE OF GP2017, A LOW CONCENTRATION ADALIMUMAB BIOSIMILAR VERSUS HIGH CONCENTRATION ADALIMUMAB CITRATE-FREE FORMULATION IN HEALTHY VOLUNTEERS
 Fabricio Furlan, DE

09:00 - 09:00 P0458
DIAGNOSTIC DELAY AND ECONOMIC BURDEN IN IBD: A SINGLE-CENTRE EXPERIENCE IN PATIENTS TREATED WITH BIOLOGICS
 Alessia Todeschini, IT

09:00 - 09:00 P0459
COMPARATIVE OUTCOMES AND SAFETY OF BUDESONIDE-MMX VERSUS PREDNISOLONE FOR ULCERATIVE COLITIS AND POSSIBLE GENETICAL PREDICTORS OF SIDE-EFFECTS
 Tamás Resál, HU

09:00 - 09:00 P0460
EFFECTS OF AN ESTABLISHED SPECIALIST INFLAMMATORY BOWEL DISEASE NURSING SERVICE ON PATIENT OUTCOMES, QUALITY OF CARE AND HEALTHCARE COSTS
 Natalie Yu, AU

09:00 - 09:00 P0461
EFFECT OF MIRIKIZUMAB ON BOWEL URGENCY CLINICALLY MEANINGFUL IMPROVEMENT AND REMISSION: RESULTS FROM THE PHASE 3 LUCENT INDUCTION AND MAINTENANCE STUDIES
 Simon Travis, GB

09:00 - 09:00 P0462
PERI-PARTUM INFECTIONS AMONG WOMEN WITH INFLAMMATORY BOWEL DISEASE
 Irit Avni-Biron, IL

09:00 - 09:00 P0463
IMPACT OF MIRIKIZUMAB TREATMENT ON HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH CROHN'S DISEASE: A PHASE 2 STUDY ANALYSIS USING THE SF-36
 Vipul Jairath, CA

09:00 - 09:00 P0464
ASSOCIATION OF HISTOLOGIC MEASUREMENT WITH ENDOSCOPIC OUTCOMES AFTER ONE YEAR OF TREATMENT WITH MIRIKIZUMAB IN PATIENTS WITH MODERATE TO SEVERE CROHN'S DISEASE
 Fernando Magro, PT

09:00 - 09:00 P0465
ABDOMINALLY TARGETED, YOGA-BASED PHYSICAL EXERCISES AS A THERAPEUTIC INTERVENTION FOR INFLAMMATORY BOWEL DISEASE
 Lael Werner, IL

09:00 - 09:00 P0466
USE OF TUMOR NECROSIS FACTOR-A ANTAGONISTS IS ASSOCIATED WITH ATTENUATED IGG ANTIBODY RESPONSE AGAINST SARS-COV-2 IN VACCINATED PATIENTS WITH INFLAMMATORY BOWEL DISEASE
 Antonius Timotheus Otten, NL

09:00 - 09:00 P0467
ESTIMATING LOCAL TNF MRNA LEVELS PRIOR TO ANTI-TNFA TREATMENT MAY HELP THERAPEUTIC OPTIMIZATION IN CHILDREN WITH IBD
 Jaslin P James, DK

09:00 - 09:00 P0468
IMPROVEMENT IN FATIGUE WITH MIRIKIZUMAB THERAPY IS ASSOCIATED WITH CLINICAL REMISSION AND PAIN IMPROVEMENTS BUT NOT WITH ENDOSCOPIC RESPONSE IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE
 Peter Bossuyt, BE

09:00 - 09:00 P0469
VEDOLIZUMAB IS ASSOCIATED WITH STEROID-FREE CLINICAL REMISSION AND DISCONTINUATION-FREE SURVIVAL IN PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE PROCTITIS
 Marc Ferrante, BE

09:00 - 09:00 P0470
POSTOPERATIVE IMMUNOSUPPRESSIVE THERAPY DOES NOT INFLUENCE ENDOSCOPIC RECURRENCE RATES AFTER BOWEL RESECTIONS DUE TO CROHN'S DISEASE – A RETROSPECTIVE MULTICENTRE ANALYSIS
 Nikolaus Pfisterer, AT

09:00 - 09:00 P0471
PREDICTORS OF RESPONSE TO WASHED MICROBIOTA TRANSPLANTATION IN PATIENTS WITH ULCERATIVE COLITIS: DATA ENVELOPMENT ANALYSIS APPROACH
 Fatema Tabak, CN

09:00 - 09:00 P0473
INTERLEUKIN-23 AND INTERLEUKIN-12/23 INHIBITORS FOR THE TREATMENT OF CROHN'S DISEASE: SYSTEMATIC REVIEW AND META-ANALYSIS
 Sudheer K. Vuyyuru, CA

09:00 - 09:00 P0474
SZN-1326, A TETRAVALENT, BISPECIFIC ANTIBODY DEVELOPED FOR THE TREATMENT OF ULCERATIVE COLITIS, HAS A FAVORABLE PROFILE IN 13-WEEK GLP TOXICITY STUDIES
 Anh Diep, US

09:00 - 09:00 P0475
LONG-TERM TREATMENT PERSISTENCE OF ADALIMUMAB AND USTEKINUMAB IN BIO-NAÏVE PATIENTS WITH CROHN'S DISEASE: A RETROSPECTIVE DATABASE STUDY
 Alen Bišćanin, HR

09:00 - 09:00 P0476
MIRIKIZUMAB IMPROVES QUALITY OF LIFE IN MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: IMPROVEMENT IN INFLAMMATORY BOWEL DISEASE SCORES IN PARTICIPANTS OF THE LUCENT-1 AND LUCENT-2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 INDUCTION AND MAINTENANCE TRIALS
 Bruce E. Sands, US

09:00 - 09:00 P0477
LONG TERM SAFETY AND EFFICACY OF THIOPURINES WITHDRAWAL IN IBD PATIENTS
 Dima Shbita, IL

09:00 - 09:00 P0478
A PH-SENSITIVE OPIOID PROVIDES SUSTAINED AND SAFE PAIN RELIEF BY TARGETING THE ACIDIFIED LAYERS OF THE INFLAMED COLON
 Claudius E Degro, CA

09:00 - 09:00 P0479
PROBIOTIC TREATMENT OF ULCERATIVE COLITIS WITH *TRICHURIS SUIS* OVA: A RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED CLINICAL TRIAL
 Michelle Vernstrøm Prosberg, DK

09:00 - 09:00 P0480
NEED FOR USTEKINUMAB INTENSIFICATION IN REAL LIFE CLINICAL PRACTICE
 Spyridon Vrakas, GR

09:00 - 09:00 P0481
IDENTIFICATION OF TARGET USTEKINUMAB LEVELS IN MAINTENANCE THERAPY IN INFLAMMATORY BOWEL DISEASE
 Ciarán McDonald, IE

09:00 - 09:00 P0482
REAL WORLD EXPERIENCE OF USTEKINUMAB IN A WEST OF IRELAND COHORT
 Olga Fagan, IE

09:00 - 09:00 P0483
EFFICACY AND SAFETY OF ADVANCED ORAL THERAPIES FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS
 Virginia Solitano, CA

09:00 - 09:00 P0484
TOLERANCE TO ADALIMUMAB CITRATE-FREE AND CITRATE FORMULATIONS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
 Beatriz Gros, ES

09:00 - 09:00 P0485
POTENTIAL OF HIGH-ACETATE PRODUCING *SACCHAROMYCES BOULARDII* TO ATTENUATE INFLAMMATION IN DSS-INDUCED COLITIS
 Sara Deleu, BE

09:00 - 09:00 P0486
VEDOLIZUMAB SUBCUTANEOUSLY: REAL-WORLD DATA BEFORE AND AFTER SWITCH IN IBD PATIENTS - A HESSIAN COHORT
 Alica Kubesch, DE

09:00 - 09:00 P0487
CROHN'S DISEASE PATIENTS WITH USTEKINUMAB-INDUCED REMISSION ARE CHARACTERIZED BY HIGH BASELINE IL23 RECEPTOR EXPRESSION IN THE LAMINA PROPRIA TH1 CELLS

Amalia Di Petrillo, IT

09:00 - 09:00 P0488
ASSESSMENT OF HISTOLOGICAL REMISSION IN PATIENTS TREATED WITH FILGOTINIB BY DIFFERENT SCORES AND CONCORDANCE WITH ENDOSCOPIC AND HEALTH-RELATED QUALITY OF LIFE OUTCOMES: *POST HOC* ANALYSIS FROM THE SELECTION STUDY

Fernando Magro, PT

09:00 - 09:00 P0489
EFFECTIVENESS OF POLYMERIC EXCLUSIVE ENTERAL NUTRITION AS AN ADJUNCT TO STANDARD OF CARE IN PATIENTS WITH ACUTE SEVERE ULCERATIVE COLITIS


Laura Willmann, AU

09:00 - 09:00 P0490
OPIOID EXPOSURE IN IBD AND ASSOCIATED FACTORS: A UK PROSPECTIVE MULTICENTRE AUDIT OF 1362 PATIENTS

Samantha Baillie, GB

09:00 - 09:00 P0491
ORAL IRON THERAPY WITH IRON MALTOL VERSUS FERROUS SULPHATE IN INFLAMMATORY BOWEL DISEASE: INTRA-INDIVIDUAL COMPARISON INDICATES LEVEL PEGGING ON INCREASE IN PLASMA HEPICIDIN LEVELS

Aysegül Aksan, DE

09:00 - 09:00 P0492
THE BENEFICIAL EFFECTS OF INCREASING DIETARY FIBER CONSUMPTION ON CLINICAL FLARE AND INFLAMMATORY MARKERS AMONG PATIENTS WITH CLINICALLY QUIESCENT INFLAMMATORY BOWEL DISEASE: A PROSPECTIVE LONGITUDINAL STUDY 

Phalat Sathirawich, TH

09:00 - 09:00 P0493
PERSONALISED AZITHROMYCIN+METRONIDAZOLE (PAZAZ), IN COMBINATION WITH STANDARD INDUCTION THERAPY, TO ACHIEVE A FAECAL MICROBIOME COMMUNITY STRUCTURE AND METAGENOME CHANGES ASSOCIATED WITH SUSTAINED REMISSION IN PAEDIATRIC CROHN'S DISEASE (CD): INITIAL RESULTS OF A PILOT FEASIBILITY STUDY

Charlotte M. Verburgt, NL

09:00 - 09:00 P0494
EFFECTIVENESS OF USTEKINUMAB AS INDUCTION THERAPY FOR CHRONIC ANTIBIOTIC REFRACTORY POUCHITIS

An Outtier, BE

09:00 - 09:00 P0495
OUTCOME PREDICTORS FOR VEDOLIZUMAB THERAPY IN CROHN'S DISEASE PATIENTS IN A REAL-WORLD SETTING

So Jung Han, KR

09:00 - 09:00 P0496
FISTULOUS SKIN METASTASES IN CROHN'S DISEASE: A CASE REPORT AND REVIEW OF THE LITERATURE

Tanja Elger, DE

09:00 - 09:00 P0497
IN HIGHLY REFRACTORY ULCERATIVE COLITIS PATIENTS, USTEKINUMAB IS A GOOD THERAPEUTIC OPTION

Alejandro Mínguez Sabater, ES

09:00 - 09:00 P0498
REAL-LIFE EXPERIENCE OF ANTI-DRUG ANTIBODIES AGAINST ANTI-TNF AGENTS AT TWO TERTIARY CARE PAEDIATRIC INFLAMMATORY BOWEL DISEASE CENTRES

Jasmijn Jagt, NL

09:00 - 09:00 P0499
BERBERINE SUPPLEMENTATION SIGNIFICANTLY IMPROVED ANTI-TNFAEFFICACY IN MURINE COLITISMICEHUMANIZED WITH NON-RESPONDER GUT MICROBIOTA

Le Liu, CN

09:00 - 09:00 P0500
ASSOCIATION OF ULCERATIVE COLITIS BOWEL URGENCY IMPROVEMENT WITH CLINICAL RESPONSE AND REMISSION

David Clemow, US

09:00 - 09:00 P0501
IN PATIENTS WITH CROHN'S DISEASE, FECAL CALPROTECTIN DROP-SLOPE DURING INDUCTION WITH USTEKINUMAB CAN AFFECT ITS LEVELS AND DISCRIMINATE THE NEED FOR INTENSIFICATION AT WEEK 52

Alejandro Mínguez Sabater, ES

09:00 - 09:00 P0502
PATIENTS PERSPECTIVE ON SWITCHING FROM INTRAVENOUS TO SUCUTANEOUS THERAPY

Spyridon Vrakas, GR

09:00 - 09:00 P0503
THE VEDOLIZUMAB CLINICAL DECISION SUPPORT TOOL FOR CROHN'S DISEASE EFFECTIVELY PREDICTS CLINICAL REMISSION AT 54 WEEKS IN A "REAL WORLD" SETTING

Konstantina Chalakatevaki, GR

09:00 - 09:00 P0504
MEDICAL TREATMENT OF VEO-IBD EXPOSES CHILDREN TO CRITICAL EXCIPIENTS - RESULTS FROM A RETROSPECTIVE OBSERVATIONAL SINGLE CENTER ANALYSIS

Monika Pintar-Hitzl, AT

09:00 - 09:00 P0505
THE ROLE OF THE GUT MICROBIOTA AND EXPRESSION OF TIGHT JUNCTION PROTEINS IN ALLEVIATION BY INTESTINAL ALKALINE PHOSPHATASE TREATMENT OF EXPERIMENTAL COLITIS EXACERBATED IN HIGH-FAT-DIET FED MICE BY FORCED PHYSICAL ACTIVITY

Thomas Brzozowski, PL

09:00 - 09:00 P0506
CROHN'S DISEASE EXCLUSION DIET (CDED) FOR THE TREATMENT OF CROHN'S DISEASE – AN OBSERVATIONAL STUDY FROM A TERTIARY CENTER

Ayal Hirsch, IL

09:00 - 09:00 P0507
TOFACITINIB OR USTEKINUMAB FOR THIRD-LINE TREATMENT OF REFRACTORY ULCERATIVE COLITIS: A MULTICENTER RETROSPECTIVE PROPENSITY SCORE-MATCHED ANALYSIS

Camille Meunier, FR

09:00 - 09:00 P0508
COMPARISON OF TWO ANALYTICAL TECHNIQUES FOR QUANTIFYING INFLIXIMAB LEVELS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE

Teresa Valdes-Delgado, ES

09:00 - 09:00 P0509
EFFECT OF STANDARD AND MODIFIED BUDESONIDE THERAPEUTIC PROTOCOL ON MAINTENANCE OF ONE-YEAR REMISSION IN PATIENTS WITH MICROSCOPIC COLITIS-PILOT STUDY FROM A TERTIARY REFERRAL CENTER

Katja Grubelic Ravic, HR

09:00 - 09:00 P0510
EFFECTIVENESS AND SAFETY OF SWITCHING FROM INTRAVENOUS TO SUBCUTANEOUS VEDOLIZUMAB FORMULATION IN INFLAMMATORY BOWEL DISEASE PATIENTS IN CLINICAL REMISSION

Laura Parisio, IT

09:00 - 09:00 P0511
RETROSPECTIVE ONE-CENTER STUDY COMPARING SAFETY AND EFFICACY OF IRON FORMULATIONS (FERRIC DERISOMALTOSE AND CARBOXYMALTOSE) IN GASTROENTEROLOGICAL PATIENTS

Edyta Maria Tulewicz-Marti, PL

09:00 - 09:00 P0512
MEDICAL CANNABIS REDUCES PAIN AND IMPROVES SLEEP QUALITY IN CROHN'S DISEASE PATIENTS. A PROSPECTIVE OBSERVATIONAL STUDY

Ayal Hirsch, IL

09:00 - 09:00 P0513
FACTORS INFLUENCING INFLIXIMAB FAILURE IN ANTI-TNF NAIVE CHILDREN WITH ACTIVE ULCERATIVE COLITIS

Huda Atta, GB

09:00 - 09:00 P0514
PROACTIVE INFLIXIMAB IS MORE EFFECTIVE THAN VEDOLIZUMAB IN INDUCING FECAL CALPROTECTIN REMISSION IN INFLAMMATORY BOWEL DISEASE

Sérgio Bronze, PT

09:00 - 09:00 P0515
EFFECTS OF REPEAT INFLIXIMAB TO STEADY STATE ON BLOOD PROINFLAMMATORY BIOMARKERS TNFA, IL-6, IFN γ AND NITRITE/NITRATE IN CROHN'S DISEASE

Per Martin Hellström, SE

09:00 - 09:00 P0516
NEED FOR VEDOLIZUMAB INTENSIFICATION IN REAL LIFE CLINICAL PRACTICE

Spyridon Vrakas, GR

09:00 - 09:00 P0517
THE USE OF NUTRITION AS A THERAPEUTIC STRATEGY IN CHILDREN AND ADOLESCENTS WITH CROHN'S DISEASE IN BELGIUM

Gigi Veereman, BE

09:00 - 09:00 P0518
RESTORATION OF MICROBIOME COMPOSITION AND INCREASED BUTYRATE PRODUCTION ARE ASSOCIATED WITH RESPONSE TO SYSTEMIC CORTICOSTEROIDS IN PATIENTS WITH ACTIVE ULCERATIVE COLITIS

Andreas Blesl, AT

09:00 - 09:00 P0520
CUTANEOUS MANIFESTATIONS IN BIOLOGICAL-TREATED PEDIATRIC INFLAMMATORY BOWEL DISEASE: A 10 YEARS' EXPERIENCE FROM A TERTIARY CENTER

Zakhar Shchomak, PT

09:00 - 09:00 P0521
IMPACT OF BIOLOGIC ERA ON COLECTOMY RATE OF ULCERATIVE COLITIS; ASSESSMENT OF 22 YEAR IN A TERTIARY REFERRAL CENTER COHORT FROM A DEVELOPING COUNTRY

Oguz Kagan Bakkaloglu, TR

09:00 - 09:00 P0522
LOSS OF RESPONSE AND DOSE ESCALATION OF INFLIXIMAB AND ADALIMUMAB IN ULCERATIVE COLITIS PATIENTS: A SYSTEMATIC REVIEW AND META-ANALYSIS

Edo Savelkoul, NL

09:00 - 09:00 P0523
LONG-TERM COLECTOMY RATES IN ULCERATIVE COLITIS OVER DIFFERENT ERAS – A POPULATION-BASED STUDY FROM WESTERN HUNGARY BETWEEN 1977-2020, DATA FROM THE VESZPREM COUNTY COHORT

Lorant Gonczi, HU

09:00 - 09:00 P0524
INFLUENCE OF DIABETES MELLITUS ON INFLAMMATORY BOWEL DISEASE COURSE AND TREATMENT OUTCOMES. A SYSTEMATIC REVIEW WITH META-ANALYSIS

Gianluca Pellino, IT

09:00 - 09:00 P0525
DEFINITIVE SURGICAL MANAGEMENT OF PERIANAL FISTULAS IN ADULTS WITH CROHN'S DISEASE: A CROSS-SECTIONAL ANALYSIS OF LOCAL PRACTICE IN AUSTRALIA AND NEW ZEALAND

Michael De Gregorio, AU

09:00 - 09:00 P0526
HAS BODY IMAGE IMPROVED AMONGST INDIVIDUALS WITH INFLAMMATORY BOWEL DISEASE IN THE MODERN ERA?

Shauna Madigan, AU

09:00 - 09:00 P0527
FACTORS ASSOCIATED WITH RESECTION IN ISOLATED ILEAL CROHN'S DISEASE IN AN ASIAN COHORT

Yi Yuan Tan, SG

09:00 - 09:00 P0528

MRI EVOLUTION AND EFFICACY OF BONE MARROW-DERIVED MESENCHYMAL STEM CELLS IN PERIANAL FISTULAE IN CROHN'S DISEASE: RESULTS FROM A PROSPECTIVE MONOCENTRIC STUDY

Catherine Reenaers, BE

09:00 - 09:00 P0529

CZECH EXPERIENCE WITH TREATMENT OF CROHN'S DISEASE PERIANAL FISTULAS BY ALLOGENIC MESENCHYMAL STEM CELLS

Zuzana Serclova, CZ

09:00 - 09:00 P0530

MESENCHYMAL STEM CELLS INJECTION INTO COMPLEX PERIANAL FISTULAS IN CROHN'S DISEASE: PRELIMINARY REAL-LIFE RESULTS

Laurent Siproudhis, FR

09:00 - 09:00 P0531

PREHABILITATION STRATEGIES PRIOR TO ILEOCOLIC (RE-)RESECTION IN PATIENTS WITH CROHN'S DISEASE: A MISSED WINDOW OF OPPORTUNITY?

Michiel T.J. Bak, NL

09:00 - 09:00 P0532

EFFICACY AND SAFETY OF MESENCHYMAL STEM CELL THERAPY WITH DARVADSTROCEL FOR COMPLEX PERIANAL FISTULIZING CROHN'S DISEASE: MULTICENTRIC EXPERIENCE IN THE BASQUE COUNTRY AND NAVARRE

Ainara Elorza, ES

09:00 - 09:00 P1043

LOW FREQUENCIES OF CIRCULATING INHIBITORY TIGIT⁺CD38⁺ EFFECTOR T CELLS IDENTIFY AN IMMUNOLOGICALLY DISTINCT SUBGROUP OF PEDIATRIC PATIENTS WITH SEVERE CROHN'S DISEASE

Maud Heredia, NL

Moderated Poster

09:30 - 10:30 Poster Stage 1

Basic and translational science in the pancreas

Chairs: Ihsan Ekin Demir, DE

Alberto Balduzzi, IT

09:30 - 09:36 MP011

AN AUTOMATED HIGH-THROUGHPUT DRUG ASSAY FOR TREATMENT SELECTION OF PATIENT-DERIVED ORGANOID FROM PANCREATIC DUCTAL ADENOCARCINOMA

09:36 - 09:42 MP012

CEACAM6'S ROLE AS A CHEMORESISTANCE AND PROGNOSTIC BIOMARKER FOR PANCREATIC CANCER: A COMPARISON OF CEACAM6'S DIAGNOSTIC AND PROGNOSTIC CAPABILITIES WITH THOSE OF CA19-9 AND CEA

Benediktas Kurlinkus, LT

09:42 - 09:48 MP013

EFFECT OF IL-18 RECEPTOR DEFICIENCY ON CYTOTOXIC T-CELL MIGRATION PATTERNS AND INTERACTION BEHAVIOR IN A PANCREATIC CARCINOMA MODEL

Christian Bauer, DE

09:48 - 09:54 MP014

ADVANCED APICAL MEMBRANE PHYSIOLOGY IS REVEALED BY POLARITY-SWITCHED HUMAN PANCREATIC DUCTAL ORGANOID

Aletta Kata Kiss, HU

09:54 - 10:00 MP015

GENDER-SPECIFIC CHANGES OF THE GUT MICROBIOME CORRELATE WITH TUMOR DEVELOPMENT IN MURINE MODELS OF PANCREATIC CANCER

Jonas Rosendahl, DE

10:00 - 10:06 MP017

PIWIL1, A KEY REGULATOR IN THE PROCESS OF PANCREATIC STELLATE CELL ACTIVATION VIA PI3K/AKT/MTOR SIGNALING PATHWAY

Ran Xue, CN

10:06 - 10:12 MP018

USING LIGHT-BASED THERAPY TO ENHANCE THE EFFECTS OF PANCREATIC CANCER CHEMOTHERAPY

Pilar Acedo, GB

10:12 - 10:18 MP019

PORCINE PANCREATIC DUCTAL ORGANOID RECAPITULATE THE ION TRANSPORT PROPERTIES OF PANCREATIC DUCTAL CELLS

Dora Angyal, NL

10:18 - 10:24 MP020

THE EPIGENETIC FACTOR EZH2 ORCHESTRATES ONCOGENIC FEATURES IN ATM-DEFICIENT PANCREATIC CANCER

Anna Härle, DE

Moderated Poster

09:30 - 10:30 Poster Stage 2

Colonoscopy: Polyp detection and characterisation

Chairs: Barbara A.J. Bastiaansen, NL

Michal Filip Kaminski, PL

09:30 - 09:36 MP031

ARTIFICIAL INTELLIGENCE ASSISTED WITHDRAWAL TIME DOCUMENTATION IN A RETROSPECTIVE MULTI-CENTER STUDY

Thomas J. Lux, DE

09:36 - 09:42 MP032

TEXTURE AND COLOR ENHANCING IMAGING (TXI) INCREASES ADENOMA DETECTION RATE IN COLONOSCOPY: INTERIM ANALYSIS OF A RANDOMIZED CONTROLLED TRIAL

Giulio Antonelli, IT

09:42 - 09:48 MP033

POLYP DETECTION RATE AND CUMULATIVE INCIDENCE OF POST-COLONOSCOPY COLORECTAL CANCER IN GERMANY

Sarina Schwarz, DE

09:48 - 09:54 MP034
PRIMARY TREATMENT FOR COLORECTAL CANCER IS LESS INVASIVE IN PATIENTS WHO WERE DIAGNOSED BECAUSE OF COLORECTAL CANCER SCREENING - A RETROSPECTIVE COHORT STUDY

Jannie Dressler, DK

09:54 - 10:00 MP035
SEX SPECIFIC PREVALENCE OF ADENOMAS, ADVANCED ADENOMAS, AND COLORECTAL CANCER LEADS TO DIFFERENCES IN COLORECTAL CANCER MORTALITY IN INDIVIDUALS UNDERGOING SCREENING COLONOSCOPY
 Elisabeth Waldmann, AT

10:00 - 10:06 MP036
LEARNING CURVE FOR OPTICAL DIAGNOSIS OF SMALL POLYPS AT SCREENING COLONOSCOPY (DISCARD3)
 Ahmir Ahmad, GB

10:06 - 10:12 MP037
EFFECTIVENESS AND SAFETY OF THE 1L POLYETHYLENE GLYCOL + ASCORBIC ACID BOWEL PREPARATION FOR COLONOSCOPY IN A LARGE COHORT OF PATIENTS IN SPAIN: A SUBGROUP ANALYSIS OF A RETROSPECTIVE, MULTI-CENTRE, OBSERVATIONAL REAL-WORLD EVIDENCE STUDY
 Sarbelio Rodriguez Muñoz, ES

10:12 - 10:18 MP038
ABNORMAL GLUCOSE LEVELS IN DIABETIC PATIENTS DURING COLONOSCOPY PREPARATION – AN OBSERVATIONAL STUDY
 Sun-Hye Ko, KR

10:18 - 10:24 MP039
ADENOMA DETECTION RATE WITH POLYETHYLENE GLYCOL/ASCORBATE VERSUS SODIUM PICOSULFATE/MAGNESIUM CITRATE IN COLORECTAL CANCER SCREENING: A PARALLEL RANDOMISED CONTROLLED TRIAL (LOWOL STUDY)
 Maria Pellisé Urquiza, ES

10:24 - 10:30 MP040
SECOND FORWARD-VIEW EXAMINATION INCREASES POLYP DETECTION RATE DURING UNSEDATED COLONOSCOPY: BETWEEN MYTH AND REALITY
 Mariem Kefi, TN

Moderated Poster

09:30 – 10:30 Poster Stage 3
Artificial Intelligence and screening in endoscopy
 Chairs: Marietta Iacucci, GB
 Tom Konikoff, IL

09:30 - 09:36 MP001
CAN "VASCULAR HEALING" DIAGNOSED BY ARTIFICIAL INTELLIGENCE-ASSISTED NARROW-BAND IMAGING DURING COLONOSCOPY BE A NOVEL THERAPEUTIC TARGET FOR PATIENTS WITH ULCERATIVE COLITIS?
 Takanori Kuroki, JP

09:36 - 09:42 MP002
AN ARTIFICIAL INTELLIGENCE SYSTEM TO DETECT HISTOLOGICAL REMISSION AND PREDICT CLINICAL OUTCOMES IN ULCERATIVE COLITIS PATIENTS
 Tommaso Lorenzo Parigi, IT

09:42 - 09:48 MP003
AN AUTOMATED SYSTEM FOR ESTIMATION OF HISTOLOGICAL DISEASE ACTIVITY IN ULCERATIVE COLITIS: COMPARISON OF PERFORMANCES WITH WHITE LIGHT VERSUS SINGLE WAVELENGTH ENDOSCOPY
 Pieter Sinonquel, BE

09:48 - 09:54 MP004
AI-ASSISTED ENDOSCOPIC VIDEO FRAME SELECTION FOR ULCERATIVE COLITIS CLASSIFICATION
 Bobby Lo, DK

09:54 - 10:00 MP005
UTILITY OF COMPUTER-AIDED DIAGNOSTIC SYSTEM USING WHITE LIGHT IMAGING FOR THE OPTICAL DIAGNOSIS OF COLORECTAL CANCER WITH DEEP INVASION: COMPARATIVE STUDY WITH PROSPECTIVE STUDY USING MAGNIFYING CHROMOENDOSCOPY
 Tomoaki Matsumura, JP

10:00 - 10:06 MP006
RISK OF ADVANCED LESIONS AT SURVEILLANCE COLONOSCOPY AFTER DETECTION OF SERRATED LESIONS: A MATCHED COHORT STUDY
 Roupen Djinbanchian, CA

10:06 - 10:12 MP007
CT-COLONOGRAPHY IN FECAL IMMUNOCHEMICAL TEST POSITIVE PATIENTS IN A COLORECTAL CANCER SCREENING PROGRAM – YIELD AND INCIDENCE OF INTERVAL CARCINOMAS
 Manon C.W. Spaander, NL

10:12 - 10:18 MP008
CLINICAL VALIDATION OF A FAECAL BACTERIAL SIGNATURE TEST FOR COLORECTAL CANCER SCREENING
 Sara Ramió-Pujol, ES

10:18 - 10:24 MP009
ANALYSIS OF COLORECTAL CANCER AND ADENOMA MICROBIOME SIGNATURES AND THE APPLICATION OF MACHINE LEARNING CLASSIFICATION AS A POTENTIAL SCREENING TOOL
 Katarina Priselac, AT

10:24 - 10:30 MP010
CAN ROUTINE BIOPSY OF COLORECTAL ENDOSCOPIC MUCOSAL RESECTION SCARS BE ABANDONED? - A MULTICENTRE RANDOMIZED SINGLE-BLINDED CROSSOVER TRIAL
 Mafalda João, PT

Moderated Poster

09:30 – 10:30 Poster Stage 4
Artificial Intelligence and upper-GI neoplasia
 Chairs: Yuichi Mori, NO

09:30 - 09:36 MP022
DEVELOPMENT OF A RESIDENT GASTRIC MICROBIOTA DYSBIOSIS TEST TO STRATIFY CANCER RISK IN PATIENTS WITH ATROPHIC GASTRITIS

Alice Zaramella, IT

09:36 - 09:42 MP024
THE ROLE OF RANDOM BIOPSIES IN EARLY DIAGNOSIS OF SIGNET RING CELL CARCINOMA IN HEREDITARY DIFFUSE GASTRIC CANCER SYNDROME: A 16-YEAR LONGITUDINAL PROSPECTIVE STUDY

Colin Lee, GB

09:42 - 09:48 MP025
A COMPUTER-AIDED DIAGNOSIS (CADX) SYSTEM FOR CHARACTERIZATION OF BARRETT'S NEOPLASIA

Jelmer Jukema, NL

09:48 - 09:54 MP026
DIAGNOSTIC PERFORMANCE OF GASTROCLEAR FOR DETECTING GASTRIC CANCER IN THE JAPANESE POPULATION

Tatsuro Murano, JP

09:54 - 10:00 MP027
THE VALUE OF INCISURA IN GASTRIC INTESTINAL METAPLASIA SURVEILLANCE

Sabrina Quek, SG

10:00 - 10:06 MP028
SINGLE WAVELENGTH ENDOSCOPY FOR THE ASSESSMENT OF BARRETT'S OESOPHAGUS: EXPERT AND NON-EXPERT OPTICAL DIAGNOSIS USING DIFFERENT IMAGING TECHNIQUES

Pieter Sinonquel, BE

10:06 - 10:12 MP029
A SYSTEMATIC AND UNIVERSAL ARTIFICIAL INTELLIGENCE METHOD FOR OROPHARYNGEAL DYSPHAGIA SCREENING: ACCURACY OF MACHINE LEARNING IS HIGHER THAN CLASSIC MULTIVARIATE ANALYSIS

Pere Clavé, ES

10:12 - 10:18 MP030
MACHINE LEARNING IMPROVES THE PREDICTION RATE OF NON-CURATIVE RESECTION OF ENDOSCOPIC SUBMUCOSAL DISSECTION IN PATIENTS WITH EARLY GASTRIC CANCER

Cheal Wung Huh, KR

Moderated Poster

09:30 – 10:30 Poster Stage 5

Covid-19 in GI

Chairs: Maria T. Abreu, US
 Henriette Heinrich, CH

09:30 - 09:36 MP041
GASTROINTESTINAL MANIFESTATIONS IN COVID-19:A PROSPECTIVE STUDY

Soukaina Rokhsi, MA

09:36 - 09:42 MP043
ANALYSIS OF MENTAL DISTRESS AMONG HEALTH PROFESSIONALS DURING THE FIRST SARS-COV-2 WAVE AS PART OF A COMPREHENSIVE SURVEY OF INTERPROFESSIONAL COLLABORATION AND ITS IMPACT ON MENTAL HEALTH

Kirstin Ruttman, DE

09:42 - 09:48 MP044
OUTPATIENT ENDOSCOPY WITHOUT SARS-COV-2 TESTING: FROM THE RESUMPTION OF ENDOSCOPIC ACTIVITY TO VACCINATION. WAS IT SAFE TO DO THAT?

Cristina Olmedo, ES

09:48 - 09:54 MP045
ASSOCIATION BETWEEN RECENT ANTIBIOTIC USE AND EARLY IMMUNOGENICITY OF COVID-19 BNT162B2 VACCINE

Ka Shing Cheung, HK

09:54 - 10:00 MP046
PROTON PUMP INHIBITORS USE IS NOT ASSOCIATED WITH THE RISK OF COVID-19-RELATED MORTALITY OR HOSPITALIZATION: CROATIAN NATIONWIDE COHORT STUDY

Ivan Kodvanj, HR

10:00 - 10:06 MP047
IMPACT OF DELAYED SCREENING INVITATIONS DUE TO COVID-19 ON OUTCOMES OF THE DUTCH FIT-BASED COLORECTAL CANCER SCREENING PROGRAMME: INDIVIDUAL-LEVEL DATA ANALYSIS

Esther Toes-Zoutendijk, NL

10:06 - 10:12 MP048
FXR INHIBITION AS A NEW STRATEGY AGAINST COVID19

Teresa Brevini, GB

10:12 - 10:18 MP049
EVALUATION OF THE IMMUNE RESPONSE AGAINST SARS-COV-2 AFTER TWO AND THREE DOSES OF MRNA VACCINATION IN PATIENTS WITH LIVER CIRRHOSIS

Samer Al-Dury, SE

10:18 - 10:24 MP050
EFFECT OF PREADMISSION PROTON PUMP INHIBITOR (PPI) ON THE CLINICAL OUTCOME OF COVID -19 HOSPITALISED PATIENTS DURING THE PANDEMIC AT THE JAMES COOK UNIVERSITY HOSPITAL, MIDDLESBROUGH ,CLEVELAND, UNITED KINGDOM

Tasneem Elkanzi, GB

PGT: Clinical Case-based Session

10:00 – 11:30 D3

Roadmap for treatment success in Crohn's disease

Chairs: Peter Bossuyt, BE
 Britta Siegmund, DE
 Antonino Spinelli, IT

Q+A LIVE

10:00 - 10:15 IP126

Luminal CD CASE

Carl Weidinger, DE

10:15 - 10:30 IP127

Luminal CD: Assess, treat, repeat

Britta Siegmund, DE

10:30 - 10:45

Q&A

10:45 - 11:00 IP128

Fistulising CD CASE

Carl Weidinger, DE

11:00 - 11:15 IP129

Fistulising CD: Assess, treat, error

Peter Bossuyt, BE

11:15 - 11:30

Q&A

Industry Symposia

10:00 – 11:00 A1

Assessing ulcerative colitis: Is there something your patient isn't telling you?

PGT: Clinical Case-based Session

10:00 – 11:30 A3

30 Years of UEG - Focus on IBS: Did we make any progress in the diagnosis and management?

Chairs: Giovanni Barbara, IT

Lin Chang, US

Magnus Simrén, SE

10:00 - 10:15 IP130

Abdominal pain and constipation in a patient with fibromyalgia CASE

Wendi LeBrett, US

10:15 - 10:30 IP131

Management of IBS-C: A multidisciplinary approach

Lin Chang, US

10:30 - 10:45

Q&A

10:45 - 11:00 IP132

Abdominal pain and diarrhea after a bout of infectious gastroenteritis CASE

Giovanni Marasco, IT

11:00 - 11:15 IP133

Management of IBS-D: Pathophysiology driven approaches

Giovanni Barbara, IT

11:15 - 11:30

Q&A

PGT: Clinical Case-based Session

10:00 – 11:30 C2

If prednisolon works: Autoimmune diseases of liver and bile

Chairs: Ulrich Beuers, NL

Herbert Tilg, AT

Eleonora De Martin, FR

10:00 - 10:15 IP134

Blue collar worker with acute jaundice CASE

Lowiek Hubers, NL

10:15 - 10:30 IP135

IgG4-related disease: The great mimicker

Ulrich Beuers, NL

10:30 - 10:45

Q&A

10:45 - 11:00 IP136

Autoimmune hepatitis: Always look at the whole picture CASE

Maria Effenberger, AT

11:00 - 11:15 IP137

Approach to the adult with autoimmune liver disease

Herbert Tilg, AT

11:15 - 11:30

Q&A

PGT: Clinical Case-based Session

10:00 – 11:30 D4

Obesity: Life threatening but treatable

Chairs: Stephan Bischoff, DE

Ivo Boskoski, IT

10:00 - 10:15 IP138

Redo-ESG in super obese CASE

Silvana Perretta, FR

10:15 - 10:30 IP139

Endoscopic sleeve gastropasty: Is mini-invasive better?

Ivo Boskoski, IT

10:30 - 10:45

Q&A

10:45 - 11:00 IP140

Revisonal bariatric endoscopy in bypass and sleeve gastrectomy CASE

Christine Stier, DE

11:00 - 11:15 IP141

Lifestyle change, GLP-1-agonists and endosleeve: Alternative to bariatric surgery?

Stephan Bischoff, DE

11:15 - 11:30

Q&A

PGT: Clinical Case-based Session

10:00 – 11:30 Strauss 3
From Maastricht VI to CPI therapy: Gastric cancer in 2022
 Chairs: Massimiliano di Pietro, GB
 Christian Schulz, DE
 Tamara Matysiak-Budnik, FR

Q+A LIVE

10:00 - 10:20 IP142
Who is at risk of gastric cancer and how do I manage this risk in my practice?
 Christian Schulz, DE

10:20 - 10:25 IP143
Early gastric cancer ^{CASE}
 Judith Honing, GB

10:25 - 11:00 IP144
How do I recognise the pre-malignant stomach and manage the early cancer?
 Massimiliano di Pietro, GB

11:00 - 11:05 IP145
Patient with advanced (EBV+) gastric cancer ^{CASE}
 Lukas Macke, DE

11:05 - 11:30 IP146
Molecular biomarkers and personalised treatment of gastric cancer: Are we there yet?
 Christian Schulz, DE

Nurse Programme

10:00 – 11:30 Lehar 2
Advanced endoscopy techniques: Key to success
 Chairs: Ela Bąk, PL
 Siiri Maasen, EE

Q+A LIVE

10:00 - 10:20 IP147
ERCP and EUS: The pilot is only as good as the co-pilot. What nurses need to know
 Rainer Schöfl, AT

10:20 - 10:40 IP148
6 eyes – 6 hands: Teamwork during polypectomy, EMR, ESD
 Werner Dolak, AT

10:40 - 11:00 IP149
Hemostasis of variceal and non-variceal bleeding. Give me 5: When, where, why, who, which technique?
 Ian Mark Gralnek, IL

11:00 - 11:30 IP150
Free Paper: Accurate measurement leads to improved localisation of colonic pathology
 Joseph Garzia, MT

Nurse Programme

10:00 – 11:30 Lehar 3
Liver nurses
 Chairs: J. Patricia Burga, IT
 Camilla Leidcker, DK

Q+A LIVE

10:00 - 10:25 IP151
How to establish a specialisation: Resources and limitations
 Denise Schäfer, AT

10:25 - 10:50 IP152
Free Paper: Liver and nutrition: A quality development project
 Kevin Hansen, DK

10:50 - 11:15 IP153
Free Paper: Palliation to patients with alcohol related liver cirrhosis: A literature review
 Dorthe Wiinholdt Christensen, DK

11:15 - 11:30
Liver Nurses in Europe: Round table discussion

Common Interest Group

10:00 – 13:00 Schubert
ESsCD annual meeting

myUEG Community Programme

10:30 – 11:00 MyUEG Community Area
Connect with... #UEGResearch Fellows
 Chairs: Chloé Melchior, FR
 Lucas Wauters, BE
 Michal Żorniak, PL

Moderated Poster

11:00 – 12:00 Poster Stage 1
Clinical hepatology
 Chairs: Dragos Ciocan, FR
 Rafael Banares, ES

11:00 - 11:06 MP061
IMPACT OF BACTERIAL INFECTIONS PRIOR LIVER TRANSPLANTATION ON POST-TRANSPLANT OUTCOMES IN PATIENTS WITH CIRRHOSIS
 Simone Incicco, IT

11:06 - 11:12 MP062
POTENTIAL BIOMARKERS FOR DIFFERENTIATING ALCOHOLIC HEPATITIS FROM DECOMPENSATED CIRRHOSIS BY SERUM METABOLOMIC ANALYSIS
 Adelina Horhat, RO

11:12 - 11:18 MP063
THE SEVERITY OF PORTAL HYPERTENSION DETERMINES CLINICAL OUTCOMES IN SEVERE ALCOHOLIC HEPATITIS
 Ankur Jindal, IN

11:18 - 11:24 MP064
REPRODUCIBILITY AND ACCURACY OF A POCKET-SIZE ULTRASOUND DEVICE IN ASSESSING AND GRADING LIVER STEATOSIS

Andrea Costantino, IT

11:24 - 11:30 MP066

THE IMPACT OF TRANSMEMBRANE 6 SUPERFAMILY 2 (TM6SF2) RS58542926 ON LIVER-RELATED EVENTS IN PATIENTS WITH ADVANCED CHRONIC LIVER DISEASE

Lorenz Balcar, AT

11:30 - 11:36 MP067

PHYSICAL ACTIVITY OF OBESE CHILDREN AND ADOLESCENTS WITH THE NONALCOHOLIC FATTY LIVER DISEASE DURING THE COVID-19 PANDEMIC

Natalia Zavhorodnia, UA

11:36 - 11:42 MP068

MICROBIAL INTERVENTION WITH *BACTEROIDES THETAIOOTAOMICRON* PREVENTS STEATOSIS IN ALCOHOL-RELATED LIVER DISEASE PRECLINICAL MODEL BY MODULATING INTESTINAL HOMEOSTASIS

Moris Sangineto, IT

11:42 - 11:48 MP069

THE EPIDEMIOLOGY OF ALCOHOL USE DISORDER AND VALIDATION OF AUDIT-C IN SECONDARY CARE: A RETROSPECTIVE COHORT CONTROL STUDY

Mohsan Subhani, GB

11:48 - 11:54 MP070

CHANGES IN CAROTID ATHEROSCLEROSIS, LIVER STEATOSIS AND ASSOCIATED METABOLIC COMORBIDITIES AFTER VIRAL ERADICATION BY DAAS IN PATIENTS WITH CHRONIC HEPATITIS C: A SYSTEMATIC REVIEW

Annalisa Cespiati, PT

Moderated Poster

11:00 - 12:00 Poster Stage 2

Advanced endoscopy

Chairs: Mathieu Pioche, FR
 Jérémie Jacques, FR

11:00 - 11:06 MP081

THE USEFULNESS AND SAFETY OF COLORECTAL ESD BASED ON A NATIONAL HEALTH INSURANCE SERVICE IN KOREA

Bohyoung Kim, KR

11:06 - 11:12 MP082

APPLICATION OF THE AGREE CLASSIFICATION IN ENDOSCOPIC SUBMUCOSAL DISSECTION – A SINGLE-CENTER RETROSPECTIVE COHORT STUDY

Rui Mendo, PT

11:12 - 11:18 MP083

CAP-SUCTION UNDERWATER ENDOSCOPIC MUCOSAL RESECTION (CAP-UEMR) AS AN EASY-TO-USE AND EFFICIENT TECHNIQUE FOR TREATING FLAT COMPLEX COLORECTAL LESIONS: A PROOF OF CONCEPT PILOT STUDY

Hugo Uchima, ES

11:18 - 11:24 MP084

LINKED-COLOR IMAGING VERSUS HIGH-DEFINITION WHITE LIGHT ENDOSCOPY FOR EVALUATION OF POST-POLYPECTOMY SCARS OF NON-PEDUNCULATED LESIONS. LCI-SCAR STUDY

Oswaldo Ortiz, ES

11:24 - 11:30 MP085

ENDOSCOPIC VACUUM THERAPY FOR PATIENTS WITH ESOPHAGEAL PERFORATION: A MULTI-CENTER RETROSPECTIVE COHORT STUDY

Lisanne Pattynama, NL

11:30 - 11:36 MP086

ENDOSCOPIC RESECTION IN SUBEPITHELIAL LESIONS; EXPERIENCE OF A TERTIARY REFERRAL HOSPITAL IN THE NETHERLANDS

Cynthia Verloop, NL

11:36 - 11:42 MP087

THE EVALUATION OF THE MODIFIED TRACTION ASSISTED ENDOSCOPIC SUBMUCOSAL DISSECTION WITH ATTACHMENT OF TRACTION CLIP PRIOR TO MAKING MUCOSAL FLAP

Shuichi Miyamoto, JP

11:42 - 11:48 MP088

SAFETY AND FEASIBILITY OF OUTPATIENT FULL-THICKNESS RESECTION FOR COLORECTAL LESIONS: GET A CLEAR SKY FROM THE COVID-19 STORM

Mario Gagliardi, IT

11:48 - 11:54 MP089

WEIGHT-LOSS ENDOSCOPY TRIAL (WET): A MULTI-CENTER, RANDOMIZED, CONTROLLED TRIAL COMPARING WEIGHT LOSS IN ENDOSCOPICALLY IMPLANTED DUODENAL-JEJUNAL BYPASS LINERS VS. INTRAGASTRIC BALLOONS VS. A SHAM PROCEDURE

Marcus Hollenbach, DE

11:54 - 12:00 MP090

ENDOSCOPIC VACUUM THERAPY FOR PATIENTS WITH ANASTOMOTIC LEAKAGE AFTER ESOPHAGO-GASTRIC SURGERY

Lisanne Pattynama, NL

Moderated Poster

11:00 - 12:00 Poster Stage 3

Safety and emergencies in lower GI disease

Chairs: Adi Lahat, IL

11:00 - 11:06 MP051

SAFETY OF INFLAMMATORY BOWEL DISEASE TREATMENTS IN PATIENTS WITH SOLID ORGAN TRANSPLANTATION (EITOS STUDY OF GETECCU)

Iria Bastón-Rey, ES

11:06 - 11:12 MP052

MAJOR ADVERSE CARDIOVASCULAR EVENTS BY BASELINE CARDIOVASCULAR RISK STRATIFICATION IN PATIENTS WITH ULCERATIVE COLITIS TREATED WITH TOFACITINIB: DATA FROM THE OCTAVE CLINICAL PROGRAMME

Stefan Schreiber, DE

11:12 - 11:18 MP053
BIOLOGIC AGENTS IN IBD PATIENTS AFTER SOLID ORGAN TRANSPLANTATION DO NOT INCREASE THE RATES OF INFECTION OR ADVERSE EVENTS

Linda Cingolani, IT

11:18 - 11:24 MP054
THE EFFECT OF OZANIMOD ON CIRCULATING NEUTROPHILS: RESULTS FROM THE TRUE NORTH STUDY OF PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS

Sarah Harris, US

11:24 - 11:30 MP055
HEPATIC SAFETY OF OZANIMOD IN ULCERATIVE COLITIS AND RELAPSING MULTIPLE SCLEROSIS PHASE 3 TRIALS

David T. Rubin, US

11:30 - 11:36 MP056
PROTECTIVE EFFECTS OF *SACCHAROMYCES BOULARDII* CNCM I-745 AGAINST NONSTEROIDAL ANTI-INFLAMMATORY DRUG-INDUCED INTESTINAL INJURY

Laura Benvenuti, IT

11:36 - 11:42 MP058
LONG-TERM SAFETY OF USTEKINUMAB IN IBD PATIENTS WITH A HISTORY OF BIOLOGIC FAILURE: POOLED SAFETY ANALYSIS THROUGH 5 YEARS IN CROHN'S DISEASE AND 2 YEARS IN ULCERATIVE COLITIS

Subrata Ghosh, IE

11:42 - 11:48 MP059
STOPPING 5-AMINOSALICYLIC ACID IN PATIENTS WITH LONG-STANDING INACTIVE ULCERATIVE COLITIS IS NOT ASSOCIATED WITH AN INCREASED RISK OF RELAPSE: RESULTS FROM A MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL

11:48 - 11:54 MP060
RISK PREDICTION FOR ADVANCED NEOPLASIA USING LONGITUDINAL ADHERENCE MEASURES TO FECAL IMMUNOCHEMICAL TEST-BASED COLORECTAL CANCER SCREENING PROGRAMS

Lucie de Jonge, NL

Moderated Poster


11:00 - 12:00 Poster Stage 4

Nutrition

Chairs: Francisca Joly, FR
 Lucas Wauters, BE

11:00 - 11:06 MP071
GLP-2 MODULATED GENES IN ADULT PATIENTS WITH SHORT BOWEL SYNDROME TREATED WITH TEDUGLUTIDE

Brune de Dreuille, FR

11:06 - 11:12 MP072
ORAL ERYTHRITOL REDUCES SUBSEQUENT ENERGY INTAKE: A RANDOMIZED, CONTROLLED, CROSSOVER STUDY IN LEAN PARTICIPANTS 

Fabienne Teyssie, CH

11:12 - 11:18 MP073
FEASIBILITY, SAFETY AND EFFICACY OF ENDOSCOPIC GASTROPLASTY FOR TREATMENT OF OBESE PATIENTS. PRELIMINARY RESULTS AT 6 MONTHS FOLLOW-UP FROM A PROSPECTIVE, SINGLE CENTER, RANDOMIZED CONTROLLED TRIAL

Milutin Bulajic, IT

11:18 - 11:24 MP074
EFFECT OF COLESEVELAM ON BILE ACID DIARRHOEA DIAGNOSED WITH 7A-HYDROXY-4-CHOLESTEN-3-ONE (C4) AND 75-SELENIUM HOMOCHOLIC ACID RETENTION TEST (SEHCAT), RESPECTIVELY: A RANDOMISED PLACEBO-CONTROLLED MULTICENTRE CLINICAL TRIAL

Christian Borup, DK

11:24 - 11:30 MP075
DIETARY DICARBONYLS AND INTESTINAL INFLAMMATION IN INFLAMMATORY BOWEL DISEASE AND IRRITABLE BOWEL SYNDROME PATIENTS

Marlijne de Graaf, NL

11:30 - 11:36 MP076
PRIMARY AND FOOD-INDUCED SECONDARY BARRIER DYSFUNCTION IN PATIENTS WITH CROHN'S DISEASE

Jost Langhorst, DE

11:36 - 11:42 MP078
TRANSFERABILITY OF METABOLIC BALANCE STUDIES IN SHORT BOWEL SYNDROME: ANALYSIS OF DRY MATTER AND ENERGY CONTENTS

Astrid Verbiest, BE

11:42 - 11:48 MP079
APRAGLUTIDE DECREASES SEVERITY OF INTESTINAL DAMAGE FROM GASTROINTESTINAL ACUTE GRAFT-VERSUS-HOST DISEASE FOLLOWING ALLOGENEIC TRANSPLANTATION WITHOUT IMPACTING ENGRAFTMENT

Barbara Biemans, CH

11:48 - 11:54 MP080
DIETARY PATTERNS ARE REFLECTED IN THE PLASMA INFLAMMATORY PROTEOME OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE

Laura A. Bolte, NL

Moderated Poster

11:00 - 12:00 Poster Stage 5

Covid-19 in IBD

Chairs: Maria T. Abreu, US

11:00 - 11:06 MP091
ANTI-TNF THERAPY IS ASSOCIATED WITH ATTENUATED HUMORAL RESPONSE TO SARS-COV-2 VACCINES IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE (IBD): A CROSS-SECTIONAL STUDY FROM A PORTUGUESE IBD UNIT

Filipa Bordalo Ferreira, PT

11:06 - 11:12 MP092
SEROLOGIC RESPONSE AND SAFETY AFTER THIRD DOSE OF THE COVID-19 BNT162B2 VACCINE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES

Iris Dotan, IL

11:12 - 11:18 MP093
SERUM PROTEOMICS AND METABOLOMICS STUDY ON SUSCEPTIBILITY TO SARS-COV-2 INFECTION IN IBD PATIENTS

Laura Francesca Pisani, IT

11:18 - 11:24 MP094
IMPACT OF IMMUNOTHERAPIES ON RESPIRATORY TRACT INFECTIONS INCLUDING SARS-COV-2 IN IBD PATIENTS

Thomas Ochsenkühn, DE

11:24 - 11:30 MP095
IMMUNOSUPPRESSANTS EXERT DIFFERENTIAL EFFECTS AGAINST PAN-CORONAVIRUS INFECTION AND DISTINCT COMBINATORY ANTIVIRAL ACTIVITY WITH MOLNUPIRAVIR AND NIRMATRELVIR

Yining Wang, NL

11:30 - 11:36 MP096
ANALYSIS OF THE SEROLOGIC RESPONSE TO COVID-19 VACCINATION IN PAEDIATRIC INFLAMMATORY BOWEL DISEASE

Laura María Palomino Pérez, ES

11:36 - 11:42 MP097
THE NATURAL HISTORY OF COVID-19 IN VACCINATED INFLAMMATORY BOWEL DISEASE PATIENTS

Gerassimos J. Mantzaris, GR

11:42 - 11:48 MP098
EXPLORING THE TRANSCRIPTOMIC UNDERPINNING THE EFFECT OF BIOLOGICAL THERAPIES ON SARS-COV-2 SUSCEPTIBILITY IN INFLAMMATORY BOWEL DISEASE (IBD) PATIENTS

Laura Francesca Pisani, IT

11:48 - 11:54 MP099
HUMORAL IMMUNOGENICITY AFTER VACCINATION AGAINST SARS-COV-2 INFECTION IN INFLAMMATORY BOWEL DISEASE PATIENTS UNDER IMMUNOSUPPRESSIVE THERAPY: SHOULD WE PRIORITIZE AN ADDITIONAL BOOSTER INJECTION?

Tiago Lima Capela, PT

myUEG Community Programme

11:30 – 12:00 MyUEG Community Area
Career Development Level 4 - Growing to be a leader

Chairs: Marianna Arvanitakis, BE
 Muhammad Imran Aslam, GB
 Ignacio Catalan-Serra, NO
 Charles Murray, GB

Industry Symposia

12:00 – 13:00 A1
Exploring the evolution of care in Crohn’s disease

Q+A LIVE

Industry Symposia

12:00 – 13:00 A2
Precision medicine with precision tools in Crohn’s disease: can we translate science into clinical practice?

Q+A LIVE

Industry Symposia

12:00 – 13:00 A3
JAK of all trades, master of IBD? Refocusing our clinical expectations

Q+A LIVE

Industry Symposia

12:00 – 13:00 C1
Targeted oral therapies for the treatment of moderate to severe UC

Q+A LIVE

Industry Symposia

12:00 – 13:00 D4
Solving the Riddle of Disease Control in EoE

Q+A LIVE

Common Interest Group

12:00 – 13:00 Lehar 4
Rome Foundation GastroPsych European Meeting

Opening Session

13:30 – 14:30 D3
Opening Session Part I
 Chairs: Helena Cortez-Pinto, PT
 Julia Mayerle, DE

Q+A LIVE

13:30 - 13:35 IP154
Words of welcome
 Julia Mayerle, DE

13:35 - 13:55 IP155
Target discovery for GI-diseases
 Roland Rad, DE

13:55 - 14:07 OP001
EFFICACY AND SAFETY OF UPADACITINIB MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: FINAL RESULTS FROM THE PHASE 3 U-ACHIEVE MAINTENANCE STUDY
 Severine Vermeire, BE

14:07 - 14:12
UEG Research Prize 2022 award hand over

14:12 - 14:27 IP156
UEG Research Prize 2022: Using integrated single cell genomics and spatial transcriptomics approaches to identify the key therapeutic targets driving the progression of human NASH
 Neil Henderson, GB

Common Interest Group
 14:00 - 16:00 Schubert
Healthy Stomach Initiative

Session
 15:00 - 16:00 D3
Novel approaches in the medical management of cirrhosis
 Chairs: Annalisa Berzigotti, CH
 Jörn Schattenberg, DE

Q+A LIVE

15:00 - 15:20 IP157
Rising Star: Management of bacterial infections in cirrhosis
 Salvatore Piano, IT

15:20 - 15:40 IP158
Portal hypertension: Risk stratification and screening
 Thomas Reiberger, AT

15:40 - 16:00 IP159
Acute on chronic liver failure: Still a novel concept or accepted truth?
 Florent Artru, GB

Session
 15:00 - 16:00 A1
Mistakes in...: Luminal IBD and endoscopy
 Chairs: Charles Murray, GB
 Manuele Furnari, IT

Q+A LIVE

15:00 - 15:03 IP160
Introduction Mistakes in...: Luminal IBD and endoscopy
 Charles Murray, GB

15:03 - 15:21 IP161
Endoscopic resection
 Alessandro Repici, IT

15:21 - 15:39 IP162
Nutrition in IBD
 Richard K Russell, GB

15:39 - 15:57 IP163
Surveillance of IBD
 Matt Rutter, GB

15:57 - 16:00
Conclusion Mistakes in...: Luminal IBD and endoscopy
 Charles Murray, GB

Session
 15:00 - 16:00 A2
How to handle complications of IBD
 Chairs: Lissy de Ridder, NL
 Tim Raine, GB

Q+A LIVE

15:00 - 15:20 IP164
VTE - risks and mitigation
 Ignacio Catalan-Serra, NO

15:20 - 15:40 IP165
Fibrosis and strictures - treatment at last?
 Florian Rieder, US

15:40 - 16:00 IP166
Managing and preventing psychological complications of IBD
 Fiona Eldridge, GB

Session
 15:00 - 16:00 A3
Update on pancreatic cysts
 Chairs: Johanna Laukkarinen, FI
 Jonas Rosendahl, DE

Q+A LIVE

15:00 - 15:20 IP167
Incidental pancreatic cyst: Lifelong follow up for small cysts or molecular markers for risk stratification?
 Georg Beyer, DE

15:20 - 15:27 IP168
EUS: The best imaging modality for pancreatic cysts
 Djuna L. Cahen, NL

15:27 - 15:34 IP169
MRI: The best imaging modality for pancreatic cyst
 Wolfgang Schima, AT

15:34 - 15:40
Q&A

15:40 - 16:00 IP170
When should we call the surgeon?
 Roberto Salvia, IT

Session
 15:00 - 16:00 C1
Small things that matter: Premalignant gastric lesions
 Chairs: Juozas Kupcinskis, LT
 Christian Schulz, DE

Q+A LIVE

15:00 - 15:20 IP171
Is screening for premalignant gastric lesions in Europe feasible?
 Marcis Leja, LV

15:20 - 15:40 IP172
Biomarkers for premalignant gastric conditions: Ready for prime time?

Annemieke Smet, BE

15:40 - 15:45 IP173

Premalignant gastric lesions: Biopsies are the goldstandard.

Cord Langner, AT

15:45 - 15:50 IP174

Premalignant gastric lesions: AI and machine learning is key

Pedro Pimentel-Nunes, PT

15:50 - 16:00

Q&A

Session

15:00 - 16:00

C2

Obesity and the lower GI tract

Chairs: Simon Gabe, GB

Caroline Tuck, AU

Q+A LIVE

15:00 - 15:30 IP175

Complications of bariatric surgery in the lower GI tract

Ahmed Ahmed, GB

15:30 - 16:00 IP176

Obesity and GI cancers

Zohar Levi, IL

Abstract-based Session

15:00 - 16:00

D4

Impact of CRC screening

Chairs: Carlo Senore, IT

Eglė Dieninytė - Misiūnė, LT

Q+A LIVE

15:00 - 15:12 OP002

SYSTEMATIC REVIEW AND META-ANALYSIS: THE GLOBAL THREE-YEAR POST-COLONOSCOPY COLORECTAL CANCER RATE AS PER THE WORLD ENDOSCOPY ORGANIZATION METHODOLOGY

Rawen Kader, GB

15:12 - 15:24 OP003

INCIDENCE AND PREDICTORS OF POST-COLONOSCOPY COLORECTAL CANCER – POPULATION-BASED RETROSPECTIVE STUDY

Zsófia Bősze, HU

15:24 - 15:36 OP004

THE EFFECTS OF THE DANISH COLORECTAL CANCER SCREENING PROGRAM ON INTRA-/POST-OPERATIVE COMPLICATIONS AND DURATION HOSPITAL STAY AFTER SURGERY FOR COLORECTAL CANCER: A RETROSPECTIVE COHORT STUDY

Jannie Dressler, DK

15:36 - 15:48 OP005

POST-POLYPECTOMY COLORECTAL CANCER RISK IN IMMUNOCHEMICAL FAECAL TEST SCREENING PROGRAMS

Giulio Antonelli, IT

15:48 - 16:00 OP006

DETECTION RATES OF COLORECTAL NEOPLASIA DURING COLONOSCOPIES AND THEIR ASSOCIATED FACTORS IN THE SCREESCO STUDY

Masau Sekiguchi, JP

Session

15:00 - 16:00

Strauss 2

What's new in 2022?

Chairs: Joost P.H. Drenth, NL

Q+A LIVE

15:00 - 15:15 IP178

What's new in Gastroenterology?

Herbert Tilg, AT

15:15 - 15:30 IP179

What's new in Hepatology?

Paolo Angeli, IT

15:30 - 15:45 IP180

What's new in Endoscopy?

Thomas Rösch, DE

15:45 - 16:00 IP181

UEG Journal: The story of success

Joost P.H. Drenth, NL

Session

15:00 - 16:00

Strauss 3

Eosinophilic GI disorders: Take the challenge!

Chairs: Arjan Bredenoord, NL

Paola Iovino, IT

Q+A LIVE

15:00 - 15:20 IP182

Pathophysiology of EoE: Genetics, aberrant immune response or food allergies?

Maria Antonella Muraro, IT

15:20 - 15:40 IP183

Diagnostic challenges: Endoscopy and histology

Ulrike von Arnim, DE

15:40 - 16:00 IP184

What happens if first-line treatment of EoE fails?

Alfredo J. Lucendo, ES

Abstract-based Session

15:00 - 16:00

Lehar 2

Management of liver disease

Chairs: Omar Elshaarawy, GB

Maja Thiele, DK

Q+A LIVE

15:00 - 15:00 OP007
MORE THAN JUST AN ITCH: IMPACT OF CHOLESTATIC PRURITUS IN PRIMARY BILIARY CHOLANGITIS ON HEALTH-RELATED QUALITY OF LIFE

Helen Smith, GB

15:00 - 15:00 OP008
EFFICACY OF ORAL VANCOMYCIN FOR TREATMENT OF PRURITUS IN PATIENTS WITH PRIMARY SCLEROSING CHOLANGITIS: A RANDOMIZED CONTROLLED CLINICAL TRIAL

Ahad Eshraghian, IR

15:00 - 15:00 OP009
HEPATIC RECOMPENSATION ACCORDING TO BAVENO VII CRITERIA IS LINKED TO A CLEAR SURVIVAL BENEFIT IN PATIENTS WITH DECOMPENSATED ALCOHOL-RELATED CIRRHOSIS

Benedikt Hofer, AT

15:00 - 15:00 OP010
LOW LEVELS OF QHBSAG AND LONG TERM ANTIVIRAL THERAPY ARE ASSOCIATED WITH SUCCESSFUL TREATMENT WITHDRAWAL IN NON-CIRRHOTIC HBEAG-NEGATIVE CHRONIC HEPATITIS B

Anna Pocurull Aparicio, ES

15:00 - 15:00 OP011
MANIPULATION OF A P75^{NTR}-POSITIVE HEPATIC STELLATE CELL SUBPOPULATION PROTECTS MICE FROM ACETAMINOPHEN-INDUCED LIVER INJURY

Laura J Kitto, GB

Abstract-based Session

15:00 - 16:00 Lehar 3
Burden of functional GI disorders
 Chairs: Lukas Van Oudenhove, BE
 Asma Fikree, GB

Q+A LIVE

15:00 - 15:12 OP012
SEXUAL DYSFUNCTION IN PATIENTS WITH GASTROENTEROLOGICAL DISORDERS: DO GASTROENTEROLOGISTS CARE ENOUGH?

Marco Romano, IT

15:12 - 15:24 OP013
HIGH-DIMENSIONAL CLUSTERING OF 4000 IRRITABLE BOWEL SYNDROME PATIENTS REVEALS SEVEN DISTINCT SUBSETS

Madhusudan Grover, US

15:24 - 15:36 OP014
DIRECT HEALTHCARE COSTS OF ROME IV OR ROME III-DEFINED IRRITABLE BOWEL SYNDROME IN THE UNITED KINGDOM

Vivek Chand Goodoory, GB

15:36 - 15:48 OP015
WORK PRODUCTIVITY AND ACTIVITY IMPAIRMENT IN SUBJECTS WITH DISORDERS OF GUT-BRAIN INTERACTION: DATA FROM THE ROME FOUNDATION GLOBAL EPIDEMIOLOGY STUDY

Åsa Frändemark, SE

15:48 - 16:00 OP016
BI-DIRECTIONAL GUT-BRAIN INTERACTIONS IN IRRITABLE BOWEL SYNDROME FROM ADOLESCENCE TO YOUNG ADULTHOOD- A SWEDISH BIRTH COHORT STUDY

Jessica Sjölund, SE

Abstract-based Session

15:00 - 16:00 Lehar 4
Gut microbiome as pathogenic and therapeutic player
 Chairs: Harry Sokol, FR
 Francesca Romana Ponziani, IT

Q+A LIVE

15:00 - 15:12 OP017
DONOR MICROBIAL ENGRAFTMENT AFTER FECAL MICROBIOTA TRANSPLANTATION: CHARACTERISTICS AND ASSOCIATION WITH CLINICAL RESPONSE ACROSS DIFFERENT DISORDERS

Serena Porcari, IT

15:12 - 15:24 OP018
GUT MICROBIOME COMPOSITION AND FUNCTION ARE LINKED TO THE DEVELOPMENT OF (PRE)CANCEROUS COLONIC LESIONS IN A PROSPECTIVE FOLLOW UP STUDY OF THE DUTCH MICROBIOME PROJECT

Ranko Gacesa, NL

15:24 - 15:36 OP019
LONG-TERM TYPE 1 DIABETES AND ITS COMPLICATIONS ARE ASSOCIATED TO CHANGES IN GUT MICROBIOTA

Ranko Gacesa, NL

15:36 - 15:48 OP020
THE GUT MICROBIOTA SHOWS CHARACTERISTICS OF INFLAMMATION AND CANCER PATHOGENESIS IN GENERAL POPULATION INDIVIDUALS WITH CLONAL HEMATOPOIESIS

Valerie Collij, NL

15:48 - 16:00 OP021
DIETARY INTAKE INFLUENCES THE RESPONSE TO CANCER IMMUNOTHERAPY

Laura A. Bolte, NL


Moderated Poster

15:00 - 16:00 Poster Stage 1
What's hot in hepatocellular carcinoma?
 Chairs: Najib Ben Khaled, DE

15:00 - 15:06 MP111
STUDY ON THE MECHANISM OF CHEMOKINE CCL21 MEDIATING IRBIT IN THE MALIGNANT BIOLOGICAL BEHAVIOR OF LIVER CANCER

15:06 - 15:12 MP113
ESTROGEN-INDUCED EPIGENETIC SILENCING OF CELL GROWTH-RELATED GENES INCREASES THE SENSITIZATION OF HEPATOCELLULAR CARCINOMA CELLS TOWARDS CHEMOTHERAPY-INDUCED CELL DEATH

Jibrán Sualeh Muhammad, AE

- 15:12 - 15:18 MP114
DYNAMICS OF LIVER STIFFNESS PREDICTS HEPATOCELLULAR CARCINOMA AND ASCITES IN PATIENTS WITH HEPATITIS C VIRUS RELATED CIRRHOSIS TREATED WITH DIRECT ACTING ANTIVIRALS
 Alberto Nicoletti, IT
- 15:18 - 15:24 MP115
CENTRAL HISTOPATHOLOGY REVIEW OF HEPATOCELLULAR CARCINOMA: IMPACT OF THE WHO 2019 CLASSIFICATION ON HISTOLOGICAL DIAGNOSIS AND TNM STAGING
 Konstantina Dimopoulou, GR
- 15:24 - 15:30 MP116
THE LONG TERM EFFICACY AND SAFETY OF PROTON BEAM THERAPY FOR HEPATOCELLULAR CARCINOMA
 Hajime Sunagozaka, JP
- 15:30 - 15:30 MP117
PORTAL HYPERTENSION ON PORTAL CAVERNOMA 
 Rhita Alaoui mdaghri, MA
- 15:30 - 15:36 MP118
TRANSARTERIAL CHEMOEMBOLIZATION: TEN YEARS OF EXPERIENCE IN A PORTUGUESE CENTER
 Raquel Ortigão, PT
- 15:36 - 15:42 MP119
PREDICTIVE VALUE OF AMAP HEPATOCELLULAR CARCINOMA RISK SCORE IN TUNISIAN PATIENTS WITH CHRONIC VIRAL HEPATITIS
 Myriam Ayari, TN
- 15:42 - 15:48 MP120
EFFICACY OF COMBINE DEXAMETHASONE AND N-ACETYLCYSTEINE FOR PREVENT POST-EMBOLIZATION SYNDROME AFTER TRANSARTERIAL CHEMOEMBOLIZATION IN HEPATOCELLULAR CARCINOMA (HCC)(CD-NAC PREVENT PES) A DOUBLE-BLIND, RANDOMIZED CONTROLLED TRIAL
 Nitipon Simasiangha, TH

Moderated Poster

15:00 – 16:00 Poster Stage 2
Biliopancreatic endoscopy I
 Chairs: Ivo Boskoski, IT
 Paraskevas Gkolfakis, BE

15:00 - 15:06 MP132
ENDOSCOPIC PAPILLECTOMY FOR AMPULLARY LESIONS IN PATIENTS WITH FAMILIAL ADENOMATOUS POLYPOSIS COMPARED TO SPORADIC LESIONS IN A PROPENSITY-SCORE MATCHED COHORT – A PANCREAS2000 / EUROPEAN PANCREATIC CLUB STUDY
 Marcus Hollenbach, DE

15:06 - 15:12 MP134
ENDOSCOPIC DILATION THERAPY PROLONGS TRANSPLANT-FREE SURVIVAL IN PATIENTS WITH SECONDARY SCLEROSING CHOLANGITIS
 Arne Kandulski, DE


15:12 - 15:18 MP135
PROPHYLAXIS WITH ANTIBIOTICS IN ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY FOR PRIMARY SCLEROSING CHOLANGITIS DOES NOT AFFECT POSTPROCEDURAL COMPLICATION RATES
 Arvid Gustafsson, SE

15:18 - 15:24 MP136
USEFULNESS OF DIRECT PERORAL CHOLANGIOSCOPY USING A MULTIBENDING ULTRASLIM ENDOSCOPE FOR THE MANAGEMENT OF INTRAHEPATIC BILE DUCT LESIONS
 Won Myung Lee, KR

15:24 - 15:30 MP137
EFFICACY AND SAFETY OF DIGITAL SINGLE-OPERATOR VIDEO CHOLANGIOSCOPY IN PATIENTS WITH PRIMARY SCLEROSING CHOLANGITIS
 Arne Bokemeyer, DE

15:30 - 15:36 MP138
MULTICENTRIC AND RETROSPECTIVE STUDY ON THE EFFICACY AND SAFETY OF BILIARY STENTS IN PATIENTS WITH NEOPLASTIC STENOSIS OF THE COMMON BILE DUCT (NEOSTENT)
 Cecilia Binda, IT

15:36 - 15:42 MP139
OUTCOMES OF MINOR VERSUS MAJOR PAPANICOLAOU FOR EUS-GUIDED PANCREATIC DUCT DRAINAGE
 Michiel Bronswijk, BE

15:42 - 15:48 MP140
COMPARISON OF ADVANCED ENDOSCOPIC RETROGRADE CHOLANGIO-PANCREATOGRAPHY TECHNIQUES IN PATIENTS WITH SURGICALLY ALTERED ANATOMY: A SYSTEMATIC REVIEW AND META-ANALYSIS 
 Apostolis Papaefthymiou, GR

Moderated Poster

15:00 – 16:00 Poster Stage 3
Epidemiology in GI disease
 Chairs: Rupa Banerjee, IN
 Fabiana Zingone, IT

15:00 - 15:06 MP101
LONG-TERM OUTCOMES OF VEDOLIZUMAB IN INFLAMMATORY BOWEL DISEASE - THE SWEDISH PROSPECTIVE MULTICENTRE SVEAH EXTENSION STUDY
 Isabella Visuri, SE

15:06 - 15:12 MP102
MORTALITY IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: RESULTS FROM A NORWEGIAN INCEPTION COHORT (THE IBSEN STUDY) AFTER 30 YEARS OF FOLLOW-UP

15:12 - 15:18 MP103
LONG-TERM EFFECT OF APPENDECTOMY ON CLOSTRIDIUM DIFFICILE INFECTION RISK: A POPULATION-BASED PROPENSITY SCORE ANALYSIS
 Ho Shing Louis Lau, HK

15:18 - 15:24 MP104
HEALTH-RELATED QUALITY OF LIFE IN A PEDIATRIC POPULATION AFFECTED BY INFLAMMATORY BOWEL DISEASE. A SEGHP MULTICENTER STUDY (SPANISH SOCIETY OF PEDIATRIC GASTROENTEROLOGY, HEPATOLOGY AND NUTRITION)
 Marta Velasco Rodríguez-Belvis, ES
 15:24 - 15:30 MP105
LONG-TERM TRENDS IN TARGETED THERAPIES USAGE IN INFLAMMATORY BOWEL DISEASE: TRENDY STUDY OF ENEIDA
 Celia Gomez Labrador, ES

15:30 - 15:36 MP106
LONG-TERM RESECTIVE AND PERIANAL SURGERY RATES IN CROHN'S DISEASE OVER DIFFERENT ERAS – A POPULATION-BASED STUDY FROM WESTERN HUNGARY BETWEEN 1977–2020, DATA FROM THE VESZPREM COUNTY COHORT
 Lorant Gonczi, HU

15:36 - 15:42 MP107
THE SOCIOECONOMIC IMPACT OF IRRITABLE BOWEL SYNDROME: AN ANALYSIS OF DIRECT AND INDIRECT HEALTHCARE COSTS IN THE NETHERLANDS
 Mhma Bosman, NL

15:42 - 15:48 MP108
FAVOURABLE FIRST YEAR REMISSION RATES AMONG PATIENTS WITH NEWLY DIAGNOSED CROHN'S DISEASE: DATA FROM A REAL-WORLD PROSPECTIVE INCEPTION COHORT
 Henit Yanai, IL

15:48 - 15:54 MP109
LONG TERM OUTCOMES IN OFFSPRING FROM MOTHERS WITH INFLAMMATORY BOWEL DISEASE: A NATIONWIDE POPULATION-BASED STUDY IN KOREA

15:54 - 16:00 MP110
PATTERNS OF CORTICOSTEROID EXPOSURE AND EXCESS IN INFLAMMATORY BOWEL DISEASE: RESULTS FROM THE DETERMINANTS, INCIDENCE AND CONSEQUENCES OF CORTICOSTEROID EXCESS (DICE) ONLINE MONITORING TOOL
 John Wye, GB

Moderated Poster

15:00 – 16:00 Poster Stage 4
Motility disorders
 Chairs: Daniel Sifrim, GB
 Roberta Maselli, IT

15:00 - 15:06 MP121
LONG-TERM OUTCOMES OF PER-ORAL ENDOSCOPIC MYOTOMY (POEM) IN CHILDREN WITH ACHALASIA: A SYSTEMATIC REVIEW AND META-ANALYSIS
 Zaheer Nabi, IN

15:06 - 15:12 MP122
ROLE OF THE STRAIGHT LEG RAISE MANEUVER IN IMPROVING THE DIAGNOSTIC YIELD OF HIGH-RESOLUTION MANOMETRY: A PROSPECTIVE MULTICENTER STUDY
 Stefano Siboni, IT

15:12 - 15:18 MP123
LONG-TERM RESULTS OF ENDOSCOPIC PYLOROMYOTOMY (G-POEM) IN THE TREATMENT OF REFRACTORY GASTROPARESIS: A SINGLE-CENTER EXPERIENCE
 Kristina Hugova, CZ

15:18 - 15:24 MP124
LONG-TERM EFFICACY AND GASTROESOPHAGEAL REFLUX DISEASE AFTER ESOPHAGEAL PERORAL ENDOSCOPIC MYOTOMY (POEM): A PROSPECTIVE STUDY WITH 5-YEAR OBJECTIVE FOLLOW-UP
 Edoardo Vespa, IT

15:24 - 15:30 MP125
NO INCREASE IN OESOPHAGEAL DYSMOTILITY OR HIATUS HERNIAS IN PATIENTS WITH HYPERMOBILITY SPECTRUM DISORDERS AND DYSPHAGIA COMPARED TO NON-HYPERMOBILE CONTROLS: A TWO-CENTRE CASE-CONTROL STUDY
 James Endersby, GB

15:30 - 15:36 MP126
A RANDOMIZED CLINICAL TRIAL ON THE EFFECT OF TWO WEEKS OF TREATMENT WITH CAPSAICIN IN OLDER PATIENTS WITH OROPHARYNGEAL DYSPHAGIA
 Noemí Tomsen, ES

15:36 - 15:42 MP127
LONG TERM COMPREHENSIVE ANALYSIS OF GASTROESOPHAGEAL REFLUX AFTER POEM
 Dagmar Drazilova, CZ

15:42 - 15:48 MP128
NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY METABOLOMICS INDICATE THAT KETOTIC-LIKE STATE IN PATIENTS WITH UNTREATED ACHALASIA REVERSES AFTER POEM
 Martin Ďuriček, SK

15:48 - 15:54 MP129
RANDOMISED CLINICAL TRIAL: COMPARISON OF TEGOPRAZAN AND LANSOPRAZOLE FOR THE MAINTENANCE THERAPY IN HEALED EROSIIVE ESOPHAGITIS
 Hyun Min Kim, KR

15:54 - 16:00 MP130
THE IMPACT OF CHICAGO CLASSIFICATION VERSION 4.0: REDEFINING FUNCTIONALLY-RELEVANT ESOPHAGO-GASTRIC JUNCTION OUTFLOW OBSTRUCTION
 Marcella Pesce, IT

Moderated Poster

15:00 – 16:00 Poster Stage 5
Education in GI
 Chairs: Minneke J. Coenraad, NL

15:00 - 15:06 MP141
EVALUATION OF A VIRTUAL REALITY BASED SOFTWARE FOR TEACHING MEDICAL STUDENTS ABOUT PANCREATIC CANCER

Alexander Hann, DE

15:06 - 15:12 MP142
MULTI-MODAL EVALUATION OF THE EAST MIDLANDS GI WEBINAR SERIES: A TRAINEE-LED INNOVATION BORN OUT OF ADVERSITY

Mohamed G. Shiha, GB

15:12 - 15:18 MP143
EDUCATION NEEDS IN DIAGNOSING RARE DISEASES IN GASTROENTEROLOGY/HEPATOLOGY PRACTICE: A CLINICIAN SURVEY

S Christy Rohani-Montez, GB

15:18 - 15:24 MP144
INFORMED CONSENT IN ENDOSCOPY: READ, UNDERSTOOD OR MERELY SIGNED?

Paula Sousa, PT

15:24 - 15:30 MP145
THE ERGONOMICS OF SOUTH EAST ASIAN WOMEN IN GASTROENTEROLOGY ENDOSCOPY, A TERTIARY CARE STUDY-PAKISTAN

Farhana Kayani, PK

15:30 - 15:36 MP146
ENDOFUTURE-STRATEGIES FROM CIVIL AVIATION FOR OPTIMIZED TEAMWORK AND COMMUNICATION IN INTERVENTIONAL ENDOSCOPY

Benjamin Walter, DE

15:36 - 15:42 MP147
EFFECT OF GRAPHICAL ABSTRACTS ON CITATIONS AND SOCIAL MEDIA EXPOSURE IN GASTROENTEROLOGY & HEPATOLOGY CATEGORY JOURNAL

Yohan Kim, KR

15:42 - 15:48 MP148
INTERPROFESSIONAL COLLABORATION BETWEEN PHYSICIANS, NURSES, AND PHARMACISTS IMPROVES MEDICAL AND ECONOMIC OUTCOMES IN AN INTENSIVE CARE UNIT WITH A FOCUS ON GASTROENTEROLOGY

Stephan Schmid, DE

15:48 - 15:54 MP149
SATISFACTION RATES OF PATIENTS TREATED ON THE INTERPROFESSIONAL TRAINING WARD REGENSBURG (A-STAR) ARE EXCELLENT – A PROSPECTIVE STUDY

Sophie Schlosser, DE

15:54 - 16:00 MP150
WHO WILL EXCEL IN ADVANCED ENDOSCOPY? A STUDY ASSESSING EXPERTS' CRITERIA AND PERCEPTIONS REGARDING THE SELECTION OF ERCP AND EUS TRAINEES

Sara Teles de Campos, PT

myUEG Community Programme

15:00 – 15:30 MyUEG Community Area
Connect with...#UEGWomeninGI Role Models
 Chairs: Shira Zelber-Sagi, IL

TV Studio Session

16:00 – 16:30 TV Studio

UEG Week: Digging deeper
 Chairs: Jonathan McCrea, IE
 Federico Cabitza, IT
 Cesare Hassan, IT
 Prateek Sharma, US

Q+A LIVE

Session

16:30 – 17:30 D3

Best of DDW
 Chairs: Helena Cortez-Pinto, PT
 John M. Carethers, US

Q+A LIVE

16:30 - 16:40 IP185

Clinical Guidelines
 Shahnaz Sultan, US

16:40 - 16:50 IP186

Precision Nutrition
 Andrew T. Chan, US

16:50 - 17:00 IP187

Upper GI Tract
 Rhonda Souza, US

17:00 - 17:10 IP188

GI Oncology
 John Inadomi, US

17:10 - 17:30
Panel discussion Best of DDW

Session

16:30 – 17:30 A1

Never waste a good disaster (Lower GI)
 Chairs: Alessandro Armuzzi, IT
 Willem A. Bemelman, NL

Q+A LIVE

16:30 - 16:35 IP189

What I regretted most in treatment of early rectal cancer

 Barbara A.J. Bastiaansen, NL

16:35 - 16:40 IP190

What I regretted most in treatment of early rectal cancer

 Antonino Spinelli, IT

16:40 - 16:50

Q&A

16:50 - 17:00 IP191

What I regretted most in IBD treatment
 Iris Dotan, IL

17:00 - 17:10

Q&A

17:10 - 17:15 IP193
What I regretted most in a patient with abdominal pain

Hans Törnblom, SE

17:15 - 17:20 IP194
What I regretted most in a patient with abdominal pain

Sanne ME Engelen, NL

17:20 - 17:30
Q&A

Session

16:30 - 17:30 A2
What's new in 2022? IBD
 Chairs: Matthieu Allez, FR
 Joana Torres, PT

Q+A LIVE

16:30 - 16:50 IP195
Upcoming next best therapeutic option for IBD
 Tim Raine, GB

16:50 - 17:10 IP196
AI in ulcerative colitis
 Raf Bisschops, BE

17:10 - 17:30 IP197
Personalised therapy of IBD: Already clinical practice?
 Britta Siegmund, DE

Session

16:30 - 17:30 A3
Crash Course: When to do EUS and EUS-FNA in pancreatic lesions
 Chairs: Livia Archibugi, IT
 Albrecht Neesse, DE

Q+A LIVE

16:30 - 16:40 IP198
When does EUS help to guide decision making?
 Marianna Arvanitakis, BE

16:40 - 16:50 IP199
What would prevent up-front surgery?
 Güralp Onur Ceyhan, DE

16:50 - 17:00 IP200
EUS-FNA/FNB: ROSE, MOSE, needle type - what matters most?
 Marianna Signoretti, IT

17:00 - 17:30
Panel Discussion

Session

16:30 - 17:30 C1
Emerging perspectives in non-alcoholic fatty liver disease (NAFLD/NASH)
 Chairs: Salvatore Petta, IT
 Jessica Zucman-Rossi, FR

Q+A LIVE

16:30 - 16:50 IP201
Identification of at risk patients and referral: Models of care
 Emmanuel Tsochatzis, GB

16:50 - 17:10 IP202
Defining the right patient for pharmacotherapy
 Sven Francque, BE

17:10 - 17:30 IP203
Complications in end-stage NAFLD
 Jörn Schattenberg, DE

Session

16:30 - 17:30 C2
Nutrition and HPB
 Chairs: Johanna Laukkarinen, FI
 Ewa Malecka-Wojcieszko, PL

Q+A LIVE

16:30 - 16:50 IP204
Does nutrition improve long-term outcome in chronic pancreatitis?
 Juan Enrique Dominguez-Munoz, ES

16:50 - 17:10 IP205
Rising Star: Recent advances in the diagnosis and management of early alcohol-related liver disease: And where to go next?
 Maja Thiele, DK

17:10 - 17:30 IP206
Assessment and management of the nutritional status in cirrhosis.
 Shira Zelber-Sagi, IL

Abstract-based Session

16:30 - 17:30 D4
Detection and characterisation of colorectal neoplasia
 Chairs: James Edward East, GB
 Marcus Hollenbach, DE

Q+A LIVE

16:30 - 16:42 OP022
REAL-WORLD EFFECTIVENESS AND SAFETY OF THE 1L POLYETHYLENE GLYCOL + ASCORBIC ACID BOWEL PREPARATION FOR COLONOSCOPY IN THE LARGEST TO DATE RETROSPECTIVE, MULTI-CENTRE, OBSERVATIONAL STUDY
 Jose Miguel Esteban López-Jamar, ES

16:42 - 16:54 OP023
OPTICAL DIAGNOSIS OF POLYPS & LT;10MM AND IMPACT ON SURVEILLANCE INTERVAL (DISCARD3)

Ahmir Ahmad, GB

16:54 - 17:06 OP024
INTRODUCTION AND PRELIMINARY CLINICAL EVALUATION OF NOVEL ENDOSCOPE WITH PINPOINT LASER TECHNOLOGY FOR ADEQUATE SIZE ESTIMATION OF COLON LESIONS

Helmut Neumann, DE

17:06 - 17:18 OP025
LINKED-COLOR IMAGING IMPROVES ADENOMA AND SERRATED LESION DETECTION VERSUS WHITE-LIGHT IMAGING ON SCREENING AND SURVEILLANCE COLONOSCOPY (ATLAS TRIAL): AN INTERNATIONAL, PARALLEL RANDOMIZED CONTROLLED TRIAL

Yen-Nien Chen, TW

17:18 - 17:30 OP026
USEFULNESS OF MAGNIFYING ENDOSCOPY AND ENDOCYTOSCOPY IN THE OBSERVATION OF DEPRESSED TYPE COLORECTAL CANCERS

Shinei Kudo, JP

Session

16:30 - 17:30 Strauss 2
Gastroparesis: All the aces up my sleeve!
 Chairs: Maura Corsetti, GB
 Chloé Melchior, FR

Q+A LIVE

16:30 - 16:50 IP207
Diet: A way out of gastroparesis
 Stine Störsrud, SE

16:50 - 17:10 IP208
Drugs: What really works in gastroparesis
 Vincenzo Stanghellini, IT

17:10 - 17:30 IP209
GPOEM: Ready for prime time?
 Jan Martinek, CZ

Session

16:30 - 17:30 Strauss 3
Where basic scientists meet clinicians: Are drugs friends or enemies?
 Chairs: Juozas Kupcinskas, LT
 Magnus Simrén, SE

Q+A LIVE

16:30 - 16:40 IP210
Pathogenesis of side-effects of PPI
 Annemieke Smet, BE

16:40 - 16:50 IP211
Clinical impact of PPI toxicity in daily routine
 Christian Schulz, DE

16:50 - 17:00
Q&A

17:00 - 17:10 IP212
Peripheral mechanism of action of neuromodulators in FD

Lukas Van Oudenhove, BE

17:10 - 17:20 IP213
Clinical use of neuromodulators in FD

Lin Chang, US

17:20 - 17:30
Q&A

Abstract-based Session

16:30 - 17:30 Lehar 2
Imaging and monitoring in GI disease
 Chairs: Monika Ferlitsch, AT
 Giulio Antonelli, IT

Q+A LIVE

16:30 - 16:42 OP027
EARLY REDUCTION OF BOWEL WALL THICKNESS BY TRANSPERINEAL ULTRASONOGRAPHY PREDICTS BIOLOGICS-INDUCED DEEP REMISSION IN ULCERATIVE COLITIS
 Shintaro Sagami, JP

16:42 - 16:54 OP028
DEVELOPMENT AND VALIDATION OF A DEDICATED SCORE TO ASSESS TRANSMURAL RESPONSE AND TRANSMURAL HEALING IN PATIENTS WITH CROHN'S DISEASE
 Anthony Buisson, FR

16:54 - 17:06 OP029
INTESTINAL ULTRASOUND AT IBD DIAGNOSIS PREDICTS MAJOR DISEASE EVENTS – A COPENHAGEN IBD COHORT STUDY
 Gorm Madsen, DK

17:06 - 17:18 OP030
EUS-GUIDED FINE-NEEDLE BIOPSY OF SOLID LESIONS WITH OR WITHOUT MACROSCOPIC ON-SITE EVALUATION (MOSE): A RANDOMIZED CONTROLLED TRIAL
 Benedetto Pio Mangiavillano, IT

17:18 - 17:30 OP031
SAFETY AND EFFICACY OF ENDOSCOPIC ULTRASOUND-GUIDED RADIOFREQUENCY ABLATION FOR PANCREATIC NEOPLASMS – A 2-YEAR RETROSPECTIVE FRENCH MULTICENTER STUDY
 Bertrand Napoléon, FR


Abstract-based Session

16:30 - 17:30 Lehar 3
Update in coeliac disease
 Chairs: Detlef Schuppan, DE
 Nick Trott, GB

Q+A LIVE

16:30 - 16:42 OP032
EARLY DIAGNOSIS OF COELIAC DISEASE BY CASE-FINDING AT THE PREVENTIVE YOUTH HEALTH CARE CENTRES IN THE NETHERLANDS (GLUTENSREEN)

16:42 - 16:54 OP033
THE EFFECT OF A GLUTEN FREE DIET ON FATIGUE IN CELIAC DISEASE – A PROSPECTIVE CONTROLLED STUDY
 Berit Mære Skjellerudsveen, NO

16:54 - 17:06 OP034
'TO BLOCK' OR 'NOT TO BLOCK': THE QUESTION OF ANGIOTENSIN RECEPTOR BLOCKER (ARBs) DISCONTINUATION IN COELIAC DISEASE 
 Eileen Shannon, IE

17:06 - 17:18 OP035
NO ADDED BENEFIT OF VITAMIN-D SUPPLEMENTATION OVER AND ABOVE GLUTEN-FREE DIET IN NEWLY DIAGNOSED CELIAC DISEASE PATIENTS WITH BASELINE VITAMIN-D DEFICIENCY: A RANDOMIZED CONTROLLED TRIAL
 Jahnvi Dhar, IN

17:18 - 17:30 OP036
LATIGLUTENASE – AN EFFECTIVE ORAL THERAPY IN DEVELOPMENT FOR THE TREATMENT OF CELIAC DISEASE: EXPLORING THE BENEFITS AND CHALLENGES OF ADMINISTERING AND MEASURING GLUTEN IN A CLINICAL TRIAL SETTING
 Jennifer Sealey Voyksner, US

Abstract-based Session

16:30 – 17:30 Lehar 4
Mechanisms of inflammation
 Chairs: Bram Verstockt, BE
 Loris Riccardo Lopetuso, IT

Q+A  LIVE

16:30 - 16:42 OP037
ROLE OF P2X7 RECEPTOR IN INTESTINAL FIBROSIS OF CROHN'S DISEASE PATIENTS
 Lluís Lis-López, ES

16:42 - 16:54 OP038
TRYPTOPHAN METABOLITE CHANGES WITH DIET-INDUCED REMISSION IN PEDIATRIC CROHN'S DISEASE
 Mohammed Ghiboub, NL

16:54 - 17:06 OP039
MICROBIAL SIGNALS AND HOST SENSING CONTROL METABOLIC INJURY IN THE INTESTINAL EPITHELIUM
 Doriane Aguanno, DE

17:06 - 17:18 OP040
CIRCULATING INFLAMMATORY PROTEIN AND CELLULAR PROFILES AT TIME OF DIAGNOSIS CLASSIFY INFLAMMATORY BOWEL DISEASE PATIENTS ACCORDING TO THEIR UNDERLYING IMMUNE RESPONSE AND CLINICAL DISEASE COURSE
 Maud Heredia, NL

17:18 - 17:30 OP041
HLA-DR⁺CD38⁺ EFFECTOR T HELPER CELLS DISTINGUISH CROHN'S DISEASE-ASSOCIATED PERIANAL FISTULAS FROM CRYPTOGLANDULAR FISTULAS

Laura F. Ouboter, NL

Moderated Poster

16:30 – 17:30 Poster Stage 1
Cirrhosis and transplantation
 Chairs: Ahad Eshraghian, IR

16:30 - 16:36 MP161
THROMBOELASTOGRAPHIC EVALUATION OF FACTORS AFFECTING COAGULATION STATUS OF CHILDREN WITH DECOMPENSATED CHRONIC LIVER DISEASE AND SEPSIS
 Vignesh Vinayagamoorthy, IN

16:36 - 16:42 MP162
PREVALENCE AND FACTORS ASSOCIATED WITH MINIMAL HEPATIC ENCEPHALOPATHY
 Ameny Neji, TN

16:42 - 16:48 MP163
THE ALPHA-1 ANTITRYPSIN PI*Z ALLELE INDEPENDENTLY PREDICTS LIVER TRANSPLANTATION/DEATH IN ACLD PATIENTS
 Lorenz Balcar, AT

16:48 - 16:54 MP164
COMPARISON OF INPATIENT OUTCOMES IN PATIENTS WITH HEPATITIS B, HEPATITIS C, AND HEPATITIS B AND C CO-INFECTION IN PATIENTS WITH LIVER CIRRHOSIS
 Rahul Pamarthy, US

16:54 - 17:00 MP165
PROTOCOL LIVER BIOPSY AFTER LIVER TRANSPLANTATION – IMPACT ON GRAFT SURVIVAL
 Ville Liukkonen, FI

17:00 - 17:06 MP166
CARVEDILOL INDUCES HIGHER HVPG RESPONSE RATES AND IS ASSOCIATED WITH LOWER RATES OF VARICEAL REBLEEDING THAN PROPRANOLOL IN SECONDARY PROPHYLAXIS OF PORTAL HYPERTENSION - A RETROSPECTIVE COHORT STUDY
 Mathias Jachs, AT

17:06 - 17:12 MP167
THE P53 FAMILY OF PROTEINS IN BACTERIAL DEFENSE – A NOVEL PATHOMECHANISM OF SPONTANEOUS PERITONEAL PERITONITIS
 Carina Steindl, DE

17:12 - 17:18 MP168
CLINICAL AND PROGNOSTIC CHARACTERIZATION OF THE PATTERNS OF DECOMPENSATION OF LIVER CIRRHOSIS
 Valeria Calvino, IT

Moderated Poster

16:30 – 17:30 Poster Stage 2
Small bowel and imaging
 Chairs: Cristiano Spada, IT
 Abraham (Rami) Eliakim, IL

16:30 - 16:36 MP181
**DIAGNOSTIC YIELD AND THERAPEUTIC SUCCESS IN
 MOTORIZED SPIRAL ENTEROSCOPY VS DOUBLE-BALLOON
 ENTEROSCOPY – A PROPENSITY SCORE MATCHING
 ANALYSIS**

Kim Wei Lim, SG

16:36 - 16:42 MP182
**MANAGING FDG-PET/CTINCIDENTAL UPTAKE IN
 GASTROINTESTINAL TRACT: IS IT WORTH TO
 INVESTIGATE?**

Luís Correia Gomes, PT

16:42 - 16:48 MP183
**ULCERATION IS AN INDEPENDENT RISK FACTOR FOR
 RESTENOSIS AFTER ENDOSCOPIC BALLOON DILATION
 FOR CROHN’S DISEASE-RELATED SMALL BOWEL
 STRICTURES**

Ulzii Dashnyam, JP

16:48 - 16:54 MP184
**DO FAECAL AND SERUM BIOMARKERS PREDICT SMALL
 BOWEL CROHN’S DISEASE ON CAPSULE ENDOSCOPY?**

Mohamed G. Shiha, GB

16:54 - 17:00 MP185
**ORALLY ADMINISTERED PEPPERMINT OIL SOLUTION AS
 AN AID TO PREVENT DELAYED GASTRIC EMPTYING IN
 CAPSULE ENDOSCOPY**

Fintan O'Hara, IE

17:00 - 17:06 MP186
**DEEP LEARNING AND DEVICE-ASSISTED ENTEROSCOPY:
 AUTOMATIC DETECTION OF PLEOMORPHIC
 GASTROINTESTINAL LESIONS IN DEVICE-ASSISTED
 ENTEROSCOPY USING CONVOLUTIONAL NEURAL
 NETWORKS**

Miguel Jose Mascarenhas Saraiva, PT

17:06 - 17:12 MP187
**AUTOMATIC DETECTION OF SMALL BOWEL PROTRUDING
 LESION IN DOUBLE-BALLOON ENTEROSCOPY USING A
 CONVOLUTIONAL NEURAL NETWORK: A PROOF-OF-
 CONCEPT STUDY**

Tiago Ribeiro, PT

17:12 - 17:18 MP188
**ENHANCED BETA CELL FUNCTION AND IMPROVED
 INSULIN SENSITIVITY AFTER REVITA® DMR IN PATIENTS
 WITH T2D**

Celine B. E. Busch, NL

17:18 - 17:24 MP190
**THE THICKNESS OF GASTROINTESTINAL WALL LAYERS
 MEASURED WITH ULTRASONOGRAPHY PREDICTS
 CLINICAL ENDPOINTS IN CROHN’S DISEASE**

Kim Nylund, NO

16:30 - 16:36 MP151
**PROTECTIVE EFFECTS OF SACCHAROMYCES BOULARDII
 CNCM I-745 IN AN EXPERIMENTAL MODEL OF NSAID-
 INDUCED ENTEROPATHY**

Emmanuelle Simon O'brien, FR

16:36 - 16:42 MP152
**EFFECTS OF SACCHAROMYCES BOULARDII CNCM I-745 ON
 GUT DYSBIOSIS AND ALTERED EPITHELIAL BARRIER
 INTEGRITY IN A MURINE MODEL OF NONSTEROIDAL ANTI-
 INFLAMMATORY DRUG-INDUCED ENTEROPATHY**

Matteo Fornai, IT

16:42 - 16:48 MP154
**EFFECT OF OLD AGE ON THE SUBPOPULATIONS OF
 ENTERIC GLIAL CELLS IN HUMAN DESCENDING COLON**

Nicholas Baidoo, GB

16:48 - 16:54 MP155
**HIGH INTESTINAL SECRETORY LEUKOCYTE PROTEASE
 INHIBITOR EXPRESSION CORRELATES WITH ABUNDANT
 NEUTROPHILIC INFLAMMATION AND IDENTIFIES
 INFLAMMATORY BOWEL DISEASE PATIENTS WITH A
 STRONG IL-17 RESPONSE**

Beatriz Calado, NL

16:54 - 17:00 MP156
**SEROLOGICAL BIOMARKERS OF TYPE I, III, AND IV
 COLLAGEN TURNOVER ARE ASSOCIATED WITH THE
 PRESENCE AND FUTURE PROGRESSION OF STRICTURING
 AND PENETRATING CROHN'S DISEASE**

Arno R. Bourgonje, NL

17:00 - 17:06 MP157
EOSINOPHILS IN COLONIC DIVERTICULAR DISEASE

Nicholas J. Talley, AU

17:06 - 17:12 MP158
**UNDERSTANDING THE IMPACT OF PREVIOUS TNF-A
 INHIBITORS ON VEDOLIZUMAB RESPONSE IN PATIENTS
 WITH ULCERATIVE COLITIS AND CROHN’S DISEASE USING
 SYSTEMATIC REVIEW AND GENE EXPRESSION DATA**

Bernat Regí, ES

17:12 - 17:18 MP159
**EPITHELIAL CGAS/STING GUIDES DNA DAMAGE-DRIVEN
 STEM CELL FUNCTION AND PROTECTS FROM INTESTINAL
 CARCINOGENESIS**

Hang Xiang, DE

17:18 - 17:24 MP160
**TRANSFORMING GROWTH FACTOR BETA SIGNALING IN
 CANCER-ASSOCIATED FIBROBLASTS DRIVES A HEPATIC,
 GP130 DEPENDENT PRO-METASTATIC INFLAMMATORY
 PROGRAM IN CMS4 TYPE COLORECTAL CANCER**

Lukas Hawinkels, NL

Moderated Poster

16:30 – 17:30 Poster Stage 3
Mechanisms in lower GI disease I
 Chairs: Florian Rieder, US
 Mathieu Uzzan, FR

Moderated Poster

16:30 – 17:30 Poster Stage 4
H. pylori
 Chairs: Theodore Rokkas, GR
 Gianluca Ianari, IT

16:30 - 16:36 MP171
EFFECTIVENESS OF COMBINED APPLICATION OF NON-CYTOTOXIC SILVER AND COPPER NANOPARTICLES WITH LOW-FREQUENCY ULTRASOUND AGAINST *HELICOBACTER PYLORI*

Petro Myronov, UA

16:36 - 16:42 MP174
REAL-TIME ASSESSMENT OF *H. PYLORI* GASTRITIS GUIDED BY ENDOFASTER: A PROSPECTIVE COHORT STUDY
 Riccardo Vasapolli, DE

16:42 - 16:48 MP175
THE NOTCH PATHWAY TRANSCRIPTION FACTOR HES1 REGULATES EXPRESSION OF THE PRO-INFLAMMATORY CYTOKINE IL-8 DURING *H. PYLORI* INFECTION
 Rebecca FitzGerald, IE

16:48 - 16:54 MP176
TIME COURSE OF ANTI-PARIETAL CELL ANTIBODIES IN AUTOIMMUNE ATROPHIC GASTRITIS: A PROSPECTIVE STUDY
 Laura Conti, IT

16:54 - 17:00 MP177
THE ROLE OF DOPEY1 IN THE PATHOGENESIS OF HELICOBACTER PYLORI INFECTION

17:00 - 17:06 MP179
EFFECT OF PROBIOTICS ON GASTROINTESTINAL MICROBIOTA AFTER HELICOBACTER PYLORI ERADICATION: A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL

17:06 - 17:12 MP180
INCREASED INCIDENCE OF GASTROINTESTINAL MALIGNANCIES AFTER ERADICATION THERAPY FOR *HELICOBACTER PYLORI*
 Anna Nieminen, FI

Moderated Poster

16:30 - 17:30 Poster Stage 5
Endoscopy and GI surgery
 Chairs: Mahdi Al-Taher, NL

16:30 - 16:36 MP191
SEGMENTAL VS TOTAL COLECTOMY FOR CROHN'S DISEASE OF THE COLON IN THE BIOLOGIC ERA. RESULTS FROM THE SCOTCH INTERNATIONAL, MULTICENTRIC STUDY
 Gianluca Pellino, IT

16:36 - 16:42 MP192
ENDOSCOPIC GASTROPLASTY: TECHNICAL ASPECTS OF THREE DIFFERENT TECHNIQUES FROM A PROSPECTIVE, SINGLE CENTER, RANDOMIZED OBSERVATIONAL STUDY
 Salvatore Francesco Vadalà di Prampero, IT

16:42 - 16:48 MP193
COMPARISON BETWEEN ROBOT ASSISTED ESOPHAGECTOMY AND THORACOSCOPIC ESOPHAGECTOMY
 Yusuke Taniyama, JP

16:48 - 16:54 MP194
MOTORIZED SPIRAL ENTEROSCOPY IN PATIENTS WITH PRIOR ABDOMINAL SURGERY: A PROSPECTIVE MULTICENTER OBSERVATIONAL STUDY

Antonio Giordano, ES

16:54 - 17:00 MP195
DISEASE COURSE AND TREATMENT OUTCOMES OF CROHN'S DISEASE PATIENTS WITH EARLY OR LATE SURGERY: A DANISH NATIONWIDE COHORT STUDY FROM 1997 TO 2015
 Melek-Zahra Sarikaya, DK

17:00 - 17:06 MP197
THE ROLE OF RECTAL EUS-FNA AND FNB IN PERIRECTAL UNDEFINED LESIONS IN PATIENTS WITH A HISTORY OF RECTAL AND PERIRECTAL NEOPLASIA
 Danilo Paduano, IT

17:06 - 17:12 MP198
EVALUATION OF THE IDENTIFICATION FOR GASTRIC CANCER BY NEAR-INFRARED HYPERSPECTRAL IMAGING
 Tomohiro Mitsui, JP

17:12 - 17:18 MP199
UTILITY AND LONG-TERM PROGNOSIS OF ENDOSCOPIC BALLOON DILATION IN PATIENTS WITH CROHN'S DISEASE AND 5 OR MORE SMALL INTESTINAL STRICTURES
 Jun Owada, JP

17:18 - 17:24 MP200
INFECTED CHRONIC ANAL FISSURES: TECHNICAL PARTICULARITIES AND EFFECTIVENESS OF SURGICAL TREATMENT
 Jihane Benass, MA

Opening Session

18:00 - 19:30 D3
Opening Session Part II
 Chairs: Helena Cortez-Pinto, PT
 Julia Mayerle, DE

Q+A LIVE

18:00 - 18:12 OP042
LONGITUDINAL CHANGES IN THE GUT MICROBIOME IN RESPONSE TO IMMUNE CHECKPOINT BLOCKADE
 Johannes R. Björk, NL

18:12 - 18:24 OP043
A RANDOMIZED CONTROLLED PHASE 3 TRIAL COMPARING ORAL PREDNISOLONE ADMINISTRATION AND LOCAL TRIAMCINOLONE INJECTION THERAPY FOR THE PREVENTION OF ESOPHAGEAL STRICTURE AFTER ENDOSCOPIC SUBMUCOSAL DISSECTION, JCOG1217
 Masaki Tanaka, JP

18:24 - 18:44 IP214
Propofol sedation for GI-procedures: Who should get it, who should give it?
 Eva Rivas, ES
 Paul Fockens, NL

18:44 - 18:51 IP215
Presidential address
 Helena Cortez-Pinto, PT
 18:51 - 19:03 OP044
HELICOBACTER PYLORI ERADICATION ASPIRIN TRIAL (HEAT): PRIMARY PREVENTION OF UPPER GASTROINTESTINAL ULCER BLEEDING EVALUATED IN A LARGE SCALE TRIAL IN UK PRIMARY CARE
 Christopher John Hawkey, GB

19:03 - 19:08 IP216
Laudation UEG Lifetime Achievement Awardee
 Patrizia Burra, IT

19:08 - 19:13
UEG Lifetime Achievement Award
 Michael Manns, DE

19:13 - 19:25 OP045
SYNERGIC CROSSTALK BETWEEN INTRATUMORAL NERVES AND MYELOID DERIVED SUPPRESSOR CELLS IN PANCREATIC CANCER VIA NEURONAL-DERIVED EXPRESSION OF CXCL8
 Carmen Mota Reyes, DE

Late Breaking Abstracts

18:00 - 19:00 A1
Late Breaking abstracts I
 Chairs: Sven Francque, BE
 Jonas Rosendahl, DE

Q+A LIVE

18:00 - 18:12 LB01
VONOPRAZAN VS. PANTOPRAZOLE IN PREVENTION OF POST ENDOSCOPIC VARICEAL LIGATION ULCER/BLEEDING IN PORTAL HYPERTENSION: A RANDOMIZED CONTROLLED TRIAL
 Sameh A. Lashen, EG

18:12 - 18:24 LB02
PROCTOCOLECTOMY WITH PERMANENT ILEOSTOMY IS ASSOCIATED WITH BETTER TRANSPLANT-FREE SURVIVAL IN PATIENTS WITH PRIMARY SCLEROSING CHOLANGITIS: A RETROSPECTIVE COHORT STUDY
 Bregje Mol, NL

18:24 - 18:36 LB03
LONG-TERM OUTCOME OF THE POINTER RANDOMIZED TRIAL ON IMMEDIATE VERSUS POSTPONED INTERVENTION FOR INFECTED NECROTIZING PANCREATITIS
 Noor Sissingh, NL

18:36 - 18:48 LB04
A PROCALCITONIN-BASED ALGORITHM TO GUIDE ANTIBIOTIC USE IN PATIENTS WITH ACUTE PANCREATITIS: THE FINAL RESULTS OF THE PROCAP RANDOMISED CONTROLLED TRIAL
 Ajith Siriwardena, GB

18:48 - 19:00 LB05
PORTAL HYPERTENSION SECONDARY TO CIRRHOSIS IS ASSOCIATED WITH POOR PROGNOSIS, IRRESPECTIVE OF AGE AND AETIOLOGICAL DIFFERENCES- A LARGE EPIDEMIOLOGICAL STUDY
 Philip Ambery, SE

Session

18:00 - 19:00 A2
IBD therapy: Lessons from paediatric patients and real world data
 Chairs: Hankje Escher, NL
 Joana Torres, PT

Q+A LIVE

18:00 - 18:20 IP217
Effective use of dietary therapy in IBD care
 Richard K Russell, GB

18:20 - 18:25 IP218
Timing of biological initiation: Lessons learned from paediatric IBD cohorts
 Lissy de Ridder, NL

18:25 - 18:30 IP219
Timing of biological initiation: Lessons learned from adult IBD cohorts
 Tim Raine, GB

18:30 - 18:40
Q&A

18:40 - 19:00 IP220
Rising Star: Risk and benefit of treatment in IBD: From real world data to robust real world evidence
 Julien Kirchgesner, FR

Expert Encore

18:00 - 19:30 A3
Pancreatic mass
 Chairs: Marianna Signoretti, IT
 Jean-Luc Van Laethem, BE

Q+A LIVE

18:00 - 18:20 IP221
The role of imaging to determine etiology to stage a pancreatic mass
 Wolfgang Schima, AT

18:20 - 18:27 IP222
Borderline resectable pancreatic cancer: No time for neoadjuvant treatment (surgical view)
 Elena Rangelova, SE

18:27 - 18:34 IP223
Borderline resectable pancreatic cancer: Prime time for neoadjuvant treatment (oncologist view)
 Georg Beyer, DE

18:34 - 18:40
Q&A

18:40 - 19:00 IP224
Precision oncology in pancreatic cancer
 Hana Algül, DE
 19:00 - 19:30
Panel Discussion Pancreatic mass

Expert Encore
 18:00 - 19:30 C1
Challenges in small bowel-GI bleeding
 Chairs: Edward J Despott, GB
 Monika Ferlitsch, AT

Q+A LIVE

18:00 - 18:20 IP225
Diagnosis and localisation of the bleeding
 Cristina Carretero, ES

18:20 - 18:40 IP226
Medical treatment and outcome: Are we always successful?
 Cristiano Spada, IT

18:40 - 19:00 IP227
Endoscopy, radiology or surgery for treatment: What's the ideal combination?
 Marianna Arvanitakis, BE

19:00 - 19:30
Panel Discussion Challenges in small bowel-GI bleeding

Session
 18:00 - 19:00 D4
Endoscopy and pathology: What's new in 2022?
 Chairs: Mario Dinis-Ribeiro, PT
 Peter Malfertheiner, DE

Q+A LIVE

18:00 - 18:20 IP228
Polyps of the upper GI tract: Always neoplastic?
 Roger M. Feakins, GB

18:20 - 18:40 IP229
Precancerous conditions of the stomach
 Alexander Link, DE

18:40 - 19:00 IP230
Drug induced damage in the upper GI tract
 Ann Driessen, BE

Abstract-based Session
 18:00 - 19:00 Strauss 2
Current trends in H. pylori diagnostics
 Chairs: Francis Mégraud, FR
 Mohamed Alborai, EG

Q+A LIVE

18:00 - 18:12 OP046
ISSUES OF HERPESVIRUS LESIONS IN PATIENTS WITH HELICOBACTER PYLORI
 Gulustan Babayeva, AZ

18:12 - 18:24 OP047
HELICOBACTER PYLORI INFECTION INDUCES FERROPTOSIS IN GASTRIC EPITHELIAL CELLS

18:24 - 18:36 OP049
EMPIRICAL FIRST-LINE TREATMENT USE AND EFFECTIVENESS TRENDS IN EUROPE IN THE PERIOD 2013-2021: RESULTS FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)
 Olga Perez Nyssen, ES

18:36 - 18:48 OP050
HELICOBACTER PYLORIDIAGNOSTIC TESTS USED IN 35,000 PATIENTS IN EUROPE: RESULTS FROM THE EUROPEAN REGISTRY ON H. PYLORIMANAGEMENT (HP-EUREG)
 Laimas Virginijus Jonaitis, LT

Expert Encore
 18:00 - 19:30 Strauss 3
Personalised medicine for oesophageal neoplasia
 Chairs: Raf Bisschops, BE
 Prateek Sharma, US

Q+A LIVE

18:00 - 18:20 IP231
Tailoring cancer risk in oesophageal cancer
 Sheila Krishnadath, BE

18:20 - 18:40 IP232
Tailored treatment for Barrett's oesophagus
 Alessandro Repici, IT

18:40 - 19:00 IP233
Medical therapy for locally advanced cancer
 Tamara Matysiak-Budnik, FR

19:00 - 19:30
Panel Discussion Personalised medicine for oesophageal neoplasia


Abstract-based Session
 18:00 - 19:00 Lehar 2
Diagnosis and treatment of functional lower GI disease
 Chairs: Vincenzo Stanghellini, IT
 Chloé Melchior, FR

Q+A LIVE

18:00 - 18:12 OP051
SMALL BOWEL DYSMOTILITY: DIAGNOSTIC POWER OF HIGH RESOLUTION MANOMETRY
 Luis Alcalá, ES

18:12 - 18:24 OP052
SYMPTOMS AND RESPONSE TO MRI ASSESSED DISTENSION FOLLOWING MACROGOL STIMULATION IN FUNCTIONAL CONSTIPATION AND IRRITABLE BOWEL SYNDROME WITH CONSTIPATION, FOLLOWED BY A RANDOMISED, PLACEBO-CONTROLLED TRIAL OF STIMULATION VS RELAXATION
 Victoria Wilkinson-Smith, GB

18:24 - 18:36 OP054
EXPLORING THE EFFECT OF STW 5-II TO TREAT VISCERAL HYPERSENSITIVITY USING RAT MODELS
 Ramy Ammar, DE

18:36 - 18:48 OP055
FACTOR ANALYSIS CONFIRMS VALIDITY OF ROME IV CRITERIA FOR MAJOR DISORDERS OF GUT-BRAIN INTERACTION (DGBI) GLOBALLY ACROSS GEOGRAPHICAL REGIONS, AND BY SEX AND AGE GROUPS 
 Jóhann Hreinsson, SE


Abstract-based Session

18:00 – 19:00 Lehar 3
Quality in endoscopy screening
 Chairs: Zohar Levi, IL
 Shimaa Afify, EG

Q+A  LIVE

18:00 - 18:12 OP056
ENDOSCOPIC DETECTION OF CANCER WITHIN COLORECTAL POLYPS BY YOUNG GI ENDOSCOPISTS: A PRE- AND POST-INTERVENTION ANALYSIS OF 680 INDIVIDUAL RESPONSES
 Pieter Jan Poortmans, BE

18:12 - 18:24 OP057
SAFETY INCIDENTS IN ENDOSCOPY: A HUMAN FACTORS ANALYSIS
 Manmeet Kaur Matharoo, GB

18:24 - 18:36 OP058
IMPACT OF ENDOSCOPIST ANNUAL PROCEDURE NUMBERS AND WITHDRAWAL TIME ON COLONOSCOPY QUALITY: ANALYSIS OF DATA FROM THE UK NATIONAL ENDOSCOPY DATABASE (NED) 
 David Beaton, GB

18:36 - 18:48 OP059
DEVELOPMENT OF ILEAL ADENOMAS AFTER ILEAL POUCH-ANAL ANASTOMOSIS VERSUS END ILEOSTOMY IN PATIENTS WITH FAMILIAL ADENOMATOUS POLYPOSIS
 Arthur S. Aelvoet, NL

18:48 - 19:00 OP060
STANDARDIZING THE POSITIVE PREDICTIVE VALUE IN A FIT-BASED COLORECTAL CANCER SCREENING PROGRAM
 Esther Toes-Zoutendijk, NL

Abstract-based Session

18:00 – 19:00 Lehar 4
New insights in IBD
 Chairs: Carolina Ciacci, IT
 Laura Alexandra Lucaciu, RO

Q+A  LIVE

18:00 - 18:12 OP062
EARLY RESTORATION OF TRYPTOPHAN DEGRADATION IS ASSOCIATED WITH THERAPY RESPONSE IN ULCERATIVE COLITIS AND DEPENDS ON JAK-STAT SIGNALING
 Na-mi Kim, DE

18:12 - 18:24 OP063
SZN-1326, A WNT MIMETIC, IMPROVED EPITHELIAL HEALING AND DECREASED COLLAGEN DEPOSITION IN A DEXTRAN SULFATE SODIUM-INDUCED COLITIS MOUSE MODEL

Liqin Xie, US

18:24 - 18:36 OP064
CARD9 IN NEUTROPHILS PROTECTS FROM COLITIS AND CONTROLS MITOCHONDRIAL METABOLISM AND CELL SURVIVAL
 Camille Danne, FR

18:36 - 18:48 OP065
REWIRING THE ALTERED TRYPTOPHAN METABOLISM AS A NOVEL THERAPEUTIC STRATEGY IN INFLAMMATORY BOWEL DISEASES
 Chloe Michaudel, FR

Scientific Programme by Day Monday, October 10, 2022

Session

08:00 – 09:00 D3

Upper GI bleeding: All for one, one for all!
Chairs: Cristina Carretero, ES
Ian Mark Gralnek, IL

Q+A LIVE

08:00 – 08:20 IP234

Epidemiological overview
Angel Lanas, ES

08:20 – 08:40 IP235

Balancing thrombotic and bleeding risk of anti-thrombotic therapy
Franco Radaelli, IT

08:40 – 09:00 IP236

Rescue therapy: Endoscopy, radiology or surgery?
Alanna Ebigo, DE

Advances in Clinical GI & Hepatology Session

08:00 – 09:00 A1

Immunity and intestinal ecosystem
Chairs: Gianluca Ianiro, IT
Juozas Kupcinskis, LT

Q+A LIVE

08:00 – 08:20 IP237

Intestinal immunity and leaky gut
Annemieke Smet, BE

08:20 – 08:40 IP238

The influence of host immunity on microbial engraftment
Gianluca Ianiro, IT

08:40 – 09:00 IP239

The role of host immunity in triggering chronic intestinal disorders
Britta Siegmund, DE

Session

08:00 – 09:00 A2

IBD beyond the lumen: Perianal and extraintestinal manifestations
Chairs: Lissy de Ridder, NL
Pascal Juillerat, CH

Q+A LIVE

08:00 – 08:20 IP240

From antibiotics to stem cells: What can we offer patients with perianal Crohn's disease
Antonino Spinelli, IT

08:20 – 08:40 IP241

Addressing luminal complications of extra-intestinal therapies (IL-17i and beyond)
Sebastian Zundler, DE

08:40 – 09:00 IP242

Management of subclinical and clinical overt anaemia in IBD
Stephan Vavricka, CH

Session

08:00 – 09:00 A3

Therapy update: Autoimmune and cholestatic liver diseases
Chairs: Marina Berenguer, ES
Eleonora De Martin, FR

Q+A LIVE

08:00 – 08:20 IP243

First-line treatment of autoimmune hepatitis
Ana Lleo, IT

08:20 – 08:40 IP244

First-line treatment of PSC/PBC
Ulrich Beuers, NL

08:40 – 09:00 IP245

Autoimmune liver diseases: When everything fails - second line treatment
Joost P.H. Drenth, NL

Session

08:00 – 09:00 C1

Colorectal cancer: From surveillance to surgical outcome
Chairs: Jean-Luc Van Laethem, BE
Christianne Johanna Buskens, NL

Q+A LIVE

08:00 – 08:20 IP246

Endoscopy in patients at high risk of colorectal cancer: Who, when and how?
Michal Filip Kaminski, PL

08:20 – 08:40 IP247

Paradigm shift in CRC surgery: What comes first?
Yves Panis, FR

08:40 – 09:00 IP248

Short and longterm complications of colorectal surgery
Dieter Hahnloser, CH

Abstract-based Session

08:00 – 09:00 D4

Artificial Intelligence for colonoscopy
Chairs: Yuichi Mori, NO
Alexander Hann, DE

Q+A LIVE

08:00 - 08:12 OP066
COMPUTER-ASSISTED DETECTION VERSUS CONVENTIONAL COLONOSCOPY ON DETECTION AND MISS RATES OF PROXIMAL COLONIC LESIONS: A MULTI-CENTRE, RANDOMIZED, TANDEM COLONOSCOPY STUDY
 Thomas Ka Luen Lui, HK

08:12 - 08:24 OP067
PROSPECTIVE VALIDATION STUDY OF A MOBILE PHONE APPLICATION FOR ARTIFICIAL INTELLIGENCE-BASED EVALUATION OF STOOL SCALE DURING BOWEL PREPARATION BEFORE COLONOSCOPY
 Atsushi Inaba, JP

08:24 - 08:36 OP069
ARTIFICIAL INTELLIGENCE- AIDED COLONOSCOPY DOES NOT INCREASE ADENOMA DETECTION RATE IN ROUTINE CLINICAL PRACTICE
 Uri Kopylov, IL

Today's Science, Tomorrow's Medicine Session

08:00 - 09:00 Strauss 2
Targeting MYC
 Chairs: Roland Rad, DE
 Poul Sorensen, CA

Q+A LIVE

08:00 - 08:30 IP249
Targeting MYC effector function in pancreatic cancer
 Elmar Wolf, DE

08:30 - 09:00 IP250
Deciphering MYC regulation through time-resolved functional genetics
 Johannes Zuber, AT

Session

08:00 - 09:00 Strauss 3
Small intestine bowel overgrowth: Fact or fiction?
 Chairs: Giovanni Barbara, IT
 Jutta Keller, DE

Q+A LIVE

08:00 - 08:10 IP251
Who to investigate and how? Breath test? Useless
 Tim Vanuytsel, BE

08:10 - 08:20 IP252
No, breath test is useful!
 Heinz Florian Hammer, AT

08:20 - 08:40
Q&A

08:40 - 09:00 IP253
Current treatment and treatment pipeline
 Magnus Simrén, SE

Abstract-based Session

08:00 - 09:00 Lehar 2
Biomarker in pancreatic disease
 Chairs: Albrecht Neesse, DE
 Kasper A. Overbeek, NL

Q+A LIVE

08:00 - 08:12 OP071
EXPERTS ENDOSCOPISTS VS. ARTIFICIAL INTELLIGENCE IN THE EVALUATION OF UNDETERMINED BILIARY STRICTURES IN CHOLANGIOSCOPY: A MULTICENTER, BLINDED, NESTED CONTROLLED TRIAL
 Jorge Baquerizo-Burgos, EC

08:12 - 08:24 OP072
ASSOCIATION BETWEEN HYPERTRIGLYCERIDEMIC WAIST PHENOTYPE AND RISK OF ACUTE PANCREATITIS: A NATIONWIDE POPULATION-BASED STUDY
 Kwang Hyun Chung, KR

08:24 - 08:36 OP074
EXTRACELLULAR-VESICLE MICRORNAS CAN BE FOUND IN BILE AND PLASMA EXTRACELLULAR VESICLES AND ARE A SOURCE OF POTENTIAL BIOMARKERS FOR PANCREATICOBILIARY CANCERS
 Daniel Liu, GB

08:36 - 08:48 OP075
METABOLOMIC ANALYSIS OF PANCREATIC CYST FLUID AND PLASMA BY PROTON NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY
 Ricardo Diogo Alves Conde, PT

Abstract-based Session

08:00 - 09:00 Lehar 3
Eosinophilic esophagitis and GORD
 Chairs: Ulrike von Arnim, DE
 Matteo Ghisa, IT

Q+A LIVE

08:00 - 08:12 OP076
DUPILUMAB IMPROVES CLINICAL, SYMPTOMATIC, HISTOLOGIC, AND ENDOSCOPIC ASPECTS OF EOE, REGARDLESS OF PRIOR SWALLOWED TOPICAL STEROID USE
 Arjan Bredenoord, NL

08:12 - 08:24 OP077
BUDESONIDE ORODISPERSIBLE TABLETS ARE ABLE TO MAINTAIN CLINICAL, HISTOLOGICAL AND ENDOSCOPIC REMISSION IN ADULT PATIENTS WITH EOSINOPHILIC ESOPHAGITIS: RESULTS FROM THE 96-WEEKS OPEN-LABEL EXTENSION PHASE FOLLOWING THE 1-YEAR DOUBLE-BLIND EOS-2 TRIAL
 Luc Biedermann, CH

08:24 - 08:36 OP078
EFFICACY OF SWALLOWED TOPICAL CORTICOSTEROIDS FOR EOSINOPHILIC ESOPHAGITIS IN REAL-WORLD PRACTICE: RESULTS FROM THE EOE CONNECT REGISTRY
 Alfredo J. Lucendo, ES

08:36 - 08:48 OP079
COMPARED TO HEALTHY SUBJECTS, OESOPHAGEAL MUCOSA FROM PATIENTS WITH GASTRO-OESOPHAGEAL REFLUX DISEASE HAVE INCREASED NERVE GROWTH FACTOR-RELEASING MAST CELLS, AND FEWER DENDRITIC CELLS
 Ahsen Ustaoglu, GB
 08:48 - 09:00 OP080
PSYCHOLOGICAL SYMPTOMS, NOT REFLUX PARAMETERS, ARE ASSOCIATED WITH GASTROESOPHAGEAL REFLUX DISEASE SYMPTOM REPORTING
 Livia Guadagnoli, BE

Abstract-based Session

08:00 - 09:00 Lehar 4
Mechanisms in lower GI disease
 Chairs: Carolina Malagelada, ES
 Lucas Wauters, BE

Q+A LIVE

08:00 - 08:12 OP081
SEX DIFFERENCE IN EFFICACY OF GQ-LAB DAILY IN PATIENTS WITH IRRITABLE BOWEL SYNDROME: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY
 Young Hoon Chang, KR

08:12 - 08:24 OP082
DYNAMIC SYMPTOM NETWORKS IN DISORDERS OF GUT-BRAIN INTERACTION: A NETWORK-BASED APPROACH WITH THE ROME FOUNDATION GLOBAL EPIDEMIOLOGY STUDY DATABASE
 Helen Burton Murray, US

08:24 - 08:36 OP083
CAUSES OF LOWER ROME IV VS. ROME III IRRITABLE BOWEL SYNDROME (IBS) PREVALENCE: ANALYSIS OF DATA FROM THE ROME FOUNDATION GLOBAL EPIDEMIOLOGY STUDY (RFGES)
 Olafur S. Palsson, US

08:36 - 08:48 OP084
INTESTINAL SEGMENT-SPECIFIC ALTERATIONS OF INTERLEUKIN-1B EXPRESSION IN THE MYENTERIC NEURONS OF STREPTOZOTOCIN-INDUCED DIABETIC RATS
 Afnan AL Doghmi, HU

08:48 - 09:00 OP085
PARALLELISM IN MYOGENIC OXIDATIVE ALTERATIONS BETWEEN UNCOMPLICATED AND COMPLICATED DIVERTICULAR DISEASE
 Martina Cappelletti, IT

Live Demo

08:00 - 18:00 Stolz 1-2, Foyer
Endoscopy Learning Area & Ultrasound Learning Area

TV Studio Session

09:00 - 09:30 TV Studio
Good Morning UEG Week
 Chairs: Wafaa Khannoussi, MA
 Joost P.H. Drenth, NL
 Katarzyna Pawlak, PL
 Laurent Goessens, BE

Q+A LIVE

Poster Exhibition

09:00 - 17:30 Science Lounge
Poster Exhibition

myUEG Community Programme

09:00 - 09:30 MyUEG Community Area
Young GI: Mentoring Programme
 Chairs: Muhammad Imran Aslam, GB
 Evelien Dekker, NL
 Christopher John Hawkey, GB
 Giovanni Marchegiani, IT
 Martina Müller-Schilling, DE
 Thomas Reiberger, AT
 Vita Skuja, LV
 Andreas Sturm, DE
 Dina Tiniakos, GB
 Radu Tutuian, CH
 Tim Vanuytsel, BE

Session

09:30 - 10:30 D3
Man against machine: Artificial Intelligence and Big Data in GI diseases
 Chairs: Evelien Dekker, NL
 Cesare Hassan, IT

Q+A LIVE

09:30 - 09:50 IP254
Artificial intelligence in colonoscopy: Detection, characterisation or both?
 Yuichi Mori, NO

09:50 - 10:10 IP255
Machine learning in GI disorders
 Tom Konikoff, IL

10:10 - 10:30 IP256
Rising Star: The human detection of submucosal invasive cancer in colon polyps: Bringing new psychological and big data insights to a widespread clinical problem
 David James Tate, BE

Advances in Clinical GI & Hepatology Session

09:30 – 10:30 A1
Influence of immunity in liver transplants
 Chairs: Marina Berenguer, ES
 Patrizia Burra, IT

Q+A LIVE

09:30 - 09:50 IP257
Optimal tools to assess the immune status in liver transplantation
 Alberto Sanchez Fueyo, GB

09:50 - 10:10 IP258
When and how to use immune checkpoint inhibitors in liver transplant candidates
 Eleonora De Martin, FR

10:10 - 10:30 IP259
Is there a role for cell free DNA to predict rejection in liver transplantation?
 Luca Miele, IT

Session

09:30 – 10:30 A2
The real life scenario of personalised management of colorectal cancer
 Chairs: Francesca Romana Ponziani, IT
 Isabelle Soerjomataram, FR

Q+A LIVE

09:30 - 09:50 IP260
Genetic testing in patients at high risk
 Elizabeth E Half, IL

09:50 - 10:10 IP261
Cancer detection in the young adult: Screening, surveillance and stratification
 Manon C.W. Spaander, NL

10:10 - 10:30 IP262
Personalising treatment in daily clinical practice
 Lisa Salvatore, IT

Session

09:30 – 10:30 A3
Therapy update: Pancreatitis
 Chairs: Sara Regnér, SE
 Jeanin E. van Hooft, NL

Q+A LIVE

09:30 - 09:50 IP263
Fluid resuscitation in acute pancreatitis
 Michal Žorniak, PL

09:50 - 10:10 IP264
Biliary pancreatitis and endoscopy: When and how?
 Thierry Ponchon, FR

10:10 - 10:30 IP265
Novel strategies to avoid post ERC-pancreatitis
 Christa J. Sperna Weiland, NL

Session

09:30 – 10:30 C1
Managing GI complications of radiotherapy
 Chairs: Cristina Carretero, ES
 Hanoch Kashtan, IL

Q+A LIVE

09:30 - 09:40 IP266
Endoscopic management
 Lorenzo Fuccio, IT

09:40 - 09:50 IP267
Surgical management
 Yves Panis, FR

09:50 - 10:05
Q&A

10:05 - 10:30 IP268
Radiotherapy of the lower GI tract: Ways to minimise toxicity
 Irit Ben-Aharon, IL

Abstract-based Session

09:30 – 10:30 C2
Clinical trials in ulcerative colitis I
 Chairs: Iris Dotan, IL
 Bram Verstockt, BE

Q+A LIVE

09:30 - 09:42 OP086
ETRASIMOD 2MG ONCE DAILY AS TREATMENT FOR MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 TRIALS
 Severine Vermeire, BE

09:42 - 09:54 OP087
INDUCTION COMBINATION THERAPY WITH GUSELKUMAB AND GOLIMUMAB FOLLOWED BY GUSELKUMAB MONOTHERAPY MAINTENANCE: RESULTS OF THE PHASE 2A, RANDOMIZED, DOUBLE-BLIND, PROOF-OF-CONCEPT VEGA STUDY
 Julian Panés, ES

09:54 - 10:06 OP088
A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF THE ORAL, GUT-RESTRICTED A4B7 INTEGRIN PEPTIDE ANTAGONIST PN-943 IN PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS: RESULTS FROM THE IDEAL STUDY
 Walter Reinisch, AT

10:06 - 10:18 OP089
EARLY SYMPTOM CONTROL WITH MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN THE LUCENT-1 INDUCTION TRIAL
 Silvio Danese, IT

10:18 - 10:30 OP090
ORAL RITILECITINIB AND BREPOCITINIB IN PATIENTS WITH MODERATE TO SEVERE ACTIVE ULCERATIVE COLITIS: CHRONIC THERAPY DATA FROM THE VIBRATO UMBRELLA STUDY
 Kenneth Hung, US

Session

09:30 – 10:30 D4
Challenges in enteral nutrition
 Chairs: Heinz Florian Hammer, AT
 Francisca Joly, FR

Q+A LIVE

09:30 - 09:50 IP269
Children with neurologic impairment
 Susan Hill, GB

09:50 - 10:10 IP270
Enteric dysmotility
 Simon Gabe, GB

10:10 - 10:30 IP271
Feeding problems in (older) children
 Hilde Krom, NL

Today's Science, Tomorrow's Medicine Session

09:30 – 10:30 Strauss 2
Targeting growth signalling in cancer
 Chairs: Albrecht Neesse, DE
 Jessica Zucman-Rossi, FR

Q+A LIVE

09:30 - 09:50 IP272
Microenvironmental factors driving inflammation and tumorigenesis
 Maria Sibilja, AT

09:50 - 10:20 IP273
Targeting KRAS and RHOA for the treatment of GI cancers
 Channing Der, US

Session

09:30 – 10:30 Strauss 3
H. pylori: Evolution or extinction?
 Chairs: Gianluca Ianiro, IT
 Francis Mégraud, FR

Q+A LIVE

09:30 - 09:50 IP274
Maastricht VI/Florence consensus report: What's new?
 Christian Schulz, DE

09:50 - 10:10 IP275
Risks and benefits of H.pylori eradication in childhood
 Michal Kori, IL

10:10 - 10:30 IP276
Are we approaching extinction of H.pylori? Update on world-wide epidemiology
 Theodore Rokkas, GR

Abstract-based Session

09:30 – 10:30 Lehar 2
Biomarker in liver disease: Risk and prediction
 Chairs: Frank Tacke, DE
 Ahad Eshraghian, IR

Q+A LIVE

09:30 - 09:42 OP091
DUCTULAR BILIRUBINOSTASIS IS A DIAGNOSTIC BIOMARKER FOR ACUTE-ON-CHRONIC LIVER FAILURE: RESULTS FROM A WELL-DEFINED COHORT OF PATIENTS WITH ALCOHOLIC STEATOHEPATITIS
 Annelotte Broekhoven, NL

09:42 - 09:54 OP092
MEAT CONSUMPTION AND PNPLA3 POLYMORPHISM ARE ASSOCIATED WITH FATTY LIVER IN A MULTI-CENTER CROSS-SECTIONAL STUDY
 Dana Ivancovsky-Wajcman, IL

09:54 - 10:06 OP093
DIAGNOSTIC AND PROGNOSTIC PERFORMANCE OF URINARY NEUTROPHIL GELATINASE-ASSOCIATED LIPOCALIN IN PATIENTS WITH CIRRHOSIS AND ACUTE KIDNEY INJURY
 Carmine Gambino, IT

10:06 - 10:18 OP094
CIRCULATING MIR-21 AND PREVALENCE OF IBD IN PSC PATIENTS
 André A. Santos, PT

10:18 - 10:30 OP095
NON-INVASIVE TESTS FOR CLINICALLY SIGNIFICANT PORTAL HYPERTENSION AFTER HCV-CURE - INDIVIDUAL PATIENT DATA META-ANALYSIS AND VALIDATION
 Georg Semmler, AT

Abstract-based Session

09:30 – 10:30 Lehar 3
Endoscopic submucosal dissection: Technique and outcomes
 Chairs: Yutaka Saito, JP
 Roberta Maselli, IT

Q+A LIVE

09:30 - 09:42 OP096
HYBRID ENDOSCOPIC SUBMUCOSAL DISSECTION VS. CONVENTIONAL ENDOSCOPIC SUBMUCOSAL DISSECTION FOR EARLY GASTRIC NEOPLASMS; A MULTI-CENTER RANDOMIZED CONTROLLED TRIAL (HYBRID-G TRIAL)
 Mitsuru Esaki, JP

09:42 - 09:54 OP097
MUSCULAR RETRACTION SIGN (MRS): A PREDICTIVE FACTOR OF NON-CURATIVE COLORECTAL ENDOSCOPIC SUBMUCOSAL DISSECTION (ESD)? RESULTS OF A PROSPECTIVE STUDY IN AN EXPERT CENTER

Jérémie Jacques, FR

09:54 - 10:06 OP098
VONOPRAZAN 3 WEEKS TREATMENT IS NOT INFERIOR TO 8 WEEKS TREATMENT FOR THE MANAGEMENT AFTER GASTRIC ESD: A MULTICENTER RANDOMIZED NON-INFERIORITY STUDY

Mizuki Kuramochi, JP

10:06 - 10:18 OP099
RISK OF RESIDUAL NEOPLASIA AFTER A NON-CURATIVE COLORECTAL ESD FOR MALIGNANT LESIONS; A MULTINATIONAL STUDY

João Santos-Antunes, PT

10:18 - 10:30 OP100
PROSPECTIVE SINGLE-ARM TRIAL ON FEASIBILITY AND SAFETY OF NOVEL ENDOSCOPIC ROBOTIC SYSTEM (ENDOMASTER) FOR COLORECTAL ENDOSCOPIC SUBMUCOSAL DISSECTION

Ho Shing Louis Lau, HK

Abstract-based Session

09:30 - 10:30 Lehar 4
Immune and microbial pathways in colorectal cancer

Chairs: Alexander Link, DE

Eglė Dieninytė - Misiūnė, LT

Q+A  LIVE

09:30 - 09:42 OP101
NOVEL EXON-SPECIFIC REPORTER SYSTEM FOR LIVE-CELL QUANTIFICATION OF P53 PROTEIN ISOFORMS IN REAL-TIME

Deniz Tümen, DE

09:42 - 09:54 OP102
A SINGLE-CELL RNA SEQUENCING ATLAS OF THE TUMOR ENVIRONMENT IN PERITONEAL METASTASIZED COLORECTAL CANCER IDENTIFIES ANTI-INFLAMMATORY MACROPHAGES AS POTENTIAL TARGETS FOR THERAPY

Job Saris, NL

09:54 - 10:06 OP103
THE IMPACT OF CD4⁺T CELL PLASTICITY IN COLORECTAL CANCER ON IMMUNOTHERAPEUTIC STRATEGIES

Leonie Konczalla, DE

10:06 - 10:18 OP104
THE ECM MOLECULE EMILIN-2 IMPACTS ON COLORECTAL CANCER PATIENTS PROGNOSIS BY MODULATING MACROPHAGE POLARIZATION VIA TLR-4/NFKB PATHWAY AND REPRESENTS A NEW POTENTIAL LIQUID BIOPSY MARKER FOR THE DETECTION OF CIRCULATING M2-LIKE MACROPHAGES

Eva Andreuzzi, IT

10:18 - 10:30 OP105
CYTOTOXIC NECROTIZING FACTOR 1 HINDERS COLON TUMORIGENESIS INDUCED BY COLIBACTIN-PRODUCING *ESCHERICHIA COLI* IN *APC^{MIN/+}* MICE

Héloïse Chat, FR

Moderated Poster

09:30 - 10:30 Poster Stage 1

NASH and diagnostics

Chairs: Laurent Castera, FR

Omar Elshaarawy, GB

09:30 - 09:36 MP211
FATTY LIVER QUANTIFICATION USING ULTRASOUND DERIVED FAT FRACTION (UDFF) AS COMPARED TO CONTROLLED ATTENUATION PARAMETER (CAP) IN A MIXED COHORT OF PATIENTS

Raluca Lupusoru, RO

09:36 - 09:42 MP212
ASSESSMENT OF LIVER FIBROSIS BY ACOUSTIC RADIATION FORCE IMPULSE IMAGING COMBINED WITH RESULTS OF MINI-LAPAROSCOPY AND HISTOLOGY EVALUATION: A SINGLE-CENTER TRIAL

Alexander Kalner, DE

09:42 - 09:48 MP213
EXTRACELLULAR VESICLES FROM TGR5-ACTIVATED ADIPOCYTES ELICIT ANTI-INFLAMMATORY EFFECTS UPON HEPATOCYTES EXPOSED TO NAFLD-ASSOCIATED PATHOGENIC STIMULI

André Lopes Simão, PT

09:48 - 09:54 MP214
HOW MANY AUTO PSWE AND ULTRASOUND DERIVED FAT FRACTION (UDFF) ACQUISITIONS SHOULD WE MAKE IN ORDER TO OBTAIN THE BEST RESULT?


Raluca Lupusoru, RO

09:54 - 10:00 MP215
QUALITY CRITERIA IN DETECTING LIVER FIBROSIS BY 2D SW ELASTOGRAPHY. DOES THE ETIOLOGY OF LIVER DISEASE MATTER?

Alexandra Rosu Pires, PT

10:00 - 10:06 MP216
MICRORNAS, SEROLOGICAL MARKERS OF LIVER FIBROSIS, HEMATOLOGICAL SCALES, CYTOKERATINS AND GOLGI PROTEIN 73 - A NEW POTENTIAL COMBINATION FOR THE DIAGNOSTICS OF ALCOHOL-RELATED LIVER CIRRHOSIS

Agata Michalak, PL

10:06 - 10:12 MP217
MYOSTEATOSIS AND FRAILTY FACTORS ASSOCIATED WITH THE OCCURRENCE OF COMPLICATIONS IN CIRRHOTIC PATIENTS: *MYOFACC STUDY* 

Bernard El Khoury, LB

10:12 - 10:18 MP218
THE EFFECT OF ROUX-EN-Y GASTRIC BYPASS ON NON-ALCOHOLIC FATTY LIVER DISEASE FIBROSIS ASSESSED BY FIB-4 AND NFS SCORES - AN 11.6-YEAR FOLLOW-UP-STUDY

Elfrid Sandvik, NO

10:18 - 10:24 MP219
THE EFFICACY OF QUERCETIN ADMINISTRATION IN NON-ALCOHOLIC FATTY LIVER DISEASE PATIENTS

Vasyl Prysyzhnyuk, UA

10:24 - 10:30 MP220
THE UTILITY OF PENTRAXIN 3 AND PLATELET DERIVED GROWTH FACTOR RECEPTOR BETA AS NON-INVASIVE BIOMARKERS FOR PREDICTION OF CARDIOVASCULAR RISK IN MAFLD PATIENTS

Maha El Sabawy, EG

Moderated Poster

09:30 – 10:30 Poster Stage 2

Endoscopic ultrasound I
 Chairs: Thomas Rösch, DE
 Katarzyna Pawlak, PL

09:30 - 09:36 MP231
LONG-TERM PATENCY RATES OF TRANSMURAL AND TRANSPAPILLARY EUS GUIDED BILIARY DRAINAGE – TIME TO CHOOSE TRANSMURAL OVER TRANSPAPILLARY?
 Mangesh Borkar, IN

09:36 - 09:42 MP232
THE IMPACT OF ANTROPOMETRIC PARAMETERS ON PANCREATIC STIFFNESS IN HEALTHY VOLUNTEERS
 Lenka Nosáková, SK

09:42 - 09:48 MP233
SINGLE-USE ULTRASOUND ENDOSCOPE ATTACHED TO A STANDARD SCOPE: FIRST HUMAN CASES AND RESULTS OF A PROSPECTIVE PILOT STUDY
 Juan Alcivar-Vasquez, EC

09:48 - 09:54 MP234
THE LIMITED YIELD OF ENDOSCOPIC ULTRASOUND IN UNRESECTABLE PERIHILAR CARCINOMA PATIENTS UNDERGOING WORK-UP FOR LIVER TRANSPLANTATION
 David de Jong, NL

09:54 - 10:00 MP235
EUS-GUIDED BILIARY DRAINAGE WITH A NOVEL ELECTROCAUTERY-ENHANCED LUMEN APPOSING METAL STENT AS FIRST APPROACH FOR DISTAL MALIGNANT BILIARY OBSTRUCTION: A PROSPECTIVE STUDY
 Danilo Paduano, IT

10:00 - 10:06 MP236
ENDOSCOPIC ULTRASOUND- GUIDED BILIARY DRAINAGE AS A RESCUE AND PRIMARY TREATMENT MODALITY- INITIAL EXPERIENCE WITH 88 PATIENTS
 Petko Karagyozov, BG

10:06 - 10:12 MP237
BIODEGRADABLE BILIARY STENTS ARE A USEFUL TOOL IN ENDOSCOPIC TREATMENT OF BILE LEAKS
 Raheel Ahmad, GB

10:12 - 10:18 MP238
OUTCOMES OF PERCUTANEOUS CHOLECYSTOSTOMY IN HIGH-RISK PATIENTS WITHACUTE CHOLECYSTITIS

Anne G. Overdevest, NL

10:18 - 10:24 MP239
EUS-GUIDED BILIARY DRAINAGE FOR THE MANAGEMENT OF BENIGN HEPATICOJEJUNAL ANASTOMOTIC STRICTURE: A SINGLE-CENTER EXPERIENCE
 Sarah Leblanc, FR

10:24 - 10:30 MP240
THE ROLE OF ENDOSCOPIC ULTRASOUND IN TUMOUR STAGING AND TISSUE DIAGNOSIS OF HILAR STRICTURES / HILAR CHOLANGIOCARCINOMAS –A PROSPECTIVE OBSERVATIONAL STUDY

Gangavaram Naveen Kumar Reddy, IN

Moderated Poster

09:30 – 10:30 Poster Stage 3

Mechanisms in lower GI disease II
 Chairs: Mathieu Uzzan, FR

09:30 - 09:36 MP201
QUANTIFICATION OF STEM CELL DYNAMICS AND CRYPT FISSION RATES IN INFLAMMATORY BOWEL DISEASE
 Mehmet Yalchin, GB

09:36 - 09:42 MP202
NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY MEASURE OF PROTEIN GLYCOSILATION IS A BIOMARKER OF ACTIVITY AND METABOLIC COMPLICATIONS IN INFLAMMATORY BOWEL DISEASE
 Sandra García Mateo, ES

09:42 - 09:48 MP203
STROMAL CELL SUBSETS SHOW MODEL-DEPENDENT CHANGES IN EXPERIMENTAL COLITIS AND AFFECT EPITHELIAL TISSUE REPAIR AND IMMUNE CELL ACTIVATION
 Zhou Zhou, NL

09:48 - 09:54 MP204
SELECTIVE BLOCKADE OF VISCERAL PAIN IN A RODENT MODEL OF INFLAMMATORY BOWEL DISEASE
 Nurit Engelmayer, IL

09:54 - 10:00 MP205
INHIBITION OF PFKFB3 SUPPRESSES FIBROBLAST-MEDIATED INFLAMMATION IN INFLAMMATORY BOWEL DISEASE
 Zhou Zhou, NL

10:00 - 10:06 MP206
CHARACTERIZATION OF THE FATTY ACID PROFILE OF THE CREEPING FAT OF CROHN’S DISEASE IN COMPARISON TO INFLAMMATORY BOWEL DISEASE-FREE CONTROLS
 Roger Suau, ES

10:06 - 10:12 MP207
IN-DEPTH CHARACTERIZATION OF THE SERUM ANTIBODY EPITOPE REPERTOIRE IN INFLAMMATORY BOWEL DISEASE BY HIGH-THROUGHPUT PHAGE-DISPLAYED IMMUNOPRECIPITATION SEQUENCING
 Arno R. Bourgonje, NL

10:12 - 10:18 MP208
ENHANCED GUT BACTERIAL IGG2-COATING ASSISTS IN IDENTIFYING PATHOGENIC BACTERIA ASSOCIATED WITH ACTIVE DISEASE IN CROHN'S DISEASE

Carsten Eriksen, DK

10:18 - 10:24 MP209
AUTOPHAGY IN MYELOID CELLS IS NECESSARY TO INHIBIT COLORECTAL TUMOR GROWTH IN *APC*^{MIN/+} MICE INFECTED WITH COLIBACTIN-PRODUCING *ESCHERICHIA COLI*

Laurene Salesse, FR

10:24 - 10:30 MP210
A PROSPECTIVE, SPATIAL AND COMPARATIVE ANALYSIS OF THE COLITIS ASSOCIATED CANCER MICROBIOTA REVEALS *FUSOBACTERIUM* DEPLETION AS A REPRODUCIBLE FEATURE

Duncan Roberts, GB

Moderated Poster

09:30 – 10:30 Poster Stage 4
Bleeding

Chairs: Abraham (Rami) Eliakim, IL
 Tomas Hucl, CZ

09:30 - 09:36 MP221
REDUCTION OF GASTROINTESTINAL BLEEDING IN PATIENTS WITH HEYDE SYNDROME UNDERGOING TRANSCATHETER AORTIC VALVE IMPLANTATION
 Lia Goltstein, NL

09:36 - 09:42 MP222
TARGETED DELETION OF SLC26A9 ATTENUATED MUCOSAL DEFENSE BARRIER IN PORTAL HYPERTENSIVE GASTROPATHY VIA MITOCHONDRIA-DEPENDENT APOPTOTIC SIGNALING
 Zhiyuan Ma, CN

09:42 - 09:48 MP223
AORTIC VALVE REPLACEMENT EFFECTIVELY REDUCES VON WILLEBRAND DISEASE AND GASTROINTESTINAL BLEEDING IN PATIENTS WITH HEYDE SYNDROME
 Lia Goltstein, NL

09:48 - 09:54 MP224
RISK OF GASTROINTESTINAL BLEEDING IN PATIENTS NEWLY STARTED ON WARFARIN OR DIRECT ORAL ANTICOAGULANTS AFTER *HELICOBACTER PYLORI* ERADICATION THERAPY: A POPULATION-BASED STUDY
 Fang Jiang, CN

09:54 - 10:00 MP225
DETECTION OF UPPER GASTROINTESTINAL BLEEDING USING A NOVEL BLEEDING SENSOR CAPSULE – A PILOT STUDY
 Pavel Drastich, CZ

10:00 - 10:06 MP226
LARYNGOPHARYNGEAL REFLUX PATIENTS HAVE IMPAIRED MUCOCILIARY CLEARANCE OF THE UPPER AIRWAY RESPIRATORY EPITHELIUM
 Peter Banovcin, SK

10:06 - 10:12 MP227
NOVEL UPPER-GI BLEEDING SENSOR CAPSULE (PILLSense): A FIRST IN HUMAN FEASIBILITY AND SAFETY TRIAL

Lukas Bajer, CZ

10:12 - 10:18 MP228
POSITIVE IMMUNOLOGICAL FECAL OCCULT BLOOD TEST MAY BE ASSOCIATED WITH THE RISK OF GASTROESOPHAGEAL CANCER. A POPULATION-BASED STUDY
 Zohar Levi, IL

10:18 - 10:24 MP229
HEMODYNAMIC INSTABILITY INCREASES THE RISK OF MORTALITY AND REBLEEDING IN ACUTE GASTROINTESTINAL BLEEDING: A SYSTEMATIC REVIEW AND META-ANALYSIS
 Edina Tari, HU

TV Studio Session

10:30 – 11:00 TV Studio
Grow with us: Rising Stars Award Session I

Chairs: Carolina Ciacci, IT
 Julien Kirchgesner, FR
 Benjamin Mullish, GB
 Pedro M. Rodrigues, ES
 Tim Vanuytsel, BE

Q+A  LIVE

Industry Meeting

10:30 – 11:15 Schubert
Industry Meeting - Sanofi

myUEG Community Programme

10:30 – 11:00 MyUEG Community Area
Connect with... #UEGJ Editors

Chairs: Livia Archibugi, IT
 Dragos Ciocan, FR
 Joost P.H. Drenth, NL
 Fernando Magro, PT
 Deirdre McNamara, IE
 Chloé Melchior, FR
 Alexandre Nuzzo, FR
 Katarzyna Pawlak, PL
 Iago Rodríguez-Lago, ES
 Hidekazu Suzuki, JP
 Alberto Zanetto, IT

Session

11:00 – 12:00 D3
Colorectal cancer screening in the COVID-19 era

Chairs: Michal Filip Kaminski, PL
 Zohar Levi, IL

Q+A  LIVE

11:00 - 11:20 IP277
Delay in CRC prevention and treatment: The price we pay
 Iris Lansdorp-Vogelaar, NL

11:20 - 11:40 IP278
Challenges in restarting screening: What did we learn?
 Carlo Senore, IT

11:40 - 12:00 IP279
Risk-stratification for FIT screening and surveillance
 Evelien Dekker, NL

Advances in Clinical GI & Hepatology Session

11:00 - 12:00 A1
Immunity and metainflammation
 Chairs: Alessio Aghemo, IT
 Herbert Tilg, AT

Q+A LIVE

11:00 - 11:20 IP280
Immune dysregulation of NAFLD
 Olivier Govaere, GB

11:20 - 11:40 IP281
The influence of alcohol on intestinal and liver immunity
 Dragos Ciocan, FR

11:40 - 12:00 IP282
Influence of gut microbiota on immune pathways of cirrhosis-to-cancer progression
 Francesca Romana Ponziani, IT

Session

11:00 - 12:00 A2
Managing challenging cases in functional colonic disease
 Chairs: Jan Tack, BE
 Hans Törnblom, SE

Q+A LIVE

11:00 - 11:20 IP283
Chronic pelvic and anorectal pain
 Giuseppe Chiarioni, IT

11:20 - 11:40 IP284
Colonic pseudoobstruction
 Carolina Malagelada, ES

11:40 - 12:00 IP285
Faecal incontinence
 Emma V. Carrington, GB

Session

11:00 - 12:00 A3
Hot Topics from Latin America
 Chairs: Helena Cortez-Pinto, PT
 Arnaldo Javier Riquelme Pérez, CL

Q+A LIVE

11:00 - 11:20 IP286
Biomarkers in Barrett's Esophagus for Risk Stratification
 Rhonda Souza, US

11:20 - 11:40 IP287
Non invasive biomarkers and premalignant lesions for Risk stratification of Gastric Cancer
 Arnaldo Javier Riquelme Pérez, CL

11:40 - 12:00 IP288
Microbiome and celiac disease: Microbiome and celiac disease: is there any role for probiotics?
 Edgardo Gustavo Smecuol, AR

Late Breaking Abstracts

11:00 - 12:00 C1
Late breaking abstracts II
 Chairs: Barbara A.J. Bastiaansen, NL
 Helmut Messmann, DE

Q+A LIVE

11:00 - 11:12 LB06
A NOVEL COMPUTER-AIDED POLYP DETECTION SYSTEM IN DAILY CLINICAL CARE: AN INTERNATIONAL MULTICENTER, RANDOMIZED, TANDEM TRIAL
 Michiel H. J. Maas, NL

11:12 - 11:24 LB07
CLIP PLACEMENT DOES NOT PREVENT DELAYED BLEEDING AFTER PROXIMAL COLONIC ENDOSCOPIC MUCOSAL RESECTION (CLIPPER): A MULTICENTER, RANDOMIZED CONTROLLED TRIAL
 Gijs Kemper, NL

11:24 - 11:36 LB08
LONG-TERM COLORECTAL CANCER INCIDENCE AND MORTALITY AFTER SCREENING COLONOSCOPY: THE NORDICC RANDOMIZED TRIAL
 Michael Bretthauer, NO

11:36 - 11:48 LB09
ROLE OF ARTIFICIAL INTELLIGENCE IN COLONOSCOPY DETECTION OF ADVANCED LESIONS
 Carolina Mangas-Sanjuan, ES

11:48 - 12:00 LB10
EFFECT OF REAL-TIME COMPUTER-AIDED POLYP DETECTION SYSTEM (ENDO AID) ON ADENOMA DETECTION IN ENDOSCOPIST-IN-TRAINING: A SINGLE-BLIND RANDOMIZED CONTROLLED TRIAL (ENDO AID-TRAIN STUDY)
 Ho Shing Louis Lau, HK

Session

11:00 - 12:00 C2
Personalised screening and surveillance in hepato-pancreatic disease
 Chairs: Najib Ben Khaled, DE
 Emmanuel Tsochatzis, GB

Q+A LIVE

11:00 - 11:20 IP289
Genetic testing in HPB disease: Necessary or accessory?
 Hana Algül, DE

11:20 - 11:40 IP290
How to detect and grade fibrosis in liver disease?
 Pere Ginès, ES

11:40 - 12:00 IP291
Whom to screen or surveil for pancreatic cancer?
 Vinciane Rebours, FR

11:00 - 11:20 IP292
Sensitising pancreatic cancer to immunotherapy
 Dieter Saur, DE

11:20 - 11:40 IP293
Immunevasion in NASH-HCC
 Mathias Florian Heikenwälder, DE

11:40 - 12:00 IP294
Immune tolerance in liver transplant
 Alberto Sanchez Fueyo, GB

Abstract-based Session

11:00 – 12:00 D4
Treatment strategies in IBD
 Chairs: Lissy de Ridder, NL
 Iago Rodríguez-Lago, ES

Q+A LIVE

Session

11:00 – 12:00 Strauss 3
Narrow oesophagus: Disease starts young!
 Chairs: Hankje Escher, NL
 Alexander Meining, DE

Q+A LIVE

11:00 - 11:12 OP106
CLINICAL OUTCOMES OF INCREASED VERSUS CONVENTIONAL ADALIMUMAB DOSE INTERVALS IN PATIENTS WITH CROHN'S DISEASE IN STABLE REMISSION: THE RANDOMISED CONTROLLED LADI TRIAL
 Reinier C.A. van Linschoten, NL

11:12 - 11:24 OP107
PATIENT-REPORTED BURDEN OF CORTICOSTEROID USE IN INFLAMMATORY BOWEL DISEASE IN THE UK: RESULTS FROM THE DETERMINANTS, INCIDENCE AND CONSEQUENCES OF CORTICOSTEROID EXCESS (DICE) IMPACT QUESTIONNAIRE
 Tim Raine, GB

11:24 - 11:36 OP108
TREAT-TO-TARGET MAINTENANCE EFFICACY AND PHARMACOKINETICS OF USTEKINUMAB DOSING REGIMEN UP TO WEEK 48 IN THE STARDUST TRIAL
 Geert R. D'Haens, NL

11:36 - 11:48 OP109
THE EFFECT OF GUSELKUMAB INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: QUASAR PHASE 2B INDUCTION RESULTS AT WEEK 12 BY PRIOR INADEQUATE RESPONSE OR INTOLERANCE TO ADVANCED THERAPY
 Julian Panés, ES

11:48 - 12:00 OP110
A CLUSTER-RANDOMISED CONTROLLED TRIAL OF AN ENHANCED TREATMENT ALGORITHM FOR THE MANAGEMENT OF CROHN'S DISEASE: REACT-2
 Vipul Jairath, CA

11:00 - 11:20 IP295
EoE in paediatric patients
 Salvatore Oliva, IT

11:20 - 11:40 IP296
Caustic lesions in the oesophagus
 Manon C.W. Spaander, NL

11:40 - 12:00 IP297
Oesophageal atresia
 Ausra Lukosiute-Urboniene, LT

Abstract-based Session

11:00 – 12:00 Lehar 2
Clinical care for patients with cirrhosis
 Chairs: Annalisa Berzigotti, CH
 Maria Varela, ES

Q+A LIVE

Today's Science, Tomorrow's Medicine Session

11:00 – 12:00 Strauss 2
Immunomodulation in GI disease
 Chairs: Channing Der, US
 Jean-Luc Van Laethem, BE

Q+A LIVE

11:00 - 11:12 OP111
LIVER-HEART PREDICTION SCORE TO EARLY RULE OUT CIRRHOTIC CARDIOMYOPATHY BY MYOCARDIAL STRAIN IMAGING
 Marcel Razpotnik, AT

11:12 - 11:24 OP112
THE USE OF INFORMATION TECHNOLOGY TO IMPROVE THE CARE OF PATIENTS WITH DECOMPENSATED CIRRHOSIS - A UK UNIVERSITY HOSPITAL EXPERIENCE
 Henna Bhavsar, GB

11:24 - 11:36 OP113
HEPATIC STEATOSIS POST LIVER TRANSPLANTATION: A SYSTEMATIC REVIEW AND META-ANALYSIS
 Ana Carolina Silva, PT

11:36 - 11:48 OP114
CLINICAL COURSE OF FURTHER DECOMPENSATION/MORTALITY IN PATIENTS WITH CIRRHOSIS AND ASCITES AS THE FIRST SINGLE DECOMPENSATION EVENT – AN INCEPTION COHORT STUDY
 Thomas Reiberger, AT

11:48 - 12:00 OP115
MAGNETIC RESONANCE IMAGING FOR THE DIAGNOSIS OF HEPATOCELLULAR CARCINOMA IN ADULTS WITH CHRONIC LIVER DISEASE – A COCHRANE SYSTEMATIC REVIEW
 Tin Nadarevic, HR

Abstract-based Session

11:00 – 12:00 Lehar 3
Achalasia: Diagnosis and treatment
 Chairs: Arjan Bredenoord, NL
 Amir Mari, IL

Q+A LIVE

11:00 - 11:12 OP116
SINGLE-VERSUS MULTIPLE-DOSE ANTIMICROBIAL PROPHYLAXIS IN PER-ORAL ENDOSCOPIC MYOTOMY: A RANDOMIZED CONTROLLED STUDY
 Zaheer Nabi, IN

11:12 - 11:24 OP117
ASSESSING THE DIAGNOSTIC YIELD OF ACHALASIA USING PROVOCATIVE TESTING IN HIGH-RESOLUTION MANOMETRY
 James Endersby, GB

11:24 - 11:36 OP118
THE EFFICACY OF PERORAL ENDOSCOPIC MYOTOMY VS. PNEUMATIC DILATIONS TREATMENT FOR PATIENTS WITH ACHALASIA SUFFERING FROM PERSISTENT OR RECURRENT SYMPTOMS AFTER LAPAROSCOPIC HELLER MYOTOMY. A RANDOMIZED CLINICAL TRIAL
 Caroline Saleh, NL

11:36 - 11:48 OP119
POST PER-ORAL ENDOSCOPIC MYOTOMY HEARTBURN: IT'S NOT ALWAYS TRUE REFLUX
 Neeraj Singla, IN

11:48 - 12:00 OP120
ESOPHAGOGASTRIC JUNCTION CONTRACTILE INTEGRAL (EGJ-CI) COMPLEMENTS REFLUX DISEASE SEVERITY AND PROVIDES INSIGHT INTO THE PATHOPHYSIOLOGY OF REFLUX DISEASE
 James Endersby, GB

Abstract-based Session

11:00 – 12:00 Lehar 4
The microbiome as disease modulator
 Chairs: Gianluca Ianiro, IT
 Brigida Barberio, IT

Q+A LIVE

11:00 - 11:12 OP121
PEPTOSTREPTOCOCCUS ANAEROBIUS PROMOTES GASTRIC MUCOSAL LESIONS THROUGH TLR4/TRIF/NF-KB SIGNALING PATHWAY
 Yaobin Ouyang, CN

11:12 - 11:24 OP123
FACTORS AFFECTING THE OUTCOME OF FECAL MICROBIOTA TRANSPLANTATION FOR PATIENTS WITH IRRITABLE BOWEL SYNDROME

Magdy El-Salhy, NO

11:24 - 11:36 OP124
THE ROLE OF ARYL HYDROCARBON RECEPTOR SIGNALING IN POSTOPERATIVE INTESTINAL HEALING
 Vasiliki Bantavi, DE

11:36 - 11:48 OP125
EXPRESSION OF THE COINHIBITORY RECEPTOR TIGIT ON MEMORY CD4⁺ T CELLS IS INDUCED BY TCR LIGATION AND RETINOIC ACID CO-STIMULATION AND IS ELICITED DURING MICROBIAL COLONIZATION OF THE INTESTINE
 Daniëlle M. H. Barendregt, NL

Moderated Poster

11:00 – 12:00 Poster Stage 1

Imaging in the pancreas
 Chairs: Martina Pezzullo, BE
 Christoph Zech, CH

11:00 - 11:06 MP331
ENDOSCOPIC ULTRASOUND (EUS): AN IMPORTANT ROLE IN DETECTION AND MANAGEMENT OF PANCREATIC NEUROENDOCRINE TUMOURS (PNET) IN MULTIPLE ENDOCRINE NEOPLASIA TYPE 1 (MEN1) PATIENTS BEYOND RADIOLOGICAL IMAGING
 Chris Chia, SG

11:06 - 11:12 MP332
A DEEP LEARNING APPROACH CAN DISTINGUISH LOW GRADE IPMN FROM HIGH GRADE IPMN/INVASIVE CARCINOMA FROM ENDOSCOPIC ULTRASOUND IMAGES WITH HIGH ACCURACY

11:12 - 11:18 MP333
ENDOSCOPIC ULTRASOUND-GUIDED FINE NEEDLE ASPIRATION PANCREATIC ADENOCARCINOMA SAMPLES ARE ADEQUATE FOR NEXT GENERATION SEQUENCING - A PROSPECTIVE COHORT ANALYSIS
 Stefania Bunduc, RO

11:18 - 11:24 MP334
ADVANCED IMAGING TECHNIQUES ASSOCIATED WITH EUS VS EUS-GUIDED SAMPLING FOR THE DIAGNOSIS OF MALIGNANCY IN SOLID PANCREATIC LESIONS: ANALYSIS OF A PROSPECTIVE EUS REGISTRY
 Daniel De la Iglesia-García, ES


11:24 - 11:30 MP335
INTRATUMORAL MICROBIOME ANALYSIS OF UNRESECTABLE PANCREATIC CANCER VIA EUS-FNB AND ELASTOGRAPHY
 Min Woo Lee, KR

11:30 - 11:36 MP336
SAFETY AND EFFICACY OF ENDOSCOPIC ULTRASOUND-GUIDED RADIOFREQUENCY ABLATION FOR THE TREATMENT OF FUNCTIONAL AND NON-FUNCTIONAL PANCREATIC NEUROENDOCRINE NEOPLASMS: PRELIMINARY RESULTS OF A MULTICENTRE PROSPECTIVE STUDY

Gianenrico Rizzatti, IT

11:36 - 11:42 MP337
LONG-TERM OUTCOMES OF EUS GUIDED RFA IN PANCREATIC NEUROENDOCRINE TUMORS: A TERTIARY CARE CENTRE EXPERIENCE
 Zaheer Nabi, IN

11:42 - 11:48 MP338
COMPARISON OF TISSUE AMOUNT AND DIAGNOSTIC YIELD BETWEEN A NOVEL FRANSEEN TYPE FNB NEEDLE AND A STANDARD FNA NEEDLE – A RANDOMIZED CONTROLLED STUDY IN SOLID PANCREATIC LESIONS
 Bojan Kovacevic, DK

11:48 - 11:54 MP339
IMPACT OF ENDOLUMINAL RADIOFREQUENCY ABLATION ON IMMUNITY IN PANCREATIC CANCER AND CHOLANGIOCARCINOMA 
 Jana Jarosova, CZ

11:54 - 12:00 MP340
THE EMT PROGRAM PROTEINS HAVE RELEVANT IMPACT ON CLINICAL OUTCOMES OF PANCREATIC CANCER PATIENTS THAT MIGHT BE DEPENDENT ON HUR AND AHR POST-TRANSCRIPTIONAL REGULATION
 Kestutis Urbonas, LT

Moderated Poster

11:00 – 12:00 Poster Stage 2
Diagnostic colonoscopy
 Chairs: Matt Rutter, GB
 Shimaa Afify, EG

11:00 - 11:06 MP271
WHAT WE SHOULD KNOW TO PERFORM A PAINLESS COLONOSCOPY FOR PATIENTS
 Keita Harada, JP


11:06 - 11:12 MP272
ASSESSING OUR SCOPE OF PRACTICE: ADHERENCE TO 2019 BSG / 2020 ESGE POST-POLYPECTOMY/POST-COLORECTAL CANCER RESECTION SURVEILLANCE GUIDELINES
 Tom Hosack, GB

11:12 - 11:18 MP273
RETROSPECTIVE MULTICENTER ANALYSIS OF POLYP REPORTING IN COLONOSCOPY
 Thomas J. Lux, DE

11:18 - 11:24 MP274
EXAMINATION OF SMALL POLYP DETECTION ABILITY USING A NOVEL IMAGE-ENHANCED ENDOSCOPY SYSTEM: A VIDEO STUDY
 Kunihiko Wakamura, JP

11:24 - 11:30 MP275
COMPARATIVE EFFICACY AND SAFETY OF DIFFERENT ENDOSCOPIC RESECTION TECHNIQUES FOR TREATMENT OF 6-20 MM COLORECTAL POLYPS: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS
 Apostolis Papaefthymiou, GR

11:30 - 11:36 MP276
DEVELOPMENT AND VALIDATION OF A NOVEL SCORE FOR THE COMPLETENESS OF CAECAL INTUBATION - THE CCIS (COMPLETENESS OF CAECAL INTUBATION SCORE)
 David James Tate, BE

11:36 - 11:42 MP277
IMPACT OF A LOW-RESIDUE DIET ON BOWEL CLEANSING QUALITY BEFORE COLONOSCOPY: A PROSPECTIVE SINGLE BLINDED RANDOMIZED CONTROLLED TRIAL 
 Khellaf Amalou, DZ

11:42 - 11:48 MP278
EFFECT OF POSITION ON CECAL INTUBATION RATE FOR COLONOSCOPY TRAINEES : RT. LATERAL VS LT. LATERAL DECUBITUS
 Tae-Geun Gweon, KR

11:48 - 11:54 MP279
ASSESSMENT OF QUALITY OF LIFE IN PATIENTS UNDERGOING SACRAL NEUROMODULATION FOR FECAL INCONTINENCE IN BRAZIL
 Rogerio Parra, BR

11:54 - 12:00 MP280
ARTIFICIAL INTELLIGENCE: A NEW TOOL IN ENDOSCOPIC SURVEILLANCE IN INFLAMMATORY BOWEL DISEASE PATIENTS
 Katja Grubelic Ravic, HR

Moderated Poster

11:00 – 12:00 Poster Stage 3
Clinical trials in IBD
 Chairs: Alessandro Armuzzi, IT
 Abraham (Rami) Eliakim, IL

11:00 - 11:06 MP241
MUCOSAL HEALING WITH VEDOLIZUMAB IN INFLAMMATORY BOWEL DISEASE: EVIDENCE FROM EARNEST, A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL IN CHRONIC POUCHITIS
 Vipul Jairath, CA

11:06 - 11:12 MP242
SUSTAINED SYMPTOM CONTROL WITH MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN THE LUCENT-2 MAINTENANCE TRIAL
 Axel Dignass, DE

11:12 - 11:18 MP243
BENEFIT-RISK ASSESSMENT OF UPADACITINIB TREATMENT IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
 Remo Panaccione, CA

11:18 - 11:24 MP244
MATCHING-ADJUSTED INDIRECT COMPARISON OF UPADACITINIB VERSUS VEDOLIZUMAB AS INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS

Walter Reinisch, AT

11:24 - 11:30 MP245
EFFICACY OF MIRIKIZUMAB IN RESOLVING ACTIVE HISTOLOGIC INFLAMMATION IN ULCERATIVE COLITIS IN LUCENT-1 INDUCTION AND LUCENT-2 MAINTENANCE TRIALS

Fernando Magro, PT

11:30 - 11:36 MP246
EFFECT OF ETASIMOD ON CIRCULATING LYMPHOCYTES IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: DATA FROM THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 TRIALS

Silvio Danese, IT

11:36 - 11:42 MP247
OZANIMOD IS AN EFFECTIVE ORAL TREATMENT FOR PATIENTS WITH ULCERATIVE COLITIS REGARDLESS OF MODERATE OR SEVERE ENDOSCOPIC DISEASE ACTIVITY: A POST HOC ANALYSIS OF TRUE NORTH

Laurent Peyrin-Biroulet, FR

11:42 - 11:48 MP248
RECAPTURE OF RESPONSE WITH OZANIMOD IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS WHO WITHDREW THERAPY: DATA FROM THE TRUE NORTH OPEN-LABEL EXTENSION STUDY

Michael Chiorean, US

11:48 - 11:54 MP249
THE EFFECT OF GUSELKUMAB INDUCTION THERAPY ON INFLAMMATORY BIOMARKERS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: QUASAR PHASE 2B INDUCTION RESULTS THROUGH WEEK 12

Axel Dignass, DE

11:54 - 12:00 MP250
ABX464 (OBEFAZIMOD) IN PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS: AN INTERIM 48-WEEK SAFETY AND EFFICACY ANALYSIS FROM AN ONGOING 96-WEEK OPEN-LABEL MAINTENANCE PHASE 2B STUDY

Severine Vermeire, BE

Moderated Poster

11:00 - 12:00 Poster Stage 4
Reflux disease
 Chairs: Roos E. Pouw, NL
 Massimiliano di Pietro, GB

11:00 - 11:06 MP261
THE UTILITY OF A MULTI-GENE METHYLATION PANEL TO RISK-STRATIFY PATIENTS WITH BARRETT'S ESOPHAGUS AFTER RADIOFREQUENCY ABLATION

W. Keith Tan, GB

11:06 - 11:12 MP262
RANGE OF PATHOLOGIES DIAGNOSED AMONG A SCREENING POPULATION OF PATIENTS WITH REFLUX DISEASE: RESULTS FROM THE CYTOSPONGE-BEST3 TRIAL

W. Keith Tan, GB

11:12 - 11:18 MP263
ENDOSCOPIC FOLLOW-UP OF RADICALLY RESECTED SUBMUCOSAL ADENOCARCINOMA IN BARRETT'S ESOPHAGUS: EARLY RESULTS OF AN ONGOING PROSPECTIVE, INTERNATIONAL, MULTICENTER COHORT REGISTRY (PREFER TRIAL)

Man Wai Chan, NL

11:18 - 11:24 MP264
THE CLINICAL UTILITY OF AN ENDOSCOPIC DIAGNOSIS OF HIATUS HERNIA

Joseph Cooney, GB

11:24 - 11:30 MP265
MEAN NOCTURNAL BASELINE IMPEDANCE: A NOVEL METRIC WHICH MAY INCREASE THE DIAGNOSTIC VALUE OF 24 HOUR PH AND IMPEDANCE MONITORING

Lillian Barry, IE

11:30 - 11:36 MP266
IMPEDANCE-PH FINDINGS SUGGEST THAT GRADE B ESOPHAGITIS PROVIDES CONCLUSIVE DIAGNOSIS OF GERD: REAPPRAISAL OF LYON CONSENSUS CRITERIA FOR GERD DIAGNOSIS

Pierfrancesco Visaggi, IT

11:36 - 11:42 MP267
FACTORS ASSOCIATED WITH HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH BARRETT ESOPHAGUS. A MULTI-CENTER CROSS SECTIONAL STUDY

Mirjam van der Ende, NL

11:42 - 11:48 MP268
RESULTS FROM A RANDOMIZED CONTROLLED TRIAL: INTRODUCING A PRECISION MEDICINE DIAGNOSTIC TOOL INCREASES ADHERENCE TO GUIDELINES IN PATIENTS WITH BARRETT'S ESOPHAGUS

Rebecca J. Critchley-Thorne, US

11:48 - 11:54 MP269
THE EFFECT OF DEXRABEPRAZOLE ON INTRAGASTRIC AND INTRAESOPHAGEAL ACIDITY AND SYMPTOMS OF GASTROESOPHAGEAL REFLUX DISEASE

Serhat Bor, TR

11:54 - 12:00 MP270
ESOPHAGEAL MUCOSAL AND MOLECULAR DIFFERENCES BETWEEN FUNCTIONAL HEARTBURN AND HEALTHY ASYMPTOMATIC SUBJECTS

Ahsen Ustaoglu, GB

TV Studio Session

12:00 - 12:30 TV Studio
UEG Week: Digging deeper
 Chairs: Jonathan McCrea, IE

Q+A LIVE

Industry Symposia

12:30 – 13:30 A1
Avant-garde treatment approaches in IBD management: targeting the IL-23 pathway

Q+A  LIVE

Industry Symposia

12:30 – 13:30 A2
Which clinical targets have the potential to change the natural course of IBD?

Q+A  LIVE

Industry Symposia

12:30 – 13:30 A3
New vision of remission: Aiming for mucosal healing in Crohn's disease through IL-23 inhibition

Q+A  LIVE

Case-based Discussion

12:30 – 13:30 C1
Functional dyspepsia and gastroparesis: Where do we draw a line?



Chairs: Maura Corsetti, GB
 Vincenzo Stanghellini, IT
 Hidekazu Suzuki, JP
 Jan Tack, BE

 CASE Q+A  LIVE

Case-based Discussion

12:30 – 13:30 C2
Indeterminate biliary strictures

Chairs: Lars Aabakken, NO
 Andrea Anderloni, IT
 Marco J. Bruno, NL
 Johanna Laukkarinen, FI

 CASE Q+A  LIVE

Industry Symposia

12:30 – 13:30 D4
A Deeper Dive Into the Clinical Implications of Type 2 Inflammation in EoE and Approaches to Patient Care

Q+A  LIVE

Industry Symposia


12:30 – 13:30 Strauss 2
JAK to the future: a patient-centric choice in UC

 Q+A  LIVE

Case-based Discussion

12:30 – 13:30 Strauss 3
NASH

Chairs: Alessio Aghemo, IT
 Laurent Castera, FR
 Frank Tacke, DE
 Shira Zelber-Sagi, IL

 CASE Q+A  LIVE

On-site Poster Rounds

12:30 – 13:30 Science Lounge - Liver, Biliary & Pancreas Terminals 1-5

On-site Poster Rounds - Liver, Biliary and Pancreas I

On-site Poster Rounds

12:30 – 13:30 Science Lounge - Surgical, Endoscopic and Imaging Terminals 6-12

On-site Poster Rounds - Surgery, Endoscopy and Imaging I

On-site Poster Rounds

12:30 – 13:30 Science Lounge - Lower GI Terminals 13-21

On-site Poster Rounds - Lower GI I

On-site Poster Rounds

12:30 – 13:30 Science Lounge - Upper GI Terminals 22-30

On-site Poster Rounds - Upper GI I

myUEG Community Programme

12:30 – 13:30 MyUEG Community Area

Young GI: Mentoring Programme

Chairs: Muhammad Imran Aslam, GB
 Evelien Dekker, NL
 Christopher John Hawkey, GB
 Giovanni Marchegiani, IT
 Martina Müller-Schilling, DE
 Thomas Reiberger, AT
 Vita Skuja, LV
 Andreas Sturm, DE
 Dina Tiniakos, GB
 Radu Tutuian, CH
 Tim Vanuytsel, BE

TV Studio Session

13:30 – 14:00 TV Studio

Digestive diseases: Big burden, low funding?
 Chairs: Luigi Ricciardiello, IT
 Neil Henderson, GB
 Chloé Melchior, FR
 Mathilde Ollivier, AT

Q+A LIVE

Session

14:00 – 15:00 D3

30 years of UEG - Anniversary Session
 Chairs: Helena Cortez-Pinto, PT
 Christoph Beglinger, CH

Q+A LIVE

14:00 - 14:10 IP298
Pancreatic cancer: Will it ever be solved?
 Hana Algül, DE

14:10 - 14:20 IP299
The history of Hepatitis C: A book closed, a problem solved
 Christoph Sarrazin, DE

14:20 - 14:30 IP300
Everything has become resectable: Is endoscopy the ultimate solution?
 Alessandro Repici, IT

14:30 - 14:40 IP301
IBD: Ever increasing treatment options and still not solved
 Severine Vermeire, BE

14:40 - 14:50 IP302
What UEG contributed in 30 years and where we are going
 Michael Farthing, GB

14:50 - 15:00
Panel Discussion 30 years of UEG - Anniversary Session

Session

14:00 – 15:00 A1

Mistakes in....: Neurogastroenterology & motility and nutrition
 Chairs: Charles Murray, GB
 Klaartje Bel Kok, GB

Q+A LIVE

14:00 - 14:03 IP303
Introduction Mistakes in....: Neurogastroenterology & motility and nutrition
 Charles Murray, GB

14:03 - 14:21 IP304
Dietary management of IBS
 Jean W.M. Muris, NL

14:21 - 14:39 IP305
Gastroparesis
 Asma Fikree, GB

14:39 - 14:57 IP306
Refractory coeliac disease
 Roberto De Giorgio, IT

14:57 - 15:00
Conclusion Mistakes in....: Neurogastroenterology & motility and nutrition
 Charles Murray, GB

Session

14:00 – 15:00 A2

Autoimmune and rare liver disease
 Chairs: Verena Keitel-Anselmino, DE
 Michael Trauner, AT

Q+A LIVE

14:00 - 14:20 IP307
Autoimmune hepatitis: Transition from adolescence to adulthood
 Marianne Samyn, GB

14:20 - 14:40 IP308
The hidden face of Wilson's disease
 Zoe Mariño, ES

14:40 - 15:00 IP309
Update on the pathophysiology of polycystic liver disease
 Joost P.H. Drenth, NL

Abstract-based Session

14:00 – 15:00 A3

Clinical trials in Crohn's disease
 Chairs: Silvio Danese, IT
 Lieven Pouillon, BE

Q+A LIVE

14:00 - 14:12 OP127
ETROLIZUMAB AS INDUCTION AND MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE: RESULTS FROM THE PHASE 3 BERGAMOT STUDY
 Severine Vermeire, BE

14:12 - 14:24 OP126
52-WEEKS RISANKIZUMAB SUBCUTANEOUS MAINTENANCE DOSING IS EFFICACIOUS AND WELL TOLERATED IN PATIENTS WITH MODERATE TO SEVERE CROHN'S DISEASE WHO HAD DELAYED RESPONSE TO 12-WEEKS IV RISANKIZUMAB INDUCTION
 Geert R. D'Haens, NL

14:24 - 14:36 OP128
CLINICAL AND ENDOSCOPIC IMPROVEMENTS WITH RISANKIZUMAB INDUCTION AND MAINTENANCE DOSING VERSUS PLACEBO ARE OBSERVED IRRESPECTIVE OF NUMBER OF PRIOR FAILED BIOLOGICS
 Marc Ferrante, BE

14:36 - 14:48 OP129
EFFICACY AND SAFETY OF UPADACITINIB INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE: RESULTS FROM A RANDOMIZED PHASE 3 U-EXCEL STUDY
 Julian Panés, ES

14:48 - 15:00 OP130
HIGHER ENDOSCOPIC AND CLINICAL REMISSION RATES WITH VEDOLIZUMAB IN EARLY THAN IN LATE CROHN'S DISEASE: RESULTS FROM THE LOVE-CD STUDY (LOW COUNTRIES VEDOLIZUMAB IN CD STUDY)
 Geert R. D'Haens, NL

Session

14:00 - 15:00 C1
Crash Course: Complications after upper GI surgery
 Chairs: Sheraz Markar, GB
 Mark Ivo van Berge Henegouwen, NL

Q+A LIVE

14:00 - 14:20 IP310
Endoluminal treatment of upper-GI leakage
 Suzanne S. Gisbertz, NL

14:20 - 14:40 IP311
Functional disorders after oesophageal surgery: Incidence and treatment options
 Daniel Sifrim, GB

14:40 - 15:00 IP312
Treatment of dysphagia and strictures after bariatric surgery
 Roberta Maselli, IT

Session

14:00 - 15:00 C2
Recurrent acute or chronic pancreatitis
 Chairs: Gabriele Capurso, IT
 Vinciane Rebours, FR

Q+A LIVE

14:00 - 14:20 IP313
Autoimmune versus idiopathic pancreatitis: A pathologists view
 Ann Driessen, BE

14:20 - 14:40 IP314
Chronic pancreatitis: Early diagnosis is crucial but how?
 Jeanin E. van Hooft, NL

14:40 - 15:00 IP315
Idiopathic chronic pancreatitis: More than genetic testing?
 Jonas Rosendahl, DE

Abstract-based Session

14:00 - 15:00 D4
Endoscopic resection of GI neoplasia
 Chairs: Alexander Meining, DE
 Diogo Libânio, PT

Q+A LIVE

14:00 - 14:12 OP131
IMPLEMENTATION OF THE OPTICAL MODEL INCREASES SENSITIVITY OF REAL-TIME OPTICAL DIAGNOSIS AND RO-RESECTION RATES OF NON-PEDUNCULATED T1 COLORECTAL CARCINOMAS: A PROSPECTIVE MULTICENTER STUDY (OPTICAL II)
 Leon M.G. Moons, NL

14:12 - 14:24 OP132
ENDOSCOPIC MUCOSAL RESECTION COMBINED WITH HYBRID ARGON PLASMA COAGULATION TO PREVENT RECURRENCE OF LARGE NONPEDUNCULATED COLORECTAL POLYPS
 Roupen Djinbanchian, CA

14:24 - 14:36 OP133
ENDOSCOPIC MUCOSAL RESECTION OF GASTROINTESTINAL POLYPS WITH A NOVEL PLASMA RADIOFREQUENCY GENERATOR: A NON-INFERIORITY MULTICENTERRANDOMIZEDCONTROL STUDY
 Mingyan Cai, CN

14:36 - 14:48 OP135
COMPARISON OF MASS SPECTROMETRY AND OPTICAL SPECTROSCOPY FOR NOVEL REAL TIME DIAGNOSIS OF COLORECTAL CANCER
 Lauren Ford, GB

Today's Science, Tomorrow's Medicine Session

14:00 - 15:00 Strauss 2
Metabolic vulnerabilities in cancer
 Chairs: Axel Behrens, GB
 Elmar Wolf, DE

Q+A LIVE

14:00 - 14:30 IP316
FAMIN meets energy metabolism: How purines impact on electrons, protons and autoimmunity
 Arthur Kaser, GB

14:30 - 15:00 IP317
Targeting the adaptive response to oxidative stress in solid tumours
 Poul Sorensen, CA

Session

14:00 - 15:00 Strauss 3
From guidelines to clinical practice: Update on FMT in Clostridium difficile infection
 Chairs: Georgiana- Emmanuela Gîlcă-Blanariu, RO
 Juozas Kupcinskas, LT

Q+A LIVE

14:00 - 14:20 IP318
Clostridium difficile infections: Novel insights into the pathomechanisms
 Benjamin Mullish, GB
 14:20 - 14:40 IP319
Clostridium difficile infections: How to treat them in 2022
 Dan Lucian Dumitrascu, RO

14:40 - 15:00 IP320
FMT translated in the local clinical practice
 Georgiana- Emmanuela Gîlcă-Blanariu, RO

Abstract-based Session

14:00 - 15:00 Lehar 2
COVID-19 complications in the lower GI tract
 Chairs: Henriette Heinrich, CH
 Fabiana Zingone, IT

Q+A LIVE

14:00 - 14:12 OP136
SEROLOGIC RESPONSE TO SARS-COV-2 VACCINATION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE ON IMMUNOSUPPRESSIVE THERAPY: ASSOCIATION TO DISEASE TYPE AND SERUM DRUG LEVELS
 Kristin Kaasen Jørgensen, NO

14:12 - 14:24 OP137
REDUCED SEROLOGICAL RESPONSE TO COVID-19 BOOSTER VACCINES IN PATIENTS WITH IBD IS FURTHER DIMINISHED BY TNF INHIBITOR THERAPY; VARIATION STUDY PART 2 (VARIABILITY INRESPONSE IN IBD AGAINST SARS-COV-2 IMMUNISATION)
 Jayne Doherty, IE

14:24 - 14:36 OP138
POST-INFECTION IRRITABLE BOWEL SYNDROME IN SARS-COV-2 PATIENTS: THE GI-COVID19 STUDY
 Giovanni Marasco, IT

14:36 - 14:48 OP139
POST-COVID GASTROINTESTINAL SEQUELAE 7 MONTHS AFTER ACUTE SARS-COV-2 INFECTION
 Peter Liptak, SK

14:48 - 15:00 OP140
INFLAMMATORY BOWEL DISEASE IS ASSOCIATED WITH AN INCREASED RISK FOR COVID-19-RELATED HOSPITALIZATION, BUT NOT WITH MORTALITY: CROATIAN NATIONWIDE COHORT STUDY
 Ivan Kodvanj, HR

Abstract-based Session

14:00 - 15:00 Lehar 3
Gastric cancer and lymphoma
 Chairs: Lukas Macke, DE
 Massimiliano di Pietro, GB

Q+A LIVE

14:00 - 14:12 OP141
IS GASTRIC CANCER SCREENING NECESSARY IN LYNCH SYNDROME?
 Ariadna Sánchez, ES
 14:12 - 14:24 OP142
MIR125A-5P AFFECTS THE PROTECTIVE ROLE OF EMILIN-1 IN GASTRIC CANCER (GC) MICROENVIRONMENT
 Alessandra Capuano, IT

14:24 - 14:36 OP144
DEVELOPMENT AND VALIDATION OF ENDOSCOPIC CLASSIFICATION FOR SUPERFICIAL MUCOSAL LESIONS IN HEREDITARY DIFFUSE GASTRIC CANCER (HDGC)
 Judith Honing, GB

14:36 - 14:48 OP145
QUALITY OF DEATH IN CANCER PATIENTS MANAGED BY GASTROENTEROLOGISTS: ARE WE DOING IT RIGHT?
 Catarina Nascimento, PT

Abstract-based Session

14:00 - 15:00 Lehar 4
Upper GI bleeding: Stratification and treatment
 Chairs: Cristiano Spada, IT
 Yegor Tryliskyy, GB

Q+A LIVE

14:00 - 14:12 OP205
RISK OF SEVERE UPPER GASTROINTESTINAL BLEEDING IN DIRECT ORAL ANTICOAGULANT USERS: A LARGE ASIAN POPULATION-BASED ANALYSIS
 Ho Shing Louis Lau, HK

14:12 - 14:24 OP206
OCTREOTIDE SIGNIFICANTLY REDUCES TRANSFUSION REQUIREMENTS COMPARED TO STANDARD CARE IN PATIENTS WITH ANGIODYSPLASIA-RELATED ANAEMIA: A MULTICENTRE RANDOMISED CONTROLLED TRIAL
 Lia Goltstein, NL

14:24 - 14:36 OP207
A MACHINE LEARNING APPROACH TO DETERMINING OPTIMAL MEAN ARTERIAL PRESSURE TARGETS FOR MANAGEMENT OF NON-VARICEAL UPPER GASTROINTESTINAL BLEEDING
 Readon Teh, SG

14:36 - 14:48 OP208
EUS-GUIDED TREATMENT OF GASTRIC FUNDAL VARICES WITH COIL AND GLUE INJECTION FARES BETTER THAN ENDOSCOPIC GLUE INJECTION: AN INTERNATIONAL MULTI-CENTER PROPENSITY-MATCHED ANALYSIS
 Jayanta Samanta, IN

14:48 - 15:00 OP209
ENDOSCOPIC GLUE INJECTION VS ENDOSCOPIC HUMAN THROMBIN INJECTION FOR BLEEDING GASTRIC VARICES - A RANDOMIZED CONTROLLED TRIAL
 Ashok Jhajharia, IN

Moderated Poster

14:00 – 15:00 Poster Stage 1
Pancreatic cancer clinical
 Chairs: Matthias Löhr, SE
 Pilar Acedo, GB

14:00 - 14:06 MP251
PANCREATIC CANCER SCREENING IN HIGH-RISK INDIVIDUALS
 Joan Llach, ES

14:06 - 14:12 MP253
BODY COMPOSITION PARAMETERS AS SURVIVAL PREDICTORS IN PATIENTS WITH PANCREATIC CANCER – A RETROSPECTIVE MULTICENTER ANALYSIS
 Marko Damm, DE

14:12 - 14:18 MP254
UTILITY OF HISTOPATHOLOGICAL REVISION IN THE MANAGEMENT OF GASTRO-ENTERO-PANCREATIC NEUROENDOCRINE NEOPLASIA
 Matteo Marasco, IT

14:18 - 14:24 MP255
LOW SERUM VITAMIN D3 AND FECAL ELASTASE LEVELS ARE MARKERS OF DECREASED SURVIVAL IN PATIENTS WITH PANCREATIC CANCER
 Siddharth Wable, IN

14:24 - 14:30 MP256
SYNCHRONOUS PREMALIGNANT LESIONS IN PATIENTS WITH PANCREATOBILIARY CANCERS
 Seon-Mee Park, KR

14:30 - 14:36 MP257
SURVIVAL AFTER RESECTION OF PANCREATIC CANCER ASSOCIATED WITH PANCREATIC CYSTIC NEOPLASM: NATIONWIDE REGISTRY-BASED STUDY
 Myrte Gorris, NL

14:36 - 14:42 MP258
CHANGES OF ORAL AND DUODENAL MICROBIOTA IN PATIENTS WITH PANCREATIC CANCER ARE POSSIBLE DIAGNOSTIC AND PROGNOSTIC BIOMARKERS
 Livia Archibugi, IT

14:42 - 14:48 MP259
PREDICTIONS AND PREVENTING OF POSTOPERATIVE PANCREATIC FISTULA IN PATIENTS FOLLOWING PANCREATODUODENECTOMY
 Liudmyla Pererva, UA

14:48 - 14:54 MP260
DIAGNOSTIC ACCURACY AND SAFETY OF ENDOSCOPIC ULTRASOUND BASED CONFOCAL LASER ENDOMICROSCOPY FOLLOWED BY THROUGH-THE-NEEDLE MICROFORCEPS BIOPSY IF REQUIRED FOR PATIENTS WITH INDETERMINATE PANCREATIC CYSTIC LESIONS
 Gianenrico Rizzatti, IT

Moderated Poster

14:00 – 15:00 Poster Stage 2
Endoscopy in upper GI
 Chairs: Sheila Krishnadath, BE
 Mohamed Alboraei, EG

14:00 - 14:06 MP312
INCIDENTAL AND RADIOFREQUENCY ABLATION-INDUCED ENDOSCOPIC FINDINGS AFTER ATRIAL FIBRILLATION ABLATION: DO WE NEED A SCREENING ENDOSCOPY FOR UPPER GASTROINTESTINAL TRACT IN THE GENERAL POPULATION?
 Christian Meinhardt, DE

14:06 - 14:12 MP313
ENDOFASTER AND EGGIM FOR THE DIAGNOSIS OF HELICOBACTER PYLORI INFECTION AND ADVANCED STAGES OF GASTRICINTESTINAL METAPLASIA
 Gianluca Esposito, IT

14:12 - 14:18 MP314
APPLICABILITY OF THE BARCELONA SCALE TO ASSESS THE CLEANLINESS OF HIGH-QUALITY UPPER GASTROINTESTINAL ENDOSCOPY
 Angella Da Fieno, ES

14:18 - 14:24 MP315
ROLE OF GASTROSCOPY IN PATIENTS UNDERGOING SCREENING COLONOSCOPY FOR ASSESSMENT OF A POSITIVE FAECAL OCCULT BLOOD TEST: A SYSTEMATIC REVIEW AND META-ANALYSIS
 Ali Eqbal, AU

14:24 - 14:30 MP316
UTILITY OF ENDOSCOPIC SURVEILLANCE USING MAGNIFYING ENDOSCOPY WITH NARROW-BAND IMAGING AFTER ENDOSCOPIC RESECTION FOR GASTRIC NEOPLASM
 Yohan Kim, KR

14:30 - 14:36 MP317
THE REAL-TIME AUTOMATIC ENDOSCOPIC DETECTION OF GASTRIC DYSPLASIA AND EARLY GASTRIC CANCER THROUGH ARTIFICIAL INTELLIGENCE-BASED SYSTEM: A PILOT STUDY
 Young Hoon Chang, KR

14:36 - 14:42 MP318
ENDOSCOPIC MANAGEMENT OF PERFORATING FOREIGN BODIES IN UPPER GASTROINTESTINAL TRACT: A RETROSPECTIVE STUDY OF 296 CASES IN CHINA
 Ke-yang Fan, CN

14:42 - 14:48 MP319
IMPACT OF IMPROVED UPPER ENDOSCOPY QUALITY ON DETECTION OF GASTRIC PRECANCEROUS LESIONS
 Guido Manfredi, IT

14:48 - 14:54 MP320
STEPPING IT UP: PHYSICAL INACTIVITY IS ASSOCIATED WITH CAPSULE ENDOSCOPY PROLONGED GASTRIC TRANSIT TIME
 Marta Freitas, PT

Moderated Poster

14:00 – 15:00 Poster Stage 3

Investigator studies in IBD IChairs: Iris Dotan, IL
Iago Rodríguez-Lago, ES

14:00 - 14:06 MP321

COMPARATIVE DIAGNOSTIC ACCURACY OF MAGNETIC RESONANCE ENTEROGRAPHY WITH INTRAVENOUS GADOLINIUM CONTRAST ENHANCEMENT OR QUANTIFIED SMALL BOWEL MOTILITY INDEX FOR SMALL BOWEL CROHN'S DISEASE ACTIVITY: A MULTI-READER STUDY
Heather Fitzke, GB

14:06 - 14:12 MP322

THE ADDITION OF HIGH-DOSE INTRAVENOUS BOLUS OF METHYL-PREDNISOLONE INCREASES THE EARLY CLINICAL RESPONSE TO ORAL CORTICOSTEROIDS IN MODERATELY ACTIVE ULCERATIVE COLITIS. PRELIMINARY RESULTS OF A PROSPECTIVE, CONTROLLED, MULTICENTRE, RANDOMISED, OPEN-LABEL STUDY
Eugeni Domènech, ES


14:12 - 14:18 MP323

ORAL FERRIC MALTOL IMPROVES QUALITY OF LIFE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE AND IRON DEFICIENCY ANAEMIA
Juha Halonen, GB

14:18 - 14:24 MP324

COST-EFFECTIVENESS ANALYSIS OF INCREASED ADALIMUMAB DOSE INTERVALS IN PATIENTS WITH CROHN'S DISEASE IN STABLE REMISSION: ECONOMIC EVALUATION OF THE RANDOMISED CONTROLLED LAD1 TRIAL
Reinier C.A. van Linschoten, NL

14:24 - 14:30 MP325

MODIFIED CRP CUT-OFF IS AS GUIDING AS FCP FOR PREDICTION OF BOTH ENDOSCOPIC AND HISTOLOGIC REMISSIONS IN ULCERATIVE COLITIS PATIENTS 
Oguz Kagan Bakkaloglu, TR

14:30 - 14:36 MP326

CLINICAL AND BIOMARKER REMISSION IS MAINTAINED AFTER SWITCH FROM MONTHLY DOSED VEDOLIZUMAB TO THE NOVEL SUBCUTANEOUS FORMULATION IN INFLAMMATORY BOWEL DISEASE
Gregor Novak, SI

14:36 - 14:42 MP327

ON-LINE PSYCHOLOGICAL INTERVENTION IMPROVES DISEASE-RELATED COPING STRATEGIES IN PATIENTS WITH CROHN'S DISEASE
Orly Sarid, IL

14:42 - 14:48 MP328

MULTIPLE INFlixIMAB BIOSIMILAR SWITCHES APPEAR TO BE SAFE AND EFFECTIVE IN A REAL-WORLD IBD COHORT
Beatriz Gros, ES

14:48 - 14:54 MP329

REAL-WORLD MULTICENTER COMPARISON OF SHORT AND LONG-TERM EFFECTIVENESS AND SAFETY BETWEEN TOFACITINIB AND VEDOLIZUMAB IN PATIENTS WITH ULCERATIVE COLITIS AFTER FAILURE TO AT LEAST ONE ANTI-TNF AGENT

Anthony Buisson, FR

14:54 - 15:00 MP330

USTEKINUMAB IS ASSOCIATED WITH SUPERIOR TREATMENT PERSISTENCE BUT NOT WITH HIGHER REMISSION RATES COMPARED TO VEDOLIZUMAB IN REFRACTORY CROHN'S DISEASE PATIENTS: RESULTS FROM A MULTICENTRE COHORT STUDY
Péter Bacsur, HU

Moderated Poster

14:00 – 15:00 Poster Stage 4

DyspepsiaChairs: Maura Corsetti, GB
Sebastien Kindt, BE

14:00 - 14:06 MP301

FACTORS ASSOCIATED WITH PLACEBO TREATMENT RESPONSE IN A FUNCTIONAL DYSPEPSIA CLINICAL TRIAL
Michael P. Jones, AU

14:06 - 14:12 MP302

DIAGNOSTIC YIELD OF UPPER GASTROINTESTINAL ENDOSCOPY IN PATIENTS WITH SYMPTOMS COMPATIBLE WITH FUNCTIONAL DYSPEPSIA
Hannah Lorraine-Francis, GB

14:12 - 14:18 MP303

PSYCHOLOGICAL DISTRESS PREDICTS GASTROINTESTINAL SYMPTOMS AND VICE VERSA OVER HOURS AND DAYS: GUT-BRAIN INTERACTIONS ASSESSED VIA ECOLOGICAL MOMENTARY ASSESSMENT
Michael P. Jones, AU

14:18 - 14:24 MP304

CONFOCAL LASER ENDOMICROSCOPY FOOD ALLERGY TESTING IN FUNCTIONAL DYSPEPSIA AND IRRITABLE BOWEL SYNDROME
Lukas Balsiger, BE

14:24 - 14:30 MP305

SUPRAGASTRIC BELCHING: MORE FREQUENT THAN EXPECTED AND ASSOCIATED WITH ESOPHAGEAL HYPOMOTILITY AND ACID REFLUX
Ilia Sergeev, GB

14:30 - 14:36 MP306

EFFICACY ANALYSIS OF TRADIPITANT IN IDIOPATHIC AND DIABETIC GASTROPARESIS IN STUDY VP-VLY-686-3301
Jesse L. Carlin, US

14:36 - 14:42 MP307

THE EFFECT OF CORTICOTROPIN-RELEASE HORMONE ON DUODENAL PERMEABILITY IN HEALTHY VOLUNTEERS
Jolien Schol, BE

14:42 - 14:48 MP308
EFFECTIVENESS OF TREATMENTS AGAINST *HELICOBACTER PYLORI* ACCORDING TO RESISTANCE TO CLARITHROMYCIN: DATA FROM THE EUROPEAN REGISTRY ON *HELICOBACTER PYLORI* MANAGEMENT (HP-EUREG)
 Olga Perez Nyssen, ES

14:48 - 14:54 MP309
ONLINE EDUCATION SIGNIFICANTLY IMPROVED PHYSICIANS' AND PHARMACISTS' KNOWLEDGE AND CONFIDENCE IN THE MANAGEMENT OF REFLUX DISEASE
 James White, GB

14:54 - 15:00 MP310
CLINICAL PHENOTYPES THROUGH MACHINE LEARNING OF FIRST-LINE TREATED PATIENTS IN EUROPE DURING THE PERIOD 2013-2021: DATA FROM THE EUROPEAN REGISTRY ON *H. PYLORI* MANAGEMENT (HP-EUREG)
 Olga Perez Nyssen, ES

TV Studio Session

15:00 - 15:30 TV Studio
UEG Week digested
 Chairs: Cesare Hassan, IT
 Evelien Dekker, NL

Q+A LIVE

myUEG Community Programme

15:00 - 15:30 MyUEG Community Area
Connect with... #UEGEdu Chair
 Chairs: Henriette Heinrich, CH

Session

15:30 - 16:30 D3
COVID-19 still here: Lessons and questions
 Chairs: Iris Dotan, IL
 Tine Jess, DK

Q+A LIVE

15:30 - 15:42 OP151
IMMUNOGENICITY AND SAFETY OF A THREE-DOSE SARS-COV-2 VACCINATION STRATEGY IN PATIENTS WITH IMMUNE-MEDIATED INFLAMMATORY DISEASES ON IMMUNOSUPPRESSIVE THERAPY
 Kristin Hammersbøen Bjørlykke, NO

15:42 - 16:04 IP321
GI patients at risk due to COVID-19
 Francisca Joly, FR

16:04 - 16:26 IP322
Transition to digital healthcare & research: What do we keep and what do we forget?
 Maria T. Abreu, US

Session

15:30 - 16:30 A1
Never waste a good disaster (Upper GI)
 Chairs: Ian Mark Gralnek, IL
 Alessandro Repici, IT

Q+A LIVE

15:30 - 15:40 IP324
What I regretted most in staging of Barrett's cancer
 Ahmed Ba-Ssalamah, AT

15:40 - 15:50 IP323
What I regretted most in the treatment of Barrett's early cancer
 Jacques J. Bergman, NL

15:50 - 15:55 IP325
What I regretted most in the diagnosis of coeliac disease

15:55 - 16:00 IP326
What I regretted most in the diagnosis of coeliac disease

 Rachel Gingold-Belfer, IL

16:00 - 16:10
Q&A

16:10 - 16:15 IP327
What I regretted most in the treatment of gastric varices

 Max Seidensticker, DE

16:15 - 16:20 IP328
What I regretted most in the treatment of gastric varices

 Tomas Hucl, CZ

16:20 - 16:30
Q&A

Session

15:30 - 16:30 A2
HCC and CCA
 Chairs: Ana Lleo, IT
 Jessica Zucman-Rossi, FR

Q+A LIVE

15:30 - 15:50 IP329
Benefits and harms of novel therapeutics in HCC
 Maria Varela, ES

15:50 - 16:10 IP330
Molecular Subtyping in HCC and CCA: Does it matter?
 Jessica Zucman-Rossi, FR

16:10 - 16:30 IP331
Evaluation of the treatment response in HCC and CCA
 Christoph Zech, CH

Session

15:30 – 16:30 A3
Therapy update: Coeliac disease
 Chairs: Christophe Cellier, FR
 Nick Trott, GB

Q+A LIVE

15:30 - 15:50 IP332
Nutritional support in celiac disease: Less is more
 Nick Trott, GB

15:50 - 16:10 IP333
Therapy of coeliac disease with oral transglutaminase 2 inhibitors
 Detlef Schuppan, DE

16:10 - 16:30 IP334
Drugs in the pipeline
 Markku Mäki, FI

Session

15:30 – 16:30 C1
Constipation: A challenge in paediatric and adult care
 Chairs: Hankje Escher, NL
 Magnus Simrén, SE

Q+A LIVE

15:30 - 15:50 IP335
Role of diet in constipation: Lessons from fiber
 Kristin Verbeke, BE

15:50 - 16:00 IP336
How do I manage constipation in children?
 Marc A. Benninga, NL

16:00 - 16:07 IP337
How do I manage constipation in adults?
 Maura Corsetti, GB

16:07 - 16:17 IP338
What to do when everything fails?
 Emma V. Carrington, GB

16:17 - 16:30
Q&A Constipation: A challenge in paediatric and adult care

Session

15:30 – 16:30 C2
Where basic scientists meet clinicians: GI complications of CPI therapy
 Chairs: Irit Ben-Aharon, IL
 Ausra Lukosiute-Urboniene, LT

Q+A LIVE

15:30 - 15:40 IP339
Pathogenesis of immune check point inhibitor side effects
 David Weinberg, US

15:40 - 15:50 IP340
Complications of check point therapies in daily clinical practice

Enrico De Toni, DE
 15:50 - 16:05

Q&A

16:05 - 16:30 IP342
Graft-versus-Host-Disease: Why does it matter and how to handle?

Evgenii Shumilov, DE

Translational/Basic Science Session

15:30 – 16:30 D4

Entero-endocrine cells: Key sensors in health and disease

Chairs: Guy E. Boeckstaens, BE
 Jutta Keller, DE

Q+A LIVE

15:30 - 16:00 IP344

EEC cells in IBS

Alexandre Denadai-Souza, BE

16:00 - 16:30 IP345

EEC cells in obesity

Ashley Blackshaw, GB

Today's Science, Tomorrow's Medicine Session

15:30 – 16:30 Strauss 2

Targeting cellular processes in regeneration and cancer

Chairs: Marina Berenguer, ES
 Dieter Saur, DE

Q+A LIVE

15:30 - 15:50 IP346

Molecular mechanisms regulating cellular heterogeneity in pancreatic cancer

Axel Behrens, GB

15:50 - 16:10 IP347

Rising Star: Organoids in bile duct regeneration

Fotios Sampaziotis, GB

Session

15:30 – 16:30 Strauss 3

Therapy update: Useful tips in gastroprotection

Chairs: Dan Lucian Dumitrascu, RO
 Peter Malfertheiner, DE

Q+A LIVE

15:30 - 15:50 IP348

Antiplatelet, NSAID and anticoagulant therapy

Jan Bornschein, GB

15:50 - 16:10 IP349

PPI treatment: New players on the rise

Prateek Sharma, US

16:10 - 16:30 IP350
H. Pylori vaccination: Rrelevant progress?
 Francis Mégraud, FR

Abstract-based Session

15:30 - 16:30 Lehar 2
Real world evidence in IBD
 Chairs: Richard K Russell, GB
 Ignacio Catalan-Serra, NO

Q+A LIVE

15:30 - 15:42 OP152
REAL WORLD EVIDENCE OF TOFACITINIB IN ULCERATIVE COLITIS: SHORT AND LONG-TERM EFFECTIVENESS, SAFETY AND IMPACT OF EXTRAINTESTINAL MANIFESTATIONS AND IMMUNOMEDIATED DISEASES
 Maria Chaparro Sanchez, ES

15:42 - 15:54 OP153
THIRD-LINE THERAPY IN REFRACTORY ULCERATIVE COLITIS: A COMPARISON BETWEEN TOFACITINIB AND USTEKINUMAB
 Mariangela Allocca, IT

15:54 - 16:06 OP154
SAFETY AND LONG-TERM PERSISTENCE OF BIOLOGICAL TREATMENTS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE. DIFFERENCES BETWEEN WOMEN AND MEN: SEXEII STUDY OF ENEIDA
 Fernando Gomollon, ES

16:06 - 16:18 OP155
BENEFITS OF PAEDIATRIC TO ADULT TRANSITION PROGRAM IN INFLAMMATORY BOWEL DISEASE: THE BUTTERFLY STUDY OF GETECCU
 Cristina Rubín de Célix, ES

16:18 - 16:30 OP156
WHAT FACTOR PREDICTS THE DEVELOPMENT OF ABDOMINAL PAIN IN CHILDREN?
 Kazuya Takahashi, GB

Abstract-based Session

15:30 - 16:30 Lehar 3
Artificial intelligence in endoscopy
 Chairs: Roos E. Pouw, NL
 Alexander Hann, DE

Q+A LIVE

15:30 - 15:42 OP157
TRANSFERABILITY OF A CONVOLUTIONAL NEURAL NETWORK TO CHARACTERISE COLORECTAL POLYPS
 Rawen Kader, GB

15:42 - 15:54 OP158
AN INTELLIGENT AND REAL-TIME ENDOSCOPIC ANALYTICAL DEVICE(IREAD) AIMED AT DIAGNOSING GASTRIC NEOPLASTIC LESIONS UNDER WHITE LIGHT AND WEAK MAGNIFICATION ENDOSCOPY
 Hongliu Du, CN

15:54 - 16:06 OP159
PRELIMINARY RESULTS OF A NOVEL COMPUTER AIDED DETECTION SYSTEM FOR PANCREATIC LESIONS ON EUS
 Tom Konikoff, IL

16:06 - 16:18 OP161
A COMPUTER AIDED DETECTION SYSTEM FOR BARRETT'S NEOPLASIA IMPROVES NEOPLASIA DETECTION
 Kiki Fockens, NL

Abstract-based Session

15:30 - 16:30 Lehar 4
Molecular mechanisms of cancer development
 Chairs: Loris Riccardo Lopetuso, IT
 Luigi Ricciardiello, IT

Q+A LIVE

15:30 - 15:42 OP146
MICROBIAL-DEPENDENT INTESTINAL TUMOURIGENESIS IN ATF6-DRIVEN COLITIS-ASSOCIATED-CANCER
 Janine Kövilein, DE

15:42 - 15:54 OP147
BLOCKING IL-20 CYTOKINE FAMILY SIGNALING ATTENUATED COLITIS-ASSOCIATED CANCER BY MODULATING GAS6-MEDIATED WOUND HEALING
 Jan Hendrik Niess, CH

15:54 - 16:06 OP148
DETAILED MAPPING OF COPY NUMBER ALTERATIONS IN THE INFLAMMATORY BOWEL DISEASE COLON REVEALS LARGE CLONAL EXPANSIONS AND PATTERNS OF CONVERGENT EVOLUTION
 Mehmet Yalchin, GB

16:06 - 16:18 OP149
ATM DEFICIENCY DRIVES METABOLIC REPROGRAMMING IN PANCREATIC CANCER CELLS
 Anna Härle, DE

16:18 - 16:30 OP150
COMPARTMENT-SPECIFIC ROLE OF DKK3 IN THE DEVELOPMENT OF PANCREATIC DUCTAL ADENOCARCINOMA
 Dharini Srinivasan, DE

Moderated Poster

15:30 - 16:30 Poster Stage 1
Update on the biliary compartment
 Chairs: Thierry Ponchon, FR
 Rogier P. Voermans, NL

15:30 - 15:36 MP291
LEARNING FOR AUTOMATIC DIAGNOSIS AND CHARACTERIZATION OF MALIGNANT BILIARY STRICTURES IN DIGITAL SINGLE-OPERATOR CHOLANGIOSCOPY: A PILOT STUDY
 Tiago Ribeiro, PT

15:36 - 15:42 MP292
POST-ERCP PERSISTENT HEPATOCELLULAR SECRETORY FAILURE (PHSF): A MULTICENTER RETROSPECTIVE CASE SERIES
 Mohsan Subhani, GB

15:42 - 15:48 MP293
EFFICACY OF A NEWLY DEVELOPED 0.025-INCH GUIDEWIRE FOR SELECTIVE BILIARY ACCESS: TECHNICAL PROPERTY ANALYSIS AND A MULTICENTER NON-INFERIORITYCLINICAL TRIAL
 Tae Hoon Lee, KR

15:48 - 15:54 MP294
PREOPERATIVE BILIARY DRAINAGE IN PATIENTS WITH RESECTABLE PERIHILAR CHOLANGIOCARCINOMA: DO UNCOVERED METAL STENTS BEAT PLASTIC STENTS?
 David de Jong, NL

15:54 - 16:00 MP295
INCIDENCE OF RECURRENT CHOLANGITIS IN PATIENTS WITH A NON-STENOTIC HEPATICOJEJUNOSTOMY
 Bernice Margu rite van der Lecq, NL

16:00 - 16:06 MP296
USEFULNESS AND SAFETY OF A NEW DIGITAL SINGLE-OPERATOR CHOLANGIOSCOPY: A SINGLE-CENTER EXPERIENCE
 Jorge Baquerizo-Burgos, EC

16:06 - 16:12 MP297
OPTIMIZATION OF CHOLANGIOSCOPY-GUIDED BIOPSIES IN THE DIAGNOSIS OF CHOLANGIOCARCINOMA
 Joel Ferreira-Silva, PT

16:12 - 16:18 MP298
CHOLECYSTECTOMY INCREASES LONG-TERM MORTALITY AND MYOCARDIAL INFARCTION
 Myong Ki Baeg, KR

16:18 - 16:24 MP299
EFFECTS OF BILE ACID COMPOSITION ON BACTERIAL STRAINS IN BILIARY TRACT INFECTION
 Kihyun Ryu, KR

16:24 - 16:30 MP300
PSC RADIOMICS SCORE (PRS): A RADIOMICS-BASED MODEL FOR MEDIUM-TERM OUTCOME PREDICTION IN PRIMARY SCLEROSING CHOLANGITIS
 Laura Cristoferi, IT

Moderated Poster

15:30 – 16:30 Poster Stage 2
Colonoscopy
 Chairs: Matt Rutter, GB
 Marianna Signoretti, IT

15:30 - 15:36 MP351
POST-COLONOSCOPY RECTAL CANCER IN SWEDISH PATIENTS WITH CROHN’S DISEASE 2001-2015 – A POPULATION-BASED CASE REVIEW STUDY
 Jessica Stj rngrim, SE

15:36 - 15:42 MP352
INFLAMMATORY BOWEL DISEASE IS NOT LINKED TO MORE ADVERSE EVENTS IN COLONOSCOPY
 Bjarki B r Alexandersson, SE

15:42 - 15:48 MP353
CORRELATION BETWEEN ULTRASOUND AND ENDOSCOPIC SCORES FOR ASSESSING INFLAMMATORY ACTIVITY IN CROHN'S DISEASE
 Irene Rodr guez, ES

15:48 - 15:54 MP354
OPTICAL DIAGNOSIS PRACTICE IN THE UK: A NATIONAL SURVEY
 Ahmir Ahmad, GB

15:54 - 16:00 MP355
SCREEN-DETECTED VS. NON-SCREEN-DETECTED COLORECTAL CANCER IN GERMANY: A CLAIMS DATA ANALYSIS
 Sarina Schwarz, DE

16:00 - 16:06 MP356
WATER-ASSISTED COLONOSCOPY PRACTICE IN THE UK: A NATIONAL SURVEY
 Ahmir Ahmad, GB

16:06 - 16:12 MP357
EFFECTIVENESS OF DIFFERENT VOLUMES OF PEG PREPARATION FOR COLONOSCOPY IN THE ELDERLY: A RETROSPECTIVE ANALYSIS OF A PROSPECTIVE COHORT
 Marcello Fabio Maida, IT

16:12 - 16:18 MP358
TRUST IN ARTIFICIAL INTELLIGENCE FOR THE OPTICAL DIAGNOSIS OF COLORECTAL POLYPS
 Quirine Eunice Wennie van der Zander, NL

16:18 - 16:24 MP359
INFLUENCE OF ARTIFICIAL INTELLIGENCE ON THE ADENOMA DETECTION RATE THROUGHOUT THE DAY
 Jochen Weigt, DE

16:24 - 16:30 MP360
DOES ENDOSONOGRAPHIC ESTIMATION OF INFILTRATION DEPTH IN SUSPECTED POLYP OR EARLY CARCINOMA OF THE RECTUM DESERVE RECONSIDERATION?
 Frank ter Borg, NL


Moderated Poster

15:30 – 16:30 Poster Stage 3
Investigator studies in IBD II
 Chairs: Georgiana- Emmanuela G lc -Blanariu, RO
 Lieven Pouillon, BE

15:30 - 15:36 MP281
EARLY ANTI-TNF RESULTS IN HIGHER SUSTAINED STEROID FREE REMISSION RATES IN NEWLY DIAGNOSED PAEDIATRIC CROHN’S DISEASE PATIENTS
 Renz Klomberg, NL

15:36 - 15:42 MP282
ENDOTROPHIN (PRO-C6) IS ASSOCIATED WITH MRE CONFIRMED INTESTINAL STRICTURES AND PROTEIN FINGERPRINT BIOMARKERS OF COLLAGEN DEGRADATION IS ASSOCIATED WITH ULCERATIONS IN PAEDIATRIC CROHN'S DISEASE PATIENTS – RESULTS FROM THE IMAGEKIDS STUDY

Joachim Høg Mortensen, DK

15:42 - 15:48 MP283
MATRIX METALLOPROTEINASES GENETIC VARIANTS DETERMINE RISK OF COLON DIVERTICULOSIS 
 Piotr Nehring, PL

15:48 - 15:54 MP284
THE EFFECT OF MIRIKIZUMAB ON FECAL CALPROTECTIN AND C-REACTIVE PROTEIN IN PHASE 3 STUDIES OF PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
 Britta Siegmund, DE

15:54 - 16:00 MP285
DEVELOPMENT AND VALIDATION OF A REMOTE MONITORING TOOL FOR REAL-WORLD ASSESSMENT OF MILD, MODERATE, AND SEVERE INFECTIONS IN INFLAMMATORY BOWEL DISEASE PATIENTS
 Ashkan Rezazadeh Ardabili, NL

16:00 - 16:06 MP286
TRANSMURAL REMISSION IMPROVES CLINICAL OUTCOMES UP TO 5 YEARS IN PATIENTS WITH CROHN'S DISEASE A MULTICENTER CASE-COHORT STUDY
 Samuel Raimundo Fernandes, PT

16:06 - 16:12 MP287
SWITCH FROM INTRAVENOUS TO SUBCUTANEOUS INFlixIMAB THERAPY IN CLINICAL PRACTICE: EFFICACY AND SAFETY IN INFLAMMATORY BOWEL DISEASE
 Berta Caballol Oliva, ES

16:12 - 16:18 MP288
EARLY ULTRASOUND ASSESSMENT PREDICTS THERAPY RESPONSE: AN EASYTOOL FOR CLINICAL DECISION MAKING
 Emma Calabrese, IT

16:18 - 16:24 MP289
ETRASIMOD 2MG ONCE DAILY AS TREATMENT FOR BIOLOGIC/JANUS KINASE INHIBITOR-NAÏVE AND -EXPERIENCED PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: SUBGROUP ANALYSIS FROM THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 TRIALS
 Brian Feagan, CA

16:24 - 16:30 MP290
SUPERIOR EFFECTIVENESS OF TOFACITINIB COMPARED TO VEDOLIZUMAB IN ANTI-TNF EXPERIENCED ULCERATIVE COLITIS PATIENTS: A NATIONWIDE DUTCH REGISTRY STUDY
 Tessa Straatmijer, NL

Moderated Poster

15:30 – 16:30 Poster Stage 4

Neoplasia

Chairs: Cesare Hassan, IT
 Juozas Kupcinskas, LT

15:30 - 15:36 MP341
MISMATCH REPAIR PROTEIN STATUS AND EBSTEIN-BARR VIRUS POSITIVITY IN GASTRIC CANCER DO NOT SEEM TO INFLUENCE RESPONSE TO PERI-OPERATIVE CHEMOTHERAPY
 Catarina Nascimento, PT

15:36 - 15:42 MP342
CLINICOPATHOLOGICAL CHARACTERISTICS AND PROGNOSTIC FACTORS OF SMALL BOWEL LYMPHOMAS: A RETROSPECTIVE SINGLE-CENTER STUDY
 Renato Medas, PT

15:42 - 15:48 MP343
CLINICAL CHARACTERISTICS AND LONG-TERM PROGNOSIS OF GASTRIC NEUROENDOCRINE TUMORS WITH AUTOIMMUNE GASTRITIS: RETROSPECTIVE, MULTICENTER STUDY IN JAPAN
 Tomoari Kamada, JP

15:48 - 15:54 MP344
GASTRIC CANCER MUCOSAL MICROBIOME IS ASSOCIATED WITH PROGNOSIS OF GASTRIC CANCER PATIENTS
 Konrad Lehr, DE

15:54 - 16:00 MP345
CHARACTERISTICS AND RISK FACTORS OF PATIENTS WITH SYNCHRONOUS MULTIPLE GASTRIC CANCERS IN ONE TERTIARY HOSPITAL IN SOUTH KOREA
 Du Hyun Song, KR

16:00 - 16:06 MP346
IMPACT OF VONOPRAZAN ON GASTROINTESTINAL MICROBIOTA IN INS-GAS MICE
 Chao Peng, CN

16:06 - 16:12 MP347
RISK SCORE FOR METACHRONOUS GASTRIC LESIONS FOLLOWING ENDOSCOPIC RESECTION
 Andreia Rei, PT

16:12 - 16:18 MP348
POTASSIUM-COMPETITIVE ACID BLOCKER TEGOPRAZAN SUPPRESSED THE PROLIFERATION AND PROGRESSION OF GASTRIC CANCER CELL
 Sang Kil Lee, KR

16:18 - 16:24 MP349
SERUM PEPSINOGEN LEVELS IN PATIENTS WITH DIFFERENT TYPES OF ATROPHIC GASTRITIS MEASURED BY ELISA AND CHEMILUMINESCENT IMMUNOASSAY
 Nicolas Chapelle, FR

16:24 - 16:30 MP350
CANCER YIELD FROM OGDS IN THE UK: ANALYSIS USING AUTOMATICALLY UPLOADED REPORTS FROM THE NATIONAL ENDOSCOPY DATABASE (NED)
 David Beaton, GB

TV Studio Session

16:30 – 17:00

TV Studio

Grow with us: UEG beyond UEG Week

Chairs: Jeanin E. van Hooft, NL

Berthold Koletzko, DE

Pilar Acedo, GB

Myriam Ayari, TN

Q+A  LIVE

Industry Symposia

17:00 – 18:00

A1

What do UC on the horizon: exploring the emerging management optionsQ+A  LIVE

Industry Symposia

17:00 – 18:00

A2

Navigating Experience and Possibilities with Subcutaneous Infliximab as a Biobetter in IBDQ+A  LIVE

Industry Symposia

17:00 – 18:00

A3

On the breadcrumb path – discussing lymphocyte egress in UCQ+A  LIVE

Industry Symposia

17:00 – 18:00

C1

JAK Inhibition in Practice: Continuing the Story ThreadQ+A  LIVE

Industry Symposia

17:00 – 18:00

D4

IBD management: From the present to the futureQ+A  LIVE

Scientific Programme by Day

Tuesday, October 11, 2022


Session

08:00 – 09:00 D3

Ongoing dilemmas in refractory ulcerative colitis
Chairs: Emma V. Carrington, GB
Roel Hompes, NL

Q+A  LIVE

08:00 – 08:20 IP351


Rising Star: Bowel decontamination: “Haute couture” manipulation of the gut microbiome - what for? 

Gianluca Pellino, IT

08:20 – 08:40 IP352


Colectomy and pouch anatomy: The optimal procedure!
Willem A. Bemelman, NL

08:40 – 08:47 IP353

Additional (experimental) therapy to save the colon in therapy refractory UC: How? Who? When? - The surgeon's view 

Christianne Johanna Buskens, NL

08:47 – 08:54 IP354

Additional (experimental) therapy to save the colon in therapy refractory UC: How? Who? When? - The gastroenterologist's view 

Carmen Stefanescu, FR

08:54 – 09:00
Q&A

Session

08:00 – 09:00 A1

What's new in HPB oncology 2022?
Chairs: Jesús M. Bañales, ES
Vinciane Rebours, FR

Q+A  LIVE

08:00 – 08:20 IP355

Hot topics in HPB medical oncology
Thomas Seufferlein, DE

08:20 – 08:40 IP356

When is transplant a cure for CholangioCa?
Gabriela A. Berlakovich, AT

08:40 – 09:00 IP357

What's new HPB surgery?
Marc G. Besselink, NL

Session

08:00 – 09:00 A3

Therapy update: Ulcerative colitis
Chairs: Alessandro Armuzzi, IT
Iris Dotan, IL

Q+A  LIVE

08:00 – 08:20 IP358

Janus Kinase inhibition: Class(y) effects or unique drugs?

Laurent Peyrin-Biroulet, FR

08:20 – 08:40 IP359

Blockade of cellular trafficking: Anti-integrins and beyond?

Tim Raine, GB

08:40 – 09:00 IP360

Anti-TNF-still the best option in ulcerative colitis?
Maria T. Abreu, US

Session

08:00 – 09:00 C1

What's new in 2022? IBS: A psychosomatic disorder or food allergy
Chairs: Lin Chang, US
Robin Spiller, GB

Q+A  LIVE

08:00 – 08:20 IP361

Psychological factors
Lukas Van Oudenhove, BE

08:20 – 08:40 IP362

Biological factors
Giovanni Barbara, IT

08:40 – 09:00 IP363

Food allergy
Guy E. Boeckxstaens, BE

Translational/Basic Science Session

08:00 – 09:00 D4

Studying individual cells: The human cell atlas
Chairs: Alexandre Denadai-Souza, BE
Fotios Sampaziotis, GB

Q+A  LIVE

08:00 – 08:20 IP364

Single-cell transcriptomics to study the biology of cells in health and disease
Thierry Voet, BE

08:20 – 08:40 IP365

Putting single-cell data in anatomical context: Spatial transcriptomics
Eduardo Villablanca, SE

08:40 – 09:00 IP366

Human genetic variation at the single cell level
Henry Lee-Six, GB

Abstract-based Session

08:00 – 09:00 Strauss 2


Immune checkpoints in liver disease
Chairs: Mathias Florian Heikenwälder, DE

Q+A  LIVE

08:00 - 08:12 OP167
SAFETY AND EFFICACY OF ATEZOLIZUMAB PLUS BEVACIZUMAB IN PATIENTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA IN EARLY CLINICAL PRACTICE: A MULTICENTER ANALYSIS
 Makoto Chuma, JP

08:12 - 08:24 OP168
EARLY NIVOLUMAB ADDITION TO REGORAFENIB IN PATIENTS WITH HEPATOCELLULAR CARCINOMA PROGRESSING UNDER 1ST LINE THERAPY (GOING TRIAL). INTERIM ANALYSIS AND SAFETY PROFILE
 Marco Sanduzzi Zamparelli, ES

08:24 - 08:36 OP169
THE SPATIAL AND UNIQUE COMPOSITION OF INFILTRATING IMMUNE CELLS DEFINES AUTOIMMUNE- AND CHECKPOINT-THERAPY ASSOCIATED HEPATITIS
 Laurenz Krimmel, DE

08:36 - 08:48 OP170
MODULATION OF THE IMMUNE ENVIRONMENT BY RIPK3 IN HEPATOCELLULAR CARCINOMA 
 André Cardador, PT

08:48 - 09:00 OP171
MORTALITY AMONG PATIENTS WITH PAEDIATRIC ONSET IMMUNE MEDIATED INFLAMMATORY DISEASE – A NATIONWIDE STUDY FROM DENMARK

Session

08:00 – 09:00 Strauss 3
Reflux disease at 360° degree view
 Chairs: Jacques J. Bergman, NL
 Alanna Ebigbo, DE

Q+A  LIVE

08:00 - 08:20 IP367
Pathophysiology and epidemiology of GERD
 Edoardo Vincenzo Savarino, IT

08:20 - 08:40 IP368
Approach to PPI-refractory reflux
 Sabine Roman, FR

08:40 - 09:00 IP369
Anti-reflux surgery: Success and failure
 Almantas Maleckas, LT

Abstract-based Session

08:00 – 09:00 Lehar 2
Clinical aspects in chronic pancreatitis
 Chairs: Juan Enrique Dominguez-Munoz, ES
 Jonas Rosendahl, DE

Q+A  LIVE

08:00 - 08:12 OP172
SINGLE-OPERATOR VIDEO PANCREATOSCOPY (SOVP) FOR THE MANAGEMENT OF SYMPTOMATIC PANCREATIC DUCT STONES IN SELECTED CHRONIC PANCREATITIS PATIENTS. A PROSPECTIVE INTERNATIONAL MULTICENTRE COHORT TRIAL

Christian Gerges, DE

08:12 - 08:24 OP173
THE HYBRID ALLELE 1 OF CARBOXYL-ESTER LIPASE (CEL-HYB1) ELEVATES THE RISK OF CHRONIC PANCREATITIS IN HUNGARY: A CASE-CONTROL STUDY
 Gergő Berke, HU

08:24 - 08:36 OP174
PULMONARY FUNCTION IS COMPROMISED IN PATIENTS WITH CHRONIC PANCREATITIS
 Amer Hadi, DK

08:36 - 08:48 OP175
A MULTICENTER RETROSPECTIVE STUDY OF COMPARISON WITH STEP-UP TREATMENT AFTER EUS-GUIDED TRANSMURAL DRAINAGE FOR WALLED-OFF NECROSIS: WONDERFUL STUDY GROUP
 Tomotaka Saito, JP

Abstract-based Session

08:00 – 09:00 Lehar 4
Epidemiology in GI disease
 Chairs: Rupa Banerjee, IN
 Julien Kirchgesner, FR

Q+A  LIVE

08:00 - 08:12 OP176
INFLAMMATORY BOWEL DISEASE AND SOLID ORGAN TRANSPLANTATION. NATURAL HISTORY OF PRE-EXISTING AND DE NOVO IBD PATIENTS. (EITOS STUDY OF GETECCU)
 Iria Bastón-Rey, ES

08:12 - 08:24 OP177
MORBID OBESITY, A NEW SUSCEPTIBILITY FACTOR FOR DEVELOPING INFLAMMATORY BOWEL DISEASE. RESULTS OF A POPULATION-BASED STUDY
 Fiorella Cañete, ES

08:24 - 08:36 OP179
EXPERIENCE WITH SINGLE-CAPSULE BISMUTH QUADRUPLE THERAPY IN 6,000 PATIENTS FROM THE EUROPEAN REGISTRY ON *H. PYLORI* MANAGEMENT (HP-EUREG)
 Olga Perez Nyssen, ES

08:36 - 08:48 OP180
THE ASSOCIATION OF INFLAMMATORY BOWEL DISEASE WITH CELIAC DISEASE AND CELIAC AUTOIMMUNITY, IN CHILDREN AND ADULTS: A NATIONWIDE STUDY FROM THE EPI-IIRN
 Michal Kori, IL

Live Demo
 08:00 – 16:30 Stolz 1-2, Foyer
Endoscopy Learning Area & Ultrasound Learning Area

Live Demo
 08:30 – 09:30 A2
Live Endoscopy I
 Chairs: Paraskevas Gkolfakis, BE
 Cesare Hassan, IT
 Helmut Messmann, DE
 Marianna Arvanitakis, BE
 Raf Bisschops, BE
 Ulrike Walburga Denzer, DE
 Pierre Henri Deprez, BE
 Jacques Deviere, BE
 Pierre Eisendrath, BE
 Tomas Hucl, CZ
 Arnaud Lemmers, BE
 Horst Neuhaus, DE

Q+A LIVE

TV Studio Session
 09:00 – 09:30 TV Studio
Good Morning UEG Week
 Chairs: Patrizia Burra, IT
 Henriette Heinrich, CH
 Charles Murray, GB
 Dieter Hahnloser, CH

Q+A LIVE

Poster Exhibition
 09:00 – 15:30 Science Lounge
Poster Exhibition

myUEG Community Programme
 09:00 – 09:30 MyUEG Community Area
Young GI: Mentoring Programme
 Chairs: Annalisa Berzigotti, CH
 Jan Bornschein, GB
 Iris Dotan, IL
 Ana Lleo, IT
 Hans Törnblom, SE
 Yasmijn van Herwaarden, NL

Session
 09:30 – 10:30 D3
Challenges and lessons managing lower GI disorders with limited healthcare resources
 Chairs: Mohamed Alboraei, EG
 Wafaa Khannoussi, MA

Q+A LIVE

09:30 - 09:50 IP370
Managing lower GI disorders in immigrant populations
 09:50 - 10:10 IP371
Terminal ileitis in tuberculosis endemic populations
 Rupa Banerjee, IN

10:10 - 10:30 IP372
Surgical challenges and opportunities
 Hanoch Kashtan, IL

Session
 09:30 – 10:30 A1
From guidelines to clinical practice: IgG4-related diseases
 Chairs: Ulrich Beuers, NL
 Matthias Löhr, SE

Q+A LIVE

09:30 - 09:50 IP373
What have we learned from the 2020 guideline?
 Miroslav Vujasinovic, SE

09:50 - 10:10 IP374
Diagnosing IgG4-related diseases: Is histology still the gold-standard?
 Ann Driessen, BE

10:10 - 10:30 IP375
Treatment of IgG4-related diseases: Where is the evidence?
 Vinciane Rebours, FR

Session
 09:30 – 10:30 A3
Therapy update: Crohn's disease
 Chairs: Florian Rieder, US
 Severine Vermeire, BE

Q+A LIVE

09:30 - 09:50 IP376
IL-23p19 inhibitors
 Matthieu Allez, FR

09:50 - 10:10 IP377
Anti-TNF's: Still the best option in Crohn's disease
 Joana Torres, PT

10:10 - 10:30 IP378
Small molecules for Crohn's disease
 Silvio Danese, IT

Session
 09:30 – 10:30 C1
Gastric cancer: New insights
 Chairs: Jan Bornschein, GB
 Marcis Leja, LV

Q+A LIVE

09:30 - 09:50 IP379
Epidemiology and trends in gastric cancer
 Isabelle Soerjomataram, FR

09:50 - 10:10 IP380
Endoscopic diagnosis and treatment
 Mario Dinis-Ribeiro, PT

10:10 - 10:30 IP381
Advances in medical management of gastric cancer
 Tamara Matysiak-Budnik, FR

Session

09:30 - 10:30 C2
Where basic scientists meet clinicians: Mechanisms of injury and implications for the clinician
 Chairs: Luca Miele, IT
 Emmanuel Tsochatzis, GB

Q+A LIVE

09:30 - 09:40 IP382
Pathophysiological implications of the microbiome in pancreatic disease
 Fabian Frost, DE

09:40 - 09:50 IP383
Linking the microbiome to pancreatic diseases in the clinic today
 Verena Keitel-Anselmino, DE

09:50 - 10:00
Q&A

10:00 - 10:10 IP384
Rising Star: A role for miRNA-21 in non-alcoholic fatty liver disease (NAFLD) pathogenesis
 Pedro M. Rodrigues, ES

10:10 - 10:20 IP385
Genetic risk stratification of NAFLD in clinical care: Where do we stand today?
 Salvatore Petta, IT

10:20 - 10:30
Q&A

Translational/Basic Science Session

09:30 - 10:30 D4
Faecal microbial transplantation: Fact or fiction?
 Chairs: Gianluca Ianaro, IT
 Benjamin Mullish, GB

Q+A LIVE

09:30 - 09:50 IP386
How to select the perfect donor?
 Harry Sokol, FR

09:50 - 10:10 IP387
Faecal transplantation in IBD: Does it work?
 Gianluca Ianaro, IT

10:10 - 10:30 IP388
Faecal transplantation in IBS: Does it help?
 Robin Spiller, GB

Abstract-based Session

09:30 - 10:30 Strauss 2
Techniques in endoscopy
 Chairs: Adi Lahat, IL
 Pradeep Mundre, GB

Q+A LIVE

09:30 - 09:42 OP181
EN BLOC RESECTION BY ENDOSCOPIC SUBMUCOSAL DISSECTION VERSUS ENDOSCOPIC PIECEMEAL MUCOSAL RESECTION FOR LARGE NON-PEDUNCULATED COLONIC ADENOMAS: A RANDOMIZED COMPARATIVE TRIAL (RESECT COLON)
 Jérémie Jacques, FR

09:42 - 09:54 OP182
RECTAL PRESERVATION FOLLOWING ENDOSCOPIC INTERMUSCULAR DISSECTION (EID) FOR DEEP SUBMUCOSAL INVASIVE RECTAL CANCER: SHORT TO INTERMEDIATE-TERM FOLLOW-UP
 Lisa van der Schee, NL

09:54 - 10:06 OP183
EFFICACY AND SAFETY OF A NOVEL HEMOSTATIC PEPTIDE SOLUTION DURING ENDOSCOPIC SUBMUCOSAL DISSECTION: A MULTICENTER RANDOMIZED CONTROLLED TRIAL
 Tsuneo Oyama, JP

10:06 - 10:18 OP184
CLINICAL OUTCOMES AND PREDICTION OF RISK FACTORS FOR RESIDUAL NEOPLASIA AFTER A NON-CURATIVE GASTRIC ESD: A MULTICENTER, MULTINATIONAL STUDY
 João Santos-Antunes, PT

10:18 - 10:30 OP185
INTERRUPTION OF ANTI-THROMBOTIC THERAPIES AND RISK OF POST-COLONOSCOPY THROMBOEMBOLIC EVENTS: A REAL-WORLD COHORT STUDY
 Wai Keung Leung, HK

Session

09:30 - 10:30 Strauss 3
Dysphagia: Achalasia and beyond
 Chairs: Roberta Maselli, IT
 Sabine Roman, FR

Q+A LIVE

09:30 - 09:50 IP389
Treatment of achalasia
 Thomas Rösch, DE

09:50 - 10:10 IP390
Abnormal manometry: EGJ outflow obstruction
 Henriette Heinrich, CH


10:10 - 10:30 IP391
Reflux after achalasia treatment
 Edoardo Vincenzo Savarino, IT

Abstract-based Session

09:30 – 10:30 Lehar 2
Understanding the biology of therapeutic response in IBD
 Chairs: Brigida Barberio, IT
 Sebastian Zundler, DE

Q+A  LIVE

09:30 - 09:42 OP186
DIFFERENTIAL AND COMBINATORIAL MECHANISM OF ACTION OF GOLIMUMAB AND GUSELKUMAB IN ULCERATIVE COLITIS INDUCTION THERAPY: IL-23 BLOCKADE DRIVES RESTORATION OF NORMAL EPITHELIUM AND MUCOSAL HEALING
 Patrick Branigan, US

09:42 - 09:54 OP187
JAK INHIBITION IN *EX-VIVO* HUMAN INTESTINAL MUCOSA ALTERS INFLAMMATORY RESPONSES MORE PROFOUNDLY IN COLON THAN IN ILEUM WHILE DISPLAYING INDIVIDUAL RESPONSES 
 Kawsar Kaboub, IL

09:54 - 10:06 OP188
EARLY MOLECULAR SIGNATURES OF THERAPEUTIC RESPONSE TO VEDOLIZUMAB THERAPY IN INFLAMMATORY BOWEL DISEASE PATIENTS IDENTIFIED USING A LONGITUDINAL MULTI-OMICS APPROACH
 Neha Mishra, DE


10:06 - 10:18 OP189
BASELINE SERUM BIOMARKERS PREDICT CLINICAL EFFICACY AND TISSUE MOLECULAR RESPONSE TO INDUCTION THERAPY WITH RITLECITINIB, AN ORAL JAK3/TEC INHIBITOR, IN ULCERATIVE COLITIS (UC) (PHASE 2B VIBRATO STUDY)
 Kenneth Hung, US

10:18 - 10:30 OP190
ANALYSIS OF THE INTERGENERATIONAL EPIGENETIC CONTRIBUTION AND THE EPIGENETIC CLOCK IN PAEDIATRIC IBD
 Alexandra Noble, GB

Abstract-based Session

09:30 – 10:30 Lehar 4
Natural history in pancreatic cancer
 Chairs: Julia Mayerle, DE

Q+A  LIVE

09:30 - 09:42 OP191
INTRADUCTAL PAPILLARY MUCINOUS NEOPLASMS IN INDIVIDUALS AT HIGH RISK OF HEREDITARY PANCREATIC CANCER: HIGHER INCIDENCE, GROWTH RATE, AND MALIGNANCY RISK 
 Kasper A. Overbeek, NL

09:42 - 09:54 OP192
HOW OFTEN IS PANCREATIC CANCER MISSED ON CT OR MRI IMAGING? A NOVEL ROOT CAUSE ANALYSIS SYSTEM TO ESTABLISH THE MOST PLAUSIBLE EXPLANATION FOR POST IMAGING PANCREATIC CANCER
 Nosheen Umar, GB

09:54 - 10:06 OP193
IN SITU DETECTION OF *KRAS(G12D)* MUTATIONS IN THE SPATIAL CONTEXT OF PANCREATIC CANCER SUBTYPES
 Ellis Michiels, BE

10:06 - 10:18 OP194
TUMORAL STATUS OF ATM DETERMINES CANCER-ASSOCIATED FIBROBLAST CELL FATE IN PANCREATIC DUCTAL ADENOCARCINOMA
 Anna Härle, DE

Moderated Poster

09:30 – 10:30 Poster Stage 1
Immune activation and autoimmune disease
 Chairs: Eleonora De Martin, FR

09:30 - 09:36 MP371
TLR4, SIBO AND GUT MICROBIOTA IN PATIENTS WITH HYPERLIPIDEMIA
 Khrystyna Kvit, UA

09:36 - 09:42 MP372
ACUTE-ON-CHRONIC LIVER FAILURE: STILL AN UNRECOGNIZED SYNDROME?
 Joana Revés, PT

09:42 - 09:48 MP373
2022 INTERNATIONAL AUTOIMMUNE HEPATITIS GROUP NON-RESPONSE CRITERIA IN AUTOIMMUNE HEPATITIS: A TOO EARLY ENDPOINT?
 Renato Medas, PT

09:48 - 09:54 MP374
FASTER DISEASE PROGRESSION OF PSC IN PATIENTS WITH ISOLATED DISEASE COMPARED TO PATIENTS WITH CONCOMITANT IBD: A RETROSPECTIVE MONOCENTRIC COHORT ANALYSIS
 Florian Rennebaum, DE

09:54 - 09:54 MP375
IS PORTAL BILIOPATHY SYMPTOMATIC ?
 Saber Hmimass, MA

09:54 - 10:00 MP376
ORTHOTOPIC LIVER TRANSPLANTATION FOR PRIMARY SCLEROSING CHOLANGITIS – DIFFERENT INDICATION GROUPS OUTCOMES, A SINGLE CENTRE EXPERIENCE
 Mojmír Hlavatý, CZ

10:00 - 10:06 MP377
ENRICHMENT OF VEILLONELLA SPECIES AND DEPLETION OF SULFATED SERUM BILE ACIDS IS CHARACTERISTIC OF PRIMARY SCLEROSING CHOLANGITIS INFLAMMATORY BOWEL DISEASE COMORBIDITY COMPARED TO INFLAMMATORY BOWEL DISEASE ALONE
 Haim Leibovitzh, CA

10:06 - 10:12 MP378
NON-ALCOHOLIC STEATOHEPATITIS (NASH) OVERLAP WITH AUTOIMMUNE HEPATITIS IS MARKED BY SEVERE PORTAL INFLAMMATION AND WEIGHT REDUCTION APPEARS TO BE ASSOCIATED WITH BIOCHEMICAL AND FIBROSIS IMPROVEMENT

Shi Ni Tan, SG

10:12 - 10:18 MP379
RESULTS OF PILOT STUDY BEFORE STARTING OF HEPATITIS C SCREENING PROGRAM IN LITHUANIA
 Limas Kupcinskas, LT

10:18 - 10:24 MP380
NON-INVASIVE MARKERS OF DISEASE TO SUPPORT MANAGEMENT OF PAEDIATRIC PATIENTS WITH AUTOIMMUNE HEPATITIS

Elizabeth Shumbayawonda, GB

Moderated Poster

09:30 – 10:30 Poster Stage 2

Biliopancreatic endoscopy II

Chairs: István Hritz, HU

George Webster, GB

09:30 - 09:36 MP431
COMPARISON OF TWO INTRADUCTAL BRUSH CYTOLOGY DEVICES FOR SUSPECTED MALIGNANT BILIARY STRICTURES: INTERIM-ANALYSIS OF A RANDOMIZED CONTROLLED TRIAL

Myrte Gorris, NL

09:36 - 09:42 MP432
EFFICACY OF ENDOSCOPIC PAPILLECTOMY FOR AMPULLARY LESIONS – DEVELOPMENT AND VALIDATION OF THEESAP-SCORE

Marcus Hollenbach, DE

09:42 - 09:48 MP433
RADIATION EXPOSURE DURING MODERN THERAPEUTIC EUS PROCEDURES: IMPLICATIONS FOR PATIENTS AND HEALTH-CARE WORKERS

Giuseppe Vanella, IT

09:48 - 09:54 MP434
PREDICTION OF MALIGNANCY WITH RGB PROFILING OF PANCREATIC MASS- ELASTOGRAPHIES AND CONTRAST-ENHANCED IMAGES BY ENDOSCOPIC ULTRASOUND

Marcel Razpotnik, AT

09:54 - 10:00 MP435
COMPARISON BETWEEN SHORT-TYPE AND LONG-TYPE SINGLE BALLOON ENTEROSCOPE FOR ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY IN SURGICALLY ALTERED ANATOMY

Yohan Lee, KR

10:00 - 10:06 MP436
ASSOCIATION BETWEEN POST ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY PANCREATITIS AND VARIOUS GENETIC VARIANTS

Young Hoon Choi, KR

10:06 - 10:12 MP437
ANALYSIS OF PANCREATIC GUIDEWIRE-ASSISTED ADVANCED CANNULATION METHODS – DATA FROM THE HUNGARIAN ERCP REGISTRY

Dániel Pécsi, HU

10:12 - 10:18 MP439
ENDOSCOPIC TREATMENT OF DIGESTIVE-RESPIRATORY FISTULAS: A MULTIDISCIPLINARY SINGLE CENTER EXPERIENCE

Paraskevas Gkolfakis, BE

10:18 - 10:24 MP440
SINGLE CENTER EXPERIENCE OF RADIOLOGICAL EMBOLIZATION OF LIVER METASTASES IN PATIENTS WITH PANCREATIC NEUROENDOCRINE NEOPLASMS

Anna Caterina Milanetto, IT

Moderated Poster

09:30 – 10:30 Poster Stage 3

Outcomes in functional GI disease

Chairs: Magnus Simrén, SE

09:30 - 09:36 MP361
A VALID SYMPTOM ASSESSMENT WITH THE ACPQ AFTER CARBOHYDRATE CHALLENGES ALLOWS THE DIFFERENTIATION OF AN INDIVIDUAL SYMPTOM RESPONSE TO SPECIFIC POORLY-FERMENTABLE CARBOHYDRATES


Johann Hammer, AT

09:36 - 09:42 MP362
A POSSIBLE GUT MICROBIOTA SIGNATURE IN PATIENTS WITH BLOATING: RESULTS FROM REAL LIFE

Stefania Piccirelli, IT

09:42 - 09:48 MP363
A STARCH- AND SUCROSE-REDUCED DIET IN IRRITABLE BOWEL SYNDROME LEADS TO LOWER CIRCULATING LEVELS OF PAI-1 AND VISFATIN: A RANDOMIZED CONTROLLED STUDY

Bodil Ohlsson, SE

09:48 - 09:54 MP364
WWW.CHECKIBS.COM: AN ONLINE WEB APPLICATION FOR PSYCHOSOMATIC SYMPTOMS BASED EVALUATION OF IRRITABLE BOWEL SYNDROME USING MACHINE LEARNING METHODS 

Noman Haleem, NO

09:54 - 10:00 MP365
SUB-DIAGNOSTIC GASTROINTESTINAL SYMPTOMS ARE COMMON IN THE GLOBAL ADULT POPULATION: ASSESSMENT OF PREVALENCE AND IMPACT

Olafur S. Palsson, US

10:00 - 10:06 MP366
IMPACT OF IRRITABLE BOWEL SYNDROME (IBS) ON WORK AND ACTIVITIES OF DAILY LIVING AMONG PATIENTS WITH ROME IV-IBS

Vivek Chand Goodoory, GB

10:06 - 10:12 MP367
BERGEN BRAINGUT STUDY: RELATIONS BETWEEN FECAL MICROBIOTA PROFILE AND ITS METABOLITES (SHORT-CHAIN FATTY ACIDS) AND SYMPTOMS IN IRRITABLE BOWEL SYNDROME

Erica Sande Teige, NO

10:12 - 10:18 MP369
SPECIFYING THE UNSPECIFIED. A GLOBAL STUDY OF UNSPECIFIED FUNCTIONAL BOWEL DISORDER
 Navkiran Tornkvist, SE

10:18 - 10:24 MP370
SYMPTOM BURDEN AFTER A LACTOSE CHALLENGE EVALUATED WITH THE TEST SPECIFIC ADULT CARBOHYDRATE PERCEPTION QUESTIONNAIRE (ACPQ)
 Johann Hammer, AT

Moderated Poster

09:30 - 10:30 Poster Stage 4
Coeliac disease
 Chairs: Carolina Ciacci, IT
 Fabiana Zingone, IT

09:30 - 09:36 MP381
TRENDS IN CELIAC DISEASE PREVALENCE AND PREDICTING FACTORS: A LONG-TERM NATIONWIDE FOLLOW-UP STUDY
 Juha Taavela, FI

09:36 - 09:42 MP382
LONG-TERM FOLLOW-UP OF PATIENTS WITH TYPE 2 REFRACTORY CELIAC DISEASE TREATED WITH AMG 714, AN ANTI-INTERLEUKIN 15 MONOCLONAL ANTIBODY, AT GEORGES POMPIDOU HOSPITAL
 Olivier Chatelangat, FR

09:42 - 09:48 MP383
THE PREVALENCE OF COELIAC DISEASE IN THE UNSELECTED GENERAL POPULATION
 Polina Lukina, NO

09:48 - 09:54 MP384
REFRACTORY TYPE 2 CELIAC DISEASE AND ASSOCIATED CIRCULATING MICRORNAs: NETWORKS WITH BIOLOGICAL FUNCTIONS
 Nicoletta Nandi, IT

09:54 - 10:00 MP385
ONE THIRD OF CELIAC PATIENTS DOES NOT PRESENT ANY SIGNS OF DISEASE ACTIVITY IN CASE OF OCCASIONAL GLUTEN INGESTION: RESULTS FROM AN ENDOSCOPIC-ENTEROSCOPIC STUDY
 Margherita Maregatti, IT

10:00 - 10:06 MP386
PREDICTIVE FACTORS FOR ENTEROPATHY ASSOCIATED T-CELL LYMPHOMA DEVELOPMENT IN REFRACTORY CELIAC DISEASE TYPE II PATIENTS
 Olivier Chatelangat, FR

10:06 - 10:12 MP387
MUCOSAL RECOVERY IN COELIAC DISEASE: AN ACHIEVABLE TARGET OR AN UNREALISTIC GOAL?
 Eileen Shannon, IE

10:12 - 10:18 MP388
THE PERSISTENCE OF A HIGH INCIDENCE OF COELIAC DISEASE IN THE WEST OF IRELAND; 50 YEARS ON
 Gillian Madders, IE

10:18 - 10:24 MP389
CROSS-REACTIVE COELIAC MONOCLONAL ANTI-TG2 ANTIBODIES TARGET TG3 IN DERMATITIS HERPETIFORMIS SKIN
 Ilma Korponay-Szabo, HU

10:24 - 10:30 MP390
NO BIOPSY APPROACH FOR THE DIAGNOSIS OF COELIAC DISEASE IN ADULTS
 Suzanne Cauchi, MT

Live Demo

10:00 - 11:00 A2

Live Endoscopy II

Chairs: Paraskevas Gkolfakis, BE
 Lars Aabakken, NO
 Evelien Dekker, NL
 Marianna Arvanitakis, BE
 Raf Bisschops, BE
 Ulrike Walburga Denzer, DE
 Pierre Henri Deprez, BE
 Jacques Deviere, BE
 Pierre Eisendrath, BE
 Tomas Hucl, CZ
 Arnaud Lemmers, BE
 Horst Neuhaus, DE

Q+A LIVE

TV Studio Session

10:30 - 11:00 TV Studio

Grow with us: Rising Stars Award Session II

Chairs: Martina Müller-Schilling, DE
 David James Tate, BE
 Salvatore Piano, IT
 Fotios Sampaziotis, GB
 Gianluca Pellino, IT

LIVE

myUEG Community Programme

10:30 - 11:00 MyUEG Community Area

Connect with... #UEGEdu Web Editors

Chairs: Ignacio Catalan-Serra, NO
 Rui Castro, PT
 Manuele Furnari, IT
 Nedra Jouini, AT
 Klaartje Bel Kok, GB
 Spyros Siakavellas, GB

Session

11:00 – 12:00 D3
Crash course: T1 colorectal cancer
 Chairs: Elizabeth E Half, IL
 Maria Pellisé Urquiza, ES

Q+A LIVE

11:00 - 11:20 IP392
Endoscopic therapy
 Leon M.G. Moons, NL

11:20 - 11:40 IP393
Histologic classification
 Maurice Loughrey, GB

11:40 - 12:00 IP394
Post endoscopy surgery: For whom?
 Mahdi Al-Taher, NL

Abstract-based Session

11:00 – 12:00 A1
Clinical trials in ulcerative colitis II
 Chairs: Severine Vermeire, BE
 Pascal Juillerat, CH

Q+A LIVE

11:00 - 11:12 OP195
EFFICACY AND SAFETY OF MIRIKIZUMAB AS MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 LUCENT-2 STUDY
 Geert D'Haens, NL

11:12 - 11:24 OP196
EXTENDED THERAPY WITH OZANIMOD FOR DELAYED RESPONDERS TO OZANIMOD IN MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: DATA FROM THE TRUE NORTH OPEN-LABEL EXTENSION STUDY
 Remo Panaccione, CA

11:24 - 11:36 OP197
BENEFITS OF HIGH VERSUS LOW DOSE UPADACITINIB AS MAINTENANCE TREATMENT IN ULCERATIVE COLITIS PATIENTS WHO WERE RESPONDERS TO 8-WEEK INDUCTION WITH UPADACITINIB: RESULTS FROM THE U-ACHIEVE PHASE 3 MAINTENANCE TRIAL
 Brian Feagan, CA

11:36 - 11:48 OP198
EFFICACY OF DEUCRAVACITINIB, AN ORAL, SELECTIVE, TYROSINE KINASE 2 INHIBITOR, IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS AND PRIOR EXPOSURE TO BIOLOGIC THERAPY: SUBANALYSIS FROM THE PHASE 2 LATTICE-UC STUDY
 Stefan Schreiber, DE

11:48 - 12:00 OP199
EFFICACY OF UPADACITINIB DOSE ESCALATION IN A PHASE 3 LONG-TERM EXTENSION ULCERATIVE COLITIS STUDY
 Remo Panaccione, CA

Session

11:00 – 12:00 A3
When functional disorders overlap with organic diseases
 Chairs: Maura Corsetti, GB
 Hans Törnblom, SE

Q+A LIVE

11:00 - 11:20 IP395
When IBS occurs in coeliac disease patients in remission
 David Surendran Sanders, GB

11:20 - 11:40 IP396
When IBS occurs in IBD patients in remission
 Chloé Melchior, FR

11:40 - 12:00 IP397
Is IBS a functional disorder? New molecular targets in the management of IBS
 Guy E. Boeckxstaens, BE

Session

11:00 – 12:00 C1
Rising Stars in basic and translational science from Europe and Japan
 Chairs: Luigi Ricciardiello, IT

Q+A LIVE

11:00 - 11:20 IP398
Novel biomarkers for small intestinal Crohn's disease
 Ami Kawamoto, JP

11:20 - 11:40 IP399
miRNAs as modulators of NAFLD pathogenesis and progression towards liver cancer
 Pedro M. Rodrigues, ES

11:40 - 12:00 IP400
Mapping the chromatin profiles of intraductal papillary mucinous neoplasm lineages to unveil their biological vulnerabilities
 Hiroyuki Kato, JP

Late Breaking Abstracts

11:00 – 12:00 C2
Late breaking abstracts III
 Chairs: Matthieu Allez, FR
 Jan Tack, BE

Q+A LIVE

11:00 - 11:12 LB11
TO THE SOURCES OF INFLAMMATORY BOWEL DISEASE: PRE-HISTORIC INTRODUCTION OF IL-23 RECEPTOR RELATED GENETIC SUSCEPTIBILITY TO INFLAMMATION INTO TODAY'S EUROPEAN POPULATION
 Stefan Schreiber, DE

11:12 - 11:24 LB12
POLIPROTECT VS OMEPRAZOLE IN THE RELIEF OF HEARTBURN, EPIGASTRIC PAIN AND BURNING IN NERD AND EPS PATIENTS: A RANDOMIZED, DOUBLE-BLIND, DOUBLE DUMMY, REFERENCE PRODUCT CONTROLLED, PARALLEL GROUP, NON-INFERIORITY CLINICAL STUDY
 Enrico Stefano Corazziari, IT

11:24 - 11:36 LB13
FOUR SARS-COV-2 VACCINE DOSES OR HYBRID IMMUNITY IN PATIENTS WITH IMMUNE-MEDIATED INFLAMMATORY DISEASES ON IMMUNOSUPPRESSIVE THERAPIES. A PROSPECTIVE, OBSERVATIONAL COHORT STUDY
 Kristin Kaasen Jørgensen, NO

11:36 - 11:48 LB14
DUPILUMAB IMPROVES HISTOLOGICAL AND ENDOSCOPIC FEATURES OF EOSINOPHILIC OESOPHAGITIS IN CHILDREN AGED 1-11 YEARS IN THE PHASE 3 EOE KIDS TRIAL
 Evan S. Dellon, US

11:48 - 12:00 LB15
COVID-19 VACCINE-INDUCED ANTIBODY AND T CELL RESPONSES IN IMMUNOSUPPRESSED PATIENTS WITH INFLAMMATORY BOWEL DISEASE AFTER THE THIRD VACCINE DOSE
 James Alexander, GB

Translational/Basic Science Session

11:00 - 12:00 D4
The microbiome as modulators of gut function
 Chairs: Harry Sokol, FR
 Tim Vanuytsel, BE

Q+A LIVE

11:00 - 11:20 IP401
A glimpse at the healthy microbiome
 Jeroen Raes, BE

11:20 - 11:40 IP402
The role of the microbiome in IBS
 Nicolas Cenac, FR

Session

11:00 - 12:00 Strauss 2
Transplant: Cure in hepatology
 Chairs: Marina Berenguer, ES
 Patrizia Burra, IT

Q+A LIVE

11:00 - 11:20 IP404
Rehabilitation pre- and post-transplant nutrition
 Annalisa Berzigotti, CH

11:20 - 11:40 IP405
When does cardiovascular disease precludes liver transplantation?
 Annabel Blasi, ES

11:40 - 12:00 IP406
Futility of liver transplantation in ACLF
 Rajiv Jalan, GB

Session

11:00 - 12:00 Strauss 3
Complicated coeliac disease: Make it simple!
 Chairs: Rachel Gingold-Belfer, IL
 Detlef Schuppan, DE

Q+A LIVE

11:00 - 11:20 IP407
Incidence and risk of complications?
 Christophe Cellier, FR

11:20 - 11:40 IP408
Autoimmunity in coeliac disease
 Kalle Kurppa, FI

11:40 - 12:00 IP409
Coeliac disease and bone health
 Carolina Ciacci, IT

Abstract-based Session

11:00 - 12:00 Lehar 2
Management of acute pancreatitis
 Chairs: Markus M. Lerch, DE
 Rogier P. Voermans, NL

Q+A LIVE

11:00 - 11:12 OP200
LOW-PHOSPHOLIPID-ASSOCIATED CHOLELITHIASIS SYNDROME AND INTERVENTIONAL ENDOSCOPY
 Grégoire Salin, FR

11:12 - 11:24 OP201
AUTOIMMUNE PANCREATITIS IN EUROPE: CLINICAL PROFILE AND RESPONSE TO TREATMENT
 Kasper A. Overbeek, NL

11:24 - 11:36 OP202
ANTICOAGULANTS DECREASE MORTALITY AND MAJOR COMPLICATION RATES IN MODERATELY SEVERE AND SEVERE ACUTE PANCREATITIS – A SYSTEMATIC REVIEW AND META-ANALYSIS
 Cristina Patoni, HU

11:36 - 11:48 OP203
USE OF BALANCED CRYSTALLOID SOLUTIONS IN THE EARLY TREATMENT OF ACUTE PANCREATITIS - INTERIM ANALYSIS AND PRELIMINARY DATA
 Anja Radovan, HR

11:48 - 12:00 OP204
AGGRESSIVE VERSUS MODERATE FLUID RESUSCITATION IN ACUTE PANCREATITIS, A MULTI-CENTER RANDOMIZED CLINICAL TRIAL (WATERFALL TRIAL)
 Lucía Guilabert, ES

Industry Meeting

11:00 – 12:00 Lehar 3
Industry Exhibitor Debrief
 Chairs: Jeanin E. van Hooft, NL

Abstract-based Session

11:00 – 12:00 Lehar 4
Upper GI cancer: Basic aspects
 Chairs: Alexander Link, DE
 Gianluca Esposito, IT

Q+A  LIVE

11:00 - 11:12 OP162
ROLES OF L-TYPE AMINO ACID TRANSPORT 1 IN THE DEVELOPMENT OF INTESTINAL TUMORS
 Yunlong Sui, JP

11:12 - 11:24 OP163
MULTI-LAYER MOLECULAR ANALYSIS IN GASTRIC CANCER PATIENTS' BLOOD
 Ruta Inciuraite, LT

11:24 - 11:36 OP164
INTEGRATING SINGLE-CELL RNA-SEQ AND MICROARRAY-BASED SPATIAL TRANSCRIPTOMICS REVEALS MICROENVIRONMENT OF EARLY GASTRIC CANCER FORMATION
 Pingting Gao, CN

11:36 - 11:48 OP166
APRAGLUTIDE TREATMENT REDUCES CHEMOTHERAPY-INDUCED GASTROINTESTINAL DAMAGE IN MICE AND PRESERVES CELLULAR INTEGRITY DURING CHEMOTHERAPY
 Barbara Biemans, CH

Moderated Poster

11:00 – 12:00 Poster Stage 1
Acute and chronic pancreatitis
 Chairs: Gabriele Capurso, IT
 Miroslav Vujasinovic, SE

11:00 - 11:06 MP411
AUTOIMMUNE PANCREATITIS TYPE 2 AND INFLAMMATORY BOWEL DISEASE: A BICENTRIC ANALYSIS AND SYSTEMATIC REVIEW OF THE LITERATURE
 Sara Nikolic, SI

11:06 - 11:12 MP412
ASSOCIATION BETWEEN GLYCEMIC STATUS AND THE RISK OF ACUTE PANCREATITIS: A NATIONWIDE POPULATION-BASED STUDY
 Sang Hyub Lee, KR

11:12 - 11:18 MP413
THE ASSOCIATION BETWEEN PHOSPHATE LEVEL AT ADMISSION AND THE CLINICAL COURSE AND OUTCOMES OF ACUTE PANCREATITIS
 Itai Ghersin, IL

11:18 - 11:24 MP414
THE USE OF A PATIENT SUPPORT PROGRAM FOR PATIENTS WITH PANCREATIC EXOCRINE INSUFFICIENCY IN SWEDEN TO IMPROVE USAGE AND ADHERENCE TO TREATMENT

Joakim Svahn, SE
 11:24 - 11:30 MP415
B-DIHR: A NEW TOOL FOR SEVERITY PREDICTION BASED ON DYNAMIC PARAMETERS
 Francisco Valverde-López, ES

11:30 - 11:36 MP416
PANCREATOSCOPY-GUIDED ELECTROHYDRAULIC LITHOTRIPSY FOR THE TREATMENT OF OBSTRUCTIVE DISTAL MAIN PANCREATIC DUCT STONES; LONG-TERM OUTCOMES
 Florence E. M. de Rijk, NL

11:36 - 11:42 MP417
THE PREVALENCE OF SARCOPENIA IN CHRONIC PANCREATITIS: RESULTS FROM A TERTIARY CENTER
 Eugenio Marconato, IT

11:42 - 11:48 MP418
MESENTERIC CHANGES IN THE INDEX COMPUTED TOMOGRAPHY SCAN CAN PREDICT OUTCOME IN ACUTE PANCREATITIS: A NOVEL MESENTERY-BASED CLASSIFICATION
 Jayanta Samanta, IN

11:48 - 11:54 MP419
POST-PANCREATITIS DIABETES MELLITUS– A HIGH-VOLUME TERTIARY CENTER EXPERIENCE
 Ana Dugic, SE

11:54 - 12:00 MP420
PANCREATIC SIZE RELATED TO PANCREATIC FUNCTION IN A LARGE PATIENT COHORT WITH CHRONIC PANCREATITIS
 Trond Engjom, NO

Moderated Poster

11:00 – 12:00 Poster Stage 2
Surgery
 Chairs: Roel Hompes, NL
 Paula Sousa, PT

11:00 - 11:06 MP399
RESULTS AND TRENDS OF TREATMENT OF INTESTINAL TUBERCULOSIS REQUIRING SURGERY
 Daisuke Hojo, JP

11:06 - 11:12 MP391
USEFULNESS OF POINT-OF-CARE ULTRASONOGRAPHY FOR CONSTIPATION IN PALLIATIVE CARE USING PORTABLE ULTRASOUND
 Tsumugi Jono, JP

11:12 - 11:18 MP392
EVENTRATION OF INNER ORGANS FOR PENETRATING GUNSHOT ABDOMINAL TRAUMA AS A PREDICTOR OF COMPLICATIONS AND MORTALITIES
 Oksana Popova, UA

- 11:18 - 11:24 MP394
THE INTERFERON GAMMA-RELATED LONG NONCODING RNA SIGNATURE PREDICTS PROGNOSIS AND INDICATES IMMUNE MICROENVIRONMENT INFILTRATION IN COLON ADENOCARCINOMA
- 11:24 - 11:30 MP395
DECREASE IN DIAMETER OF A CAECUM DOME AS A SENSITIVE AND SPECIFIC SONOGRAPHIC SIGN OF COLON INJURY FOR WOUNDED WITH PENETRATING GUNSHOT ABDOMINAL TRAUMA (EXPERIENCE OF WAR IN UKRAINE 2014-2022 YY.)
 Oksana Popova, UA
- 11:30 - 11:36 MP396
PERCUTANEOUS GASTROSTOMY IN PATIENTS WITH ADVANCED DEMENTIA - A PATIENT SELECTION TOOL
 Mayan Eitan, IL
- 11:36 - 11:42 MP397
ENDOSCOPIC SUBMUCOSAL DISSECTION FOR EARLY ESOPHAGEAL AND ESOPHAGOGASTRIC JUNCTION NEOPLASMS: ANALYZING OUTCOMES AND SAFETY
 Ana Rita Franco, PT
- 11:42 - 11:48 MP398
ENDOSCOPIC SUBMUCOSAL DISSECTION FOR RESECTIONS LARGER THAN 10 CM: OUTCOMES FROM A PORTUGUESE REFERENCE CENTER
 Raquel R. Mendes, PT
- 11:48 - 11:54 MP400
MATHEMATICAL MODELS COMBINING CLINICAL AND TRANSCRIPTIONAL VARIABLES MAY PREDICT POSTOPERATIVE RECURRENCE IN CROHN 'S DISEASE PATIENTS
 Karine Mariane Steigleder, BR

Moderated Poster

- 11:00 – 12:00 Poster Stage 3
Patient reported outcomes in IBD
 Chairs: Ulrike von Arnim, DE
 Axel Dignass, DE
- 11:00 - 11:06 MP401
IMPROVEMENT IN FATIGUE WITH MIRIKIZUMAB THERAPY IS ASSOCIATED WITH IMPROVEMENTS IN PATIENT-REPORTED OUTCOMES IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE
 Peter Bossuyt, BE
- 11:06 - 11:12 MP402
DEVELOPMENT OF A 'NORMAL LIFE INDEX' (NLI) FOR PATIENTS WITH IBD: ITEM SELECTION THROUGH A WORLD-WIDE PATIENT-CENTRED APPROACH
 Joep van Oostrom, NL

- 11:12 - 11:18 MP403
MIRIKIZUMAB IMPROVES WORK PRODUCTIVITY AND ACTIVITY IMPAIRMENT QUESTIONNAIRE SCORES IN MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: THE LUCENT-1 AND LUCENT-2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 INDUCTION AND MAINTENANCE STUDIES
 Bruce E. Sands, US
- 11:18 - 11:24 MP404
PSYCHOMETRIC VALIDATION AND INTERPRETATION OF A PATIENT-REPORTED OUTCOMES INSTRUMENT TO ASSESS BOWEL URGENCY AMONG ADULTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS
 Laure Delbecque, US
- 11:24 - 11:30 MP405
DEVELOPMENT OF A CORE OUTCOME SET FOR PATIENTS WITH INFLAMMATORY BOWEL DISEASE THROUGH AN INTERNATIONAL MULTI-STAKEHOLDER DELPHI EXERCISE
 Liselotte Fierens, BE
- 11:30 - 11:36 MP406
FATIGUE IN NEWLY DIAGNOSED INFLAMMATORY BOWEL DISEASE PATIENTS: RESULTS FROM A PROSPECTIVE INCEPTION COHORT, THE IBSEN III STUDY
 Kristina I. Aass Holten, NO
- 11:36 - 11:42 MP407
EFFICACY OUTCOMES BY SYMPTOM-BASED RESPONSE STATUS AFTER INDUCTION: WEEK-48 RESULTS FROM THE GALAXI 1 TRIAL OF GUSELKUMAB IN CROHN'S DISEASE
 Julian Panés, ES
- 11:42 - 11:48 MP408
SURGERY IMPROVES SHORT AND LONG-TERM DISABILITY IN IBD: A 5-YEAR PROSPECTIVE ASSESSMENT OF THE SURGICAL PATIENT WITH IBD DISK
 João A. Cunha Neves, PT
- 11:48 - 11:54 MP409
SYMPTOMS AND LABORATORY VALUES AS PROXIES FOR ENDOSCOPIC AND HISTOLOGIC CLINICAL ENDPOINTS IN ULCERATIVE COLITIS: A MEDIATION ANALYSIS BASED ON UPADACITINIB PHASE 3 INDUCTION TRIALS
 Silvio Danese, IT
- 11:54 - 12:00 MP410
REAL-WORLD OUTCOMES OF TRANSITIONING FROM INTRAVENOUS TO SUBCUTANEOUS VEDOLIZUMAB TREATMENT: A NATIONWIDE COHORT BASED ON THE SWEDISH INFLAMMATORY BOWEL DISEASE QUALITY REGISTER
 Nishan Lamichhane, SE

Moderated Poster

- 11:00 – 12:00 Poster Stage 4
Upper GI: Basic science
 Chairs: Juozas Kupcinskis, LT

11:00 - 11:06 MP421
UNRAVELLING THE HUMAN GASTRIC IMMUNE SYSTEM BY SPECTRAL CYTOMETRY CONFIRMS THE PRESENCE OF INTER-INDIVIDUAL VARIABILITY AND LACK OF REGIONAL VARIATION WITHIN THE GASTRIC MUCOSA

David Bernardo, ES

11:06 - 11:12 MP422
THE ROLE OF M1 TO M2 MACROPHAGE POLARIZATION IN THE ETIOLOGY OF IDIOPATHIC GASTROPARESIS: GWAS PERSPECTIVE

Sandra Smieszek, US

11:12 - 11:18 MP425
A POSITIVE FEEDBACK LOOP OF THE TAZ/B-CATENIN AXIS PROMOTES THE PATHOGENESIS OF HELICOBACTER PYLORI INFECTION

Xinbo Xin, CN

11:18 - 11:24 MP426
TREATMENT WITH APRAGLUTIDE PRESERVES THE GLOBAL HOMEOSTATIC ENVIRONMENT OF INTESTINAL MICROBIOTA DURING CHEMOTHERAPY IN MICE

Barbara Biemans, CH

11:24 - 11:30 MP428
UP-REGULATION OF MMP-9 VIA MAPK/ERK PATHWAY MIGHT BE RESPONSIBLE FOR SEVERITY OF REFLUX ESOPHAGITIS

Pelin Ergun, TR

11:30 - 11:36 MP430
THE ABSENCE OF INTESTINAL MICROBIOTA IMPEDES THE ACTIVITY OF THE CRE-LOX SYSTEM IN A MOUSE MODEL OF CONDITIONAL PANETH CELL DEPLETION

Oriol Juanola, CH

Live Demo

11:30 - 12:30 A2

Live Endoscopy III

Chairs: Paraskevas Gkolfakis, BE
 Ian Mark Gralnek, IL
 George Webster, GB
 Marianna Arvanitakis, BE
 Raf Bisschops, BE
 Ulrike Walburga Denzer, DE
 Jacques Deviere, BE
 Pierre Henri Deprez, BE
 Pierre Eisendrath, BE
 Tomas Hucl, CZ
 Arnaud Lemmers, BE
 Horst Neuhaus, DE

Q+A LIVE

TV Studio Session

12:00 - 12:30 TV Studio

UEG Week: Digging deeper

Chairs: Jonathan McCrea, IE
 Uri Kopylov, IL
 Thomas Seufferlein, DE
 Judit Simon, AT

Q+A LIVE

Industry Symposia

12:30 - 13:30 A1

BEYOND THE PODIUM: A Scientific Exchange Examining Advances in Ulcerative Colitis

Case-based Discussion

12:30 - 13:30 C1

Dilemmas in diagnosing small bowel disease

Chairs: Cristina Carretero, ES
 Edward J Despott, GB
 Abraham (Rami) Eliakim, IL
 Jordi Rimola, ES

CASE Q+A LIVE

Case-based Discussion

12:30 - 13:30 C2

Oesophageal leakage after surgery: How to manage it?

Chairs: Sheraz Markar, GB
 Ahmed Ba-Ssalamah, AT
 Roos E. Pouw, NL
 Mark Ivo van Berge Henegouwen, NL

CASE Q+A LIVE

Case-based Discussion

12:30 - 13:30 Strauss 3

Diverticular disease

Chairs: Giovanni Barbara, IT
 Nader K Francis, GB
 Adi Lahat, IL
 Stuart Taylor, GB

CASE Q+A LIVE

Industry Symposia

12:30 - 13:30 Lehar 2

Gazing into the Crystal Ball: Current and Future Perspectives for Crohn's Disease Complications

LIVE

On-site Poster Rounds

12:30 – 13:30 Science Lounge - Liver, Biliary & Pancreas Terminals 1-5
On-site Poster Rounds - Liver, Biliary and Pancreas II

On-site Poster Rounds

12:30 – 13:30 Science Lounge - Surgical, Endoscopic and Imaging Terminals 6-12
On-site Poster Rounds - Surgery, Endoscopy and Imaging II

On-site Poster Rounds

12:30 – 13:30 Science Lounge - Lower GI Terminals 13-21
On-site Poster Rounds - Lower GI II

On-site Poster Rounds

12:30 – 13:30 Science Lounge - Upper GI Terminals 22-30
On-site Poster Rounds - Upper GI II

myUEG Community Programme

12:30 – 13:30 MyUEG Community Area
Young GI: Mentoring Programme
 Chairs: Annalisa Berzigotti, CH
 Jan Bornschein, GB
 Iris Dotan, IL
 Ana Lleo, IT
 Hans Törnblom, SE
 Yasmijn van Herwaarden, NL

myUEG Community Programme

13:30 – 14:00 MyUEG Community Area
Career Development Level 4 - Writing & publishing
 Chairs: Livia Archibugi, IT
 Dragos Ciocan, FR
 Joost P.H. Drenth, NL
 Ana Dugic, SE
 Chloé Melchior, FR
 Katarzyna Pawlak, PL
 Iago Rodríguez-Lago, ES

Session

14:00 – 15:00 D3
FMT: Current practice and future perspectives
 Chairs: Harry Sokol, FR
 Serena Porcari, IT

Q+A LIVE

14:00 - 14:20 IP410
Indications and obstacle in infectious diseases
 Gianluca Ianaro, IT

14:20 - 14:40 IP411
Can FMT treat cancer?
 Adi Lahat, IL

14:40 - 15:00 IP412
Risign Star: Faecal microbiota transplant: An essential tool to explore microbiome host interactions.
 Benjamin Mullish, GB

Session

14:00 – 15:00 A1
Mistakes in...: Hepatobiliary and pancreas incl. imaging
 Chairs: Charles Murray, GB
 Spyros Siakavellas, GB

Q+A LIVE

14:00 - 14:03 IP413
Introduction Mistakes in...: Hepatobiliary and pancreas incl. imaging
 Charles Murray, GB

14:03 - 14:21 IP414
Imaging biliopancreatic disease
 Martina Pezzullo, BE

14:21 - 14:39 IP415
Chronic HBV diagnosis and management
 Patrick Kennedy, GB

14:39 - 14:57 IP416
Decompensated cirrhosis
 Benjamin Maasoumy, DE

14:57 - 15:00
Conclusion Mistakes in...: Hepatobiliary and pancreas incl. imaging
 Charles Murray, GB

Session

14:00 – 15:00 A2
East meets West: Towards common management for colorectal neoplasia
 Chairs: Shinji Tanaka, JP
 Cesare Hassan, IT

Q+A LIVE

14:00 - 14:20 IP417
Characterisation of superficial colorectal neoplasia: Is JNET the final answer?
 Yutaka Saito, JP

14:20 - 14:40 IP418
Colorectal ESD in Europe: Are we closing the gap?
 Helmut Messmann, DE

14:40 - 15:00 IP419
Post-polypectomy surveillance: Lessons from the Japan Polyp Study
 Takahisa Matsuda, JP

Session

14:00 – 15:00 A3
Viral hepatitis: On its way out?
 Chairs: Vincenza Calvaruso, IT
 Salvatore Petta, IT

Q+A LIVE

14:00 - 14:20 IP420
HEV: Of increasing concern?
 Thomas Horvatits, DE

14:20 - 14:40 IP421
HBV: From suppression to cure
 Fabien Zoulim, FR

14:40 - 15:00 IP422
HDV: Towards individualised treatment
 Heiner Wedemeyer, DE

Session

14:00 – 15:00 C1
Management of acute pancreatitis
 Chairs: Livia Archibugi, IT
 Albrecht Neeße, DE

Q+A LIVE

14:00 - 14:20 IP423
Medical management of acute pancreatitis
 Sara Regné, SE

14:20 - 14:40 IP424
When do we need endoscopy?
 Paul Fockens, NL

14:40 - 15:00 IP425
Multimodal treatment: What are the minimally invasive surgical options?
 Jan-Hendrik Egberts, DE

Session

14:00 – 15:00 C2
Nutritional failure associated with lower GI disease
 Chairs: Francisca Joly, FR
 Shira Zelber-Sagi, IL

Q+A LIVE

14:00 - 14:20 IP426
Nutritional challenges in IBS
 Caroline Tuck, AU

14:20 - 14:40 IP427
Nutritional challenges in inflammatory bowel disease
 Kevin Whelan, GB

14:40 - 15:00 IP428
Challenges in case of large output stomach
 Simon Gabe, GB

Translational/Basic Science Session

14:00 – 15:00 D4
New insights in IBD
 Chairs: Matthieu Allez, FR
 Florian Rieder, US

Q+A LIVE

14:00 - 14:20 IP429
IBD and cell migration: There is more to it
 Sebastian Zundler, DE

14:20 - 14:40 IP430
Modulation of S1P receptors: Towards the real mechanism
 Bram Verstockt, BE

14:40 - 15:00 IP431
Somatic mutations: Impact on IBD
 Sigurgeir Olafsson, GB

Abstract-based Session

14:00 – 15:00 Strauss 2
Endoscopic treatment of Barrett's and oesophageal neoplasia
 Chairs: Jan Bornschein, GB
 Henriette Heinrich, CH

Q+A LIVE

14:00 - 14:12 OP210
HIGH RISK FOR UNRELATED MORTALITY AFTER SUCCESSFUL ENDOSCOPIC ERADICATION THERAPY FOR BARRETT'S NEOPLASIA IN A NATIONWIDE COHORT OF 1154 PATIENTS
 Eva Verheij, NL

14:12 - 14:24 OP211
CLINICAL STRATIFICATION FOR ENDOSCOPIC SUBMUCOSAL DISSECTION VERSUS ENDOSCOPIC MUCOSAL RESECTION FOR BARRETT'S ASSOCIATED NEOPLASIA: LONG-TERM FOLLOW-UP
 Fadi Younis, DE

14:24 - 14:36 OP212
OUTCOMES OF ENDOSCOPIC SUBMUCOSAL DISSECTION (ESD) FOR BARRETT'S NEOPLASIA – A SINGLE CENTRE PROSPECTIVE STUDY
 Sunil Gupta, AU

14:36 - 14:48 OP213
RANDOM BIOPSIES FROM THE GASTRO-ESOPHAGEAL JUNCTION AFTER COMPLETE ERADICATION OF BARRETT'S ESOPHAGUS: UTILE OR FUTILE?
 Charlotte N. Frederiks, NL

14:48 - 15:00 OP214
FEASIBILITY OF THE CYTOSPONGE COUPLED WITH TISSUE BIOMARKERS IN EARLY DIAGNOSIS OF OESOPHAGEAL SQUAMOUS CELL CARCINOMA AND SURVEILLANCE OF HIGH-RISK INDIVIDUALS: PRELIMINARY RESULTS FROM THE EDEN STUDY
 Aisha Yusuf, GB

Session

14:00 – 15:00 Strauss 3
All you wanted to know about functional dyspepsia
 Chairs: Dan Lucian Dumitrascu, RO
 Annemieke Smet, BE

Q+A LIVE

14:00 - 14:20 IP432
Rising Star: Paradigm shift in functional dyspepsia: Focus on the duodenum
 Tim Vanuytsel, BE

14:20 - 14:40 IP433
Dyspepsia in a young adult: Scope or not?
 Paola Iovino, IT

14:40 - 15:00 IP434
Dyspepsia management
 Jutta Keller, DE

Abstract-based Session

14:00 – 15:00 Lehar 2
Interventional EUS
 Chairs: Paolo Giorgio Arcidiacono, IT
 Katarzyna Pawlak, PL

Q+A LIVE

14:00 - 14:12 OP215
RISK FACTORS OF STENT OBSTRUCTION AFTER EUS GUIDED CHOLEDOCYDODENOSTOMY WITH LUMEN APPOSING METAL STENT: A LARGE PROSPECTIVE STUDY OF 118 CASES
 Benjamin Redelsperger, FR

14:12 - 14:24 OP216
CLASSIFICATION, RISK FACTORS AND MANAGEMENT OF LAMS DYSFUNCTION DURING FOLLOW-UP OF EUS-GUIDED CHOLEDOCHODUODENOSTOMY: A MULTICENTRE EVALUATION FROM THE LEUVEN-AMSTERDAM-MILAN STUDY (LAMS)-GROUP
 Giuseppe Vanella, IT

14:24 - 14:36 OP217
ENDOSCOPIC VERSUS PERCUTANEOUS MODALITIES FOR DRAINAGE OF PANCREATIC FLUID COLLECTIONS: ASSESSMENT OF CLINICAL AND ECONOMIC OUTCOMES
 Shyam Sundar Varadarajulu, US

14:36 - 14:48 OP218
PLASTIC VERSUS METAL STENT FOR ENDOSCOPIC ULTRASOUND-GUIDED TRANSMURAL DRAINAGE OF WALLED-OFF NECROSIS WITH SIGNIFICANT SOLID DEBRIS: A RANDOMISED CONTROLLED NON-INFERIORITY TRIAL
 Rinkalben Kakadiya, IN

14:48 - 15:00 OP219
EUS-GUIDED DRAINAGE OF LARGE WALLED-OFF PANCREATIC NECROSES USING PLASTIC DOUBLE PIGTAIL STENTS VS LUMEN-APPPOSING METAL STENT - A SINGLE-CENTRE, OPEN-LABEL, RANDOMIZED, SUPERIORITY TRIAL (PLAMS)
 John Gásdal Karstensen, DK

Abstract-based Session

14:00 – 15:00 Lehar 4
Basic science in pancreatic disease
 Chairs: Pilar Acedo, GB
 Najib Ben Khaled, DE

Q+A LIVE

14:00 - 14:12 OP220
SPCA2/STIM1 TRIGGERED CONSTITUTIVE ACTIVITY OF ORAI1 CA²⁺ CHANNEL FINE-TUNES CFTR IN SECRETORY EPITHELIAL CELLS
 Arpad Varga, HU

14:12 - 14:24 OP221
OLAPARIB AND TRAIL-TARGETING AGENTS SYNERGIZE IN PANCREATIC CANCER INDEPENDENT OF DNA DAMAGE REPAIR STATUS
 Katharina Hammer, DE

14:24 - 14:36 OP222
HARNESSING PLURIPOTENT STEM CELL DERIVED TRILINEAGE-COMPETENT PANCREATIC PROGENITORS TO GENERATE DUCT-LIKE ORGANOIDS
 Sarah Merz, DE

14:36 - 14:48 OP223
CXCL12 – CXCR4 SIGNALING IS IMPERATIVE FOR MAINTENANCE AND METASTATIC PROPENSITY OF MIGRATING CANCER STEM CELLS
 Kanishka Tiwary, DE

14:48 - 15:00 OP224
SELECTIVE ELIMINATION OF CD133+ CANCER STEM CELLS AS THERAPY FOR PDAC USING NOVEL DUAL BET/HDAC INHIBITOR TW09
 Kanishka Tiwary, DE

Moderated Poster

14:00 – 15:00 Poster Stage 1
The pressure is on: Portal hypertension
 Chairs: Jonel Trebicka, DE
 Philipp Schwabl, AT

14:00 - 14:06 MP451
ENDOSCOPIC VARICEAL BAND LIGATION IS SAFE DESPITE LOW PLATELET COUNT AND HIGH INR
 Nikolaus Pfisterer, AT

14:06 - 14:12 MP452
GLOBAL HEMOSTATIC PROFILING IN DECOMPENSATED CIRRHOSIS WITH BACTERIAL INFECTIONS SHOWS SUSTAINED IMPAIRMENT OF PLATELET AGGREGATION AND REDUCED LEVEL OF NATURAL ANTICOAGULANTS
 Alberto Zanetto, IT

14:12 - 14:18 MP453
DOES EXPOSURE TO NON-CARDIOSELECTIVE BETA-BLOCKERS INCREASE THE RISK OF PORTAL THROMBOSIS IN CIRRHOTICS?

Fatma Ben Farhat, TN

14:18 - 14:24 MP454
CIRRHOTIC CARDIOMYOPATHY DEFINED ACCORDING TO THE NEW MULTIDISCIPLINARY DIAGNOSTIC CRITERIA SEEMS TO BE ASSOCIATED WITH INCREASED OVERALL MORTALITY AMONG CIRRHOTIC PATIENTS

Simona Bota, AT

14:24 - 14:30 MP455
SEQUENTIAL CONSIDERATION OF VITRO SUBSTANTIALLY REDUCES THE DIAGNOSTIC AND PROGNOSTIC GREY ZONE OF THE BAVENO-VII CRITERIA FOR CLINICALLY SIGNIFICANT PORTAL HYPERTENSION

Lukas Hartl, AT

14:30 - 14:36 MP456
ALCOHOL ABSTINENCE IMPROVES PROGNOSIS ACROSS ALL STAGES OF PORTAL HYPERTENSION IN ALCOHOL-RELATED CIRRHOSIS

Benedikt Hofer, AT

14:36 - 14:42 MP457
THE USE OF SPLEEN STIFFNESS MEASUREMENT FOR THE DETECTION OF HIGH-RISK ESOPHAGEAL VARICES IN PATIENTS WITH PORTAL HYPERTENSION

Angelo Armandi, IT

14:42 - 14:48 MP458
RISK ASSESSMENT IN TIPS PATIENTS: TIME TO RE-ASSESS AFTER TIPS IMPLANTATION

Leon Louis Seifert, DE

14:48 - 14:54 MP459
VARICEAL BLEEDING AND BAVENO VII CONSENSUS: CLARIFYING PRE-EMPTIVE TIPS RISK STRATIFICATION CRITERIA

Tiago Lima Capela, PT

14:54 - 15:00 MP460
PERIORTAL HYPERINTENSITY FACILITATES DIAGNOSIS OF PORTO-SINUSOIDAL VASCULAR DISORDER

Georg Semmler, AT

Moderated Poster

14:00 – 15:00 Poster Stage 2

Endoscopic ultrasound II

Chairs: Thomas Rösch, DE

Lars Aabakken, NO

14:00 - 14:06 MP471
A CONVOLUTIONAL NEURAL NETWORK DEEP LEARNING MODEL ACCURATELY DETECTS RECTAL CANCER IN ENDOANAL ULTRASOUND

Dan Carter, IL

14:06 - 14:12 MP472
GASTROINTESTINAL SUBEPITHELIAL LESIONS (GI SELS): OPTIMIZING UNNECESSARY SURVEILLANCE AND RESOURCES WITH ENDOSCOPIC ULTRASOUND (EUS)

Chris Chia, SG

14:12 - 14:18 MP473
IMPACT OF ENDOSCOPIC ULTRASOUND WITH TISSUE ACQUISITION OF LYMPH NODES IN RESECTABLE PERIHILAR CHOLANGIOCARCINOMA PATIENTS

David de Jong, NL

14:18 - 14:24 MP474
EUS-GUIDED FINE NEEDLE ASPIRATION WITH ROSE VS EUS-GUIDED BIOPSY FOR THE CYTO-HISTOLOGICAL DIAGNOSIS OF SOLID PANCREATIC TUMORS: ANALYSIS OF A PROSPECTIVE EUS REGISTRY

Daniel De la Iglesia-García, ES

14:24 - 14:30 MP475
COMBINED ENDOSCOPIC MANAGEMENT OF BILIARY AND GASTRIC OUTLET OBSTRUCTION (CABRIOLET STUDY): A MULTICENTRE RETROSPECTIVE ANALYSIS

Giuseppe Vanella, IT

14:30 - 14:36 MP476
'THROUGH-STENT-ENTEROGRAPHY': A SIMPLE TECHNIQUE FOR HIGHER SAFETY IN ENDOSONOGRAPHY-GUIDED GASTROENTEROSTOMY

Mohamed Abdelhafez, DE

14:36 - 14:42 MP477
PROGNOSIS ASSESSMENT OF CD44 EXPRESSION ON ENDOSCOPIC ULTRASOUND FINE NEEDLE BIOPSY PANCREATIC DUCTAL ADENOCARCINOMA SAMPLES

Bogdan Silviu Ungureanu, RO

14:42 - 14:48 MP478
SAFETY, PERFORMANCE STATUS, LOCAL CONTROL, AND OVERALL SURVIVAL AFTER ENDOSCOPIC ULTRASOUND-GUIDED RADIOFREQUENCY ABLATION OF UNRESECTABLE PANCREATIC ADENOCARCINOMA: A SINGLE-CENTER HISTORIC COHORT STUDY

Juan Alcivar-Vasquez, EC

14:48 - 14:54 MP479
MOTORIZED SPIRAL ENTEROSCOPY-ASSISTED ERCP IN SURGICALLY ALTERED UPPER GASTROINTESTINAL ANATOMY: INTIAL EXPERIENCE

14:54 - 15:00 MP480
AGE IS JUST A NUMBER; FRAILTY IS A MORE ACCURATE PREDICTOR OF ADVERSE OUTCOMES IN ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY

Eileen Shannon, IE

Moderated Poster

14:00 – 15:00 Poster Stage 3

Response prediction in IBD

Chairs: Paula Sousa, PT

14:00 - 14:06 MP441
IMPACT OF INFLAMMATORY BURDEN ON EFFICACY OF UPADACITINIB MAINTENANCE THERAPY IN ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 U-ACHIEVE STUDY

Brian Feagan, CA

- 14:06 - 14:12 MP442
BASELINE AND EARLY PREDICTORS OF RESPONSE TO RISANKIZUMAB INDUCTION AND MAINTENANCE TREATMENT IN PATIENTS WITH MODERATE TO SEVERE CROHN'S DISEASE
 Walter Reinisch, AT
- 14:12 - 14:18 MP443
TRAJECTORY MODELLING TO IDENTIFY DIFFERENT TYPES OF INDIVIDUAL RESPONSE TO THERAPY: A *POST HOC* ANALYSIS FROM THE SELECTION STUDY
 Stefan Schreiber, DE
- 14:18 - 14:24 MP444
SEX-BASED DIFFERENCES IN RESPONSE TO VEDOLIZUMAB THERAPY FOR ULCERATIVE COLITIS: A POST-HOC ANALYSIS OF VARSITY AND GEMINI-1 STUDY
 Walter Reinisch, AT
- 14:24 - 14:30 MP445
MYELOID CELL COMPARTMENT COLLECTED BY LONGITUDINAL SINGLE CELL TRANSCRIPTION PROFILING DISENTANGLES SHARED AND BIOLOGIC-SPECIFIC PATTERNS OF EARLY REMISSION IN IBD
 Joana P. Bernardes, DE
- 14:30 - 14:36 MP446
COMPARISON OF INTESTINAL US WITH CRP, FECAL CALPROTECTIN AND THEIR COMBINATIONS TO PREDICT ENDOSCOPIC REMISSION OF UC
 Oguz Kagan Bakkaloglu, TR
- 14:36 - 14:42 MP447
PREDICTORS OF RESPONSE TO FILGOTINIB IN ULCERATIVE COLITIS: *POST HOC* ANALYSIS FROM THE SELECTION STUDY
 Brian Feagan, CA
- 14:42 - 14:48 MP448
BASELINE IL-23 SERUM LEVELS PREDICT THERAPEUTIC RESPONSE TO USTEKINUMAB THERAPY IN CROHN'S DISEASE. A PROSPECTIVE STUDY
 Lorenzo Bertani, IT
- 14:48 - 14:54 MP449
USTEKINUMAB TROUGH CONCENTRATIONS ARE ASSOCIATED WITH BIOCHEMICAL OUTCOMES IN PATIENTS WITH CROHN'S DISEASE
 Tessa Straatmijer, NL
- 14:54 - 15:00 MP450
COMPARISON OF THE RISK OF CROHN'S DISEASE POSTOPERATIVE RECURRENCE BETWEEN MODIFIED RUTGEERTS SCORE I2A AND I2B CATEGORIES: AN INDIVIDUAL PATIENT DATA META-ANALYSIS
 Mathurin Fumery, FR

Moderated Poster

- 14:00 – 15:00 Poster Stage 4
Eosinophilic oesophagitis
 Chairs: Arjan Bredenoord, NL
 Matteo Ghisa, IT

- 14:00 - 14:06 MP461
DIFFERENCES IN TREATMENT PATTERNS AMONG PATIENTS DIAGNOSED WITH EOSINOPHILIC OESOPHAGITIS IN THE UNITED STATES
 Evan S. Dellon, US
- 14:06 - 14:12 MP462
PHYSICIAN-DOCUMENTED SYMPTOMS AND TREATMENT AMONG PATIENTS WITH EOSINOPHILIC ESOPHAGITIS IN FIVE EUROPEAN COUNTRIES: EVIDENCE FROM REAL-WORLD CLINICAL PRACTICE
 Xiao Xu, US
- 14:12 - 14:18 MP463
DEVELOPMENT OF THE EOSINOPHILIC ESOPHAGITIS DAILY DYSPHAGIA DIARY, A PATIENT REPORTED OUTCOME ASSESSMENT TO MEASURE FREQUENCY AND SEVERITY OF DYSPHAGIA EPISODES IN EOSINOPHILIC ESOPHAGITIS
 Calvin N. Ho, US
- 14:18 - 14:24 MP464
DUPILUMAB FOR THE TREATMENT OF EOSINOPHILIC ESOPHAGITIS: A MULTICENTER REAL-LIFE EXPERIENCE
 Carla Felice, IT
- 14:24 - 14:30 MP466
OPTIMAL PROCEDURAL TIME ENSURES ADHERENCE TO SEATTLE PROTOCOL AND MAXIMIZES DYSPLASIA DETECTION IN BARRETT'S ESOPHAGUS SURVEILLANCE
 Wladyslaw Januszewicz, PL
- 14:30 - 14:36 MP467
PATIENT-REPORTED SYMPTOMS OF EOSINOPHILIC ESOPHAGITIS IN FIVE EUROPEAN COUNTRIES: EVIDENCE FROM REAL-WORLD CLINICAL PRACTICE
 Xiao Xu, US
- 14:36 - 14:42 MP468
CHANGING STRATEGY FOR BARRETT'S SURVEILLANCE: USING CYTOSPONGE AND GASTROSCOPY OVER 14 MONTHS DURING COVID-19
 Iana Martini, GB
- 14:42 - 14:48 MP469
INHIBITORY EFFECT OF PHARMACOLOGICALLY-DERIVED OR ENDOGENOUSLY PRODUCED HYDROGEN SULFIDE (H₂S) ON THE DEVELOPMENT OF BARRETT'S METAPLASIA THROUGH IL-1B/COX-2/PGE2 PATHWAY LOOP
 Edyta Korbut, PL
- 14:48 - 14:54 MP470
NOVEL ROBUST METHOD FOR EOSINOPHIL COUNTING IN DUODENAL BIOPSY SECTIONS
 Matthias Ceulemans, BE

TV Studio Session

- 15:00 – 15:30 TV Studio
UEG Week digested
 Chairs: Helena Cortez-Pinto, PT
 Iris Dotan, IL
 Julia Mayerle, DE
 Albrecht Neesse, DE

Q+A  LIVE

myUEG Community Programme
 15:00 – 15:30 MyUEG Community Area
Connect with...#UEGWomeninGI Role Models
 Chairs: Marina Berenguer, ES

Session
 15:30 – 16:30 D3
Artificial intelligence for upper GI-endoscopy: What's new in 2022?
 Chairs: Helmut Messmann, DE
 Yuichi Mori, NO

Q+A LIVE

15:30 - 15:50 IP435
Detecton and characterisation of Barrett's neoplasia
 Alanna Ebigbo, DE

15:50 - 16:10 IP436
Detection and characterisation of squamous-cell neoplasia
 Rehan Jamil Haidry, GB

16:10 - 16:30 IP437
Detection and characterisation of gastric neoplasia
 Mario Dinis-Ribeiro, PT

Session
 15:30 – 16:30 A1
Never waste a good disaster (HPB)
 Chairs: Marine Camus, FR
 Elena Rangelova, SE

Q+A LIVE

15:30 - 15:35 IP438
What I regretted most in the treatment of CBD stones
 Henrike Lenzen, DE

15:35 - 15:40 IP439
What I regretted most in the treatment of CBD stones
 István Hritz, HU

15:40 - 15:50
Q&A

15:50 - 15:55 IP440
What I regretted most in treating biliary pancreatitis
 Marco J. Bruno, NL

15:55 - 16:00 IP441
What I regretted most in treating biliary pancreatitis
 Julia Mayerle, DE

16:00 - 16:10
Q&A

16:10 - 16:15 IP442
What I regretted most in acute liver failure
 Christian Lange, DE

16:15 - 16:20 IP443
What I regretted most in acute liver failure
 Patrizia Burra, IT

16:20 - 16:30
Q&A

Session
 15:30 – 16:30 A2
What's new in HPB 2022?
 Chairs: Alessio Aghemo, IT
 Thomas Reiberger, AT

Q+A LIVE

15:30 - 15:50 IP444
Acute-on-chronic liver failure and artificial support systems
 Rafael Banares, ES

15:50 - 16:10 IP445
NETs: Any news?
 Michal Žorniak, PL

16:10 - 16:30 IP446
How to use albumin in cirrhosis
 Vincenza Calvaruso, IT

Session
 15:30 – 16:30 A3
From guidelines to clinical practice: Oesophagus, stomach
 Chairs: Eglė Dieninytė - Misiūnė, LT
 Tamara Matysiak-Budnik, FR

Q+A LIVE

15:30 - 15:50 IP447
Low-grade Barrett's oesophagus: What to do?
 Roos E. Pouw, NL

15:50 - 16:10 IP448
Precancerous lesions in the stomach: Relevant points for daily practice
 Pedro Pimentel-Nunes, PT

16:10 - 16:30 IP449
Coeliac disease guideline revisited: Adaptions needed?

Session
 15:30 – 16:30 C1
Keeping the flow: Diagnostic and therapeutic challenges for the bile and pancreas duct
 Chairs: Lars Aabakken, NO
 Alexander Art, DE

Q+A LIVE

15:30 - 15:50 IP450
Pancreatic and biliary duct stones: Endoscopic management strategies
 Paolo Giorgio Arcidiacono, IT

15:50 - 16:10 IP451
How to deal with a suspicious biliary stricture
 George Webster, GB

16:10 - 16:30 IP452
Microlithiasis: Do we know when it causes trouble?
 Markus M. Lerch, DE

Translational/Basic Science Session
 15:30 – 16:30 D4
Targeted therapies for biliary tract cancers
 Chairs: Ana Lleo, IT
 Pedro M. Rodrigues, ES

Q+A LIVE

15:30 - 15:50 IP453
Cholangiocarcinoma landscape in Europe: Updates from the European Registry
 Jesús M. Bañales, ES

15:50 - 16:10 IP454
FGFR2 fusion inhibitors: Updates on efficacy and therapy resistance
 Lorenza Rimassa, IT

16:10 - 16:30 IP455
Targeting IDH1/2 and beyond
 Juan Valle, GB

Abstract-based Session
 15:30 – 16:30 Strauss 2
Old and new molecules in IBD
 Chairs: Matthieu Allez, FR
 Charles Murray, GB

Q+A LIVE

15:30 - 15:42 OP225
WITHDRAWAL OF THIOPURINES IN INFLAMMATORY BOWEL DISEASE PATIENTS IN STABLE REMISSION: A PROSPECTIVE, MULTICENTER COHORT STUDY
 Edo Savelkoul, NL

15:42 - 15:54 OP226
MUCOSAL HEALING AND CLINICAL EFFICACY OF ADALIMUMAB IN SMALL INTESTINAL CROHN'S DISEASE (SIMCHA STUDY):FINAL RESULTS FROM A PROSPECTIVE, OPEN-LABEL, SINGLE-ARM STUDY
 Panu Wetwittayakhleng, CA

15:54 - 16:06 OP228
MERCAPTOPYRINE TREATMENT USING THERAPEUTIC DRUG MONITORING IS EFFECTIVE IN ULCERATIVE COLITIS: A PLACEBO-CONTROLLED RANDOMIZED TRIAL
 Adriaan Volkers, NL

16:06 - 16:18 OP229
EFAVALEUKIN ALFA IS A NOVEL IL-2 MUTEIN THAT SELECTIVELY EXPANDS REGULATORY T CELLS: PHASE 1 RESULTS AND RATIONALE FOR PHASE 2 CLINICAL INVESTIGATION IN ULCERATIVE COLITIS
 Farshid Firoozbakht, US

Video Case Session
 15:30 – 16:30 Strauss 3
Video Case session
 Chairs: Albrecht Neesse, DE
 Jonas Rosendahl, DE

Q+A LIVE

15:30 - 15:39 VC01
POTENTIAL ROLE OF ENDOSCOPIC INTERMUSCULAR DISSECTION IN RECTAL ADENOCARCINOMA
 Rui Mendo, PT

15:39 - 15:43 VC02
ENDOSONOGRAPHY GUIDED SHORT GASTRIC ARTERY PSEUDOANEURYSM COILING IN WALLED OFF PANCREATIC NECROSIS BLEED
 Aditya Kulkarni, IN

15:43 - 15:52 VC03
BLEEDING GIANT PSEUDOANEURYSM NON-VISUALIZED ON ARTERIAL PHASE IMAGING: ENDOSCOPIC ULTRASOUND-GUIDED THERAPY TO THE RESCUE
 Jayanta Samanta, IN

15:52 - 16:02 VC04
EFFICACY OF A GEL INJECTED USING AN ENDOSCOPY WITH WATER-JET FUNCTION FOR VISUALISATION OF ACTIVE BLEEDING DURING OESOPHAGEAL ENDOSCOPIC SUBMUCOSAL DISSECTION
 Masaya Sano, JP

16:02 - 16:11 VC05
LOCAL EXCISION OF T1 RECTAL CANCER IN PATIENT UNWILLING OR UNFIT FOR SURGERY
 Giuseppe Grande, IT

16:11 - 16:20 VC06
ENDOSCOPIC SUBMUCOSAL DISSECTION IN THE COLON BY USING THE NOVEL A-TRACT DEVICE WITH MULTIPOLAR ADJUSTABLE TRACTION FORCE
 Mathieu Pioche, FR

16:20 - 16:30 VC07
SUBMUCOSAL TUNNELING ENDOSCOPIC RESECTION (STER) OF RECTAL SUB EPITHELIAL TUMOR ARISING FROM THE INTERNAL ANAL SPHINCTER
 Jaseem Ansari, IN

Abstract-based Session
 15:30 – 16:30 Lehar 2
Pancreatic cancer: Aspects of treatment and detection
 Chairs: Anna Burelli, IT
 Najib Ben Khaled, DE

Q+A LIVE

15:30 - 15:42 OP230
CHARACTERIZATION OF PANCREATIC INTRAEPITHELIAL NEOPLASIA WITH DIFFUSION TENSOR IMAGING: A PRE-CLINICAL AND TRANSLATIONAL STUDY
 Carlos Bilreiro, PT

15:42 - 15:54 OP231
RESPONSE MONITORING WITH CTDNA IN METASTATIC PANCREATIC CANCER 

Jinwoo Ahn, KR

15:54 - 16:06 OP233
PREDICTORS OF MAJOR PATHOLOGICAL RESPONSE AFTER NEOADJUVANT THERAPY FOR BORDERLINE AND LOCALLY ADVANCED PANCREATIC DUCTAL ADENOCARCINOMA

Quoc Riccardo Bao, IT

Abstract-based Session

15:30 – 16:30 Lehar 4

AI in Lower GI

Chairs: Peter Bossuyt, BE
Haluk Tarik Kani, TR

Q+A  LIVE

15:30 - 15:42 OP235
ARTIFICIAL INTELLIGENCE AND HIGH-RESOLUTION ANOSCOPY: AUTOMATIC IDENTIFICATION OF ANAL SQUAMOUS CELL CARCINOMA PRECURSORS USING A CONVOLUTIONAL NEURAL NETWORK

Miguel Jose Mascarenhas Saraiva, PT

15:42 - 15:54 OP236
A VIRTUAL CHROMOENDOSCOPY ARTIFICIAL INTELLIGENCE SYSTEM TO DETECT ENDOSCOPIC AND HISTOLOGIC ACTIVITY/REMISSION AND PREDICT CLINICAL OUTCOMES IN ULCERATIVE COLITIS

Tommaso Lorenzo Parigi, IT

15:54 - 16:06 OP237
A SIMPLE WEB-BASED TOOL FOR PREDICTING DRUG SUSTAINABILITY OF INFLIXIMAB AND VEDOLIZUMAB IN MODERATE-TO-SEVERE ULCERATIVE COLITIS USING EXPLAINABLE ARTIFICIAL INTELLIGENCE

Tom Konikoff, IL

16:06 - 16:18 OP238
VALIDATION OF A NOVEL ARTIFICIAL INTELLIGENCE (AI) BASED ALGORITHM FOR IN VIVO CHARACTERISATION OF COLORECTAL POLYPS

Ejaz Hossain, GB

16:18 - 16:30 OP239
IMPACTS OF A NOVEL AI-ENABLED POLYP DETECTION SYSTEM: A PROSPECTIVE RANDOMIZED CLINICAL TRIAL

Jesse Lachter, IL